Identification of neuroblastoma tumor suppressor genes

ABSTRACT

The present invention relates to a new tumor suppressor gene family. More specifically the present invention relates to a tumor suppressor involved in suppression of neuroblastoma. Said tumor suppressor is involved in the generation of micronuclei and in the removal of acentric chromosomal fragments that might contain amplified DNA.

[0001] The present invention relates to a new tumor suppressor gene family. More specifically the present invention relates to a tumor suppressor involved in suppression of neuroblastoma. Said tumor suppressor is involved in the generation of micronuclei and in the removal of acentric chromosomal fragments that might contain amplified DNA.

[0002] Non-random structural rearrangements of the short arm of chromosome 1 (1p) are among the most common abnormalities in solid tumors as well as in hematological malignancies (for review, see Schwab et al. 1996). The most common structural rearrangements affecting 1p are deletions, thus suggesting the implication of tumor suppressor gene(s) located in this region. For several tumor types including neuroblastoma (Caron, 1995), meningioma (Cai et al., 2001), colorectal cancer (De Angelis et al., 2001), gastric carcinoma (Igarashi et al., 2000), and breast cancer (Ragnarsson et al., 1999), it has been shown that loss of 1p is correlated with poor prognosis or with tumor progression. The presence of a tumor suppressor gene on chromosome 1p is further supported by somatic cell fusion experiments. The delivery of chromosome 1p into the neuroblastoma cell line NGP by microcell-mediated chromosome transfer resulted in complete differentiation of the cells (Bader et al., 1991) and the introduction of the 1p36 chromosomal region in a colon carcinoma cell line suppressed tumorigenicity in nude mice (Tanaka et al., 1993). Deletion mapping in breast tumor cell lines has shown that one of the two SROs (shortest regions of overlaps) involving chromosome I overlaps with the consensus region of loss of heterozygosity (LOH) in neuroblastoma (Bieche et al., 1998). For malignant melanoma, frequent alterations of three evolutionary conserved regions on chromosome 1 (1p11-12, 1q21 and 1p36) were described (Zhang et al., 1999). Also metastatic retinoblastoma, which occasionally shows MYCN amplification, has been shown to have a recurrent LOH of chromosome 1p (Doz et al., 1996). Other LOH studies have identified several critical regions on 1p in various cancers including colon cancer, breast cancer, lung cancer, hepatocellular carcinoma, parathyroid adenoma, melanoma, and others. For different tumor types including neuroblastoma some SRO's (shortest regions of overlaps) for 1p deletions are overlapping indicating that the same tumor suppressor genes may be implicated in the different tumor types.

[0003] Tumor cells arise from normal tissues through the progressive accumulation of several mutations. These genetic changes consist of point mutations, deletions, inversions, translocations and DNA amplifications and result in the activation of proto-oncogenes or the inactivation of tumor suppressor genes. Mutations in DNA repair genes can significantly speed up this process. DNA amplification is often detected in high-grade tumors where the amplified DNA is either incorporated in a chromosome and is apparent as a homogenously staining region (HSR) or where it is present on double minute chromosomes (DMs). These DMs are small, acentric, paired structures that replicate autonomously. In many cases, it has been shown that these structures contain cellular proto-oncogenes.

[0004] The amplified genomic region is often tumor-specific and is correlated with a poor prognosis. For example, the MYC gene is amplified in several tumor types such as breast carcinoma, lung carcinoma and colon carcinoma. The related MYCN gene shows amplification in neuroblastoma and less frequently in retinoblastoma and small cell lung cancer (reviewed in Knuutila et al., 1998).

[0005] Double minutes are acentric and therefore they are not equally distributed between both daughter cells at, mitosis. It has been shown that DMs are lost from cells if their presence does not result in a selective advantage (Shimizu et al., 1994). Several drugs such as hydroxyurea and etoposide lead to a significant drop in the number of DMs in several human cell lines (Von Hoff et al., 1991; Von Hoff et al., 1992, Canute et al., 1996) and elimination of DMs can lead to a reversion of a malignant phenotype or to cellular differentiation of Colo320DM cells (Von Hoff et al., 1992), HL-60 cells (Shimizu et al., 1994; Eckhardt et al., 1994) and a number of neuroblastoma cell lines (Ambros et al., 1997).

[0006] Micronuclei are small, sphere-like structures, which are detected in the cytoplasm and are surrounded by a nuclear membrane. They are generated around acentric chromosomal fragments, such as DMs, when the nuclear membrane is reformed after mitosis. DMs can avoid this encapsulation by what is known as the ‘hitchhike’ mechanism (Levan and Levan, 1978; Kanda et al., 2001). Recently, a new mechanism of micronucleation has been described, involving the generation of micronuclei through budding from the main nucleus during S phase (Shimizu et al., 1998). It was also shown that the DMs are preferentially located at the periphery of the nucleus. Since the contents of the formed micronuclei consist mostly of amplified DNA, located on DMs, this is a mechanism through which the cell can remove amplified DNA fram the nucleus (Shimizu et al., 1998). The micronuclei are then removed via extrusion into the extracellular environment (Shimizu et al., 2000).

[0007] These results show that the elimination of DMs can be a new target in the development of tumor-selective chemotherapeutics. The treatment with hydroxyurea of patients with high-grade ovarian carcinomas led to a decrease in the number of DMs and to a better prognosis in several patients (Raymond et al., 2001).

[0008] Neuroblastoma is the most common extracranial solid tumor of childhood, originating from neuroectodermal cells. One of the hallmarks of neuroblastoma is the clinical and genetic heterogeneity. Brodeur et al. (1977) found that deletions of the short arm of chromosome 1 are a typical karyotypic finding in neuroblastoma cell lines and primary tumors. This observation has been extended by molecular genetic studies, which demonstrated LOH in 27% of primary tumors (Fong et al., 1989; Fong et al., 1992). The majority of 1p deletions are large, and virtually all 1p deletions encompass a common region within chromosome band 1p36 (Brodeur, 1998). The finding of 1p deletions together with the fact that introduction of chromosome 1p sequences in a neuroblastoma cell line induces differentiation and/or cell death (Bader et al., 1991), suggests that one or more tumor suppressor genes are located on the short arm of chromosome 1. Evidence for involvement of multiple tumor suppressor genes were provided by several studies. Schleiermacher et al. (1994) and Takeda et al. (1994) reported a case with interstitial deletions of the proximal part of 1p, suggesting the existence of a putative tumor suppressor gene in this proximal region. Furthermore, Caron et al. (1993) found that tumors with amplification of the MYCN gene generally had large deletions, whereas in single-copy MYCN cases small terminal deletions were also observed. The latter tumors showed preferential deletion of the maternal allele, which is suggestive for the presence of an imprinted gene. Several genes have been analyzed as candidate tumor suppressor genes, but until now no mutations have been found in the non-deleted allele of any of these candidate genes. The occurrence of tumor predisposing constitutional chromosome rearrangements may be helpful in positional cloning of tumor suppressor genes as was exemplified for retinoblastoma. In neuroblastoma, however, germline chromosomal abnormalities have been rarely described. Two neuroblastoma patients with constitutional interstitial deletions within chromosome band 1p36 have been identified (Biegel et al., 1993; White et al, 2001). In addition, our research group (Laureys et al., 1990) described a neuroblastoma patient with a constitutional t(1;17)(p36.2;q11.2) chromosomal translocation. In addition to the well-established recurrent occurrence of 1p-deletions, more recently the possible role of 17q in neuroblastoma came into focus.

[0009] Recurrent abnormalities of the long arm of chromosome 17 were already reported by Gilbert et al. (1984), but were only confirmed with the advent of molecular cytogenetic techniques which showed that 17q gain is the most frequently occurring structural rearrangement in high stage neuroblastomas (Van Roy et al., 1994; Van Roy et al., 1995; Brinkschmidt et al., 1997; Lastowska et al., 1997; Plantaz et al., 1997; Van Roy et al., 1997a; Vandesompele et al., 1998). Gain of 17q was also shown to be the most important independent prognostic marker in neuroblastoma, indicating that 17q gain itself or tightly associated accompanying genetic changes have an important impact on the biological characteristics of neuroblastoma (Bown et al., 1999). These accompanying genetic changes may well be the partial losses in the partner chromosomes, which participate in the formation of the unbalanced 17q translocations. This lead us to suggest that both copy number gain of genes on 17q and loss of putative tumor suppressor genes on the partner chromosome could be of functional significance. In this respect, the frequent involvement of 1p in unbalanced 17q translocations (Savelyeva et al., 1994; Van Roy et al., 1994) is of relevance as 1p36 is the presumed location for one or more neuroblastoma tumor suppressor genes (Versteeg et al., 1995; Schwab et al., 1996). Molecular analyses in neuroblastoma cell lines and primary tumors revealed that 1p and 17q breakpoints were scattered over a region of several megabases on both chromosomes, thus excluding the possibility of the classical mechanism of recurrent activation of the same proto-oncogene or recurrent formation of a specific oncogenic hybrid gene (Van Roy et al., 1995; Van Roy et al., 1997b; Lastowska et al., 1998). In view of these observations, the finding of a constitutional t(1;17) translocation in a neuroblastoma patient is intriguing. In order to obtain insight into the role of this translocation in the development of neuroblastoma in this unique patient, positional cloning and sequence analysis of the regions covering both breakpoints was performed. The 1p breakpoint was previously mapped to 1p36.2 within a large cluster containing multiple copies of genes including snRNA and tRNAs (van der Drift et al., 1994; Laureys et al., 1995; van der Drift et al., 1995). Notwithstanding this substantial amount of research by several research groups, and although initial efforts allowed to locate the constitutional 17q breakpoint between the NF1 gene and SCYA7 gene (Van Roy et al., 1997b), up to now, no neuroblastoma tumor suppressor gene could be isolated.

[0010] Surprisingly, we were able to demonstrate that the breakpoint of the constitutional t(1;17) translocation is situated within the transcribed sequence of a novel gene on chromosome 1. Analysis shows that this gene belongs to a highly conserved gene family, of which several members function as tumor suppressors. Even more surprisingly, these tumor suppressor genes were involved in the generation of micronuclei and the removal of amplified DNA. Gene disruption, caused by an event such as chromosomal translocation, may lead to a gene product that is less active, or not able to induce micronuclei, and therefore losing its tumor suppressor activity. It is a first aspect of the invention to provide an isolated tumor suppressor gene product, comprising SEQ ID N° 202 or a functional fragment, variant or fusion protein thereof. Preferentially, said tumor suppressor gene product is essentially consisting of SEQ ID N° 202, more preferentially said tumor suppressor gene product is consisting of SEQ ID 202. One preferred embodiment is a tumor suppressor gene product fragment comprising SEQ ID N° 2, preferably essentially consisting of SEQ ID N° 2, more preferentially preferably consisting of SEQ ID N° 2. Another preferred embodiment is tumor suppressor gene product fragment comprising SEQ ID N° 161, preferentially essentially consisting of SEQ ID N° 161, more preferentially consisting of SEQ ID N° 161. Still another preferred embodiment is a variant selected from the group of consisting of SEQ ID N° 175, 177, 181, 187, 189, 191 and 195, preferably essentially consisting of SEQ ID N° 175, 177, 181, 187, 189, 191 and 195, more preferably consisting of SEQ ID N° 175, 177, 181, 187, 189, 191 and 195. An even more preferred embodiment is a variant selected from the group of consisting of SEQ ID N° 167, 169, 171, 179, 183 and 193, preferably essentially consisting of SEQ ID N° 167, 169, 171, 179, 183 and 193, more preferably consisting of SEQ ID N° 167,169, 171, 179, 183 and 193. A most preferred embodiment is a variant selected from the group of consisting of SEQ ID N° 173, 185, 197, 198 and 200, preferably essentially consisting of SEQ ID N° 173, 185, 197, 198 and 200, more preferably consisting of SEQ ID N° 173,185, 197, 198 and 200. Still another preferred embodiment is a fusion protein of a tumor suppressor gene, consisting of SEQ ID N° 163 or SEQ ID N° 165 Preferentially, said tumor suppressor gene product is a tumor suppressor of meningioma, colorectal cancer, gastric carcinoma and/or breast cancer. Even more preferentially, said tumor suppressor is a neuroblastoma tumor suppressor.

[0011] It is another aspect of the invention to provide a nucleic acid encoding a tumor suppressor gene product or a tumor suppressor gene product fragment, variant or fusion product according to the invention. Said nucleic acid can be, amongst others, mRNA, cDNA or genomic DNA. A preferred embodiment is a nucleic acid, comprising SEQ ID N° 1, preferably essentially consisting of SEQ ID N° 1, more preferably consisting of SEQ ID N° 1. Another preferred embodiment is a nucleic acid, comprising SEQ ID N° 3, preferably essentially consisting of SEQ ID N° 3, more preferably consisting of SEQ ID N° 3. Still another preferred embodiment is a nucleic acid, comprising SEQ ID N° 4, preferably essentially consisting of SEQ ID N° 4, more preferably consisting of SEQ ID N°4. Still another preferred embodiment is a nucleic acid, comprising SEQ ID N° 201, preferably essentially consisting of SEQ ID N° 201, more preferably consisting of SEQ ID N° 201. Still another preferred embodiment is a nucleic acid, comprising SEQ ID N° 203,preferably essentially consisting of SEQ ID N° 203, more preferably consisting of SEQ ID N° 203. Still another preferred embodiment is a nucleic acid, comprising the sequence selected from a group consisting of SEQ ID N° 174, 176, 180, 186, 188, 190 and 194, preferably essentially consisting of SEQ ID N° 174, 176, 180, 186, 188, 190 and 194, more preferably consisting of SEQ ID N° 174, 176, 180, 186, 188, 190 and 194. An even more preferred embodiment is a variant selected from the group of consisting of SEQ ID N° 166, 168, 178, 182 and 192, preferably essentially consisting of SEQ ID N° 166, 168, 178, 182 and 192, more preferably consisting of SEQ ID N° 166, 168, 178, 182 and 192. A most preferred embodiment is a variant selected from the group of consisting of SEQ ID N° 172, 184, 196, and 199, preferably essentially consisting of SEQ ID N° 172, 184, 196, and 199, more preferably consisting of SEQ ID N° 172, 184, 196, and 199. Still another preferred embodiment is a nucleic acid, comprising the SEQ ID N°160, preferably essentially consisting of SEQ ID N° 160, more preferably consisting of SEQ ID N° 160. Still another preferred embodiment is a nucleic acid, consisting of SEQ ID N° 162 or SEQ ID N° 164.

[0012] Still another aspect of the invention is the use of a nucleic acid encoding a tumor suppressor gene product, or a functional fragment, variant or fusion product thereof according to the invention, or a nucleic acid with at least 60%, preferably 70%, more preferably 80%, most preferably 90% identity to said nucleic acid as measured by a BLASTN search (Altschul et al., 1997), or a functional fragment thereof in diagnosis of cancer and/or prediction of the likelihood of developing cancer. A preferred embodiment is the use of said nucleic acid, whereby said cancer is meningioma, colorectal cancer, gastric carcinoma and/or breast cancer. An even more preferred embodiment is the use of said nucleic acid, whereby said cancer is neuroblastoma.

[0013] Said diagnosis and/or prediction can be based on the detection of mutations, comprising point mutations, deletions, insertions and rearrangements, in the tumor suppressor gene or in a translocation target sequence such as the translocation target sequence on chromosome 17, and/or by measuring the transcription level of the tumor suppressor gene. This analysis can be performed by techniques such as, as a non-limiting example, DNA/DNA hybridization, DNA/RNA hybridization, fluorescent in situ hybridization (FISH) or PCR reaction, all known to the person skilled in the art.

[0014] Another aspect of the invention is the use of a nucleic acid encoding a tumor suppressor gene product or a functional fragment or variant thereof, according to the invention, or a nucleic acid with at least 60%, preferably 70%, more preferably 80%, most preferably 90% identity to said nucleic acid as measured by a BLASTN search (Altschul et al., 1997), or a functional fragment thereof in the treatment of cancer. A preferred embodiment is the use of said nucleic acid in gene therapy, to restore the defective function of the tumor suppressor gene. Vectors for gene therapy are known to the person skilled in the art, and include, but are not limited, retroviral vectors, adenovirus-associated vectors and lentiviral vectors. Suitable vector systems have been described, amongst others, in WO9822143, WO9812338 and WO9817816. A preferred embodiment is said use, whereby said cancer is meningioma, colorectal cancer, gastric carcinoma and/or breast cancer. An even more preferred embodiment is said use, whereby said cancer is neuroblastoma.

[0015] Still another aspect of the invention is the use of a tumor suppressor gene product, or a functional fragment or variant thereof, according to the invention, or a protein with at least 60% identity, preferably 70% identity, more preferably 80% identity, most preferably 90% identity to said tumor suppressor, as measured by a BLASTP or TBLASTN search (Altschul et al., 1997) for the manufacture of a medicament to treat cancer. A preferred embodiment is said use, whereby said cancer is meningioma, colorectal cancer, gastric carcinoma and/or breast cancer. An even more preferred embodiment is said use, whereby said cancer is neuroblastoma.

[0016] Still another aspect of the invention is the use of a tumor suppressor gene product, or a functional fragment or variant thereof, according to the invention, or a protein with at least 60% identity, preferably 70% identity, more preferably 80% identity, most preferably 90% identity to said tumor suppressor, as measured by a BLASTP or TBLASTN search (Altschul et al., 1997), for the generation of micronuclei and/or the removal of amplified DNA. Said generation of micronuclei may be useful in the suppression of different forms of cancer.

[0017] Still another aspect of the invention is a method to produce antibodies, using a tumor suppressor gene product or a functional fragment or variant or fusion protein thereof, according to the invention, or a protein with at least 60% identity, preferably 70% identity, more preferably 80% identity, most preferably 90% identity to said tumor suppressor, as measured by a BLASTP or TBLASTN search (Altschul et al., 1997), or using nucleic acid encoding such tumor suppressor gene product or a functional fragment or variant or fusion protein thereof, according to the invention, or a protein with at least 60% identity, preferably 70% identity, more preferably 80% identity, most preferably 90% identity to said tumor suppressor, as measured by a BLASTP or TBLASTN search (Altschul et al., 1997),. Antibodies include polyclonal, monoclonal and synthetic antibodies. Methods to produce such antibodies are known to the person skilled in the art.

[0018] A further aspect of the invention is an antibody obtainable by said method.

[0019] Still a further aspect of the invention is the use of said antibody in diagnosis of cancer and/or prediction of likelihood of developing cancer. A preferred embodiment is said use whereby said cancer is meningioma, colorectal cancer, gastric carcinoma or breast cancer. An even more preferred embodiment is said use whereby said cancer is neuroblastoma. Said antibody may be used in assays such as, but not limited to, Western blot or ELISA, known to the person skilled in the art.

[0020] Another aspect of the invention is use of a tumor suppressor gene product, or a functional fragment, variant or fusion product thereof, according to the invention, or a protein with at least 60% identity, preferably 70% identity, more preferably 80% identity, most preferably 90% identity to said tumor suppressor, as measured by a BLASTP or TBLASTN search (Altschul et al., 1997), for the isolation of an interacting compound. Several methods have been described to detect protein—compound interactions and to select the interacting compound. These methods include, but are not limited to, phage display, yeast two-hybrid assay, coimmunoprecipitation, DNase protection assay, electrophoretic mobility shift assay, or mass spectrometric analyses, all known to the person skilled in the art, fluorescence resonance energy transfer (FRET, WO9918124) and bioluminescence resonance energy transfer (BRET, WO9966324).

Definitions

[0021] A functional fragment of a tumor suppressor gene product, means any proteineous molecule that retains its tumor suppression activity, and preferably its micronuclei inducing activity and/or the activity to remove amplified DNA.

[0022] A variant of a tumor suppressor gene product according to the invention is a gene product with at least 60% identity, preferably 70% identity, more preferably 80% identity, most preferably 90% identity to said tumor suppressor gene product, as measured by a BLASTP or TBLASTN search (Altschul et al., 1997), and retaining its tumor suppression activity, and preferably its micronuclei inducing activity and/or the activity to remove amplified DNA.

[0023] An isolated nucleic acid encoding a tumor suppressor gene product means that said nucleic acid comprises partly or totally the coding sequence of said tumor suppressor gene. The definition covers, but is not limited to genomic DNA and messenger RNA. It does however not implicate that said genomic DNA is transcribed and translated into said tumor gene product.

[0024] A functional fragment of a nucleic acid for use in diagnosis of and/or prediction of the likelihood of means any fragment that can be used as specific probe in hybridization or as primer in PCR reactions.

[0025] A functional fragment of a nucleic acid for use in the treatment of cancer means any fragment that can be transcribed and/or translated into a functional tumor suppressor, which preferably retains its micronuclei inducing activity and or the activity to remove amplified DNA.

[0026] A functional fragment of a tumor suppressor gene product for the manufacture of a medicament to treat cancer is any fragment of said tumor suppressor gene product that retains its tumor suppression function and preferably its micronuclei inducing activity and or the activity to remove amplified DNA

[0027] A functional fragment of a tumor suppressor gene product in the production of antibodies is an immunogenic fragment that comprises at least one epitope and can be used for the production of antibodies against said tumor suppressor gene product.

[0028] A functional fragment of a tumor suppressor gene product in the isolation of an interacting compound is any fragment that can be used in an interaction screening assay, such as, but not limited to, a yeast two-hybrid assay, a phage display assay, coimmunoprecipitation, a DNase protection assay, an electrophoretic mobility shift assay, or mass spectrometric analyses.

[0029] The terms protein and polypeptide as used in this appliction are interchangeable. Polypeptide refers to a polymer of amino acids and does not refer to a specific length of the molecule. This term also includes post-translational modifications of the polypeptide, such as glycosylation, phosphorylation and acetylation

[0030] Compound as used here means any chemical or biological compound, including simple or complex organic or inorganic molecules, peptides, peptido-mimetics, proteins, antibodies, carbohydrates, nucleic acids or derivatives thereof.

[0031] Interacting compound with a protein means any compound that can bind, covalently or not, with said protein in a specific way.

BRIEF DESCRIPTION OF THE FIGURES

[0032]FIG. 1

[0033] Physical map of PAC/BAC contig covering the constitutional 17q11.2 breakpoint based on fibre FISH, FIGE and content mapping of STS and EST clones. The orientation of the map is centromere to telomere, left to right. Markers on the top row are cDNA/EST clones, polymorphic markers and STSs. Known genes are indicated by arrowheads. Partially sequenced BACs (with GenBank accession numbers) are indicated by dashed lines. Three breakpoint overlapping cosmid clones are shown, as indicated by ICRF numbers. The shaded bars indicate the approximate location of the 17q breakpoint and the distal breakpoints of NF1 deletion patients UWA 155-1 and UWA 106-3 (for details on the latter two patients, see Dorschner et al., 2000).

[0034]FIG. 2

[0035] Southern blot analysis of the t(1;17) translocation breakpoint by use of probe #6 (Table 4). Genomic DNAs extracted from a normal human placenta (normal) and from the Chinese hamster ovary cell line a3 served as controls in comparison to genomic DNAs from somatic cell hybrids 32-7A and 32-2F53VIII. Following exhaustive digestion with the restriction enzymes indicated on top, DNA fragments were subjected to Southern blot analysis. Probe #6 was prepared by PCR on the basis of the breakpoint-overlapping cosmid contig sequence (as described in Material and methods to the examples). The bands corresponding to the normal, non-rearranged DNA are indicated by arrows, whereas the rearranged bands are indicated by arrowheads. Approximate sizes are indicated in bp.

[0036]FIG. 3

[0037] Schematic representation of the normal and derivative chromosomal breakpoint region in the 32-2F53VIII somatic cell line hybrid. The location of the t(1;17) translocation breakpoint is indicated in each panel by a vertical double-pointed arrow. Restriction enzyme sites indicated are BamHI (B), PvuII (P), DraI (D), StuI (S) and EcoRV (E).

[0038] A. Schematic overview of the fragment of normal human chromosome 17 encompassing the chromosomal t(1;17) breakpoint. The horizontal bar represents the sequence (51,050 bp; GenBank Acc. No. AF148647) of a cosmid contig spanning the breakpoint in cell line 32-2F53VIII. The physical ends of the insert of cosmid ICRFc105F1060D1 were determined as indicated. An upward arrow shows the location of the SP6 end sequence of clone 841C13. Nine repeat-free probes (black boxes) were selected for use in the identification of the breakpoint by Southern hybridizations.

[0039] B. Schematic overview of a fragment of normal human chromosome 17. The breakpoint (Brkpt) in the chromosome-17 derivative of 32-2F53VIII cells was mapped to a 1,539-bp PvuII fragment. The GenomeWalker PCR products extending from primer. GSP1 to either StuI, PvuII or DraI sites each comprise the location of the t(1;17) breakpoint as evidenced by a comparison with the scheme depicted in (C).

[0040] C. Schematic overview of a fragment of derivative chromosome 17, corresponding to the fragment of normal chromosome 17 depicted in (B). Cloned and sequenced GenomeWalker PCR products spanning the t(1;17) breakpoint are as indicated. The sequence of the (GSP-1—EcoRV) fragment is shown in FIG. 5.

[0041]FIG. 4

[0042] Cloning of the t(1;17) breakpoint of chromosome der17 by GenomeWalker PCR. Genomic DNA from the 32-2F53VIII cell line was digested as described in the text and summarized in FIG. 3. GenomeWalker PCR was then performed using the following primer pairs (PR): either GSP1+AP1 (four lanes at the left), or GSP1′ plus AP1 (four lanes at the right). Restriction enzymes (RE) used are indicated on top: DraI (D), EcoRV (E), PvuII (P), and StuI (S). M, Lambda BstEII molecular weight marker. Bands were stained by ethidium bromide. The bands corresponding to normal chromosome 17 are indicated by *, whereas the bands rearranged by the t(1;17) translocation are indicated by arrowheads. The latter were cloned and sequenced (FIG. 5). Fragment sizes (FS) are indicated at the bottom in bp.

[0043]FIG. 5

[0044] Genomic DNA sequence (3,743 bp; GenBank Acc. No. AF379607) of the der17 chromosome overlapping the t(1;17)(p36.2;q11.2-q12.1) translocation breakpoint. Chromosome-17 specific sequences (602 bp) flanking the breakpoint are underlined. A spacer region of 7 bp (bold and underlined capitals) is of unknown origin. The remaining sequence of 3,134 bp represents chromosome-1 specific sequences flanking the breakpoint. Three exons, two internal ones (designated x and y) and one 3′ terminal (designated z), were predicted in the latter sequence. They are indicated by capitals; the predicted ORF is given in bold single-letter codes under the DNA sequence; the flanking splice donor and acceptor sites are underlined; a stop codon (indicated by *) in the 3′ terminal exon z is in bold and underlined.

[0045]FIG. 6

[0046] Sequence of a cDNA fragment (528 nucleotides) with corresponding amino acid sequence (175 amino acid residues), predicted to be encoded by the chromosome-1 specific genomic DNA sequence, flanking the t(1;17)(p36.2;q11.2-q12.1) translocation breakpoint in the der17 chromosome (depicted in FIG. 5). A stop codon (indicated by *) is in bold and underlined.

[0047]FIG. 7

[0048] Schematic overview of selected human cDNA (EST) sequences highly homologous or identical to exons x to z (exons 11.1, 12.5 and 14.12), flanking the t(1;17)(p36.2;q11.2-q12.1) translocation breakpoint and depicted on top as Breakpoint der17. Sequences are identified by their respective cDNA code, as summarized in Tables 5 and 6. EST cDNA sequences as deposited in GenBank were confirmed, improved and often extended on the appropriate cDNA clones. The predicted protein fragments, encoded by separate exons, were aligned as shown in FIGS. 9 to 15. Asterisks refer to sequences corresponding to incomplete exons. Thin lines correspond either to sequences predicted to be intronic, or to sequences corresponding to the 3′UTR (size given in nucleotides). If the 3′UTR is thought to be complete, it is followed by AAAA. Dotted lines represent unfinished sequences. Sizes of separate exon-encoded domains are indicated in amino acid residues (aa). Some sequence abnormalities (frameshift, internal deletion) are as indicated.

[0049]FIG. 8

[0050] Schematic overview of selected human cDNA sequences highly homologous or identical to either exons A and B (exons 6.12 and 7.1) or exons x to z (exons 11.1, 12.5 and 14.12). These exons are flanking the t(1;17)(p36.2;q11.2-q12.1) translocation breakpoints of chromosomes der1 and der17 as depicted at the bottom. Sequences are identified by their respective GenBank Acc. No, as summarized in Table 5. The predicted protein fragments were aligned as shown in FIGS. 9 to 15. Sizes of separate exon-encoded domains are indicated in amino acid residues (aa). The double broken lines in the centre of the AB033071 molecule point at a single-nucleotide frameshift and an apparent deletion as compared to the other molecules depicted. Asterisks refer to sequences corresponding to incomplete exons. Thin lines in the scheme of cDNA clone AI050141 correspond to sequences predicted to be intronic. The unlabeled black box (60 aa) in the scheme of cDNA clone AL136890 is of unknown origin.

[0051] FIGS. 9 to 15

[0052] Alignments of protein fragments predicted to be encoded by exons identified in genomic and cDNA clones and belonging to a novel gene family, comprising exons exons A, B and x to z, flanking the t(1;17)(p36.2;q11.2-q12.1) translocation breakpoints in chromosomes der1 or der17. The source of these sequences is summarized in Table 5 and partly depicted in FIGS. 7, 8, 21, 22-25, 28 and 37. On top of each sequence alignment is a corresponding phylogenetic tree (scales indicate % of non-similarity).

[0053]FIG. 9 represents exons of type 0, probably comprising highly conserved 5′UTR sequences, and exons of type 1, encoding both putative amino-terminal and internal domains (NBG proteins are probably starting with the highly conserved sequence MWSAGP . . . ).

[0054]FIG. 10 represents exons of types 2 and 3.

[0055]FIG. 11 represents exons of types 4, 5 and 6. Exon 6.12 corresponds to exon A.

[0056]FIG. 12 represents exons of types 7, 8 and 9. Exon 7.1 corresponds to exon B.

[0057]FIG. 13 represents exons of type 10 and 11. Exon 11.1 corresponds to exon x.

[0058]FIG. 14 represents exons of type 12 and 13. Exon 12.5 corresponds to exon y.

[0059]FIG. 15 represents exons of type 14, encoding carboxy-terminal protein domains. Exon 14.12 corresponds to exon z.

[0060]FIG. 16

[0061] Southern blot analysis of the t(1;17) translocation breakpoint by use of probe #9 (Table 4). Genomic DNAs extracted from a normal human placenta (normal) and from the Chinese hamster ovary cell line a3 served as controls in comparison to genomic DNAs from somatic cell hybrids 32-2F53VIII and 32-7A. Following exhaustive digestion with the restriction enzymes indicated on top, DNA fragments were subjected to Southern blot analysis. Probe #9 was prepared by PCR on the basis of the breakpoint-overlapping cosmid contig sequence (as described in Material and methods to the examples). Rearranged bands in the 32-7A genomic DNA are indicated by arrows. Size markers (DNA molecular weight marker 11, Roche) are indicated in bp.

[0062]FIG. 17

[0063] Schematic representation of the normal and derivative chromosomal breakpoint region in the 32-7A somatic cell line hybrid. The location of the t(1;17) translocation breakpoint is indicated in each panel by a vertical double-pointed arrow. Restriction enzyme sites indicated are BamHI (B), PvuII (P), DraI (D), SspI (S) and EcoRV (E).

[0064] A. Schematic overview of the fragment of normal human chromosome 17 encompassing the chromosomal t(1;17) breakpoint. The horizontal bar represents the sequence (51,050 bp; GenBank Acc. No. AF148647) of a cosmid contig spanning the breakpoint in cell line 32-7A. The physical ends of the insert of cosmid ICRFc105F1060D1 were determined as indicated. An upward arrow shows the location of the SP6 end sequence of clone 841C13. Nine repeat-free probes (black boxes) were selected for use in the identification of the breakpoint by Southern hybridizations.

[0065] B. Schematic overview of a fragment of normal human chromosome 17. The GenomeWalker PCR products extending from primer GSP1″ to a DraI site, or extending from primer GSP2 to PvuII or SspI sites each comprise the location of the t(1;17) breakpoint as evidenced by a comparison with the scheme depicted in (C).

[0066] C. Schematic overview of a fragment of derivative chromosome 1, corresponding to the fragment of normal chromosome 17 depicted in (B). Cloned and sequenced GenomeWalker PCR products spanning the t(1;17) breakpoint are as indicated. The sequence of the (GSP1″—PvuII) fragment is shown in FIG. 19.

[0067]FIG. 18

[0068] Cloning of the t(1;17) breakpoint of chromosome der1 by GenomeWalker PCR. Genomic DNA from the 32-7A cell line was digested as described in the text and summarized in FIG. 17 and GenomeWalker PCR was performed using the following primer pairs (PR): either GSP1″+AP1 (five lanes at the left), or GSP2 plus AP2 (five lanes at the right). Restriction enzymes (RE) used are indicated on top: DraI (D), EcoRV (E), PvuII (P), ScaI (Sc) or SspI (S). M, Lambda BstEII molecular weight marker. Bands were stained by ethidium bromide. The bands corresponding to normal chromosome 17 are indicated by *, whereas the bands rearranged by the t(1;17) translocation are indicated by arrowheads. The latter were cloned and sequenced (FIG. 19). Fragment sizes (FS) are indicated at the bottom in bp. Aspec, aspecifically amplified bands.

[0069]FIG. 19

[0070] Genomic DNA sequence (4,512 bp; GenBank Acc. No. AF379606) of the der1 chromosome overlapping the t(1;17)(p36.2;q11.2-q12.1) translocation breakpoint. The sequence of the first 3,845 bp represents chromosome-1 specific sequences flanking the breakpoint. This is followed by a spacer region of 4 bp (bold and underlined capitals AAAG), which is of unknown origin. The remaining underlined sequence of 663 bp represents chromosome-17 specific sequences flanking the breakpoint. Two exons (designated A and B) were predicted in the chromosome-1 sequence. They are indicated by capitals; the predicted ORF is given in bold single-letter codes under the DNA sequence; the flanking splice donor and acceptor sites are underlined.

[0071]FIG. 20

[0072] Sequence of a cDNA fragment (258 nucleotides) with corresponding amino acid sequence (86 amino acid residues), predicted to be encoded by the chromosome-1 specific genomic DNA sequence, flanking the t(1;17)(p36.2;q1.2-q12.1) translocation breakpoint in the der1 chromosome (depicted in FIG. 19).

[0073]FIG. 21

[0074] Schematic overview of selected human cDNA (EST) sequences highly homologous or identical to exons A and B (exons 6.12 and 7.1), flanking the t(1;17)(p36.2;q11.2-q12.1) translocation breakpoint and depicted on top as Breakpoint der17. Sequences are identified by their respective cDNA code, as summarized in Tables 5 and 6. EST cDNA sequences as deposited in GenBank were confirmed, improved and often extended on the appropriate cDNA clones. The predicted protein fragments, encoded by separate exons, were aligned as shown in FIGS. 9 to 14. Asterisks refer to sequences corresponding to incomplete exons. Thin lines correspond to sequences predicted to be intronic. Sizes of separate exon-encoded domains are indicated in amino acid residues (aa). Some sequence abnormalities (frameshifts) are as indicated. The sequence of cDNA clone AE02 is homologous with the 5′-end of cDNA clone AG09. When domains of type 1 are preceded by one of type 0, they are predicted to contain the start codon.

[0075]FIG. 22

[0076] Schematic overview of selected human cDNA (EST) sequences highly homologous or identical to exons x and y (exons 11.1 and 12.5), flanking the t(1;17)(p36.2;q11.2-q12.1) translocation breakpoint and depicted on top as Breakpoint der17. Sequences are identified by their respective cDNA code, as summarized in Tables 5 and 6. EST cDNA sequences as deposited in GenBank were confirmed, improved and often extended on the appropriate cDNA clones. The predicted protein fragments, encoded by separate exons, were aligned as shown in FIGS. 13 and 14. Asterisks refer to sequences corresponding to incomplete exons. Thin lines correspond to sequences predicted to be intronic. Sizes of separate exon-encoded domains are indicated in amino acid residues (aa).

[0077]FIG. 23

[0078] Schematic overview of selected human genomic sequences highly homologous or identical to either exons A and B (exons 6.12 and 7.1) or exons x to z (exons 11.1, 12.5 and 14.12). These exons are flanking the t(1;17)(p36.2;q11.2-q12.1) translocation breakpoints of chromosomes der1 and der17 as depicted at the top. Sequences are identified by their respective GenBank Acc. No, as summarized in Table 5. The predicted protein fragments were aligned as shown in FIGS. 9 to 15. Sizes of separate exon-encoded domains are indicated in amino acid residues (aa). The double-pointed horizontal arrows below the AL354666 and AL356581 molecules point at separate contigs of these unfinished genomic sequences (contigs are identified by #number). The exon types 4.1 and 5.1 between brackets were only detected in previous releases of sequence AL354666, but removed in release 5.

[0079]FIG. 24

[0080] Schematic overview of the neuroblastoma breakpoint gene (NBG) gene structure at the t(1;17)(p36.2;q11.2-q12.1) translocation breakpoint. Idiograms of normal chromosome 1, normal chromosome 17 (shaded), and derivative chromosomes der1 and der17 are shown. The structure of the chromosome-1 NBG gene, interrupted by the translocation, is predicted on the basis of sequences of cDNA clone DKFZp434G2022 (clone AB25; FIG. 7) and sequences from unfinished genomic clones RP11-284017 (GenBank Acc. No. AL355800) and RP11-4513 (GenBank Acc. No. AC015618). Only exon sequences are represented (typing according to Table 5 and FIGS. 9-15; sizes in aa, amino acid residues). Thin lines correspond to the 3′UTR sequence. Arrows denote the direction of transcription. Upon chromosomal translocation, a chromosome-1 region of about 20 kbp appears to be deleted (indicated by Del). After translocation, the gene on the der1 chromosome is expressed as chimeric transcripts (FIGS. 25-27) as splicing occurs from exon 7.1 to chromosome-17 derived sequences X (as indicated in this figure) or Y (see also FIG. 25). Similar chimeric transcripts for the der17 chromosome are not yet identified.

[0081]FIG. 25

[0082] Chimeric NBG-related transcripts. The chimera #1 and #2 transcripts were isolated by 3′-RACE on RNA from somatic cell hybrid 32-7A, containing the der1 chromosome (see FIGS. 26 and 27 for the sequences of the 3′-RACE clones). Sequences X and Y are derived from chromosome 17. In addition, two tumor-derived cDNA clones contain NBG-related sequences fused to gene sequences from chromosome 1, as documented in the text.

[0083]FIG. 26

[0084] Sequence of a chimeric cDNA fragment with corresponding amino acid sequence (GenBank Acc. No. AF420438), cloned by 3′-RACE on RNA from somatic cell hybrid 32-7A (see chimera #1 in FIG. 25). The sequence starts with gene-specific primer GSP2 located in NBG exon 6. Nucleotides from chromosome 1 (part of exon 6 plus exon 7.1) are put in capitals, and the encoded amino acid residues in bold capitals; nucleotides from chromosome 17 are put in lowercase and the encoded amino acid residues (ORF X) in underlined bold italics capitals. Asteriks, stop codon followed by 3′UTR and poly-A stretch.

[0085]FIG. 27

[0086] Sequence of a chimeric cDNA fragment with corresponding amino acid sequence, (GenBank Acc. No. AF420439) cloned by 3′-RACE on RNA from somatic cell hybrid 32-7A (see chimera #2 in FIG. 25). The sequence starts with gene-specific primer GSP2 located in NBG exon 6. Nucleotides from chromosome 1 (part of exon 6 plus exon 7.1) are put in capitals, and the encoded amino acid residues in bold capitals; nucleotides from chromosome 17 are put in lowercase and the encoded amino acid residues (ORF Y) in underlined bold italics capitals. Asteriks, stop codon followed by 3′UTR and poly-A stretch.

[0087]FIG. 28

[0088] Overview of cloned NBG-related 5′-RACE products. RNAs from four different cell lines were used as template, as indicated. Nested primers of these reactions were specific for type-11 exons but may anneal also to part of the type-10 exons. The predicted protein fragments, encoded by separate exons, were aligned as shown in FIGS. 13 and 14. Asterisks refer to sequences corresponding to incomplete exons. Thin lines correspond to sequences predicted to be intronic. Sizes of separate exon-encoded domains are indicated in amino acid residues (aa). Double pointed arrows indicate the insert sizes of the fully overlapping shorter cDNA clones indicated.

[0089]FIG. 29

[0090] Northern blot analysis of NBG-related transcripts in human tumor-derived cell lines as indicated, in somatic cell hybrid 32-7A and in mouse cell lines NMe and Neuro2A. Sequential hybridization was done with a 5′ NBG probe followed by a 3′ NBG probe (see Materials and methods to the examples). Loading of the mRNAs was estimated by hybridization with a mouse GAPDH probe. The graph shows the normalized relative amounts of the different bands (7.2 kb+5.9 kb, 4.1 kb, 0.5 kb) as quantitated by phosphor imaging. The 5′ probe (5′) allowed more efficient detection as compared to the 3′ probe (3′). SH-SY5Y cells expressed the highest levels for all NBG transcripts, except for the 0.5 kb species that was expressed mainly by HCT8/R1 cells.

[0091]FIG. 30

[0092] Flowchart of the construction of plasmid pBlue-KIAA-AB25, comprising a full-length NBG cDNA. cDNA/protein fragments, corresponding to separate exons, are labeled according to Table 5 and FIGS. 9-15.

[0093]FIG. 31

[0094] MCF7/AZ cells were transfected with different NBG constructs as indicated. Left panels show either the Myc-tag revealed by anti-Myc antibody (panels A and K) or fluorescence of the GFP-tag (panels C, E, G and I ). Right panels show DNA staining by DAPI. Cells were transfected with a construct encoding a Myc-tagged aminoterminal fragment (A, B), a construct encoding a GFP-tagged aminoterminal fragment (C, D), a construct encoding a GFP-tagged carboxyterminal fragment (E-H), a GFP-tagged full-length construct (I, J), and a Myc-tagged full-length construct (K, L). Arrows point at micronuclei, which are particularly obvious in cells transfected with the full-length constructs (I and K).

[0095]FIG. 32

[0096] MCF7/AZ cells were transfected with different NBG constructs as indicated. pCS2+MT-KIAA-AB25, a construct encoding a Myc-tagged full-length NBG protein, was used for cells in panels A-F. Cells were simultaneously stained with an anti-Myc antibody (A), a concanavalin-A conjugate to stain the endoplasmic reticulum (B), and with the DNA stain DAPI (C). This shows that the overexpressed protein is not localized in the endoplasmic reticulum. The arrows points at a micronucleus. Transfected cells were also simultaneously stained with the polyclonal NBG-specific antibody #31226 (D), with a mouse anti-lamin B antibody (E) and with DAPI (F). The 2 micronuclei in this cell (arrows) are clearly stained by the anti-lamin antibody and by DAPI, demonstrating that these structures are indeed micronuclei. Cells were also transfected with either the empty vector pEGFP-N3 (G, H) or the empty vector pEF6/Myc-His-A. GFP fluorescence is shown (G), staining with anti-Myc antibody (I) or DAPI staining (H, J).

[0097]FIG. 33

[0098] HCT8/E8 cells were transfected with constructs encoding a Myc-tagged full-length NBG protein (A, B), a GFP-tagged aminoterminal fragment (C, D), a GFP-tagged carboxyterminal fragment (E, F), or with the empty vector pEGFP (G, H). Several micronuclei are visible in the cytoplasm as indicated by arrows. GFP fluorescence is shown (C, E, G), staining with anti-Myc antibody (A) or DAPI staining (B, D, F, H).

[0099]FIG. 34

[0100] HEK293T cells were transfected with constructs encoding a Myc-tagged full-length NBG protein (A, B) or a GFP-tagged aminoterminal fragment (C, D). Micronuclei in the cytoplasm are indicated by arrows.

[0101] Colo320DM cells were transfected with a construct encoding a Myc-tagged full-length NBG protein (E, F), with the empty control vector (G, H), with a construct encoding a GFP-tagged aminoterminal fragment (I, J), or with a construct encoding a GFP-tagged carboxyterminal fragment (K, L). The cell transfected with the full-length construct shows two micronuclei (arrows), the first one in the cytoplasm and the second still attached to the main nucleus.

[0102] GFP fluorescence is shown (C, I, K), staining with anti-Myc antibody (A, E, G) or DAPI staining (B, D, F, H, J, L).

[0103]FIG. 35

[0104] Mouse NMe cells were transfected with several constructs as indicated. The latter encode a GFP-tagged full-length NBG protein (A, B), a GFP-tagged aminoterminal fragment (C, D), a Myc-tagged full-length NBG protein (E, F). In addition, empty vector pEGFP (G, H) or empty vector pCS2+MT (I, J) were used. When the full-length protein was overexpressed, many micronucleus-like structures became visible (arrows in A and E), which stain negative for DAPI. Upon expression of the aminoterminal fragment, perinuclear fluorescence was apparent, but much less micronucleus-like cytoplasmic structures (C).

[0105] GFP fluorescence is shown (A, C, G), staining with anti-Myc antibody (E, I) or DAPI staining (B, D, F, H, J).

[0106]FIG. 36

[0107] MCF7/AZ cells were transfected with two constructs expressing NBG-related chimeric transcripts as indicated. Chimeric cDNA fragments were cloned by 3′-RACE on mRNA of the 32-7A somatic cell hybrid, followed by ligation to a suitable fragment of plasmid pCS2+MT-KIAA-AB25. The transcripts encode an aminoterminal NBG fragment elongated by chromosome-17 sequences (see FIG. 25). Use of these constructs was featured by the generation of multiple vesicle-like structures in the cytoplasm (A, C). In addition, these cells contain some micronuclei as demonstrated by an arrow in (A). Staining was with anti-Myc antibody (A, C) or with DAPI staining (B, D).

[0108]FIG. 37

[0109] RT-PCR was performed on RNA from either human fetal brain (HFB) or the somatic cell hybrid 32-2FVIII. Primers used in these experiments are denoted by FVR numbers under typical NBG exonic sequences. Sequences of cloned products are as depicted (see also Table 5 and FIGS. 11-15 for the protein fragments, predicted to be encoded by separate exons). Several new exon subtypes were identified, including novel splice variants each time involving exon 8. Clone names with an asterisk contain a frameshift immediately before exon 9, as they either lack the complete exon 8 or parts of it (deletions indicated by dashed lines). In clones 27 and 28, domain 8 consists of the first 5 amino acid residues and the last 28 amino acid residues of a full-length exon-8 sequence (see also FIG. 12).

[0110]FIG. 38

[0111] MCF7/AZ cells were transfected with a construct encoding a Myc-tagged full-length NBG protein followed by simultaneous staining with an anti-Myc antibody (A), polyclonal NBG-specific antibody #31226 (B) and DAPI (C). A transfected cell (centre) is stained by both the anti-Myc antibody and the polyclonal antibody, whereas nontransfected cells are not stained by anti-Myc antibody and only very lightly by the polyclonal antibody.

EXAMPLES Material and Methods to the Examples

[0112] Library Screening and DNA Isolation

[0113] YAC- and PAC-end clones and selected STSs were used to screen for additional PAC clones. These clones were isolated by screening of a gridded RCPI-1 PAC library (loannou et al., 1994). Subsequently, breakpoint-overlapping PAC clones were used to screen a chromosome-17 specific cosmid library. The PAC and cosmid filters and clones were distributed by the Ressourcenzentrum Primärdatenbank in the Max Planck-Institut für Molekulare Genetik in Germany (RZPD) (Zehetner and Lehrach, 1994). In brief, 30 ng probe DNA (YAC- or PAC-end clone, STS) was randomly labeled using the Megaprime DNA labeling kit (AP Biotech) according to the supplier's protocol. Prehybridisation of filters, hybridization and washing steps were done according to standard procedures. BACs were obtained from the Children's Hospital Oakland Research Institute (C.H.O.R.I.) in Oakland, Calif., USA (http://www.chori.org/bacpac).

[0114] PACs, BACs and cosmids were cultured in LB-broth medium containing the appropriate antibiotics. DNA was isolated using a rapid alkaline lysis miniprep method (C.H.O.R.I.).

[0115] The following databases were consulted for identification of publicly available genetic markers and clones: Whitehead Institute for Biomedical Research (http://www-genome.wi.mit.edu/), Marshfield Medical Research Foundation Center for Medical Genetics (http://www.marshmed.org/genetics), CEPH-Généthon (http://www.cephb.fr/ceph-genethon-map.html), National Center for Biotechnology Information (NCBI, http://www.ncbi.nlm.nih.gov/) and the Human Genome Project Working Draft at UCSC (http://genome.ucsc.edu/).

[0116] YAC and PAC End Isolation and Generation of Sequence-tagged Sites

[0117] YAC end clones were isolated using an Alu-vector based method (Nelson et al., 1989). PAC end clones were obtained by vectorette PCR (Riley et al., 1990), or were obtained by direct sequencing and subsequent PCR amplification. For direct sequencing, PAC DNA was subjected to cycle sequencing using BigDye chemistry on an ABI377 automatic sequencer (Applied Biosystems) with the following vector based primers: T7 (5′-TAATACGACTCACTATAGGG-3′) and SP6 (5′-CAAGCT ATTTAGGTGACACTATAGA-3′). Screening for repetitive sequences was done using the program ‘Repeat Masker’

[0118] (http://ftp.genome.washington.edu/RM/RepeatMasker.html). In total, 17 end sequences were generated of which 9 were submitted as GGS to Genbank [SP6 RPCI-1 105C17 (acc. n° BH021100); SP6 RPCI-1 605A3 (acc. n° BH021101); T7 RPCI-1 1167N14 (acc. n° BH021102); SP6 RPCI-1 835C10 (acc. n° BH021103); T7 RPCI-1 835C10 (acc. n° BH021104); SP6 RPCI-1 55N16 (acc. n° BH021105); SP6 RPCI-1 266J21 (acc. n° BH021106); T7 RPCI-1 118B4 (acc. n° BH021107); T7 RPCI-1 266J21 (acc. n° BH021108)] and 8 were used to develop end STSs. Primers were designed using the PrimerExpress software (Applied Biosystems). The novel STSs and primer sequences have also been submitted to GenBank (see Table 1).

[0119] Fluorescence in situ Hybridization (FISH)

[0120] PACs, BACs and cosmids were biotinylated (biotin-16-dUTP, Roche) or digoxigenated (digoxigenin-11-dUTP, Roche) by standard nick translation. FISH was performed according to Van Roy et al. (1994). Slides were mounted in Vectashield (Vector laboratories) plus DAPI (4′,6-diamidino-2′-phenylindole dihydrochloride, Roche) for counterstaining and observed under a standard ZEISS epifluorescence microscope equipped with a 100 W Hg lamp. FISH images were recorded using the ISIS digital imaging system (MetaSystems). Verification of the chromosomal localization of the isolated clones was done by hybridization to normal metaphase chromosomes. Subsequently, the position of the probes with respect to the constitutional 17q breakpoint was determined by FISH on hybrid cell lines containing either derivative chromosome 1 or derivative chromosome 17 (Laureys et al., 1995). To facilitate the detection of the respective derivative chromosomes, dual color hybridization was performed with a chromosome-17.specific library pBS-17 (Collins et al., 1991) and a chromosome- 1p36 specific probe p1-79 (D1Z2) (Buroker et al., 1987).

[0121] Fiber FISH

[0122] Fiber FISH slides were prepared according to Speleman et al. (1997). Prior to hybridization, fiber FISH slides were counterstained with DAPI and evaluated by fluorescence microscopy. Probe order, degree of overlap and estimation of size of gaps between probes was determined by dual color FISH experiments. Hybridization on fiber FISH slides was performed according to Van Roy et al. (1994) with minor modifications. Fiber slides were only pretreated with RNase A. Pepsin treatment and postfixation were omitted. Antibody concentration for the immunohistochemical detection of biotin and digoxigenin labeled probes was doubled in comparison with the standard FISH procedure and incubation of antibodies was performed at 37° C. for 30 min instead of 20 min at room temperature.

[0123] The lengths of probe signals, overlaps and gaps were measured from digitized images with the ISIS software program (MetaSystems, Atlussheim, Germany). The gap measurements were normalized based on the signal lengths of probes on both sides of the gap to compensate for the variation in the level of DNA stretching. For the purpose of probe ordering and length measurements, at least ten images were analyzed.

[0124] Estimation of Clone Insert Sizes by Field Inversion Gel Electrophoresis (FIGE)

[0125] PAC DNA (1 μg) was digested with restriction enzyme NotI according to the suppliers protocol (Gibco BRL). An agarose gel (1%) was run for 16 h, at 180 V forward and at 120 V reverse, at 20° C. in 0.5×TBE buffer on a Biorad FIGE Mapper™. Insert fragment sizes were determined by comparison with size standards (Lambda DNA-PFGE marker; Pharmacia Biotech)(Table 3).

[0126] Mapping of STSs and ESTs

[0127] Mapping of STSs and ESTs was done by hybridization of PCR products on PAC dot blots. PCR products were purified using a QIAquick PCR purification column (Qiagen). Purified PCR products were labeled using the Megaprime kit. Hybridization was performed according to standard procedures. Furthermore, STSs and ESTs were mapped by PCR on PAC and BAC clones or positions were inferred by BLAST query of the nr and htgs NCBI databases (http://www.ncbi.nlm.nih.gov).

[0128] Shotgun DNA Sequencing

[0129] Three overlapping cosmids (ICRFc105F1060D1, ICRFc105F1065D1, ICRFc105G3072D1), presumed to span the t(1;17) breakpoint on chromosome 17, were chosen for shotgun DNA sequencing. Cosmids were grown in LB with 25 μg/ml kanamycin to late log phase. Cosmid DNA was isolated using columns (Qiagen) and sheared on ice using an ultrasound sonicator. Treated DNA was analyzed in an agarose gel. Fragments of 0.8-1.0 kbp were cut from the gel, extracted and the ends were polished using T4 DNA polymerase and Klenow polymerase. Fragments were ligated into the pUC18Srf plasmid. A shotgun-sequencing library was generated using DH5α competent cells and checked for insert size by digestion with EcoRI and HindIII enzymes. More than 313 shotgun clones were selected from the three different cosmid fragment libraries and plasmid DNA was prepared using a BioRobot 9600 (Qiagen, Valencia, Calif., USA) and Qiagen Turbo kits. Clones were sequenced using universal M13 primers. In addition, specific walking primers were selected to fill the remaining gaps according to standard procedures.

[0130] DNA Sequence Analysis

[0131] Dye terminator sequencing (Sanger, 1981) was carried out by use of Big Dye chemistry (Perkin Elmer, Foster City, Calif.). The gels were run on a ABI Prism 377 DNA sequencer (Perkin Elmer, Foster City, Calif.). Nucleotide sequences were edited and assembled using GAP4 of the Staden software package (Bonfield et al., 1995)(URL http://www.mrc-lmb.cam.uk/pubseq/). RepeatMasker programs were used to screen DNA sequences for interspersed repeats known to exist in mammalian genomes (URL http://ftp.genome.washington.edu/RM/RepeatMasker.html).

[0132] All DNA sequences were analyzed using BLAST programs (Altschul et al., 1997)(URL http://www.blast.genome.ad.jp) to determine similarities or identities to known genes or EST sequences using non-redundant and EST compilation databases from Genbank and EMBL-EBI. Searches for amino-acid homologies were carried out using non-redundant Swiss-Prot and PIR databases with the BLASTP and FASTA programs. Exons were predicted by use of GENSCAN (URL http://CCR-081.mit.edu/GENSCAN.html) and GeneMark software (URL http://opal.biology.gatech.edu/GeneMark). Alignment of cDNA sequences to the genomic data (DNAstar software, Madison, Wis.) revealed exon-intron boundaries.

[0133] Southern Blotting

[0134] Genomic DNA from normal human placenta, from the Chinese hamster ovary cell line a3, and from somatic cell hybrids 32-7A and 32-2F53VIII were restricted with BglII, HindIII, SacI, XhoI, XbaI, McoI, PvuII, KpnI or HincII restriction enzyrfies. The restricted DNA was ethanol-precipitated, washed, dissolved in 20 μl, run on an 0.8% agarose gel and transferred to Hybond N⁺ nylon membranes (Amersham) following the recommendations of the manufacturer. Membranes were hybridized, washed and revealed by autoradiography and phosphor imaging using a Molecular Imager Fx (BioRad, Herts, UK). Probes used for hybridization were labeled by incorporation of [α-³²P]dCTP (Amersham) using a random priming kit (GibcoBRL). In order to generate probes adjacent to the t(1;17) breakpoint for Southern blot analysis, the cosmid contigs sequence spanning the breakpoint was screened with Repeatmasker (URL http://ftp.genome.washington.edu/cgi-bin/RepeatMasker) to select 9 repeat-free probes representative for the cosmid sequence contig (Table 4) (depicted in FIGS. 3A and 17A). The resulting PCR products, probe #1 (516 bp), probe #2 (789 bp), probe #3 (465 bp), probe #4 (478 bp), probe #5 (678 bp), probe #6 (478 bp; also depicted in FIG. 3B, FIGS. 3C and 17B); probe #7 (673 bp), probe #8 (761 bp) and probe #9 (567 bp; also depicted in FIGS. B and 17C) were directly sequenced to confirm their identity.

[0135] GenomeWalker Libraries

[0136] Libraries were generated according to the manufacturer's instructions (Clontech Laboratories, Palo Alto, Calif., USA). For the 32-2F53VIII somatic cell hybrid, 2.5 μg of genomic DNA was digested with blunt-end generating restriction enzymes PvuII, DraI, StuI, and EcoRV, for 2 h at 37° C. in a final reaction volume of 100 μl. After this incubation, the reaction was vortexed at low speed and returned to 37° C. for 16 h. DNA was purified by phenol-chloroform extraction and ethanol precipitation. Then, the digested DNA was dissolved in 20 μl.

[0137] Appropriate blunt-ended GenomeWalker adaptors (1.9 μl of 25 μM) with sequence 5′-GTAATACGACTCACTATAGGGCACGCGTGGTCGACGGCCCGGGCTGGT-3′                                     3′ H₂N-CCCGACCA-PO₄-5′

[0138] (Clontech), 0.5 μl of T4 DNA ligase (1 U/μl) and 1.6 μl of 5× ligase buffer were added. The mixture was incubated at 16° C. for 16 h. TE (72 μl; pH 7.4) was added and the obtained libraries, designated 32-2F53VIII/PvuII, 32-2F53VIII/StuI, 32-2F53VIII/EcoRV and 32-2F53VIII/DraI, were stored at −20° C. in 10-μl aliquots until use.

[0139] For the 32-7A somatic cell hybrid, 2 μg of genomic DNA was digested with blunt-end generating restriction enzymes DraI, EcoRV, PvuII, ScaI and SspI, for 2 h at 37° C. in a final reaction volume of 80 μl. After this incubation, the reaction was vortexed at low speed: and returned to 37° C. for 16 h. DNA was purified by phenol-chloroform extraction and ethanol precipitation. Then, the digested DNA was dissolved in 16 μl.

[0140] Appropriate blunt-ended GenomeWalker adaptors (1.9 μl of 25 μM) with sequence 5′-GTAATACGACTCACTATAGGGCACGCGTGGTCGACGGCCCGGGCTGGT-3′                                     3′ H₂N-CCCGACCA-PO₄-5′

[0141] (Clontech), 0.5 μl of T4 DNA ligase (1 U/μl) and 0.8 μl of 10× ligase buffer were added to 4.8 μl of the digested DNA. The mixture was incubated at 16° C. for 16 h. TE (72 μl; pH 7.4) was added and the obtained libraries, designated 32-7A/DraI, 32-7A/EcoRV, 32-7A/PvuII, 32-7A/ScaI and 32-7A/SspI, were stored at −20° C.

[0142] Long-range PCR Amplification of GenomeWalker Products

[0143] Takara LA TAQ mix (Takara) was used. Four μl dNTPs (2.5 mM), 5 μl 10×LA reaction buffer, 1 μl adaptor primer 1 (10 μM; 5′-GTAATACGACTCACTATAGGGC-3′), 1 μl Gene-specific primer (10 μM) and 1 μl GenomeWalker library DNA (see above) were mixed in a final volume of 50 μl. DNA was amplified using a two-step PCR with 7 cycles of denaturation at 94° C. for 2 sec plus extension at 72° C. for 3 min, followed by 35 cycles of denaturation at 94° C. for 2 sec plus extension at 67° C. for 3 min. After completion of the reaction, PCR products were analyzed on a 1% agarose gel. For nested PCR reactions, 1/50 μl of the first PCR amplification mixture was used as a template in the next reaction.

[0144] For the 32-2F53VIII libraries, gene-specific primers (GSP) were selected on the basis of DNA sequence of probe #6 (Table 4): GSP1: 5′-CCCCTCAGCTCTGTGCATTTTGTCTA-3′ GSP1′: 5′-CCTCTTGCCCCCACCTAGTGTTTATTT-3′

[0145] For the 32-7A libraries, nested PCR reactions were done with adaptor primer 2 (5′-ACTATAGGGCACGCGTGGT-3′) and with gene-specific primers GSP1″ and GSP2, which were selected on the basis of the DNA sequence of probe #9 (Table 4):

[0146] GSP1″: 5′-CATAGTGGGGGACATCATGACAGTCAC-3′

[0147] GSP2: 5′ ACACCACCAGCCTCCCTCCATTTCTGA-3′ (probe #9 was elongated with 23 bp 5′ to obtain GSP2).

[0148] Cloning of PCR Products

[0149] PCR products were cloned by the TA cloning procedure in the pGEMTeasy vector (Promega). In the case of long-range PCR products (GenomeWalker experiment), PCR products were treated with normal TAQ polymerase after amplification in order to generate overhanging A ends to enable TA cloning.

[0150] Plasmid Constructions

[0151] All enzymes were purchased from Promega, New England Biolabs, Roche, Invitrogen or Fermentas.

[0152] pBlueKIAA1245 (FIG. 30) stands for cDNA clone hg04073 (GenBank Acc No: AB033071-GI:6330825; backbone vector pBluescriptII SK+); pSport-AB25 (FIG. 30) stands for cDNA clone DKFZp434G2022 (GenBank Acc No: AL042839-GI:5935596; backbone vector pSport).

[0153] Construction of pBlue-KIAA-AB25 (FIG. 30)

[0154] The pBlue-KIAA1245 plasmid was digested with NotI and NcoI and a fragment of 5,952 bp was isolated. Plasmid pSport-AB25 was digested with NotI, NcoI and BstEII and a NotI-NcoI fragment of 4,385 bp was isolated. These two fragments were ligated together with T4 DNA ligase, which produced pBlue-KIAA-AB25.

[0155] Construction of pEF6/Myc-His-A-KIAA-AT

[0156] Plasmid pEF6/Myc-His-A (Invitrogen) was digested with BamHI and EcoRV and a fragment of 5,898 bp was isolated. Plasmid pBlue-KIAA1245 was cut with NcoI, blunted with Pfu DNA polymerase (Promega) and cut with BclI resulting in a fragment of 2,326 bp. These fragments were ligated with T4 DNA ligase, which produced plasmid pEF6/Myc-His A-KIAA-AT.

[0157] Construction of pCS2+MT-KIAA-AB25

[0158] Plasmid pCS2+MT (Roth et al., 1991) was linearized with StuI and dephosphorylated with CIP (calf intestinal phosphatase). Plasmid pBlue-KIAA-AB25 was cut with BclI and a fragment of 5,401 bp was isolated. This fragment was blunted using Pfu DNA polymerase. Vector and insert were ligated using T4 DNA ligase.

[0159] Construction of pEF6/Myc-His-B-KIAA-AB25

[0160] Plasmid pEF6/Myc-His-B (Invitrogen) was digested with BamHI and EcoRV and a fragment of 5,902 bp was isolated. Plasmid pBlue-KIAA-AB25 was digested with BclI and SapI, which resulted in a fragment of 4,946 bp. PCR was used to mutate a stop codon using primers FVR2803 (5′-CGCATAGTGCGGTGTGCTGATGGAAGT-3′) and FVR2804 (5′-GCGATATCGTACTGTGGGAATATGACTC-3′), which contains an EcoRV recognition site. 40 ng DNA (pSport-AB25) was used as a template in a PCR mix with VENT DNA polymerase. The DNA was denatured at 95° C. for 5 min, followed by 35 cycles of denaturation at 95° C. for 30 sec, annealing at 56° C. for 30 sec and extension at 75° C. for 30 sec. The reaction had a final extension of 10 min at 75° C. After completion of the reaction, PCR products were analyzed on a 1% agarose gel and purified using Concert™ Rapid PCR Purification System (Invitrogen). Subsequently, the DNA was digested with EcoRV and SapI. The three fragments were ligated using T4 DNA ligase.

[0161] Construction of pEGFP-C3-AB25-CT

[0162] pEGFP-C3 (Clontech) was digested with Ecl13611 and BamHI and a fragment of 4,685 bp was isolated. Plasmid pSport-AB25 was cut with NcoI, blunted with Pfu DNA polymerase (Promega) and digested with BclI. A fragment of 3,079 bp was isolated. These fragments were ligated with T4 DNA ligase, which resulted in plasmid pEGFP-C3-AB25-CT.

[0163] Construction of pEGFP-C3-KIAA-AB25

[0164] Plasmid pEGFP-C3 (Clontech) was linearized with BamHI and dephosphorylated with calf intestinal phosphatase. Plasmid pBlue-KIAA-AB25 was cut with BclI, which resulted in a fragment of 5,401 bp. This was ligated with the linearized vector using T4 DNA ligase.

[0165] Construction of pEGFP-N3-KIAA-AT

[0166] Plasmid pEGFP-N3 (Clontech) was linearized with Ecl13611 and dephosphorylated with calf intestinal phosphatase, which resulted in a fragment of 4,729 bp. Plasmid pBlue-KIAA-AB25 was digested with NcoI and BclI and blunted with Pfu DNA polymerase resulting in a fragment of 2,326 bp. These fragments were ligated with T4 DNA ligase, which resulted in plasmid pEGFP-N3-KIAA-AT.

[0167] Construction of pCS2+MT-chimera1

[0168] Plasmid pCS2+MT-KIAA-AB25 was linearized with XcmI and blunted with T4 DNA polymerase. Subsequently, the DNA was cut with BsrGI and a fragment of 6,939 bp was isolated. Plasmid pGEM-T Easy-chimera1 (see further) was digested with HincII and BsrGI and a fragment of 417 bp was isolated. The fragments were ligated using T4 DNA ligase.

[0169] Construction of pCS2+MT-chimera2

[0170] Plasmid pCS2+MT-KIAA-AB25 was linearized with XcmI and blunted with T4 DNA polymerase. Subsequently, the DNA was cut with BsrGI and a fragment of 6,939 bp was isolated. Plasmid pGEM-T Easy-chimera2 (see further) was linearized with BstXI, blunted with T4 DNA polymerase and cut with BsrGI. A fragment of 245 bp was isolated and ligated into the vector using T4 DNA ligase.

[0171] DNA Transfections

[0172] MCF7/AZ cells were maintained in DMEM, 10% FCS, non-essential amino acids, sodium pyruvate and 6 ng/ml bovine insulin and transfected using Fugene6 Reagent (Roche) according to the manufacturer's instructions. Colo320DM cells were maintained in RPMI1640, 10% FCS, L-Gln and penicillin/streptomycin and transfected using Lipofectamine (Invitrogen) according to the manufacturer's instructions. HEK293T cells were maintained in DMEM, 10% FCS, L-Gln, penicillin/streptomycin, sodium pyruvate and non-essential amino acids and transfected using the calcium phosphate method. HCT8 cells were maintained in RPMI1640, 10% FCS, L-Gln, penicillin/streptomycin and sodium pyruvate and transfected using Lipofectamine Plus (Roche) according to the manufacturer's instructions. Mouse NMe cells were maintained in DMEM, 10% FCS, penicillin/streptomycin, L-Gln and 10 μg/ml insulin and transfected using Lipofectamine (Roche) according to the manufacturer's instructions.

[0173] Immunofluorescence

[0174] After transfection, cells were kept in culture for 48 h. After this period, cells were washed twice with PBS-A and fixed with ice-cold methanol. Incubation with primary antibody was during 1 h for anti-Myc (diluted 1/125) and anti-lamin B1 (diluted 1/60) antibodies (Calbiochem) or during 2 h for the polyclonal antibodies (diluted 1/100). As secondary antibodies anti-mouse IgG Alexa488, Alexa594, anti-rabbit IgG Alexa488 and Alexa594 (Molecular Probes) were used (diluted 1/300). The endoplasmic reticulum of MCF7/AZ cells was stained using 20 μg/ml Concanavalin A Alexa594 conjugate (Molecular Probes) in PBS-A for 30 min, followed by two washes with PBS-A.

[0175] Coverslips were mounted using Vectashield (Vector Laboratories) and observations were made through an Axiophot microscope (Zeiss). Images were obtained using MetaMorph software.

[0176] Northern Analysis

[0177] Total RNA was isolated from cell lines using the RNeasy kit (Qiagen). 23 μg of RNA was loaded on a 1% agarose gel and blotted on Hybond N⁺ Membrane (Amersham Pharmacia) using standard protocols (Sambrook et al., 1989). For generating a 5′-specific probe, PCR was performed on 2 ng of pCS2+MT-KIAA-AB25 DNA using primers 5′-TGAGGAATGAGCGACAGT-3′ and 5′-TTTGAGGCTTCTGAACTG-3′ in a PCR mix with Taq DNA polymerase. The DNA was denatured at 94° C. for 2 min, followed by 35 cycles of denaturation at 94° C. for 20 sec, annealing at 56° C. for 20 sec and extension at 72° C. for 1 min. The products were treated by a final extension of 10 min at 72° C. After completion of the reaction, PCR products were analyzed on a 1% agarose gel and purified using Concert™ Rapid PCR Purification System (Invitrogen). For generation of a 3′-probe, cDNA clone DKFZp434M0628 (clone AB18, Table 6) was digested with EcoRI and PstI and a fragment of 691 bp was isolated. Probes were labelled using RadPrime Labelling Kit (Invitrogen) and alpha-³²P-dCTP (Amersham). Hybridisation was performed overnight in 1% BSA, 7% SDS, 0,5 M Na₂HPO₄, pH 7,2, 1 mM EDTA and 100 μg/ml ssDNA. After hybridisation, filters were washed at 65° C. with a final stringency of 0.1 M sodium phosphate, pH 7.2, 1% SDS and 1 mM EDTA. For detection and quantitation, a Phosphor Imager cassette (Molecular Dynamics, Sunnyvale, Calif.) was exposed and scanned with a Molecular Imager® FX using the Quantity One software (BioRad, Richmond, Calif.).

[0178] 5′-RACE Reactions

[0179] 5′-RACE was performed using the 5′-RACE system for Rapid Amplification of cDNA Ends (Invitrogen) according to the manufacturer's instructions. Briefly, 2 μg total RNA, isolated from either 32-7A, or 32-2F53VIII, or SK-N-SH or TR-14 cells was first-strand transcribed using the gene-specific primers FVR2458 (5′-TTGTTCCCATCAAAGTAAGAAAC-3′, located in type-14 exons) or FVR2457 (5′-ATTGACGGAGTCGAATAACATCTA-3, located in type-10, -11 or -14 exons). PCR was executed using the Abridged Anchor Primer (AAP) and a gene-specific primer FVR2456 (5′-CCCCTTCTCCTTCTTTTCTTCGT-3′, located in exons 12.5, 12.6 and 12.7) or FVR2455 (5′-CTCCCACGTCAAGAGAAAAG-3′, located in type-11 exons). Nested PCR was performed using the Unabridged Anchor Primer (UAP) and FVR2455 or FVR2454 (5′-CATAGGGCAGGCAGGAGTCAG-3′, located in type-11 exons but with high homology to part of the type-10 exons). Products were separated on a 1% agarose gel, eluted using the Concert™ Rapid Gel Extraction Purification System (Invitrogen) and cloned into plasmid pGEM-T Easy (Promega).

[0180] 3′-RACE

[0181] 3′-RACE was performed using the 3′-RACE System for Rapid Amplification of cDNA Ends (Invitrogen) according to the manufacturer's instructions. Briefly, 2 μg of total RNA isolated from the 32-7A cell line was first-strand transcribed using the AP (Adapter Primer). Two PCRs (PCR A and PCR B) were set up using the UAP (Universal Anchor Primer) and a gene-specific primer (either GSP1 or GSP2): PCR A: GSP1 (5′-GCCCTTATGACTCCAACCAG-3′), PCR B: GSP2 (5′-ATTGGCTCATCCTCTCATGTT-3′).

[0182] Nested PCRs were done using the Abridged Universal Anchor Primer (AUAP) and GSP2 (for nested PCR on PCR A), or the AUAP and GSP3 primer pair (for nested PCR on PCR B). GSP3: 5′-TCCCAGAAAATGAAAGTGATG-3′.

[0183] Products were separated on a 1% agarose gel and eluted using the Concert™ Rapid Gel Extraction Purification System (Invitrogen) and cloned in pGEM-T Easy (Promega). This yielded plasmids pGEM-T Easy-chimera1 and -chimera2 in the case of 32-7A RNA as template.

[0184] RT-PCR

[0185] RT-PCR was performed on RNA from the 32-2F53VIII somatic hybrid cell line and from human fetal brain (HFB). Total RNA was isolated from 32-2F53VIII cells using RNeasy RNA Extraction Kit (Qiagen), whereas HFB RNA was purchased (Clontech). First-strand synthesis was done using SuperScript II reverse transcriptase (Invitrogen) and oligo(dT) primers. Primers for RT-PCR on cDNA from 32-2F53VIII cells were FVR2457 (5′-ATTGACGGAGTCGAATAACATCTA-3′) as reverse primer and FVR2511 (5′-TTGGCTCTTGACGTGGACAGAATTA-3′) or FVR2512 (5′-AAGGACCAGGAAGAGGAAGAAGA-3′) as forward primer. For RT-PCR on HFB cDNA, primers FVR2686 (5′-CTCAACTCTCATTGGCTCATC-3′) and FVR2687 (5′-GTCCTCCTTTTTCACTTGATC-3′) were used. PCR fragments were separated on a 1% agarose gel and purified using the Concert™ Rapid Gel Extraction Purification System (Invitrogen) and cloned in pGEM-T Easy (Promega).

[0186] Antibodies

[0187] Antibodies specific for NBG proteins were raised by immunisation of rabbits with 200 μg of synthetic peptides with sequence NH₂-VGEIEKKGKGKKRRG-COOH (peptide #1059), NH₂-GEEDQNPPSPRLSGVLM-COOH (peptide #1060) or NH₂-PEILQDSLDRSYSTPSM-COOH (peptide #1061). These peptides were coupled to keyhole limpet hemocyanin via an additional cysteine residue at the NH₂-terminal end using the Imject® Maleimide Activated mcKLH Kit (Pierce). Boosts were given with intervals of minimum two weeks. Sera were tested by ELISA on the peptides used for injection, using nonrelevant peptide as a negative control. Sera were also tested on lysates of HEK293 cells transfected with pEGFP-C3-AB25-CT encoding the GFP-tagged carboxyterminal part of the NBG protein. The specificity of the antibodies was also evaluated by use of immunofluorescence. To this end, MCF7/AZ cells were transfected with the pCS2+MT-KIAA-AB25 construct encoding the Myc-tagged full-length NBG-protein.

Example 1 Construction of a 1.4 Mb PAC/BAC Contig Covering the Constitutional 17q Breakpoint

[0188] Previous YAC mapping lead to the identification of apparently breakpoint overlapping clones (954-e-11 and 936-g-11) (Van Roy et al., 1997b). However, upon subsequent screening of a chromosome-17 specific cosmid library no breakpoint-overlapping cosmid clones could be identified suggesting that the region covering the breakpoint region was not present in any of the analyzed YAC clones. To overcome this problem, a PAC/BAC contig covering the 17q breakpoint region was constructed (FIG. 1). The RCPI-1 PAC library was screened with end clones (Table 2) from YACs 725-g-2, 728-f-1, 15FD11, 776-d-7 and 681-c-3, cosmid clone cCI17-1079 (Van Roy et al., 1997b) and STS markers D17S1850, D17S1656 (WI-2906), D17S798 and PAC end clones to further close the remaining gaps. Additional STSs were generated from end sequences of the PACs, that covered the breakpoint or were located within its immediate vicinity (Table 1). BLAST searches with PAC end sequences allowed the identification of partially or completely sequenced BAC clones. Further analysis of the partial maps from the Map Viewer at NCBI (http://www.ncbi.nlm.nih.gov/) and from the Human Genome Project Working Draft at UCSC (http://genome.ucsc.edu/) allowed the identification of additional BACs in the breakpoint region. A 1.4 Mb contig was constructed by STS (including newly developed STSs) and EST content mapping by hybridization of PCR products on dot blots containing the PAC clones and/or PCR analyses of PAC and BAC clones. Further careful positioning of all clones was done by fiber FISH. The minimum tiling path of the contig was determined as: centromere * RPCI-11 29G21 * RPCI-11 421O15 * RPCI-11 205P19 * RPCI-1 105C17 * RPCI-1 733P21 * RCPI-1 880L8 * RPCI-1 952I18 * RPCI-1 243F6 * RPCI-1 682F9 * RPCI-1 194A10 * RPCI-1 55N16 * RPCI-1 257G22 * telomere (FIG. 1). PCR content mapping showed that the order of the markers assigned to BAC clone AC011824 had to be inversed. Despite the progress in the mapping of the human genome, inconsistencies exist with regard to the position of markers and genes within this region as reflected by the different and changing mapping information available at the NCBI and UCSC databases. Ordering of contigs and closing of gaps between contigs, as described here, will be crucial in the construction of the final human genome map.

Example 2 Identification of Breakpoint Overlapping Clones

[0189] The position of the PAC/BAC clones with respect to the constitutional 17q breakpoint, was analyzed using FISH on metaphases from somatic hybrid cell lines, containing the derivative chromosomes 1 and 17. A total of 21 and 18 PAC/BAC clones mapped to the derivative chromosome 1 or derivative chromosome 17, respectively. Using this FISH approach, four PACs and one BAC were shown to be breakpoint overlapping (RPCI-1 880L8, RPCI-1 624A6, RPCI-1 1020I1, RPCI-1 1167N14 and RPCI-11 118G23) (Table 2). PAC clone RPCI-1 880L8 was used to screen a chromosome 17 specific cosmid library. Eleven positive cosmid clones including three overlapping cosmids were identified (ICRFc105F1060D1, ICRFc105F1065D1 and ICRFc105G3072D1) (Table 2). The DNA of these three mutually overlapping cosmids was largely sequenced after shotgun subcloning (see Example 3).

Example 3 Shotgun Sequencing of a Cosmid Contig on Chromosome 17 Overlapping the Constitutional 17q Breakpoint

[0190] After shotgun cloning and sequencing, we constructed a sequence contig of three chromosome-17 specific mutually overlapping cosmids (ICRFc105F1060D1, ICRFc105F1065D1, ICRFc105G0372D1) encompassing the translocation breakpoint. A total contiguous sequence of 51,050 bp was obtained (GenBank Acc. N° AF148647). Within this sequence, the end clone sequence SP6 841C3 was detected (position 13112-13806), but not these of SP6 829O10 or SP6 835C10 (FIG. 1 and FIG. 3A). Further, these cosmid sequences showed identity with one unfinished BAC sequences of the Human Genome Project (Genbank Acc. No. AC013739, version .2) and with two complete BAC sequences (GenBank Acc. No. AC011824, version .8-GI:13940712; and AC024614, version .5-GI:14575793).

[0191] So far, BLAST analysis did not show any evidence for the presence of exons or single-exon genes in these chromosome-17 sequences. However, the exon prediction algorithms GeneMark (URL http://opal.biology.gatech.edu/GeneMark) predicted several putative exons of which one was cloned by exon trapping (see annotation in GenBank Acc. No. AF148647). One EST cluster (stSG50857, Unigene cluster Hs.125747) was located at a maximum distance of ˜180 kb proximal to the 17q breakpoint. Sequence analysis of 4 cDNA clones (IMAGE clones 742727, 2356570, 1471272, 1471196; Genbank Acc. No. AF381171-AF381174) showed alignment of three putative exons with the genomic sequence of BAC clone RPCI-11 31122. On the basis of the stop codons observed, several possibilities can be proposed: either these ESTs represent a multi-exonic 3′UTR, or they represent a transcribed multi-exonic pseudogene with ORF disrupting mutations, or a short open reading frame starts in the second exon, encoding a polypeptide of 78 amino acid residues. The latter polypeptide does not show significant homology with hitherto known proteins or protein domains. BLAST analysis, without masking repeat sequences, of the breakpoint overlapping cosmid sequences against the human EST database showed the presence of two partially overlapping EST sequences (GenBank Acc No AI934614 and AI571839). Although both ESTs contained a LTR/MaLR repeat they show 100% sequence similarity to the cosmid sequence.

Example 4 Identification of Rearranged Genomic Fragments Comprising the Constitutional t(1;17) Breakpoint

[0192] To facilitate the identification and cloning of the t(1;17) breakpoint, genomic DNA from the somatic cell hybrids 32-7A and 32-2F53VIII, the Chinese hamster ovary cell line a3 and a normal human placenta were digested with a panel of restriction enzymes including BglII, HindIII, KpnI, NcoI, PvuII, XbaI, EcoRI, NsiI and BglII. The somatic cell hybrids 32-7A and 32-2F53VIII contain, respectively, derivative chromosomes 1 and 17 from the original neuroblastoma patient. From the cosmid contig sequence, overspanning the translocation breakpoint, 9 DNA probes free of repetitive sequences were selected and PCR amplified. These probes are listed in Table 4. They were then used for hybridization to the digested genomic DNA in order to search for abnormal patient-specific hybridization bands. No aberrant migrating bands could be detected with probes #3, #4 or #5. However, upon using probe #6, additional bands were identified in the genomic DNA of 32-2F53VIII but not in any of the other DNAs, indicating that these fragments spanned the breakpoint on chromosome 17q (FIG. 2). The smallest rearranged band detected with probe #6 was estimated to be approximately 4 kbp long and was found in the PvuII digested genomic DNA.

[0193] Upon use of probe #9, additional bands were identified in the genomic DNA of 32-7A but not in any of the other DNAs, indicating that these fragments spanned the breakpoint on chromosome 1p (FIG. 16). Rearranged bands detected with probe #9 were found in genomic DNA of 32-7A cells upon digestion with EcoRI (˜19,500 bp instead of ˜13,500 bp), NsiI (˜8,800 bp instead of ˜7,600 bp), BglI (˜13,200 bp instead of ˜7,950 bp), HindIII (˜1,000 bp instead of ˜3,300 bp) and BglII (˜1,100 bp instead of ˜3,300 bp).

Example 5 Cloning of the Constitutional t(1;17) Translocation Breakpoint in the Somatic Cell Hybrid 32-2F53VIII

[0194] GenomeWalker PCR (Siebert et al., 1995) was used to clone the unknown genomic chromosome-1 sequences that have been juxtaposed to known, chromosome-17 sequences as a result of the human t(1;17) chromosomal translocation in the somatic cell hybrid line 32-2F53VIII. In brief (FIG. 3), genomic DNA from cell line 32-2F53VIII was digested with blunt-end generating restriction enzymes PvuII, StuI, EcoRV and DraI, and the resulting DNA fragments were then separately ligated to compatible GenomeWalker adaptors to produce four libraries. PCR amplification was performed using gene-specific primers (GSP), localized in the probe #6 sequence in combination with a GenomeWalker adaptor-specific primer (API). As pointed out above, the chromosome-17 specific probe #6 hybridizes to a 4-kbp PvuII fragment encompassing the (1,17) breakpoint. During the first cycle of the PCR, the GSP primer anneals and one strand of the adaptor is copied. Due to the lack of the binding site for the AP1 primer in the 5′-extended adaptor in combination with the 3′ end of the adaptor being blocked with an amine group to prevent extension, the AP1 primer anneals only to the newly synthesized strand and not to the adaptor-ligated primary template genomic DNA. If rare extension of the 3′ end of the adaptor should occur, efficient panhandle formation suppresses nonspecific background amplification. In consequence, only the genomic DNA fragment containing the specific GSP sequence is amplified.

[0195] Primer pair GSP1 plus AP1 was used in a first round of amplification. Specific products of 1,457 bp and 3,575 bp were amplified from, respectively, the 32-2F53VIII/StuI and 32-2F53VIII/PvuII GenomeWalker libraries. With the GSP1′ plus AP1 primer combination, products of 1,029 bp and 3,459 bp were amplified from, respectively, the 32-2F53VIII/DraI and 32-2F53VIII/EcoRV.GenomeWalker libraries (FIGS. 3 and 4). All four 32-2F53VIII-specific products mentioned were cloned and fully sequenced. Overlapping novel sequences, derived from chromosome 1, were present in all clones. In total, a maximum of 3,141 bp of novel sequences were identified in the 32-2F53VIII/EcoRV clone (FIG. 5; sequence deposited with GenBank under Acc No AF379607). Of these, 3,134 bp were found to be chromosome-1 specific (FIG. 3; see Example 7). As indicated in FIG. 3, the other clones contained shorter but completely overlapping sequences.

Example 6 Cloning of the Constitutional t(1;17) Translocation Breakpoint in the Somatic Cell Hybrid 32-7A

[0196] GenomeWalker PCR (Siebert et al., 1995) was used to clone the unknown genomic chromosome-1 sequences that have been juxtaposed to known, chromosome-17 sequences as a result of the human t(1;17) chromosomal translocation in the somatic cell hybrid line 32-7A. In brief (FIG. 17), genomic DNA from cell line 32-7A was digested with blunt-end generating restriction enzymes DraI, EcoRV, PvuII, ScaI and SspI, and the resulting DNA fragments were then separately ligated to compatible GenomeWalker adaptors to produce five libraries. PCR amplification was performed using gene-specific primers (GSP), localized in the probe #9 sequence in combination with a GenomeWalker adaptor-specific primer (API). As pointed out above (FIG. 16), the chromosome-17 specific probe #9 hybridizes to various restriction fragments encompassing the (1,17) breakpoint as their mobility is shifted in DNA digests of the 32-7A cell line as compared to the 32-2F53VIII cell line or normal human placenta.

[0197] Primer pair GSP1″ plus AP1 was used in a first round of GenomeWalker amplification, as outlined above in Example 5. Specific products of 1,649 bp and 1,888 bp were amplified from, respectively, the 32-7A/DraI and 32-7A/EcoRV GenomeWalker libraries. With the GSP2 plus AP2 primer combination, products of 1,268 bp and 4,355 bp was amplified from the 32-7A/SspI and 32-7A/PvuII GenomeWalker libraries (FIGS. 17 and 18). All four 32-7A-specific products mentioned were cloned and fully sequenced. Overlapping novel sequences, derived from chromosome 1, were present in all clones. In total, a maximum of 3,853 bp of novel sequences were identified in the 32-7A/PvuII clone (FIG. 19; sequence deposited with GenBank under Acc. No. AF379606). Of these, 3,849 bp were found to be chromosome-1 specific (see FIG. 17; Example 7). As indicated in FIG. 17, the other clones contained shorter but completely overlapping sequences.

Example 7 Analysis of Sequences Flanking the Constitutional t(1;17) Translocation Breakpoint

[0198] Sequences generated from both sides of the t(1;17)(p36.2;q11.2-q12.1) breakpoint in the derivative chromosome-17 and derivative chromosome-1 were analyzed for the presence of putative protein-encoding gene sequences by using both BLASTN and BLASTX to search public databases. This demonstrated that the breakpoint-flanking sequence adjacent to the chromosome-17 sequences were chromosome-1 derived as they show almost perfect identity with several unfinished or finished sequences of BAC clones (Genbank Acc. N° AL354666, AL356581, AC015618, AL355149, AL355800, AL022240, AL049715, AL137798 and AL049742), all mapping to chromosome 1. Regarding chromosome-1 sequences on derivative chromosome 17 (der17), high to perfect homology was also found between parts of this genomic sequence and at least eleven EST sequences (GenBank Acc. N° AL040932, AL045522, AA322028, AL043132, AA609104, AA350323, AL042839, AL044108, AL043174, AL037724 and AW160820) (Tables 5 and 6, and FIG. 7). This confirmed the prediction of three consecutive exons, designated x, y and z as indicated in FIGS. 3, 5 and 6. These exons x to z encode a carboxy-terminal fragment of a novel protein. This protein shows no identity with so far known gene products. The extended size of this particular protein, and of highly related new proteins, became apparent upon sequencing the full-size inserts of the cDNA clones represented by the EST sequences mentioned (summarized in FIG. 7, Tables 5 and 6). Corresponding nucleotide sequences were deposited with GenBank (Table 6). The predictable sequences of the protein domains, encoded by exons of the x, y or z type, are aligned in FIGS. 13 to 15. Regarding breakpoint-flanking chromosome-1 sequences on derivative chromosome-1, high to perfect homology was found between parts of this genomic sequence and the sequences of at least six cDNA clones (EST sequences deposited with GenBank under Acc. N° AI570017, AW173183, H06312, AW468059, AA704208, AI239884). Full-size insert sequences were determined and deposited with GenBank (summarized in FIG. 21, Tables 5 and 6). This confirmed the prediction of two consecutive exons, designated A and B as indicated in FIGS. 17, 19 and 20. The predictable sequences of the protein domains, encoded by exons of the A or B type, are aligned in FIGS. 11 and 12. These exons A and B encode an internal fragment of a novel protein, belonging to the same family as the protein with the carboxy-terminal sequence encoded by exons x, y and z, discussed above. This is apparent both from cDNA sequences, notably the full-size sequences of the cDNA clones depicted in FIG. 7 and FIG. 21, and from genomic sequences (see Example 8).

Example 8 Chromosome-1 Derived Exons Flanking the t(1;17) Translocation Breakpoint Belong to a Large and Novel Gene Family NBG

[0199] High homology was found between on the one hand the exons x, y and z (FIGS. 5 and 6) and the exons A and B (FIGS. 19 and 20) and on the other hand many more EST sequences than the one mentioned in Example 7 (e.g. Genbank Acc. N° AL037724, AI909921, AA705685, AA701673, AI570017, AW173183, AA350323, AI372468, F11837, AI049567, AW238577, AI537172, AI953463, . . . )(Tables 5 and 6). This became further clear upon sequencing the full-size inserts of cDNA clones represented by several of the additional EST sequences mentioned (summarized in FIG. 22, Tables 5 and 6). High homology was observed also between on the one hand exons A, B, x and y, and on the other hand two cDNA clones (Acc N° AK000726 and AB033071) and predictable exons of one genomic sequence AL049715 and this was particularly obvious upon comparison of the encoded protein fragments (Table 5, FIGS. 8 and 23). High homology was also found between exons A, B, x and z and the cDNA sequence AB051480; between exons x+y and cDNA sequences AF161426 and AI050141; between exons y-z and cDNA sequence AF131738; and between exons A+B and predictable exons of genomic sequence AL137798 (Table 5, FIGS. 8 and 23). High homology was also found between exons A, B and x to z and the cDNA sequence AL117237, predicted on the basis of the genomic sequence AL022240 (derived from clone 328E19), the cDNA sequence AL136890, and predictable exons of the genomic sequences AL354666, AL356581 and AL022240 (Table 5; FIGS. 8 and 23). When the sequences of the predicted exons in various representative cDNA and genomic clones were aligned with each other, separate classes could be discerned, as shown in Table 5, FIGS. 7 to 15, and FIGS. 21 to 23 (overview in FIGS. 7, 8, 21 to 23; alignments and pedigrees in FIGS. 9 to 15). In these figures, the three exons x to z correspond to, respectively, exon 11.1, exon 12.5 and carboxy-terminal exon 14.12, whereas exons A and B correspond to exons 6.12 and 7.1. On the basis of sequences from cDNA clone DKFZp434G2022 (AB25; Table 6 and FIG. 7) and from genomic clones RP11-284O17 and RP11-45I3 (GeneBank Acc. Nos. AL355800.5 and AC015618.3), we could predict the structure of the transcript interrupted by the chromosomal t(1;17) translocation (FIG. 24). By the translocation event, a genomic segment of about 20 kbp and comprising exons of the types 8 to 13 appears to be deleted (FIG. 24).

[0200] Within this new gene family, designated NBG (Neuroblastoma Breakpoint Gene family), 5′ exons of types 0 and 1 (Table 5) were represented by cDNA clone hg04073 (encoding protein KIAA1245; GenBank Acc. No. AB033071; FIG. 8), cDNA clone HEP17004 (GenBank Acc. No. AK000726; FIG. 8), IMAGE cDNA clone 2226413 (clone AG09; Table 6 and FIG. 21), IMAGE cDNA clone 341197 (clone AE02; Table 6 and FIG. 21), genomic clones RP11-87L17 and RP5-1020C22 (GenBank Acc. Nos. AL354666 and AL356581; FIG. 23). A likely start codon is situated in exon type 1 and yields proteins with starting sequence MWSAG . . . (FIG. 9).

[0201] Upon comparison of exons A, B, and x to z, which were found to flank the cloned breakpoints of the der1 and der17 chromosomes, with the cDNA and genomic sequences obtained so far, the transcript interrupted by the chromosomal t(1;17) translocation was predicted to have the structure depicted on top in FIG. 24. It corresponds to the sequence of cDNA clone DKFZp434G2022 (clone AB25; FIG. 7 and Table 6; exon types 6.3 and 6.12 are very closely related [cf. FIG. 11] as they differ by only two out of 68 amino acid residues due to two nucleotide differences), completed at the 5′ end by sequences from unfinished genomic clones RP11-284017 (GenBank Acc. No. AL355800) and RP11-45I3 (GenBank Acc. No. AC015618). Upon chromosomal translocation, a genomic region covering one exon of type 8, one exon of type 9, and several exons of type 10, 11, 12 and 13 are lost (FIG. 24). The total sequence that is predicted to be deleted is therefore as large as ˜20 kbp.

[0202] The interrupted gene on the der1 chromosome is transcribed into chimeric molecules, as demonstrated by a 3′-RACE experiment on mRNA from the 32-7A somatic cell hybrid. Two chimeric transcripts were cloned in this way. The fusion partner is in both cases located on chromosome 17. In one chimeric transcript, represented by eight distinct clones, the exon-7.1 sequence is spliced to chromosome-17 sequences at 338 nt from the breakpoint, and this yields a transcript extended by 295 additional nucleotides and an ORF extended by 34 additional codons in frame (represented by X in FIGS. 24 and 25; sequence depicted in FIG. 26; deposited with GenBank under Acc. No. AF420438). In a second chimeric transcript, represented by a single clone, the exon-7.1 sequence is spliced to chromosome-17 sequences at 8,602 nt from the breakpoint according to the BAC sequence with GenBank Acc. No. AC024614.3. This yields a transcript extended by 325 additional nucleotides and an ORF extended by 11 additional codons in frame (represented by Y in FIG. 25; sequence depicted in FIG. 27; deposited with GenBank under Acc. No. AF420439). A reciprocal experiment aimed at identifying chimeric transcripts by 5′-RACE from somatic cell hybrid 32-2F53VIII and several more cell lines. Although many gene-specific fragments were detected illustrating the widespread expression of NBG family members (FIG. 28), no chimeric transcripts could be cloned so far from these 5′-RACE experiments.

[0203] Unusual features were also observed in several cDNA clones corresponding to this new NBG family: translation frameshifts (e.g. cDNA clones AG07 and AE01 in FIG. 7, cDNA clone AB033071 in FIG. 8, cDNA clones AG09 and AG10 in FIG. 21), and retention of intronic sequences (e.g. cDNA clones AD02 and AB06 in FIG. 7; cDNA clone AI050141 in FIG. 8, cDNA clone AB23 in FIG. 21; cDNA clones AB13 and AB14 in FIG. 22). Such intronic sequences were also found in 5′-RACE products of 32-2F53VIII, TR-14 and SK-N-SH cells (FIG. 28).

[0204] We addressed the number of different human NBG genes by checking the occurrence of nonidentical exon-7, -8 and -9 sequences in contiguous genomic sequences of the public-domain human genome resources. To our knowledge, these three exon types occur only once per transcript as exemplified in FIGS. 7, 8 and 21. From the data, listed in Table 7, we conclude that there about 15 different NBG genes, mainly localized on chromosome arms 1p and 1q.

[0205] No homologous or orthologous sequences for this novel gene family NBG were found in the genomes of either Saccharomyces cerevisiae, Drosophila melanogaster or Caenorhabditis elegans. The repetitive nature of the transcripts and proteins, encoded by this novel gene family, is particularly striking (FIGS. 7, 8, 22 and 23). Nevertheless, upon screening various protein domain databases, no significant matches were found. These databases include: InterPro (URL http://www.ebi.ac.uk/interpro/), ProSite (URL http://www.expasy.ch/prosite/), Blocks (URL http://www.blocks.fhcrc.org), Prints (URL http://www.biochem.ucl.ac.uk/bsm/dbbrowser/PRINTS/PRINTS.html), PFAM (URL http://qenome.wustl.edu/Pfam), and other databases. In conclusion, this failure to detect known protein domains points at a fully novel protein structure and innovative functions for the gene family members described above.

Example 9 Chimeric Transcripts of the Novel Gene Family in Other Tumor Types Besides Neuroblastoma

[0206] Analysis of the non-redundant database and the EST-database at NCBI, resulted in the identification of two chimeric transcripts showing homology to to the novel NBG gene family (FIG. 25). The first one, cDNA clone Y79AA1001711 (GenBank Acc. No. AK024044) was derived from the human retinoblastoma cell line Y79, and consists of 552 nucleotides of a NBG family member, followed by 5 unrelated nucleotides and 1,657 nucleotides of the SSA2 transcript (Sjogren syndrome antigen A2; 60-kDa ribonucleoprotein autoantigen SS-A/Ro) (nucleotides 1-1,657 of the GenBank sequence with Acc. No. XM_(—)029851.1), encoded by the Sjogren syndrome gene SSA2 located at chromosome 1q31. The second chimeric transcript, cDNA clone IMAGE:3698601 (complement of sequence with GenBank Acc. No. BF478071.1) was derived from pooled germ cell tumors, and comprises some 75 NBG-specific nucleotides (encoding the exon-11 like peptide sequence TPTSCLEQPDSSQPYGSSFYALEEK), followed by a stretch of 9 A nucleotides, and 288 nucleotides of the 3′ UTR of the transcript encoding human coatomer protein complex, subunit alpha (corresponding to nucleotides 4,735-5,022 of the GenBank sequence with Acc. No. XM_(—)049690.1; gene LOC113148 on chromosome 1q).

Example 10 NBG mRNA Expression Analysis

[0207] A Northern blot was hybridized with two separate NBG-specific probes. In the first hybridisation, a 5′-specific probe was used. This resulted in a strong signal in the neuroblastoma cell lines SH-SY5Y, IMR-32, SK-N-AS and SK-N-SH, but no detectable signal in TR-14, which contains double minutes (FIG. 29, upper panel). Human non-neuroblastoma cell lines (MCF7/AZ, HEK293T, Colo320DM, and HCT8/R1) showed lower expression levels. No detectable signal was seen for mouse cell lines NMe and Neuro2A. When a 3′-specific probe was used, the signal resembled the signal from the 5′ probe, but with an additional band of approximately 500 bp that was detected in HCT8/E8 (FIG. 29). The signal intensities were measured and normalized on the basis of the GAPDH transcript in the respective cell lines. The normalized values were graphically compared (FIG. 29, lower panel) and this emphasized the high expression level in SH-SY5Y.

[0208] The expression analysis of NBG family members was extended by RT-PCR experiments on either human fetal brain (HFB) RNA (using primers in exon 6 and exon 9) or on 32-2F53VIII RNA (using primers in exon 10 and exon 14). The cloned RT-PCR products were sequenced as depicted in FIG. 37. The products were specific for the NBG family but yielded also new exonic variants. Several splice variants of exon 8 were observed (exon 8.3, 8.14, 8.13, as well as removal of exon 8; FIG. 37), and this in line with the presence of a frameshift between exon 8 and exon 9 in cDNA clones AB033071 (FIG. 8) and Y79AA1001711 (see Example 9 and FIG. 25).

Example 11 NBG Protein Expression Generates Micronuclei

[0209] To study the function of this novel NBG gene family, several eukaryotic expression plasmids were constructed. To generate a representative full-length cDNA clone, sequences from two distinct cDNA clones were fused (FIG. 30). This full-length construct pBlueKIAA-AB25 was then tagged with either an aminoterminal Myc-epitope, or a carboxyterminal Myc-epitope, or an eGFP protein, yielding constructs pCS2+MT-KIAA-AB25, pEF6/Myc-His-B-KIAA-AB25 and pEGFP-C3-KIAA-AB25, respectively. The two distinct parts (aminoterminal and carboxyterminal half) were also separately coupled to eGFP (constructs pEGFP-N3-KIAA-AT and pEGFP-C3-AB25-CT, respectively), whereas the aminoterminal domain was also tagged with a Myc-epitope (construct pEF6/Myc-His-A-KIAA-AT).

[0210] These expression vectors were transfected into several human cell lines including mammary gland tumor cells MCF7/AZ (FIGS. 31 and 32), colon tumor cells HCT8/E8 (FIG. 33), embryonic kidney cells HEK293T (FIG. 34, top panels), colon tumor cells Colo320DM (FIG. 34, middle and bottom panels), and also into the mouse mammary gland cell line NMe (FIG. 35). The ectopically expressed proteins were detected by use of an anti-Myc antibody or by GFP fluorescence. These proteins showed a preferential cytoplasmic localization with only 5% of the transfected cells showing nuclear staining (the latter exemplified in FIG. 31E). Comparable results were obtained for constructs expressing either GFP-tagged or Myc-tagged proteins. Staining of the endoplasmic reticulum did not show colocalization with the NBG product (FIGS. 32A-C). Transfection of human cells with the full-size NBG constructs resulted in increased incidence of micronuclei-containing cells (illustrated by arrows in FIGS. 31I-L; FIGS. 32A-F; FIGS. 33A,B; FIGS. 34A,B,E,F). Staining of the nuclear lamina using an anti-lamin B1 antibody confirmed clearly the presence of micronuclei (FIGS. 32,D-F), which were generally also detectable by DAPI-mediated DNA-staining (most right panels of each combination in FIGS. 31-36). Transfections of backbone vectors served as negative controls and did not yield high levels of micronuclei (FIGS. 32G-J; FIGS. 33G,H; FIGS. 34G,H). Transfections of mouse NMe cells (FIG. 35) were particularly useful to demonstrate clearly the potential of the NBG proteins, as these cells lack endogenous NBG proteins. A high number of micronucleus-like structures was induced by full-size NBG protein in NMe cells (illustrated by the arrows FIGS. 35A,B,E,F), whereas such structures were not detectable in control transfectants (FIGS. 35G-J). According to DAPI staining, the NBG-induced cytoplasmic structures lacked DNA and this might point at molecules lacking in mouse and cooperating with NBG proteins in human cells in order to remove excessive DNA from the nucleus. Altogether, these data indicate that the NBG proteins can remove amplified DNA from human cells by inducing or enhancing micronuclei generation.

[0211] Transfections of plasmids encoding amino- or carboxyterrninally truncated NBG proteins were also associated with micronuclei generation, although an aminoterminal fragment (illustrated in FIGS. 31A-D; FIGS. 33C,D; FIGS. 34C,D; FIGS. 34I,J; FIGS. 35C,D) appeared to be less efficient than a carboxyterminal fragment (illustrated in FIGS. 31E-H; FIGS. 33E,F; FIGS. 34K,L). Transfection into MCF7/AZ cells of plasmids encoding the two NBG chimeric cDNAs isolated by 3′-RACE from 32-7A cells (see Example 8) was featured by the formation of multiple vesicle-like structures in the cytoplasm, which were apparently lacking DNA (FIGS. 36A,C). Some micronuclei were still visible in these transfected cells (FIG. 36A). From this, we conclude that these chimeric NBG transcripts are reorganizing the cytoplasmic organelles and interfere with the removal of excessive DNA such as amplified oncogenic DNA in cancer cells.

Example 12 NBG-Specific Antibodies

[0212] Polyclonal antibodies were raised against NBG-specific peptides. For example, rabbit polyclonal antibody #31226 was raised against peptide #1061 with sequence NH₂-PEILQDSLDRSYSTPSM-COOH. MCF7/AZ cells were transfected with a construct encoding a Myc-tagged full-length NBG protein. FIG. 38 illustrates that an anti-Myc antibody (A) and polyclonal antibody #31226 (B) produce overlapping staining patterns, pointing at the specificity of the polyclonal antibody. Non-transfected cells were not stained by anti-Myc antibody and only very lightly stained by polyclonal antibody #31226. The same polyclonal antibody was used in combination with anti-lamin B1 antibodies in order to allow identification of NBG-transfected cells (illustrated in FIG. 32D). TABLE 1 Newly developed sequence-tagged sites (STS) obtained from sequenced PAC end clones: primer sequences, product size and annealing temperature product annealing Marker (PAC clone end) primer 1 (5′-3′ sequence) primer 2 (5′-3′ sequence) size (bp) temperature RPCI-1 880L8 SP6 GGCCATGTGAACCAATTCTG GGAGAGCTGAGTGAGGAGGG 421 58° C. RPCI-1 243F6 SP6 CGCCTGGCCTATTTACATGT TGCAGCCCATAAATACCCAC 451 55° C. RPCI-1 252F1 T7 CCTCGAGCTGAAGCCAAATT TGGCCTCCATGCTGTAGGAT 151 56° C. RPCI-1 59J12 SP6 TCAAACCCCGACTTTCAGAT TCTGTGCTGCCTGGATTCAC 501 58° C. RPCI-1 928F18 T7 GCCTGTTTCATCAAATGCCTG GGAGAAATGGCACAGAGGTGA 201 59° C. RPCI-1 841C13 T7 GAGACCAAGTTCTTTCCCAG GAGACCAAGTTCTTTCCCAG 251 54° C. RPCI-1 841C13 SP6 ACAAGCAAGACTGTGAAGCCC GGCTTCCTGTTTCTCCTCCAG 251 60° C. RPCI-1 605A3 T7 GCCTATCAGGCCATGATCCA GGACTCCAGGACAGTGGCAT 151 58° C. RPCI-1 829O10 SP6 ACCCCATCTCTTTCCAGCAT TTGCCTGGCATTCATCTAGA 201 54° C. RPCI-1 829O10 T7 GGGTCCCTGGTAGTTAACGA CCAACTCCTGACCCCAGAA 481 56° C. RPCI-1 105C17 T7 ATGGATGGGTAAACTGAGGCC GCTGACTTCCTGAGGGAGGC 151 60° C. RPCI-1 1167N14 SP6 CACCCAACTTTCCATGAGCTC TGGTGGTGTACCCCCTTGAC 301 59° C.

[0213] TABLE 2 List of PAC and cosmid clones, screened by hybridization with the YAC, PAC, STS, and end clones indicated, and confirmed to be positive for hybridization (FISH) on chromosome band 17q11.2 Screening wlth Clone type Positive clones cCl17-1079 cosmid RPCl-1 55N16, 118B4, 266J21 STS D17S1850 STS RPCl-1 243F6 STS Wl-2906 STS RPCl-1 243F6, 107O9, 52F12, 59J12, 110l13, 107O9 728-f-1 YAC RPCl-1 101G3, 194A10, 243F6, 107O9, 252F1 15FD11 YAC RPCl-1 257G22 RPCl-1 266J21 PAC RPCl-1 266J21, 257G22, 655N1, 163O13 776-d-7 (end clones) YAC end RPCl-1 201O9, 129G2 STS D17S798 STS RPCl-1 32H9, 153M23 681-c-S (end clones) YAC end RPCl-1 1027N14, 928F18, 1020l1, 880L8, 1167N14, 710N14, 841C13, 2H10, 863N19, 678O5, 624A6, 314l17 RPCl-1 243F6 PAC RPCl-1 1188C15, 572L14, 1105H14, 952l18, 682F9, 921H21, 626M5 RPCl-1 880L8 PAC lCRFc105F1060D1, lCRFc105E08156D1, lCRFc105B0832D1, lCRFc105C0471D1, lCRFc105B08115D1, lCRFc105F1065D1, lCRFc105B07149D1, lCRFc105H1244D1, lCRFc105G0372D1, lCRFc105C04161D1, lCRFc105F09116D1 RPCl-1 880L8 (end clones) PAC end RPCl-1 829O10, 733P21, 835C10, 758F20, 605A3, 758E20 RPCl-1 835C10 PAC RPCl-1 79l2, 91O8, 105C17, 307B7, 542l11, 1167N14

[0214] TABLE 3 Determination of PAC clone Insert slzes by FIGE PAC clone Insert size RPCl-1 257G22  ˜87 kb   RPCl-1 55N16 304 kb RPCl-1 118B4  94 kb RPCl-1 243F6 129 kb RPCl-1 252F1 126 kb RPCl-1 201O9 141 kb RPCl-1 129G2 141 kb RPCl-1 1027N14 ˜130 kb   RPCl-1 928F18 170 kb RPCl-1 1020l1  70 kb RPCl-1 880L8 140 kb RPCl-1 710N14 ˜155 kb   RPCl-1 841C13  ˜98 kb   RPCl-1 2H10  ˜98 kb   RPCl-1 863N19 ˜155 kb   RPCl-1 678O5 ˜100 kb   RPCl-1 624A6 112 kb RPCl-1 572L14 ˜55-60 kb    RPCl-1 194A10  83 kb RPCl-1 32H9  88 kb RPCl-1 153M23  77 kb RPCl-1 829O10  80 kb RPCl-1 266J21 105 kb

[0215] TABLE 4 Sequences of 9 hybridization probes, specific for human chromosome 17 and generated by PCR on cosmid DNA template. Probe N°. #1 Primer^(a) (+) 5′-gaactgtcgccactcgtctg-3′ (−) 5′-acaccacagcgggatgatgt-3′ Position^(b)  9,359  9,874 Probe gaactgtcgccactcgtctggatgtgcattcgcaagctgccctgcgagtgctgtcaattgcaaattcagtcaattaggact sequence cagcatcaggcagctggaatgacacttcctctagtgaagcctcagagagcttacttatgccactcatttcagatggaga gcaagggtttgaatttgccccctctagagcccatgctcgcacttctgcaccgtatggcaaggttgagtcaggcagagctt gtcctcaagaagcccgcagtctgctgtggagagaggtgggcagtaaaacacatgctccagctgtagccatgtccctgt ctggaccagttaactcaattcagtttcaacttgcagacagctccttcaagccaatcagacatcagagaaataaaaagg atgtgacaaaagagagtgaggtggagaacacagtctccctctcctggacaaactgctctgggaaagtttgcacttgga ggtagatggggatgaagccaacacatcatcccgctgtggtgt Probe N° #2 Primer^(a) (+) 5′-aaccccgagtgttgctgaaa-3′ (−) 5′-ccattccccaagcacctcat-3′ Position^(b) 14,748 15,536 Probe aaccccgagtgttgctgaaatcaaaaggctatgaagaagcagaagtcttgtgaaggtgttgttgggaaagagaattgtt sequence cagatatgggtaagccactgaaaggtgtcttgatggttcatctgaacatgggctgagaacctgaagcagatacagaaa gcaagatgaccatgctggaacaatgaggacagggaggatgggcagagtggctagggagaaggaggtcttggatg aacatctgagatagaaaatgcccctctggcggctcatgtgtgctctcctgatcacatgctctgacatggcaggccccag ccattctccttacgaacgacacttgctgggaatccctactgggcacacacaacccagtctacaagatagagtggtcc aaaccccccatcctgggctgtggtgcttggaagatgcaacacaccgactggctacgctgcagttactgcatctttctggc tggctggcaagcaaacttcccactgcctttctccccaggcctgaccccattatgacaatggagccattgttctgaacagg ggccatgaggcagctgggactggccgaccctatgctggctcctcacatctcagaagtcaagccctcagacagatcaa ggaaagtgataaaattcagcgggaagcaggacagagtattgggggtcctgagccagcttcttcctctcagttctgtatc gtgatgggaatgaataatcaccccaattacagagcaacctgaaggagacaaaatcacttaactaaatgaggtgcttg gggaatgg Probe N° #3 Primer^(a) (+) 5′-agagctgcacggcacttctc-3′ (−) 5′-cacgatgcaaaacgaactac-3′ Position^(b) 18,773 19,237 Probe agagctgcacggcacttctcagcccacaagcccactttccatgcaccaagcccaccccaccttacacttggcccctgg sequence ctccttaaccttgagctcagcctccatcttaaggtttcaccaagctgcccttcactatccggtctgttggagattttccagcta gactctgctagccacgctctgactctgtttgacccagctcccggggagaagccaagccgactcccttccactccctctgc ccccgctgctgtcttacacagccgtaccttcctttcctttgccccctctcttggctggtgctgagccacatttagcaccagcct ccaagagcaagcaccctgtgctaacttgggctcgtgtctcgcaagctaccaccctgatcttagaaacccgaagctcag aaaatagttcctatcttatgtgcgttatactcttcaagaaggtagttcgttttgcatcgtg Probe N° #4 Primer^(a) (+) 5′-gtttggggagattttgagtgtg-3′ (−) 5′-gggcagcagaccttagcaact-3′ Position^(b) 24,246 24,723 Probe gtttggggagattttgagtgtgtgggtggcagaaggtacttttaggttggggtcacagtgcagcgggccgagcaccaaa sequence gcacagatattctagaactggggttctacatcagactactactgtgagagccaagaggctcaaagcccccagagggt gactcattcttccagccctccgcctcctcctgcctgtccaggtcatcttgatcatcccattatcagaactgctggaggaatc atctggaaggcttgaagtgactggggggcatccgctgggttgtgagagctgctcggagggtcccttgtctgtcccagtcc acctcctccacccaccttatgctgtcaccccctgcccaggactggacctccattcaactcttctgagcagaaggagcag aaaccatcctatctctgcactggcctggaatggacagtgctccccagcatggttctagggagttgctaaggtctgctgcc c Probe N° #5 Primer^(a) (+) 5′-tcccaaaaggccagtttcacac-3′ (−) 5′-tctgcaggcgtctcatctcaac-3′ Position^(b) 30,057 30,734 Probe tcccaaaaggccagtttcacacactccattaatgctggctgccactgggacaattacagacagacagcttttcccatttg sequence agcaacttcttaaatttaaaaagcaactgtgcaggaaggaaggagacatgtggctgctctactacagaccttgtaaaa ggaggttcttctatgctattacccaccccctcccatacctacctttcctaccacacacaagagctgaaataaaagttgcatt tcacttgtgttgtggctgttattttattttacactccttgcttaaaaaaaaaaaaagtcttcacttaaaaaaaaatacatcacc caaacatgtctgagattttttgcaaggcttgggtctgaacccagtgcctttgataggggcatttttcttagcctgctgtggcta aagatgggcatggtcggatttcactcgcttggattaggatggacttggccctaatattttgtttcttaatgattcttccaattttta agtgtcccaagagatagctttgactttccaccccagcctgctgatgttatcttcctaggaactgctacatcttttaatacaac ctgtattcaagttctccttataggacctgagagattcaactggcagcatttaggactaccaggaatctccagtctggcgttg agatgagacgcctgcaga Probe N° #6 Primer^(a) (+) 5′-cccctcagctctgtgcattt-3′ (−) 5′-tccctgctgaatgagtgtttg-3′ Position^(b) 36,914 37,391 Probe cccctcagctctgtgcattttgtctacaagcaaggtgactttgggtttagtgtgttcatgtttcaacaagaatgtaagtttggg sequence atcagacatatgttacccctgttggatagtagctttgcaatcagtctttgcaaaaaatatccagaacaaggctagaacaa ggtggtacagaaacaaataacacgtgttacagttacatatgagcttggattacctcctttatagaaggaagtggagacat ccttcatgcagagatttaggatctctcactagcactaaccctcttgcccccacctagtgtttatttcaatcacccctgttgctttt tatcaaatgaaagatacagatccacttttaagagtaaagaagagaggaagcacagtttattaattacccattggtatccc aaggacttgtgcttccattatctcattgttttattcattcattaatccaaacactcattcagcaggga Probe N° #7 Primer^(a) (−) 5′-gaacctggtctacaaattatac-3′ (−) 5′-gactgggaccaatttgttcttc-3′ Position^(b) 42,102 42,774 Probe gaacctggtctacaaattatacaccctggcatgtccaaaagcaaaatgctgcctacatctcctgaaaatgcaggaatgt sequence cagaaaagctgctgaagtggtggctaccaggagctccaggggcctagcacccactcccagcccgaccctggggtg gggagggtggtgctcttcagagtggctcattttagagctgactacccaagtgcagaagaaacaacgttttaaatatatcg ggcagcagagcagctagatattaaggttcttctttgcaggacatcatgaaatattgttcatgacgaccctgaccctgggtt gggcgcgggtgctcttcagagtggctcattttagagctgacttcccaagtgcagaagaaacaactttttaaatacgtcgg gtaacagagcagctagacattacggttcttctttgcagaacatcatgaaatattgatgttaagctaaaacgaatataataa atgtatgattgcctgctaaattggtcattatcttttttagattctggctttgacagaaagtagcaggccccaatggtttaagaa agaaaggaaaaaatttttttaattgaggaaatcatatccacgtctttttttttttaattgttgaaaagatgtccacagtcagattt cagaggaagaacaaattggtcccagtc Probe N° #8 Primer^(a) (+) 5′-gtacacccactcacctgtgat-3′ (−) 5′-tctaagggggaaaagtaaacaa-3′ Position^(b) 46,377 47,137 Probe gtacacccactcacctgtgatgtacttaatggagcaggagggaacaggctgccatcaaagctaactcctggaaatga sequence cctagaacccacagcctgtctcagccgtgctgcatgttccagcagggaacaaagcgactgttgtattatgtaaaattact tacctgataataaaatgtttgtggattggataaatttgaacggatatattgtttccttcaccccacccccactagtggcaaaa gctgctctgtatgaatctgagtacatttctgtgacagtattcctcatatgtacagcattctatgtgaatcatctcccaaaaattg ccatggggtcattatccccagttcttaactagagaaactgagattctggaagtccctctgaatggcccatacttccccagg tgtctctgcaggaaacaatgtggacaatcacagtagttggaaggacaatgactgacctaatggagttcaggacgctat gactgttggcacctgatgtgcacagctgctcccatctgcgcagagagaatataaaggcagtggcgctgaaacatctgc tgctttcactcaccatcaagatggaactgactgtacatgcaagcaaattttgatgaagagagtgatctcagagtgcgaa gataagttgtttctccttgacacctaggaatgcacctggccaagaccctcagttgaaagacaatatcaaataaatgcaa aatctaaatatccatgtgcttgtttacttttcccccttaga Probe N°. #9 Primer^(a) (+) 5′-gttgtacccccttgacttca-3′ (−) 5′-gtgcccagcaggagattcaat-3′ Position^(b) 38,018 38,584 Probe ggtgtacccccttgacttcacctgaatgtcagggcaaggccaggagcatgcaggaggcttaaagattgggaacccct sequence attcttgggccttctccccattctttctggagcaattggaagaggcccatgggagggaggtgactgtcatgatgtccccca ctatgaactatgggaatggctggagggtcactgggcctggtgctccagctgcctgacctgcagggaagtggtacctgc aggacctacagtgagggagtgttgacaccctggctctgggaaggagctcatggaaagttgggtgaacttcttgttagac tacgcaggctttcagaagtgcattccatacggagtggggtggcctccccagggaggagcagagggcagccactgga acaagctacagctacaaaagaccacctttatccctctcaagttctcccaggggcccctgtgtctgcctgtactagagga agtttccaaaggattttcctttccccaggatgaagaatgaggccacactgccaaagcaagatctcgtgctatgtgtgattg aatctcctgctgggcac

[0216] TABLE 5 Overview of exons of a novel gene family, comprising tumor suppressor genes Source (clone name)³ Exon type¹ Exon name² Size #aa Type⁴ Genbank Acc. No. Clone No. Remark ex0.1 B02AT09 11 BAC AL356581.2 RP5-1020C22 B01AT14 11 BAC AL354666.3 RP11-87L17 KIA-AT00 11 cDNA AB033071 KIAA1245 ex0.2 AK0OAT00 13 cDNA AK00726 HEP17004 ex0.3 AE02AT01 11 EST checked W58508 zd20d07.s1 ex1.1 B01AT08 70 BAC AL354666.3 RP11-87L17 B02AT14 70 BAC AL356581.2 RP5-1020C22 ex1.2 AK00AT05 70 cDNA AK00726 HEP17004 70 BAC AC060753.8 RP11-285C11 ex1.3 KIA-AT06 70 cDNA AB033071 KIAA1245 KIA-AT11 70 cDNA AB033071 KIAA1245 70 BAC AL359176.4 RP11-47D6 ex1.5 AK00AT01 70 cDNA AK00726 RP11-47D6 70 BAC AL109937.4 HSJ322E17 70 BAC AC060753.8 RP11-285C11 ex1.6 KIA-AT01 70 cDNA AB033071 KIAA1245 70 BAC AL359176.4 RP11-47D6 ex1.7 B01AT13 70 BAC AL354666.3 RP11-87L17 70 BAC AL355149 RP5-875O13 70 BAC L355800.5 RP11-284O17 70 BAC AC084206.1 RP11-305B17 70 BAC AC015618.3 RP11-4513 70 BAC AL137798.8 RP5-1182A14 ex1.8 B02AT08 70 BAC AL356581.2 RP5-1020C22 ex1.9 AE02AT02 67 EST checked W58508 zd20d07.s1 partial ex1.10 ex1.A 70 BAC AL109937.4 HSJ322E17 70 BAC AL138796.3 RP4-791M13 ex1.11 ex1.B 70 BAC AL109937.4 HSJ322E17 AG10AT02 70 EST checked AW173183 IMAGp998J126649Q2 ex1.12 ex1.C 70 BAC AL355149 RP5-875O13 ex1.13 ex1.D 70 BAC AL355800.5 RP11-284O17 ex1.E 70 BAC AL355800.5 RP11-284O17 ex1.F 70 BAC AC015618.3 RP11-4513 ex1.G 70 BAC AC015618.3 RP11-4513 70 BAC AL137798.8 RP5-1182A14 2 X in this BAC 70 cDNA AB051480 K1AA1693 ex1.14 ex1.H 70 BAC AC027727.3 RP11-18B10 70 BAC AC026900.3 RP11-798G11 ex1.15 ex1.I 70 BAC AC027727.3 RP11-18B10 70 BAC AC026900.3 RP11-798G11 ex1.16 ex1.M 70 BAC AC018381.3 RP11-5G21 ex1.O 70 BAC AL359093.9 RP11-35B4 ex1.Q 70 BAC AC018729.3 RP11-1F5 ex1.R 70 BAC AC018729.3 RP11-1F5 stop codon!! 70 BAC AL049715.25 RP4-646P11 ex1.17 ex1.J 70 BAC AC027209.2 RP11-277H3 ex1.K 70 BAC AL390296.3 RP11-555C20 ex1.18 ex1.U 70 BAC AC079074.1 CTD-2386B2 ex1.19 ex1.L 70 BAC AL390296.3 RP11-555C20 ex1.20 ex1.N 70 BAC AC018381.3 RP11-5G21 70 BAC AC007734.3 RP11-44O1 ex1.21 ex1.P 70 BAC AL359093.9 RP11-35B4 70 BAC AC024119.2 RP11-542J23 70 BAC AC073223.4 RP11580F15 ex1.22 ex1.S 70 BAC AL391068.7 RP11-288L16 ex1.T 70 BAC AC026565.3 RP11-702G12 ex1.23 ex1.V 70 BAC AC013673.2 RP11-20I21 ex1.W 70 BAC AL356004.4 RP11-94I2 70 BAC AL049742.7 RP4-565E6 ex1.24 ex1.X 70 BAC AL359752.7 RP5-1042I8 ex1.25 ex1.Y 71 BAC AC013627.3 RP11-11L4 71 AZ!! ex1.Z 71 BAC AL359258.4 RP11-483I13 ex1.AA 71 BAC AL356110.1 RP4-562N20 ex1.AB 71 BAC AL390038.5 RP11-131J3 ex1.26 70 BAC AL049742.7 RP4-565E6 ex1.27 70 BAC AL049715.25 RP4-646P11 ex2.1 KIA-AT07 35 cDNA AB033071 KIAA1245 KIA-ATI2 35 cDNA AB033071 KIAA1245 35 BAC AL359176.4 RP11-47D6 ex2.2 AK00AT06 35 cDNA AK00726 HEP17004 AC01AT01 35 EST checked AL042283 DKFZp434L1620 35 cDNA AB051480 KIA1693 ex2.3 KIA-AT02 35 cDNA AB033071 KIAA1245 2 X in this cDNA 35 BAC AC015618.3 RP11-45I3 35 BAC AL109937.4 RP3-322E17 35 BAC AL355800.5 RP11284O17 35 BAC AL356004.4 RP11-94I2 35 BAC AC024119.2 RP11-542J23 35 BAC AC023990.1 RP11-510K4 35 BAC AC018729.3 RP11-1F5 35 BAC AL138796.3 RP4-791M13 35 BAC AC073223.4 RP11-580F15 35 BAC AL359093.9 RP11-35B4 2 X in this BAC 35 BAC AC018381.3 RP11-5G21 2 X in this BAC 35 BAC AC027727.3 RP11-18B10 35 BAC AL359176.4 RP11-47D6 35 BAC AC026900.3 RP11-798G11 2 X in this BAC 35 BAC AL355149.4 RP5-875O13 35 BAC AC007734.3 RP11-44O1 2 X in this BAC ex2.4 AL117AT1 29 pred. cDNA AL117237 HS328E191 partial ex2.5 B01AT07 35 BAC AL354666.3 RP11-87L17 B02AT10 35 BAC AL356581.2 RP5-1020C22 35 BAC AC079074.1 CTD-2386B2 35 BAC AC021397.3 35 BAC AC015618.3 RP11-45I3 2 X in this BAC 35 BAC AC060753.8 RP11-285C11 35 BAC AL109937.4 RP3-322E17 35 BAC AC084209.1 RP11-305B17 3 X in this BAC 35 BAC AC027209.2 RP11-277H3 35 BAC AL355800.5 RP11284O17 2 X in this BAC 35 BAC AL356004.4 RP11-94I2 35 BAC AL356581.4 RP5-1020C22 35 BAC AL022240.8 RP3-328E19 35 BAC AL049742.7 RP4-565E6 35 BAC AL137798.8 RP5-1182A14 AG10AT03 35 EST checked AW173183 IMAGp998J126649Q2 ex2.6 B01AT12 35 BAC AL354666.3 RP11-87L17 ex2.7 B02AT07 35 BAC AL356581.2 RP5-1020C22 35 BAC AL356581.4 RP5-1020C22 ex2.8 ex2.A 35 BAC AC060753.8 RP11-285C11 35 BAC AL109937.4 RP3-322E17 ex2.9 ex2.B 35 BAC AC027209.2 RP11-277H3 ex2.10 ex2.C 35 BAC AL355149.4 RP5-875O13 ex2.11 ex2.D 35 BAC AL390296.3 RP11-555C20 ex2.12 ex2.E 35 BAC AL359752.7 RP5-1042I8 ex2.13 ex2.F 35 BAC AC024491.4 RP11-139D23 ex2.14 ex2.G 34 BAC AC053486.4 RP11-100A19 34 AZ!!! ex2.15 ex2.H 35 BAC AC026565.3 RP11-702G12 ex2.I 35 BAC AL391068.7 RP11-288L16 ex2.16 ex2.J 35 BAC AC015706.3 RP11-325P15 ex2.17 ex2.K 34 BAC AL356110.1 RP4-562N20 34 AZ!!! ex2.L 34 BAC AL359258.4 RP11-483I13 ex2.M 34 BAC AL390038.5 RP131J3 ex2.N 34 BAC AC013627.3 RP11-11L4 ex2.18 ex2.O 35 BAC AC024468.3 RP11-495P10 ex2.P 35 BAC AC018593.3 RP11-21M21 ex2.Q 35 BAC AL162612.3 RP4-691G10 ex2.S 35 BAC AC025992.3 RP11-277L2 ex2.T 35 BAC AL358813.4 RP11-353N4 ex2.19 ex2.R 35 BAC AC068979.9 RP11-134C18 ex2.21 35 BAC AL049715.25 RP4-646P11 2 X in this BAC 35 BAC AL137798.8 RP5-1182A14 35 BAC AL049742.7 RP4-565E6 ex2.22 35 BAC AL137798.8 RP5-1182A14 ex.3.1 KIA-AT08 71 cDNA AB033071 KIAA1245 KIA-AT13 71 cDNA AB033071 KIAA1245 71 BAC AL356004.4 RP11-94I2 2 X in this BAC 71 BAC AL359093.9 RP11-35B4 71 BAC AL359176.4 RP11-47D6 71 BAC AL049742.7 RP4-565E6 2 X in this BAC ex3.2 AK00AT02 71 cDNA AK00726 HEP17004 71 BAC AC060753.8 RP11-285C11 71 BAC AL109937.4 HSJ322E17 ex3.3 AK00AT07 71 cDNA AK00726 HEP17004 AL117AT02 71 pred. cDNA AL117237 HS328E191 AC01AT02 71 EST checked AL042283 DKFZp434L1620 71 BAC AC007734.3 RP11-44O1 71 BAC AC060753.8 RP11-285C11 71 BAC AC026900.3 RP11-798G11 71 BAC AC018381.3 RP11-5G21 71 BAC AL109937.4 HSJ322E17 2 X in this BAC 71 BAC AC027727.3 RP11-18B10 71 BAC AL138796.3 RP4-791M13 71 BAC AL022240.8 RP3-328E19 ex3.4 KIA-AT03 71 cDNA AB033071 KIAA1245 ex3.5 B01AT06 71 BAC AL354666.5 RP11-87L17 B01AT11 71 BAC AL354666.5 RP11-87L17 AE4AT01′ 71 EST checked AI239884 IMAGp998N074517 AB23AT01 71 EST checked AI239884 IMAGp998N074517 71 BAC AC015618.3 RP11-4513 71 BAC AL355800.5 RP11-284O17 ex3.6 B02AT06 71 BAC AL356581.4 RP5-1020C22 B02AT11 71 BAC AL356581.4 RP5-1020C22 71 BAC AL355149.4 RP5-875O13 2 X in this BAC AG10AT04 71 EST checked AW173183 IMAGp998J126649Q2 ex3.7 AE03AT02 71 EST checked H06312 IMAGp998I02268 ex3.8 ex3.A 71 BAC AC007734.3 RP11-44O1 ex3.D 71 BAC AC018381.3 RP11-5G21 ex3.9 ex3.B 71 BAC AC026900.3 RP11-798G11 ex3.I 71 BAC AC027727.3 RP11-18B10 ex3.10 ex3.C 71 BAC AL359176.4 RP11-47D6 ex3.11 ex3.E 71 BAC AC015618.3 RP11-45I3 ex3.G 71 BAC AL355800.5 RP11-284O17 71 BAC AL137798.8 RP5-1182A14 2 X in this BAC 71 cDNA AB051480 KIAA1693 ex3.12 ex3.F 71 BAC AC015618.3 RP11-45I3 ex3.H 71 BAC AL355800.5 RP11-284O17 ex3.13 ex3.J 71 BAC AC027209.2 RP11-277H3 ex3.L 71 BAC AL390296.3 RP11-555C20 ex3.14 ex3.K 71 BAC AC027209.2 RP11-277H3 ex3.15 ex3.M 71 BAC AL390296.3 RP11-555C20 ex3.16 ex3.N 71 BAC AC073223.4 RP11580F15 ex3.O 71 BAC AC024119.2 RP11-542J23 ex3.17 ex3.P 71 BAC AL359093.9 RP11-35B4 71 BAC AL049715.25 RP4-646P11 ex3.18 ex3.Q 71 BAC AC023783.2 RP11-759I1 71 BAC AL049715.25 RP4-846P11 ex3.19 ex3.R 71 BAC AC018729.3 RP11-1F5 ex3.20 ex3.S 71 BAC AL391068.7 RP11-288L16 ex3.T 71 BAC AC026565.3 RP11-702G12 ex3.21 ex3.U 71 BAC AL359752.7 RP5-1042I8 ex3.22 ex3.V 71 BAC AC013627.3 RP11-11L4 ex3.W 71 BAC AL359258.4 RP11-483I13 ex3.X 71 BAC AL356110.1 RP4-562N20 ex3.Y 71 BAC AL390038.5 RP11-131J3 ex3.23 ex3.Z 71 BAC AC053486.4 RP11-100A19 3 stop codons ex3.24 ex3.AA 71 BAC AC024491.4 RP11-139D23 1 stop codon ex3.25 71 BAC AL137798.8 RP5-1182A14 71 cDNA AB051480 KIAA1693 ex4.1 B01AT10 25 BAC AL354666.3 RP11-87L17 deleted in Vs.5 B02AT12 25 BAC AL356581.2 RP5-1020C22 25 BAC AL355149.4 RP5-875O13 25 BAC AC007734.3 RP11-44O1 25 BAC AC018381.3 RP11-5G21 25 BAC AL355800.5 RP11-284O17 2 X in this BAC 25 BAC AC015618.3 RP11-45I3 2 X in this BAC 25 BAC AC018729.3 RP11-1F5 25 BAC AL359093.9 RP11-35B4 25 BAC AL049715.25 RP4-646P11 25 BAC AL137798.8 RP5-1182A14 2 X in this BAC ex4.2 AI117AT3 25 pred. cDNA AL117237 HS328E191 B02AT05 25 BAC AL356581.2 RP5-1020C22 25 BAC AC024119.2 25 BAC AC007734.3 RP11-44O1 25 BAC AC018381.3 RP11-5G21 25 BAC AL390296.4 RP11-555C20 25 BAC AC073223.4 RP11-580F15 25 BAC AC027727.3 RP11-18B10 25 BAC AC026900.3 RP11-798G11 25 BAC AC027209.2 RP11-277H3 25 BAC AL022240.8 RP3-328E19 25 BAC AL049715.25 RP4-646P11 25 BAC AL137798.8 RP5-1182A14 AE04AT01 25 EST checked AI239884 IMAGp998N074517 AC01AT03 25 EST checked AL042283 DKFZp434L1620 AB23AT02 25 EST checked AI239884 IMAGp998N074517 ex4.3 KIA-AT14 25 cDNA AB033071 KIAA1245 AE02AT03 25 EST checked H06312 IMAGp998I02268 25 BAC AL359176.4 RP11-47D6 25 BAC AL356004.4 RP11-9412 ex4.4 AK00AT08 25 cDNA AK00726 HEP17004 25 BAC AL109937.4 RP3-322E17 25 BAC AC060753.8 RP11-285C11 ex4.5 AK00AT03 25 cDNA AK00726 HEP17004 25 BAC AL109937.4 RP3-322E17 25 BAC AC060753.8 RP11-285C11 ex4.6 KIA-AT04 25 cDNA AB033071 KIAA1245 25 BAC AC027727.3 RP11-18B10 25 BAC AC026900.3 RP11-798G11 25 BAC AC027209.2 RP11-277H3 25 BAC AL359176.4 RP11-47D6 25 BAC AL356004.4 RP11-94I2 25 BAC AL049742.7 RP4-565E6 ex4.7 KIA-AT09 25 cDNA AB033071 KIAA1245 ex4.8 B01AT05 25 BAC AL354666.3 RP11-87L17 25 BAC AL355149.4 RP5-875O13 AG10AT05 25 EST checked AW173183 IMAGp998J126649Q2 ex4.10 ex4.A 25 BAC AL109937.4 RP3-322E17 ex4.E 25 BAC AL138796.3 RP4-791M13 ex4.11 ex4.B 25 BAC AL390296.4 RP11-555C20 first a > g (from exon3) ex4.12 ex4.C 25 BAC AL355800.5 RP11-284O17 ex4.D 25 BAC AC015618.3 RP11-45I3 ex4.13 ex4.F 25 BAC AC018729.3 RP11-1F5 ex4.14 ex4.G 25 BAC AC053486.4 RP11-100A19 ex4.15 ex4.H 25 BAC AC026565.3 RP11-702G12 ex4.I 25 BAC AL391068.7 RP11-288L16 ex4.16 ex4.J 25 BAC AC024491.4 RP11-139D23 ex4.17 AE01AT04 25 EST checked AW160820 IMAGp998I196882 25 cDNA AB051480 KIAA1693 ex4.18 AG9AT04 25 EST checked AI500017 IMAGp998E065507Q2 25 cDNA AB051480 KIAA1693 ex5.1 B01AT09 70 BAC AL354666.3 RP11-87L17 deleted in Vs.5 B02AT13 70 BAC AL356581.4 RP5-1020C22 70 BAC AC015618.3 RP11-4513 70 BAC AL355149.4 RP5-875O13 70 BAC AL355800.5 RP11-284O17 2 X in this BAC 70 BAC AL137798.8 RP5-1182A14 ex5.2 KIA-AT10 70 cDNA AB033071 KIAA1245 ex5.3 AK00AT04 70 cDNA AK00726 HEP17004 70 BAC AC060753.8 RP11-285C11 70 BAC AL109937.4 HSJ322E17 ex5.4 KIA-AT05 70 cDNA AB033071 KIAA1245 70 BAC AL359176.4 RP11-47D6 ex5.5 ex5 + 6.N 70 BAC AC026900.3 RP11-798G11 ex5.6 ex5 + 6.R 70 BAC AC027727.3 RP11-18B10 1 stop codon ex5.7 ex5 + 6.L 70 BAC AC027209.2 RP11-277H3 ex5.8 ex5 + 6.H 70 BAC AC018729.3 RP11-1F5 ex5.9 ex5 + 6.C 70 BAC AC023990.1 RP11-510K4 ex5 + 6.D 70 BAC AL390296.3 RP11-555C20 ex5 + 6.F 70 BAC AL359093.9 RP11-35B4 ex5 + 6.G 70 BAC AC018729.3 RP11-1F5 ex5 + 6.I 70 BAC AC018381.3 RP11-5G21 70 BAC AL049715.25 RP4-646P11 ex5.10 ex5 + 6.B 70 BAC AC015618.3 RP11-45I3 ex5.11 ex5 + 6.K 70 BAC AL356004.4 RP11-94I2 70 BAC AL049742.7 RP4-565E6 ex5.12 ex5 + 6.V 70 BAC AL359752.7 RP5-1042I8 ex5.13 ex5 + 6.U 70 BAC AC015706.3 RP11-325P15 1 stop codon ex5.14 ex5 + 6.Y 70 BAC AL359258.4 RP11-483I13 ex5 + 6.Z 70 BAC AL390038.5 RP11-131J3 ex5 + 6.AB 70 BAC AC068979.9 RP11-134C18 ex5.15 ex5 + 6.AA 70 BAC AC013627.3 RP11-11L4 1 stop codon ex5.16 70 cDNA AB051480 KIAA1693 70 BAC AL137798.8 RP5-1182A14 ex6.1 AL117AT4 68 pred. cDNA AL117237 HS328E191 KIA-AT15 68 cDNA AB033071 KIAA1245 B02AT04 68 BAC AL356581.2 RP5-1020C22 AC01AT04 68 EST checked AL042283 DKFZp434L1620 68 BAC AL359176.4 RP11-47D6 68 BAC AL355149.4 RP5-875O13 68 BAC AL356004.4 RP11-94I2 68 BAC AL022240.8 RP3-328E19 AG10AT06 68 EST checked AW173183 IMAGp998J126649Q2 ex6.2 AK00AT09 68 cDNA AK00726 HEP17004 AE05AT01 23 EST checked AA704208 zj17a04.s1 partial 68 BAC AL109937.4 HSJ322E17 ex6.3 B01AT04 68 BAC AL354666.5 RP11-87L17 AE4AT02 68 EST checked AI239884 IMAGp998N074517 AB23AT03 68 EST checked AI239884 IMAGp998N074517 68 BAC AC015618.3 RP11-4513 68 BAC AL355800.5 RP11-284O17 68 BAC AL137798.8 RP5-1182A14 AG03AT02 68 EST checked AW468059 IMAGp998B027200Q2 68 cDNA AB051480 KIAA1693 ex6.4 AE03AT04 68 EST checked H06312 IMAGp998I02268 ex6.5 ex5 + 6.J 68 BAC AC018381.3 RP11-5G21 68 BAC AL049715.25 RP4-646P11 ex6.6 ex5 + 6.P 68 BAC AC024119.2 RP11-542J23 ex5 + 6.Q 68 BAC AC073223.4 RP11580F15 ex6.7 ex5 + 6.E 68 BAC AL390296.3 RP11-555C20 ex5 + 6.M 68 BAC AC027209.2 RP11-277H3 ex6.8 ex5 + 6.A 68 BAC AL109937.4 HSJ322E17 ex5 + 6.O 68 BAC AC026900.3 RP11-798G11 ex5 + 6.S 68 BAC AL138796.3 RP4-791M13 ex6.9 ex5 + 6.T 68 BAC AC053486.4 RP11-100A19 1 stop codon ex6.10 ex5 + 6.W 68 BAC AL391068.7 RP11-288L16 ex5 + 6.X 68 BAC AC026565.3 RP11-702G12 ex6.11 68 cDNA Combination of KIAA1245 and AB25 ex6.12 der_1AT01 68 genomic DNA = exon A ex7.1 B01AT03 18 BAC AL354666.3 RP11-87L17 AK00AT10 18 cDNA AK00726 HEP17004 AL117AT5 18 pred. cDNA AL117237 HS328E191 KIA-AT16 18 cDNA AB033071 KIAA1245 B02AT03 18 BAC AL356581.2 RP5-1020C22 E05AT02 18 EST checked AA704208 zj17a04.s1 AC01AT05 18 EST checked AL042283 DKFZp434L1620 AB25AT02 18 EST checked AL042839 DKFZp434G2022 AE03AT05 18 EST checked H06312 IMAGp998I02268 18 BAC AL022240.8 RP3-328E19 18 BAC AL049715.25 RP4-646P11 18 BAC AL137798.8 RP5-1182A14 18 cDNA AK024044 Y79AA1001711 18 RT-PCR HFB pKNB11 18 RT-PCR HFB pKNB16 18 RT-PCR HFB pKNB21 18 RT-PCR HFB pKNB26 18 RT-PCR HFB pKNB20 18 RT-PCR HFB pKNB23 18 RT-PCR HFB pKNB27 18 RT-PCR HFB pKNB28 AG03AT03 18 EST checked AW468059 IMAGp998B027200Q2 der_1AT02 18 genomic DNA = exon B AG10AT07 18 EST checked AW173183 IMAGp998J126649Q2 18 cDNA AB051480 KIAA1693 ex7.2 ex7.A 18 BAC AC026565.3 RP11-702G12 ex7.A 18 BAC AL391068.7 RP11-288L16 ex7.3 ex7.B 18 BAC AC015706.3 RP11-325P15 ex7.4 ex7.C 20 BAC AC053486.4 RP11-100A19 ex7.5 18 RT-PCR HFB pKNB10 ex8.1 AK00AT11 54 cDNA AK00726 HEP17004 54 BAC AC018381.3 RP11-5G21 54 BAC AC024119.2 RP11-542J23 54 BAC AC109937.4 HSJ322E17 54 BAC AL359093.9 RP11-35B4 54 BAC AC060753.8 RP11-285C11 54 BAC AL022240.8 RP3-328E19 AE03AT06 54 EST checked H06312 IMAGp998I02268 AG03AT04 54 EST checked AW468059 IMAGp998B027200Q2 ex8.2 AL117AT6 54 pred. cDNA AL117237 HS328E191 AE05AT03 54 EST checked AA704208 zj17a04.s1 AC01AT06 54 EST checked AL042283 DKFZp434L1620 54 BAC AC027209.2 RP11-277H3 54 BAC AL049715.25 RP4-646P11 ex8.3 KIA-AT17 27 cDNA AB033071 KIAA1245 27 cDNA AK024044 Y79AA1001711 27 RT-PCR HFB pKNB16 ex8.4 B01AT02 54 BAC AL354666.5 RP11-87L17 ex8.5 B02AT02 54 BAC AL356581.4 RP5-1020C22 54 BAC AL355149.4 RP5-875O13 54 BAC AC015618.3 RP11-45I3 54 BAC AL355800.5 RP11-284O17 54 BAC AL137798.8 RP5-1182A14 AB25AT03 54 EST checked AL042839 DKFZp434G2022 54 RT-PCR HFB pKNB21 AG10AT08 54 EST checked AW173183 IMAGp998J126649Q2 54 cDNA AB051480 KIAA1693 ex8.6 ex8.A 54 BAC AL109937.4 HSJ322E17 ex8.B 54 BAC AL138796.3 RP4-791M13 ex8.C 54 BAC AC026900.3 RP11-798G11 ex8.7 ex8.D 54 BAC AL356004.4 RP11-94I2 ex8.E 54 BAC AL359176.4 RP11-47D6 54 RT-PCGR HFB pKNB26 ex8.8 ex8.F 54 BAC AC027727.3 RP11-18B10 ex8.9 ex8.G 54 BAC AL390296.3 RP11-555C20 ex8.10 ex8.H 54 BAC AC053486.4 RP11-100A19 ex8.11 ex8.I 54 BAC AC026565.3 RP11-702G12 ex8.J 54 BAC AL391068.7 RP11-288L16 ex8.12 ex8.K 53 BAC AC015706.3 RP11-325P15 ex8.13 33 RT-PCR HFB pKNB27 33 RT-PCR HFB pKNB28 ex8.14 27 RT-PCR HFB pKNB10 ex9.1 AK00AT12 18 cDNA AK00726 HEP17004 KIA-AT18 18 cDNA AB033071 KIAA1245 18 cDNA AK024044 Y79AA1001711 AE03AT07 18 EST checked H06312 IMAGp998I02268 ex9.2 AL117AT7 18 pred. cDNA AL117237 HS328E191 AE05AT04 18 EST AA704208 zj17a04.s1 AC01AT07 18 EST checked AL042283 DKFZp434L1620 ex9.3 B01AT01 18 BAC AL354666.5 RP11-87L17 B02AT01 18 BAC AL356581.2 RP5-1020C22 18 BAC AC015618.3 RP11-45I3 18 BAC AC027727.3 RP11-18B10 18 BAC AC026900.3 RP11-798G11 18 BAC AL355147.2 RP11-78O9 18 BAC AL356004.4 RP11-94I2 18 BAC AL109937.4 HSJ322E17 18 BAC AC018381.3 RP11-5G21 18 BAC AL355800.5 RP11-284O17 18 BAC AL355149.4 RP5-875O13 18 BAC AC024119.2 RP11-542J23 18 BAC AL138796.3 RP4-791M13 18 BAC AL359176.4 RP11-47D6 18 BAC AC060753.8 RP11-285C11 18 BAC AC073223.4 RP11580F15 18 BAC AC07734.3 RP11-4401 18 BAC AC079074.1 CTD-2386B2 2 X in this BAC 18 BAC AL049715.25 RP4-646P11 18 BAC AL137798.8 RP5-1182A14 AB25AT04 18 EST checked AL042839 DKFZp434G2022 AG10AT09 18 EST checked AW173183 IMAGp998J126649Q2 18 cDNA AB051480 KIAA1693 ex9.4 ex9.A 18 BAC AC027209.2 RP11-277H3 ex9.5 ex9.B 18 BAC AC053486.4 RP11-100A19 ex9.6 ex9.C 18 BAC AC026565.3 RP11-702G12 ex9.D 18 BAC AL391068.7 RP11-288L16 ex9.7 18 BAC AL022240.8 RP3-328E19 ex9.8 AG03AT05 18 EST checked AW468059 IMAGp998B027200Q2 ex9.9 18 cDNA AL136890 DKFZp434D177 ex10.1 KIAR04A 57 cDNA AB033071 KIAA1245 KIAR05A 57 cDNA AB033071 KIAA1245 KIAR08A 57 cDNA AB033071 KIAA1245 KIAR09A 57 cDNA AB033071 KIAA1245 KIAR12A 57 cDNA AB033071 KIAA1245 KIAR13A 57 cDNA AB033071 KIAA1245 ex10.2 KIAR1A 57 cDNA AB033071 KIAA1245 57 cDNA AK024044 Y79AA1001711 ex10.3 AL117R1A 57 pred. cDNA AL117237 HS328E191 57 BAC AL022240.8 RP3-328E19 ex10.4 AL117R4A 57 pred. cDNA AL117237 HS328E191 57 BAC AL022240.8 RP3-328E19 ex10.5 E05R05SA 57 EST AL037724 DKFZp564A057 ex10.6 AL117R5A 57 pred. cDNA AL117237 HS328E191 57 BAC AL022240.8 RP3-328E19 ex10.7 E02R02SA 57 EST checked AL045522 DKFZp434J205 B01RA04 57 BAC AL354666.3 RP11-87L17 B02RA02 57 BAC AL356581.2 RP5-1020C22 B02RA06 57 BAC AL356581.2 RP5-1020C22 1b9RA03 57 5′RACE 2F53VIII 57 BAC AL137798.8 RP5-1182A14 R1d10ra2 57 RT-PCR 2F53VIII R1a11ra2 57 RT-PCR 2F53VIII AB06RA02 57 EST checked AL045522 DKFZp434J205 AB25RA01 57 EST checked AL042839 DKFZp434G2022 AB25RA04 57 EST checked AL042839 DKFZp434G2022 AB25RA07 57 EST checked AL042839 DKFZp434G2022 AG10RA01 57 EST checked AW173183 IMAGp998J126649Q2 57 cDNA AB051480 KIAA1493 ex10.8 E03R04SA 56 EST AL043132 DKFZp434D0623 ex10.9 AL117R2A 57 pred. cDNA AL117237 HS328E191 AL117R6A 57 pred. cDNA AL117237 HS328E191 AC01RA02 57 EST checked AL042283 DKFZp434L1620 57 BAC AL022240.8 RP3-328E19 2 X in this BAC ex10.10 E09R01A 57 EST AA570017 nm48h10 2a1RA02 57 5′RACETR14 ex10.11 AC03RA01 57 EST checked AL043132 DKFZp434D0623 AC03RA04 57 EST checked AL043132 DKFZp434D0623 E10R02SA 57 EST AW173183 xj84d06.x1 1b9RA02 57 5′RACE2F53VIII 2g2Ra02 57 5′RACE 7A 2g7Ra02 57 5′RACE 7A AB18RA01 57 EST checked AL044108 DKFZp434M0628 2c4RA02 57 5′RACE SK-N-SH AB25RA02 57 EST checked AL042839 DKFZp434G2022 AB25RA05 57 EST checked AL042839 DKFZp434G2022 AB25RA08 57 EST checked AL042839 DKFZp434G2022 AG01RA02 57 EST checked AL043174 DKFZp434F2323Q2 AG10RA02 57 EST checked AW173183 IMAGp998J126649Q2 57 cDNA AB051480 KIAA1693 ex10.12 KIAR02A 57 cDNA AB033071 KIAA1245 KIAR10A 57 cDNA AB033071 KIAA1245 KIAR14A 57 cDNA AB033071 KIAA1245 1b7RA02 57 5′RACE 2F53VIII 2b10RA02 57 5′RACE TR14 ex10.13 KIAR06A 57 cDNA AB033071 KIAA1245 ex10.14 AK00R01A 57 cDNA AK00726 HEP17004 AL050R2A 57 cDNA AL050141 DKFZp586O031 AE05RA01 57 EST checked AA704208 zj17a04.s1 AG01RA04 57 EST checked AL043174 DKFZp434F2323Q2 AG04RA02 57 EST checked AI049567 IMAGp998M024318Q2 AG02ra06 57 EST checked AL037724 DKFZp564A057Q3 AG02ra09 57 EST checked AL037724 DKFZp564A057Q3 ex10.15 AK00R02A 57 cDNA AK00726 HEP17004 AL050R3A 57 cDNA AL050141 DKFZp586O031 1b3RA02 57 5′RACE 2F53VIII 1g1RA02 57 5′RACE 7A 1aBRA02 57 5′RACE 2F53VIII 1e2RA02 57 5′RACE 7A 1g1RA02 57 5′RACE 7A 57 BAC AL049715.25 RP4-646P11 2 X in this BAC AG01RA02 57 EST checked AL043174 DKFZp434F2323Q2 AG01RA05 57 EST checked AL043174 DKFZp434F2323Q2 AG04RA03 57 EST checked AI049567 IMAGp998M024318Q2 AG06RA04 57 EST checked AI537172 IMAGp998E105403Q2 AG06RA010 57 EST checked AI537172 IMAGp998E105403Q2 AG11RA03 57 EST checked AI953463 IMAGp998F196353Q2 AG11RA06 57 EST checked AI953463 IMAGp998F196353Q2 ex10.16 B01RA01 57 BAC AL354666.3 RP11-87L17 ex10.17 B01RA03 57 BAC AL354666.3 RP11-87L17 B02RA05 57 BAC AL356581.2 RP5-1020C22 AB06RA03 57 EST checked AL045522 DKFZp434J205 ex10.18 AF16R2A 57 mRNA AF161426 HSPC308 2f1RA02 57 5′RACE SK-N-SH ex10.19 1h5RA02 57 5′RACE TR14 AE03RA02 57 EST checked H06312 IMAGp998I02268 ex10.20 AB18RA01 57 EST checked AL044108 DKFZp434M0628 AC03RA03 57 EST checked AL043132 DKFZp434D0623 ex10.21 2d5RA02 57 5′RACE SK-N-SH AG06RA07 57 EST checked AI537172 IMAGp998E105403Q2 ex10.22 AC01RA01 57 EST checked AL042283 DKFZp434L1620 ex10.23 57 BAC AL049715.25 RP4-646P11 ex10.24 57 BAC AL049715.25 RP4-646P11 ex10.25 57 BAC AL049715.25 RP4-646P11 ex10.26 AE03RA01 57 EST checked H06312 IMAGp998I02268 ex10.27 AC01RA01 57 EST checked AL043174 DKFZp434F2323Q2 ex10.28 AG03RA01 57 EST checked AW468059 IMAGp998B027200Q2 ex10.29 AG08RA01 57 EST checked AW238577 IMAGp998C056777Q2 ex10.30 AG06RA03 57 EST checked AI537172 IMAGp998E105403Q2 AG06RA06 57 EST checked AI537172 IMAGp998E105403Q2 AG06RA09 57 EST checked AI537172 IMAGp998E105403Q2 AG11RA02 57 EST checked AI953463 IMAGp998F196353Q2 AG11RA05 57 EST checked AI953463 IMAGp998F196353Q2 ex10.31 AG02ra03 57 EST checked AL037724 DKFZp564A057Q3 ex10.32 AG02ra04 57 EST checked AL037724 DKFZp564A057Q3 ex10.34 AG02ra07 57 EST checked AL037724 DKFZp564A057Q3 ex10.35 AE1ra02 57 EST checked AW160820 IMAGp998I196882 ex10.36 AG9ra01 57 EST checked AI570017 IMAGp998E065507Q2 ex10.37 57 cDNA AL136890 DKFZp434D177 ex11.1 BRPEX1A 57 genomic DNA = exon x AB06RA01 57 EST checked AL045522 DKFZp434J205 AB13RA01 57 EST checked AA705685 IMAGp998I041023 AB14RA01 57 EST checked AA701673 IMAGp998HI01019 AC03RA02 57 EST checked AL043132 DKFZp434D0623 AC03RA05 57 EST checked AL043132 DKFZp434D0623 AD02RA01 57 EST checked AA322028 EST24684 B01RA02 57 BAC AL354666.3 RP11-87L17 B02RA01 57 BAC AL356581.2 RP5-1020C22 B02RA04 57 BAC AL356581.2 RPS-1020C22 AB18RA03 57 EST checked AL044108 DKFZp434M0628 2H2RA01 57 5′RACE TR14 RT1c6ra1 57 RT-PCR 2F53VIII R1d10ra1 57 RT-PCR 2F53VIII RT1a7ra1 57 RT-PCR 2F53VIII RT1b2ra1 57 RT-PCR 2F53VIII RT1b7ra1 57 RT-PCR 2F53VIII R1a11ra1 57 RT-PCR 2F53VIII RT1a1ra1 57 RT-PCR 2F53VIII AB25RA03 57 EST checked AL042839 DKFZp434G2022 AB25RA06 57 EST checked AL042839 DKFZp434G2022 AB25RA09 57 EST checked AL042839 DKFZp434G2022 AG10RA03 57 EST checked AW173183 IMAGp998J126649Q2 57 cDNA AB051480 KIAA1693 ex11.2 E10R03LA 57 EST AW173183 xj84d06.x1 ex11.3 E05R02LA 57 EST AL037724 zj17a04.s1 E09R02LA 57 EST AA570017 nm48h10.s1 E11R02LA 57 EST AI537172 tp01b05.x1 AL117R3A 57 pred. cDNA AL117237 HS328E191 AL117R7A 57 pred. cDNA AL117237 HS328E191 AK00R03A 57 cDNA AK00726 HEP17004 AL050R1A 57 cDNA AL050141 DKFZp586O031 AL050R4A 57 cDNA AL050141 DKFZp586O031 57 BAC AL022240.8 RP3-328E19 2 X in this BAC 57 BAC AL049715.25 RP4-646P11 2 X in this BAC AE03RA02 57 EST checked H06312 IMAGp998I02268 AG01RA03 57 EST checked AL043174 DKFZp434F2323Q2 AG01RA06 57 EST checked AL043174 DKFZp434F2323Q2 AG03RA01 57 EST checked AW468059 IMAGp998B027200Q2 AG04RA04 57 EST checked AI049567 IMAGp998M024318Q2 AG08RA02 57 EST checked AW238577 IMAGp998C056777Q2 AG06RA02 57 EST checked AI537172 IMAGp998E105403Q2 AG06RA05 57 EST checked AI537172 IMAGp998E105403Q2 AG06RA08 57 EST checked AI537172 IMAGp998E10540302 AG06RA011 57 EST checked AI537172 IMAGp998E105403Q2 AGIIRA04 57 EST checked AI953463 IMAGp998F196353Q2 AG11RA07 57 EST checked AI953463 IMAGp998F196353Q2 ex11.4 E06R02LA 57 EST AI909921 IL-BT228-060599-008 ex11.5 KIAR11A 57 cDNA AB033071 KIAA1245 KIAR03A 57 cDNA AB033071 KIAA1245 KIAR07A 57 cDNA AB033071 KIAA1245 KIAR15A 57 cDNA AB033071 KIAA1245 ex11.6 AF116R3A 57 mRNA AF161426 HSPC308 ex11.7 RT1a4ra1 57 RT-PCR 2F53VIII ex11.8 RT1a8ra1 57 RT-PCR 2F53VIII ex11.9 AB06RA04 57 EST checked AL045522 DKFZp434J205 ex11.10 AG02ra11 57 EST checked AL037724 DKFZp564A057Q3 ex11.11 57 cDNA AL136890 DKFZp434D177 ex12.1 E17R01LB 35 EST AW851278 IL3-CT0220-170200-067-E01 E06R02LB 35 EST AI909921 IL-BT228-060599-008 ex12.2 KIAR03B 37 cDNA AB033071 KIAA1245 KIAR07B 37 cDNA AB033071 KIAA1245 KIAR11B 37 cDNA AB033071 KIAA1245 AF131R1B 37 mRNA AF131738 24976 AG01RB07 37 EST checked AL043174 DKFZp434F2323Q2 ex12.3 E05R02LB 37 EST AL037724 zj17a04.s1 AL117R3B 37 pred. cDNA AL117237 HS328E191 AL117R7B 37 pred. cDNA AL117237 HS328E191 AL050R1b 37 cDNA AL050141 DKFZp586O031 2c3RB01 37 5′RACE SK-N-SH 37 BAC AL022240.8 RP3-328E19 37 BAC AL049715.25 RP4-646P11 2 X in this BAC AG01RB01 37 EST checked AL043174 DKFZp434F2323Q2 AC01RB04 37 EST checked AL043174 DKFZp434F2323Q2 AG04RB01 37 EST checked AI049567 IMAGp998M024318Q2 AG06RB02 37 EST checked AI537172 IMAGp998E105403Q2 AG06RB05 37 EST checked AI537172 IMAGp998E105403Q2 AG06RB08 37 EST checked AI537172 IMAGp998E105403Q2 AG11RB01 37 EST checked AI953463 IMAGp998F196353Q2 AG11RB04 37 EST checked AI953463 IMAGp998F196353Q2 ex12.4 E03R03LB 38 EST AL043132 DKFZp434D0623 AB18RB04 38 EST checked AL044108 DKFZp434M0628 AC03RB03 38 EST checked AL043132 DKFZp434D0623 AC03RB06 38 EST checked AL043132 DKFZp434D0623 ex12.5 BRPEX2B 38 genomic DNA = exon y AB06RB01 38 EST checked AL045522 DKFZp434J205 AB03RB01 38 EST checked AL040932 DKFZp434K1515 AD02RB01 38 EST checked AA322028 EST24684 B01RB01L 38 BAC AL354666.3 RP11-87L17 B02RB02L 38 BAC AL356581.2 RP5-1020C22 RT1b2RB2 38 RT-PCR 2F53VIII RT1a8RB2 38 RT-PCR 2F53VIII RT1a7RB2 38 RT-PCR 2F53VIII RT1a4RB2 38 RT-PCR 2F53VIII RT1a1RB2 38 RT-PCR 2F53VIII R1d10RB2 38 RT-PCR 2F53VIII R1a11RB2 38 RT-PCR 2F53VIII AB25RA03 38 EST checked AL042839 DKFZp434G2022 AB25RA06 38 EST checked AL042839 DKFZp434G2022 AB25RA09 38 EST checked AL042839 DKFZp434G2022 ex12.6 B02RB01L 38 BAC AL356581.2 RP5-1020C22 AB06RB04 38 EST checked AL045522 DKFZp434J205 ex12.7 AB13RB01 25 EST checked AA705685 IMAGp998I041023 partial B14RB01 25 EST checked AA701673 IMAGp998H101019 partial ex12.8 AG07RB01 37 EST checked AA609104 IMAGp998B132576Q2 ex12.9 AG02RB08 37 EST checked AL037724 DKFZp564A057Q3 ex12.10 AG02RB05 37 EST checked AL037724 DKFZp564A057Q3 ex13.1 E03R04SB 18 EST AL043132 DKFZp434D0623 diff. From EST checked ex13.2 E02R02SB 18 EST AL045522 DKFZp434J205 E10R01SB 18 EST AW173183 xj84d06.x1 KIAR13B 18 cDNA AB033071 KIAA1245 KIAR12B 18 cDNA AB033071 KIAA1245 KIAR09B 18 cDNA AB033071 KIAA1245 KIAR08B 18 cDNA AB033071 KIAA1245 KIAR05B 18 cDNA AB033071 KIAA1245 AL117R5B 18 pred. cDNA AL117237 HS328E191 KIAR01B 18 cDNA AB033071 KIAA1245 AL117R1B 18 pred. cDNA AL117237 HS328E191 AL117R4B 18 pred. cDNA AL117237 HS328E191 KIAR04B 18 cDNA AB033071 KIAA1245 AK00R1B 18 cDNA AK00726 HEP17004 B01RB02S 18 BAC AL354666.5 RP11-87L17 B02RB04S 18 BAC AL356581.2 RP5-1020C22 AL050R2B 18 cDNA AL050141 DKFZp586O031 1b3RB02S 18 5′RACE 2F53VIII 1b7RB02S 18 5′RACE 2F53VIII 1b9RB02S 18 5′RACE 2F53VIII 1e2rRB01 18 5′RACE 7A 1f4RBO1 18 5′RACE 7A 2g2RB02 18 5′RACE 7A AB18RB02 18 EST checked AL044108 DKFZp434M0628 AC03RB04 18 EST checked AL043132 DKFZp434D0623 1h5RB02 18 5′RACE TR14 2a8RB01 18 5′RACE TR14 2a1RB02 18 5′RACE TR14 2b10RB02 18 5′RACE TR14 2c4RB02 18 5′RACE SK-N-SH 2f1RB01 18 5′RACE SK-N-SH 2d5RB02 18 5′RACE SK-N-SH 18 BAC AL109937.4 HSJ322E17 18 BAC AL390296.4 RP11-555C20 18 BAC AC027727.3 RP11-18B10 18 BAC AC023990.1 RP11-510K4 2 X in this BAC 18 BAC AL356581.4 RP5-1020C22 18 BAC AC024119.2 RP11-542J23 3 X in this BAC 18 BAC AC018381.3 RP11-5G21 5 X in this BAC 18 BAC AL355800.5 RP11-284O172 2X in this BAC 18 BAC AC026900.3 RP11-798G11 18 BAC AL359093.9 RP11-35B4 8 X in this BAC 18 BAC AC079074.1 CTD-2386B2 18 BAC AL355149.4 RP5-875O13 18 BAC AL356004.4 RP11-94I2 18 BAC AC073223.4 RP11580F15 2 X in this BAC 18 BAC AL138842.4 RP4-679C16 2 X in this BAC 18 BAC AL138796.3 RP4-791M13 18 BAC AC018729.3 RP11-1F5 7 X in this BAC 18 BAC AC015618.3 RP11-45I3 18 BAC AC007734.3 RP11-44O1 6 X in this BAC 18 BAC AL355505.7 RP4-634B11 7 X in this BAC 18 BAC AC084206.1 RP11-305B17 2 X in this BAC 18 BAC AL359176.4 RP11-47D6 3 X in this BAC 18 BAC AL139152.2 RP4-704D21 18 BAC AC060753.8 RP11-285C11 5 X in this BAC R1a11RB3 18 RT-PCR 2F53VIII R1d10Rb3 18 RT-PCR 2F53VIII AC01RB01 18 EST checked AL042283 DKFZp434L1620 18 BAC AL022240.8 RP3-328E19 3 X in this BAC 18 BAC AL049715.25 RP4-646P11 2 X in this BAC 18 BAC AL137798.8 RP5-1182A14 R1a11rb3 18 RT-PCR 2F53VIII R1d10rb3 18 RT-PCR 2F53VIII AE03RB01 18 EST checked H06312 IMAGp998I02268 AB06RB02 18 EST checked AL045522 DKFZp434J205 AB25RA01 18 EST checked AL042839 DKFZp434G2022 AB25RA04 18 EST checked AL042839 DKFZp434G2022 AB25RA07 18 EST checked AL042839 DKFZp434G2022 AG01RB02 18 EST checked AL043174 DKFZp434F2323Q2 AG01RB05 18 EST checked AL043174 DKFZp434F2323Q2 AG03RB01 18 EST checked AW468059 IMAGp998B027200Q2 AG04RB02 18 EST checked AI049567 IMAGp998M024318Q2 AG06RB03 18 EST checked AI537172 IMAGp998E105403Q2 AG06RB06 18 EST checked AI537172 IMAGp998E105403Q2 AG06RB09 18 EST checked AI537172 IMAGp998E105403Q2 AG11RA02 18 EST checked AI953463 IMAGp998F196353Q2 AG11RA05 18 EST checked AI953463 IMAGp998F196353Q2 AG10RA01 18 EST checked AW173183 IMAGp998J126649Q2 18 cDNA AB051480 KIAA1693 ex13.3 AC03RB02 18 EST checked AL043132 DKFZp434D0623 AC03RB05 18 EST checked AL043132 DKFZp434D0623 KIAR02SB 18 cDNA AB033071 KIAA1245 KIAR06B 18 cDNA AB033071 KIAA1245 KIAR10B 18 cDNA AB033071 KIAA1245 KIAR14B 18 cDNA AB033071 KIAA1245 E10R02SB 18 EST AW173183 xj84d06.x1 E11R01SB 18 EST AI537172 tp01b05.x1 AL117R2B 18 pred. cDNA AL117237 HS328E191 AL117R6B 18 pred. cDNA AL117237 HS328E191 E09R01SB 18 EST AA570017 tr91b03.x1 B01RB01′ 18 BAC AL354666.3 RP11-87L17 AC03RB02 18 EST checked AL043132 DKFZp434D0623 AL050R3B 18 cDNA AL050141 DKFZp586O031 1b1RB01S 18 5′RACE 2F53VIII 1b3RB01S 18 5′RACE 2F53VIII 1b4RB01 18 5′RACE 2F53VIII 1b7RB01S 18 5′RACE 2F53VIII 1b9RB01S 18 5′RACE 2F53VIII 1c11RB01S 18 5′RACE 2F53VIII 1a8RB01 18 5′RACE 2F53VIII 2g2RB01 18 5′RACE 7A 2g7RB01 18 5′RACE 7A AB18R803 18 EST checked AL044108 DKFZp434M0628 1h5RB01 18 5′RACE TR14 1h3RB01 18 5′RACE TR14 2b2RB01 18 5′RACE TR14 2a1RB01 18 5′RACE TR14 2c4RB01 18 5′RACE SK-N-SH RT1a4RB1 18 RT-PCR 2F53VIII RT1b7RB1 18 RT-PCR 2F53VIII RT1a8RB1 18 RT-PCR 2F53VIII RT1a7RB1 18 RT-PCR 2F53VIII RT1b2RB1 18 RT-PCR 2F53VIII RT1a1RB1 18 RT-PCR 2F53VIII R1a11RB1 18 RT-PCR 2F53VIII R1d10RB1 18 RT-PCR 2F53VIII AC01RB02 18 EST checked AL042283 DKFZp434L1620 AE03RB02 18 EST checked H06312 IMAGp998I02268 RT1a4rb1 18 RT-PCR 2F53VIII RT1b7rb1 18 RT-PCR 2F53VIII RT1a8r1b 18 RT-PCR 2F53VIII RT1a7rb1 18 RT-PCR 2F53VIII RT1b2rb1 18 RT-PCR 2F53VIII RT1a11rb1 18 RT-PCR 2F53VIII R1d10rb1 18 RT-PCR 2F53VIII AB25RA02 18 EST checked AL042839 DKFZp434G2022 AB25RA05 18 EST checked AL042839 DKFZp434G2022 AB25RA08 18 EST checked AL042839 DKFZp434G2022 AG03RB02 18 EST checked AW468059 IMAGp998B027200Q2 AG04RB01 18 EST checked AI049567 IMAGp998M024318Q2 AG08RB03 18 EST checked AW238577 IMAGp9980056777Q2 AG06RB01 18 EST checked AI537172 IMAGp998E105403Q2 AG06RB04 18 EST checked AI537172 IMAGp998E105403Q2 AG06RB07 18 EST checked AI537172 IMAGp998E105403Q2 AG06RB10 18 EST checked AI537172 IMAGp998E105403Q2 AG11RB03 18 EST checked AI953463 IMAGp998F196353Q2 AG11RB06 18 EST checked AI953463 IMAGp998F196353Q2 AG10RB02 18 EST checked AW173183 IMAGp998J126649Q2 ex13.4 AK00R2B 18 cDNA AK00726 HEP17004 1e10RB01 18 5′RACE 7A 1e2RB01 18 5′RACE 7A AG01RB03 18 EST checked AL043174 DKFZp434F2323Q2 AG01RB06 18 EST checked AL043174 DKFZp434F2323Q2 ex13.5 B02RB03S 18 BAC AL356581.2 RP5-1020C22 1f10RB01 18 5′RACE 7A AB06RB03 18 EST checked AL045522 DKFZp434J205 ex13.6 AFI6R2B 18 mRNA AF161426 HSPC308 ex13.7 1e5RB01S 18 5′RACE 7A ex13.8 1g1RB01S 18 5′RACE 7A ex13.9 1g1RB02S 18 5′RACE 7A 18 BAC AL109937.4 HSJ322E17 ex13.10 2b10RB01 18 5′RACE TR14 ex13.11 1a8RB02S 18 5′RACE 2F53VIII 18 BAC AC018381.3 RP11-5G21 18 BAC AC007734.3 RP11-44O1 2 X in this BAC 18 BAC AC053486.4 RP11-100A19 ex13.12 2g7RB02 18 5′RACE 7A ex13.13 2c11RB01 18 5′RACE SK-N-SH ex13.14 2d5RB01 18 5′RACE SK-N-SH 18 cDNA AB051480 KIAA1693 ex13.15 ex13.AD 18 BAC AC007734.3 RP11-44O1 ex13.16 ex13.AJ 18 BAC AC026565.3 RP11-702G12 2 X in this BAC ex13.AM 18 BAC AL391068.7 RP11-288L16 2 X in this BAC ex13.17 ex13.AQ 18 BAC AL359258.4 RP11-483I13 ex13.AR 18 BAC AC013627.3 RP11-11L4 ex13.AS 18 BAC AL390038.5 RP11-131J3 ex13.18 ex13.F 18 BAC AC023990.1 RP11-510K4 ex13.O 18 BAC AC018381.3 RP11-5G21 ex13.Q 18 BAC AL359093.9 RP11-35B4 ex13.U 18 BAC AC073223.4 RP11580F15 2 X in this BAC ex13.W 18 BAC AC018729.3 RP11-1F5 ex13.AC 18 BAC AC007734.3 RP11-44O1 2 X in this BAC ex13.AF 18 BAC AL355505.7 RP4-634B11 18 BAC AL049715.25 RP4-646P11 ex13.19 ex13.AK 18 BAC AC026565.3 RP11-702G12 ex13.AN 18 BAC AL391068.7 RP11-288L16 ex13.20 ex13.AI 18 BAC AC053486.4 RP11-100A19 ex13.21 ex13.AB 18 BAC AC007734.3 RP11-44O1 1 stop codon ex13.22 ex13.G 18 BAC AC023990.1 RP11-510K4 1 stop codon ex13.23 ex13.AU 18 BAC AC015706.3 RP11-325P15 ex13.24 ex13.L 18 BAC AC024119.2 RP11-542J23 2 X in this BAC ex13.N 18 BAC AC018381.3 RP11-5G21 2 X in this BAC 18 BAC AL049715.25 RP4-646P11 ex13.25 ex13.AO 18 BAC AC013673.2 RP11-20I21 ex13.26 ex13.B 18 BAC AC027727.3 RP11-18B10 ex13.27 ex13.AT 18 BAC AC015706.3 RP11-325P15 ex13.28 ex13.H 18 BAC AC023990.1 RP11-510K4 ex13.29 ex13.I 18 BAC AL356581.4 RP5-1020C22 2 X in this BAC ex13.30 ex13.C 18 BAC AL109937.4 HSJ322E17 18 BAC AC060753.8 RP11-285C11 7 X in this BAC ex13.31 ex13.A 18 BAC AL359176.4 RP11-47D6 2 X in this BAC 18 BAC AL139152.2 RP4-704D21 2 X in this BAC 18 BAC AL109937.4 HSJ322E17 2 X in this BAC 18 BAC AC027727.3 RP11-18B10 2 X in this BAC 18 BAC AC023990.1 RP11-510K4 4 X in this BAC 18 BAC AC024119.2 RP11-542J23 18 BAC AC018381.3 RP11-5G21 5 X in this BAC 18 BAC AL355800.5 RP11-284O17 2 X in this BAC 18 BAC AL354666.5 RP11-87L17 18 BAC AC026900.3 RP11-798G11 2 X in this BAC 18 BAC AL359093.9 RP11-35B4 5 X in this BAC 18 BAC AL356004.4 RP11-94I2 18 BAC AC073223.4 RP11580F15 2 X in this BAC 18 BAC AL138842.4 RP4-679C16 18 BAC AL138796.3 RP4-791M13 18 BAC AC018729.3 RP11-1F5 4 X in this BAC 18 BAC AC015618.3 RP11-45I3 2 X in this BAC 18 BAC AC007734.3 RP11-44O1 6 X in this BAC 18 BAC AC084206.1 RP11-305B17 18 BAC AC053486.4 RP11-100A19 18 BAC AC026565.3 RP11-702G12 AL050R0B 18 BAC AL050141 DKFZp586O031 18 BAC AL022240.8 RP3-328E19 18 BAC AL022240.8 RP3-328E19 ex13.32 ex13.M 18 BAC AC024119.2 RP11-542J23 ex13.33 ex13.X 18 BAC AC018729.3 RP11-1F5 3 X in this BAC ex13.34 ex13.S 18 BAC AC079074.1 CTD-2386B2 ex13.35 ex13.V 18 BAC AC018729.3 RP11-1F5 1 stop codon ex13.36 AG9rb01 18 EST checked AI570017 IMAGp998E065507Q2 ex13.37 18 cDNA AL136890 DKFZp434D177 ex14.1 E16CT 80 EST C15842 GEN-181D02 80 BAC AL138842.4 RP4-679C16 80 BAC AL355505.7 RP4-634B11 80 BAC AC018381.3 RP11-5G21 80 BAC AL359093.9 RP11-35B4 80 BAC AC007734.3 RP11-44O1 AG07CT 80 EST checked AA609104 IMAGp998B132576Q2 ex14.2 E18CT 80 EST AA609104 af11c07.s1 ex14.3 E21CT 80 EST AA301198 EST14111 AE1CT 80 EST checked AW160820 IMAGp998I196882 80 BAC AL138796.3 RP4-791M13 ex14.5 E24CT 80 EST H29685 ym61b08 ex14.6 AL117R8C 80 pred. cDNA AL117237 HS328E191 80 BAC AL022240.8 RP3-328E19 ex14.7 E17CT 80 EST AW851278 IL3-CT0220-170200-067-E01 ex14.8 E19CT 80 EST AA333188 EST37291 ex14.9 AD01CT 80 EST checked AA350323 EST57569 E14CT 80 EST AI372468 EST175301 E15CT 80 EST F11837 c-32c04 ex14.10 E29CT 80 EST T65179 yc74b04.r1 ex14.11 AB03CT 80 EST checked AL040932 DKFZp434K1515 B01CT01 80 BAC AL354666.5 RP11-87L17 80 BAC AC084206.1 RP11-305B17 ex14.12 BRKPEX3L 80 genomic DNA = exon z AB25CT 80 EST checked AL042839 DKFZp434G2022 ex14.13 E23CT 80 EST AA315005 EST186812 ex14.14 E27CT 80 EST C17016 GEN-537A10 ex14.15 AF131CT 80 mRNA AF131738 24976 80 BAC AL359176.4 RP11-47D6 80 BAC AL139152.2 RP4-704D21 ex14.16 B02CT01 80 BAC AL356581.2 RP5-1020C22 AB06CT 80 EST checked AL045522 DKFZp434J205 ex14.17 AD02CT 80 EST checked AA322028 EST24684 ex14.18 AC03CT 80 EST checked AL043132 DKFZp434D0623 AB18CT 80 EST checked AL044108 DKFZp434M0628 80 BAC AL355800.5 RP11-284O17 80 BAC AL355149.4 RP5-875O13 80 BAC AC015618.3 RP11-45I3 ex14.19 ex14.A 80 BAC AC027727.3 RP11-18B10 ex14.20 ex14.B 80 BAC AC060753.8 RP11-285C11 AG01CT 80 EST checked AL043174 DKFZp434F2323Q2 ex14.21 ex14.C 80 BAC AC024119.2 RP11-542J23 ex14.D 80 BAC AC073223.4 RP11580F15 ex14.22 ex14.E 80 BAC AC027209.2 RP11-277H3 ex14.23 ex14.G 80 BAC AL356004.4 RP11-94I2 ex14.24 ex14.H 80 BAC AC053486.4 RP11-100A19 ex14.25 ex14.I 80 BAC AL391068.7 RP11-288L16 ex14.J 80 BAC AL391068.7 RP11-288L16 ex14.K 80 BAC AC026565.3 RP11-702G12 ex14.L 80 BAC AC026565.3 RP11-702G12 ex14.26 AG02ct 80 EST-checked AL037724 DKFZp564A057Q3 80 cDNA AB051480 KIAA1693

[0217] TABLE 6 Sequenced NBG-related cDNA clones Depicted in FIG./ GenBank Acc. Nos. DMB-VIB name Sequence type cDNA Clone Name(s) GenBank Acc. No. EST sequences AB01 3′-UTR DKFZp434B235 AF379611 AL045343 AL045344 AB02 3′UTR + poly-A DKFZp434J2318 AF379612 AL048907 AB03 DKFZp434K1515 AF379613 AL040932 AB04 3′UTR + poly-A IMAGp998O19822 AF379614 W95853 IMAGE: 385122 AB05 3′UTR + poly-A IMAGp998L06676 AF379615 W17223 IMAGE: 301973 AB06 DKFZp434J205 AF379616 AL045522 AB10 3′UTR + poly-A IMAGp998I18822 AF379617 W95142 IMAGE: 357977 AB11 3′UTR + poly-A IMAGp998I10824 AF379618 W94444 IMAGE: 358737 AB13 IMAGp998I041023 AF379619 AA705685 IMAGE: 435147 AB14 IMAGp998H101019 AF420437 AA701673 IMAGE: 433594 AB16 3′UTR + poly-A IMAGp998N141787 AF379621 AA398843 IMAGE: 728653 AB18 DKFZp434M0628 AF379622 AL044108 AB23 = AE04 IMAGp998N074517 AF379623 AI239884 IMAGE: 1846470 AB25 DKFZp434G2022 AF379624 AL042839 AC02 Pseudogene? DKFZp434K2231 AF379625 AL110415 AC03 DKFZp434D0623 AF379626 AL043132 AD01 EST57569 AF379627 AA350323 AD02 EST24684 AF379628 AA322028 AE01 IMAGp998I196882 5′: AF419618 AW160820 IMAGE: 2782170 3′: AF419619 AE02 5′UTR + start IMAGp9988N14778 AF379629 W58508 codon IMAGE: 341197 AE03 IMAGp998I02268 AF379630 H06312 IMAGE: 44185 AE05 IMAGp998I071063 AF379631 AA704208 IMAGE: 450510 AG01 DKFZp434F2323 AF380580 AL043174 AG02 DKFZp564A057 AF419616 AL037724 AG03 IMAGp998B027200 AF380581 AW468059 IMAGE: 2920609 AG04 IMAGp998M024318 AF379632 AI049567 IMAGE: 1700501 AG06 IMAGp998E105403 AF379633 AI537172 IMAGE: 2186481 AG07 IMAGp998B132576 AF379634 AA609104 IMAGE: 1031340 AG08 IMAGp998C056777 AF380582 AW238577 IMAGE: 2741692 AG09 IMAGp998E065507 AF419617 AI570017 IMAGE: 2226413 AG10 IMAGp998J126649 AF379635 AW173183 IMAGE: 2663915 AG11 IMAGp998F196353 AF379636 AI953463 IMAGE: 2550162

[0218] TABLE 7 Human genomic contig sequences comprising NBG-related sequences # of # Chromosomal exon of exon # of Contig Size (bp) localization 7 8 exon 9 NT_021932.4 1,279,026 bp 1q12 3 3 3 NT_004754.5 5,941,040 bp 1q12 5 6 5 NT_023400.4   373,558 bp not placed 1 1 1 (chr 6?) NT_004644.5 1,210,659 bp 1q42.11 1 1 1 NT_028134.1   147,523 bp not placed 1 1 1 (chr 3?) NT_004434.5 1,108,112 bp 1q21 1 2 1 NT_004873.5 4,329,220 bp 1p36.13 2 2 2 NT_004576.5 1,278,015 bp 1p36.11 0 1 0 NT_004966.5 5,599,926 bp 1p13.1 0 0 0 NT_021907.5 1,184,925 bp 1q21.3 0 0 0 NT_019284.5 2,180,645 bp 1p21.3 0 0 1 NT_027019.2   493,854 bp 5q14 0 0 0 NT_005580.5 1,740,243 bp 3p22.1 0 0 0 Total 14  17  15 

[0219] Result of a TBLASTN analysis (Sep. 16, 2001) to the Human Genome Data using a typical NBG-protein as query. Thirteen contigs contained NBG-related sequences. Their GenBank accesion numbers are given in the first column, their size (bp) in the second column, and their chromosomal localization as determined by MapView (NCBI: hhtp://www.ncbi.nlm.nih.gov) in the third column. The occurrence (#) of different variants of the exon types 7, 8 and 9 (generally represented by a single copy in NBG transcripts) is also determined by BLAST analysis to the Human Genome Data.

References

[0220] Altschul, S. F., Madden, T. L., Schaffer, A. A., Zhang, J. H., Zhang, Z., Miller, W., and Lipman, D. J. (1997). Gapped BLAST and PSI-BLAST: a new generation of protein database search programs, Nucleic Acids Res. 25, 3389-3402.

[0221] Ambros, I. M., Rumpler, S., Luegmayr, A., Hattinger, C. M., Strehl, S., Kovar, H., Gadner, H. and Ambros, P. F. (1997). Neuroblastoma cells can actively eliminate supernumerary MYCN gene copies by micronucleus formation-sign of tumour cell revertance? Eur. J. Cancer 33, 2043-9.

[0222] Bader, S. A., Fasching, C., Brodeur, G. M., and Stanbridge, E. J. (1991). Dissociation of suppression of tumorigenicity and differentiation in vitro effected by transfer of single human chromosomes into human neuroblastorma cells, Cell Growth Differ. 2, 245-55.

[0223] Bieche, I., Khodja, A., and Lidereau, R. (1998). Deletion mapping in breast tumor cell lines points to two distinct tumor-suppressor genes in the 1p32-pter region, one of deleted regions (1p36.2) being located within the consensus region of LOH in neuroblastoma, Oncol. Rep. 5, 267-272.

[0224] Biegel, J. A., White, P. S., Marshall, H. N., Fujimori, M., Zackai, E. H., Scher, C. D., Brodeur, G. M., and Emanuel, B. S. (1993). Constitutional 1p36 deletion in a child with neuroblastoma, Am. J. Hum. Genet. 52, 176-82.

[0225] Bonfield, J. K., Smith, K. F., and Staden, R. (1995). A new DNA sequence assembly program, Nucleic Acids Res. 23, 4992-4999.

[0226] Bown, N., Cotterill, S., Lastowska, M., O'Neill, S., Pearson, A. D., Plantaz, D., Meddeb, M., Danglot, G., Brinkschmidt, C., Christiansen, H., Laureys, G., and Speleman, F. (1999). Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma [see comments], N. Engl. J. Med. 340, 1954-61.

[0227] Brinkschmidt, C., Christiansen, H., Terpe, H. J., Simon, R., Boecker, W., Lampert, F., and Stoerkel, S. (1997). Comparative genomic hybridization (CGH) analysis of neuroblastomas-an important methodological approach in paediatric tumour pathology, J. Pathol. 181, 394-400.

[0228] Brodeur, G. M. (1998). Clinical and biological aspects of neuroblastoma. In The Genetic Basis of Human Cancer, B. Vogelstein, and K. W. Kinzler, eds. (New York, N.Y., McGraw-Hill), pp. 691-711.

[0229] Brodeur, G. M., Sekhon, G., and Goldstein, M. N. (1977). Chromosomal aberrations in human neuroblastomas, Cancer 40, 2256-63.

[0230] Buroker N., Bestwick R., Haight G., Magenis R. E., and Litt M. (1987). A hypervariable repeated sequence on human chromosome 1p36, Hum. Genet. 77, 175-81.

[0231] Cai D .X., Banerjee R., Scheithauer B. W., Lohse C. M., Kleinschmidt-Demasters B. K., Perry A. (2001). Chromosome 1p and 14q FISH analysis in clinicopathologic subsets of meningioma: diagnostic and prognostic implications, J. Neuropathol. Exp. Neurol. 60, 628-636.

[0232] Canute, G. W., Longo, S. L., Longo, J. A., Winfield, J. A., Nevaldine, B. H. and Hahn, P. J. (1996). Hydroxyurea accelerates the loss of epidermal growth factor receptor genes amplified as double-minute chromosomes in human glioblastoma multiforme, Neurosurgery 39, 976-83.

[0233] Caron, H. (1995). Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma, Med. Pediatr. Oncol. 24, 215-21.

[0234] Caron, H., van Sluis, P., van Hoeve, M., de Kraker, J., Bras, J., Slater, R., Mannens, M., Voute, P. A., Westerveld, A., and Versteeg, R. (1993). Allelic loss of chromosome 1p36 in neuroblastoma is of preferential maternal origin and correlates with N-myc amplification (with published erratum in Nat. Genet. 1993 4:4311, Nat. Genet. 4, 187-90.

[0235] Collins C., Kuo W. L., Segraves R., Fuscoe J., Pinkel D., and Gray J. W. (1991). Construction and characterization of plasmid libraries enriched in sequences from single human chromosomes, Genomics 11, 997-1006.

[0236] De Angelis, P. M., Stokke, T., Beigi, M., Mjaland, O., and Clausen, O. P. (2001). Prognostic significance of recurrent chromosomal aberrations detected by comparative genomic hybridization in sporadic colorectal cancer. Int. J. Colorectal Dis. 16, 38-45.

[0237] Dorschner M. O., Sybert V. P., Weaver M., Pletcher B. A., Stephens K. (2000). NF1 microdeletion breakpoints are clustered at flanking repetitive sequences, Hum Mol Genet 9, 35-46.

[0238] Doz, F., Peter, M., Schleiermacher, G., Vielh, P., Validire, P., Putterman, M., Blanquet, V., Desjardins, L., Dufier, J. L., Zucker, J. M., Mosseri, V., Thomas, G., Magdelenat, H., and Delattre, O. (1996). N-MYC amplification, loss of heterozygosity on the short arm of chromosome 1 and DNA ploidy in retinoblastoma, Eur. J. Cancer 32A, 645-649.

[0239] Eckhardt, S. G., Dai, A., Davidson, K. K., Forseth, B. J., Wahl, G. M. and Von Hoff, D. D. (1994). Induction of differentiation in HL60 cells by the reduction of extrachromosomally amplified c-myc, Proc. Natl. Acad. Sci. U.S.A. 91, 6674-8.

[0240] Fong, C. T., Dracopoli, N. C., White, P. S., Merrill, P. T., Griffith, R. C., Housman, D. E., and Brodeur, G. M. (1989). Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: correlation with N-myc amplification, Proc. Natl. Acad. Sci. U.S.A. 86, 3753-7.

[0241] Fong, C. T., White, P. S., Peterson, K., Sapienza, C., Cavenee, W. K., S. E., K., Vogelstein, B., Cantor, A. B., Look, A. T., and Brodeur, G. M. (1992). Loss of heterozygosity for chromosomes 1 or 14 defines subsets of advanced neuroblastomas, Cancer Res. 52, 1780-1785.

[0242] Gilbert, F., Feder, M., Balaban, G., Brangman, D., Lurie, D. K., Podoisky, R., Rinaldt, V., Vinikoor, N., and Weisband, J. (1984). Human neuroblastomas and abnormalities of chromosomes 1 and 17, Cancer Res. 44, 5444-9.

[0243] Igarashi, J., Nimura, Y., Fujimori, M., Mihara, M., Adachi, W., Kageyama, H., and Nakagawara, A. (2000). Allelic loss of the region of chromosome 1p35-pter is associated with progression of human gastric carcinoma, Jpn. J. Cancer Res. 91, 797-801.

[0244] Ioannou, P. A., Amemiya, C. T., Games, J., Kroisel, P. M., Shizuya, H., Chen, C., Batzer, M. A., and de Jong, P. J. (1994). A new bacteriophage P1-derived vector for the propagation of large human DNA fragments, Nat. Genet. 6, 84-89.

[0245] Kanda, T., Otter, M., and Wahl, G. M. (2001). Mitotic segregation of viral and cellular acentric extrachromosomal molecules by chromosome tethering, J. Cell Sci. 114, 49-58.

[0246] Knuutila, S., Bjorkqvist, A. M., Autio, K., Tarkkanen, M., Wolf, M., Monni, O., Szymanska, J., Larramendy, M. L., Tapper, J., Pere, H. et al. (1998). DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies, Am. J. Pathol. 152, 1107-23.

[0247] Lastowska, M., Nacheva, E., McGuckin, A., Curtis, A., Grace, C., Pearson, A., and Bown, N. (1997). Comparative genomic hybridization study of primary neuroblastoma tumors. United Kingdom Children's Cancer Study Group, Gene Chromosome Canc. 18, 162-9.

[0248] Lastowska, M., Van Roy, N., Brown, N., Speleman, F., Lunec, J., Strachan, T., Pearson, A. D. J., and Jackson, M. S. (1998). Molecular cytogenetic delineation of 17q translocation. breakpoints in neuroblastoma cell lines, Gene Chromosome Canc. 23, 116-122.

[0249] Laureys, G., Speleman, F., Opdenakker, G., Benoit, Y., and Leroy, J. (1990). Constitutional translocation t(1;17)(p36;q12-21) in a patient with neuroblastoma, Gene Chromosome Canc. 2, 252-4.

[0250] Laureys, G., Speleman, F., Versteeg, R., van der Drift, P., Chan, A., Leroy, J., Francke, U., Opdenakker, G., and Van Roy, N. (1995). Constitutional translocation t(1;17)(p36.31-p36.13; q11.2q12.1) in a neuroblastoma patient. establishment of somatic cell hybrids and identification of PND/a12m2 on chromosome 1 and NF1/SCYA7 on chromosome 17 as breakpoint flanking single copy markers, Oncogene 10, 1087-1093.

[0251] Levan, A. and Levan, G. (1978). Have double minutes functioning centromeres? Hereditas 88, 81-92.

[0252] Nelson, D. L., Ledbetter, S. A., Corbo, L., Victoria, M. F., Ramirez-Solis, R., Webster, T. D., Ledbetter, D. H., and Caskey, C. T. (1989). Alu polymerase chain reaction: a method for rapid isolation of human-specific sequences from complex DNA sources, Proc. Natl. Acad. Sci. U.S.A. 86, 6686-90.

[0253] Plantaz, D., Mohapatra, G., Matthay, K. K., Pellarin, M., Seeger, R. C., and Feuerstein, B. G. (1997). Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization, Am. J. Pathol. 150, 81-9.

[0254] Ragnarsson, G., Eiriksdottir, G., Johannsdottir, J. T., Jonasson, J. G., Egilsson, V., and Ingvarsson, S. (1999). Loss of heterozygosity at chromosome 1p in different solid human tumours: association with survival, Br. J. Cancer 79, 1468-1474.

[0255] Raymond, E., Faivre, S., Weiss, G., McGill, J., Davidson, K., Izbicka, E., Kuhn, J. G., Allred, C., Clark, G. M. and Von Hoff, D. D. (2001). Effects of hydroxyurea on extrachromosomal DNA in patients with advanced ovarian carcinomas, Clin. Cancer Res. 7, 1171-80.

[0256] Riley, J., Butler, R., Ogilvie, D., Finniear, R., Jenner, D., Powell, S., Anand, R., Smith, J. C., and Markham, A. F. (1990). A novel, rapid method for the isolation of terminal sequences from yeast artificial chromosome (YAC) clones, Nucleic Acid Res. 18, 2887-2890.

[0257] Roth, M. B., Zahler, A. M. and Stolk, J. A. (1991). A conserved family of nuclear phosphoproteins localized to sites of polymerase 11 transcription, J. Cell Biol. 115, 587-596.

[0258] Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989). Molecular Cloning. A Laboratory Manual (Cold Spring Harbor, N.Y., Cold Spring Harbor Laboratory Press).

[0259] Sanger, F. (1981). Determination of nucleotide sequences in DNA, Science 214, 1205-1210.

[0260] Savelyeva, L., Corvi, R., and Schwab, M. (1994). Translocation involving 1p and 17q is a recurrent genetic alteration of human neuroblastoma cells, Am. J. Hum. Genet. 55, 334-40.

[0261] Schleiermacher, G., Peter, M., Michon, J., Hugot, J. P., Vielh, P., Zucker, J. M., Magdelenat, H., Thomas, G., and Delattre, O. (1994). Two distinct deleted regions on the short arm of chromosome 1 in neuroblastoma, Gene Chromosome Canc. 10, 275-81.

[0262] Schwab, M., Praml, C., and Amler, L. C. (1996). Genomic instability in 1p and human malignancies, Gene Chromosome Canc. 16, 211-29.

[0263] Shimizu, N., Nakamura, H., Kadota, T., Kitajima, K., Oda, T., Hirano, T. and Utiyama, H. (1994). Loss of amplified c-myc genes in the spontaneously differentiated HL-60 cells, Cancer Res. 54, 3561-7.

[0264] Shimizu, N., Itoh, N., Utiyama, H. and Wahl, G. M. (1998). Selective entraprnent of extrachromosomally amplified DNA by nuclear budding and micronucleation during S phase, J. Cell Biol. 140, 1307-20.

[0265] Shimizu, N., Shimura, T. and Tanaka, T. (2000). Selective elimination of acentric double minutes from cancer cells through the extrusion of micronuclei, Mutat. Res. 448, 81-90.

[0266] Siebert, P. D., Chenchik, A., Kellogg, D. E., Lukyanov, K. A., and Lukyanov, S. A. (1995). An improved PCR method for walking in uncloned genomic DNA, Nucleic Acids Res. 23, 1087-1088.

[0267] Speleman, F., Van Gele, M., Maertens, L., and Van Roy, N. (1997). Improved protocol for chromatin fibre preparation from fixed cells. Technical Tips online, Trends Genet., T01123.

[0268] Takeda, O., Homma, C., Maseki, N., Sakurai, M., Kanda, N., Schwab, M., Nakamura, Y., and Kaneko, Y. (1994). There may be two tumor suppressor genes on chromosome arm 1p closely associated with biologically distinct subtypes of neuroblastoma, Gene Chromosome Canc. 10, 30-9.

[0269] Tanaka, K., Yanoshita, R., Konishi, M., Oshimura, M., Maeda, Y., Mori, T., and Miyaki, M. (1993). Suppression of tumourigenicity in human colon carcinoma cells by introduction of normal chromosome 1p36 region, Oncogene 8, 2253-2258.

[0270] van der Drift, P., Chan, A., Laureys, G., van Roy, N., Sickmann, G., den Dunnen, J., Westerveld, A., Speleman, F., and Versteeg, R. (1995). Balanced translocation in a neuroblastoma patient disrupts a cluster of small nuclear RNA U1 and tRNA genes in chromosomal band 1p36, Gene Chromosome Canc. 14, 35-42.

[0271] van der Drift, P., Chan, A., van Roy, N., Laureys, G., Westerveld, A., Speleman, F., and Versteeg, R. (1994). A multimegabase cluster of snRNA and tRNA genes on chromosome 1p36 harbours an adenovirus/SV40 hybrid virus integration site, Hum. Mol. Genet. 3, 2131-6.

[0272] Von Hoff, D. D., Waddelow, T., Forseth, B., Davidson, K., Scott, J. and Wahl, G. (1991). Hydroxyurea accelerates loss of extrachromosomally amplified genes from tumor cells. Cancer Res. 51, 6273-9.

[0273] Von Hoff, D. D., McGill, J. R., Forseth, B. J., Davidson, K. K., Bradley, T. P., Van Devanter, D. R. and Wahl, G. M. (1992). Elimination of extrachromosomally amplified MYC genes from human tumor cells reduces their tumorigenicity, Proc. Natl. Acad. Sci. U.S.A. 89, 8165-9.

[0274] Van Roy, N., Cheng, N. C., Laureys, G., Opdenakker, G., and Speleman, F. (1995). Molecular cytogenetic analysis of 1,17 translocations in neuroblastoma, Eur. J. Cancer 31A, 530-535.

[0275] Van Roy, N., Jauch, A., Van Gele, M., Laureys, G., Versteeg, R., De Paepe, A., Cremer, T., and Speleman, F. (1997a). Comparative genomic hybridization analysis of human neuroblastomas: Detection of distal 1p deletions and further molecular genetic characterization of neuroblastoma cell lines, Cancer Genet. Cytogenet. 97, 35-142.

[0276] Van Roy, N., Laureys, G., Cheng, N. C., Willem, P., Opdenakker, G., Versteeg, R., and Speleman, F. (1994). 1;17 translocations and other chromosome 17 rearrangements in human primary neuroblastoma tumors and cell lines, Gene Chromosome Canc. 10, 103-114.

[0277] Van Roy, N., Laureys, G., Van Gele, M., Opdenakker, G., Miura, R., vanderDrift, P., Chan, A., Versteeg, R., and Speleman, F. (1997b). Analysis of 1;17 translocation breakpoints in neuroblastoma: Implications for mapping of neuroblastoma genes, Eur. J. Cancer 33, 1974-1978.

[0278] Vandesompele, J., Van Roy, N., Van Gele, M., Laureys, G., Ambros, P., Heimann, P., Devalck, C., Schuuring, E., Brock, P., Otten, J., Gyselinck, J., De Paepe, A., and Speleman, F. (1998). Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization, Gene Chromosome Canc. 23, 141-152.

[0279] Versteeg, R., Caron, H., Cheng, N. C., Van der Drift, P., Slater, R., Westerveld, A., Voute, P. A., Delattre, O., Laureys, G., Van Roy, N., and Speleman, F. (1995). 1p36: every subband a suppressor?, Eur. J. Cancer 31A, 538-541.

[0280] White, P. S., Thompson, P. M., Seifreid, B. A., Sulman, E. P., Jensen, S. J., Guo, G., Maris, J. M., Hogarty, M. D., Allen, C., Biegel, J. A., Matise, T. C., Gregory, S. G., Reynolds, C. P., Brodeur, G. M. (2001). Detailed molecular analysis of 1p36 in neuroblastoma, Med Ped Oncol 36, 37-41.

[0281] Zehetner, G., and Lehrach, H. (1994). The reference library system—sharing biological material and experimental data, Nature (London) 367, 489-491.

[0282] Zhang, J., Glaffelter, A. A., Taetle, R., and Trent, J. M. (1999). Frequent alterations of evolutionarily conserved regions of chromosome 1 in human malignant melanoma, Cancer Genet Cytogenet. 111I, 119-123.

0 SEQUENCE LISTING <160> NUMBER OF SEQ ID NOS: 203 <210> SEQ ID NO 1 <211> LENGTH: 528 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)..(528) <400> SEQUENCE: 1 ctc agc agg gag ctg ctg gag gca gta gag cct gaa gtc ttg cag gac 48 Leu Ser Arg Glu Leu Leu Glu Ala Val Glu Pro Glu Val Leu Gln Asp 1 5 10 15 tca ctg gat aga tgt tat tca act cct tcc agt tgt ctt gaa cag cct 96 Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Ser Cys Leu Glu Gln Pro 20 25 30 gac tcc tgc ctg ccc tat gga agt tcc ttt tat gca ttg gag gaa aaa 144 Asp Ser Cys Leu Pro Tyr Gly Ser Ser Phe Tyr Ala Leu Glu Glu Lys 35 40 45 cat gtt ggc ttt tct ctt gac gtg gga gaa att gaa aag aag ggg aag 192 His Val Gly Phe Ser Leu Asp Val Gly Glu Ile Glu Lys Lys Gly Lys 50 55 60 ggg aag aaa aga agg gga aga aga tca acg aag aaa aga agg aga agg 240 Gly Lys Lys Arg Arg Gly Arg Arg Ser Thr Lys Lys Arg Arg Arg Arg 65 70 75 80 gga aga aaa gaa ggg gaa gaa gat caa aac cca cca tgc ccc agg ctc 288 Gly Arg Lys Glu Gly Glu Glu Asp Gln Asn Pro Pro Cys Pro Arg Leu 85 90 95 agc ggt gtg ctg atg gaa gtg gaa gag cct gaa atc ttg cag gac tca 336 Ser Gly Val Leu Met Glu Val Glu Glu Pro Glu Ile Leu Gln Asp Ser 100 105 110 ctg gat aga tgt tat tcg act ccg tca atg ttc ttt gaa cta cct gac 384 Leu Asp Arg Cys Tyr Ser Thr Pro Ser Met Phe Phe Glu Leu Pro Asp 115 120 125 tca ttc cag cac tac aga agt gtg ttt tac tca ttt gag gaa cag cac 432 Ser Phe Gln His Tyr Arg Ser Val Phe Tyr Ser Phe Glu Glu Gln His 130 135 140 atc agc ttc gcc ctt gac gtg gac aat agg ttt ctt act ttg atg gga 480 Ile Ser Phe Ala Leu Asp Val Asp Asn Arg Phe Leu Thr Leu Met Gly 145 150 155 160 aca agt ctc cac ctg gtc ttc cag atg gga gtc ata ttc cca cag taa 528 Thr Ser Leu His Leu Val Phe Gln Met Gly Val Ile Phe Pro Gln 165 170 175 <210> SEQ ID NO 2 <211> LENGTH: 175 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 2 Leu Ser Arg Glu Leu Leu Glu Ala Val Glu Pro Glu Val Leu Gln Asp 1 5 10 15 Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Ser Cys Leu Glu Gln Pro 20 25 30 Asp Ser Cys Leu Pro Tyr Gly Ser Ser Phe Tyr Ala Leu Glu Glu Lys 35 40 45 His Val Gly Phe Ser Leu Asp Val Gly Glu Ile Glu Lys Lys Gly Lys 50 55 60 Gly Lys Lys Arg Arg Gly Arg Arg Ser Thr Lys Lys Arg Arg Arg Arg 65 70 75 80 Gly Arg Lys Glu Gly Glu Glu Asp Gln Asn Pro Pro Cys Pro Arg Leu 85 90 95 Ser Gly Val Leu Met Glu Val Glu Glu Pro Glu Ile Leu Gln Asp Ser 100 105 110 Leu Asp Arg Cys Tyr Ser Thr Pro Ser Met Phe Phe Glu Leu Pro Asp 115 120 125 Ser Phe Gln His Tyr Arg Ser Val Phe Tyr Ser Phe Glu Glu Gln His 130 135 140 Ile Ser Phe Ala Leu Asp Val Asp Asn Arg Phe Leu Thr Leu Met Gly 145 150 155 160 Thr Ser Leu His Leu Val Phe Gln Met Gly Val Ile Phe Pro Gln 165 170 175 <210> SEQ ID NO 3 <211> LENGTH: 3033 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: exon <222> LOCATION: (1)..(171) <220> FEATURE: <221> NAME/KEY: exon <222> LOCATION: (886)..(999) <223> OTHER INFORMATION: exon y <220> FEATURE: <221> NAME/KEY: exon <222> LOCATION: (1611)..(1853) <223> OTHER INFORMATION: exon z <400> SEQUENCE: 3 ctc agc agg gag ctg ctg gag gca gta gag cct gaa gtc ttg cag gac 48 tca ctg gat aga tgt tat tca act cct tcc agt tgt ctt gaa cag cct 96 gac tcc tgc ctg ccc tat gga agt tcc ttt tat gca ttg gag gaa aaa 144 cat gtt ggc ttt tct ctt gac gtg gga ggtgagtacc tttctatgaa 191 ggtgataagg atccactgag tcttccatat aaagatcata ttcctgctcc aagtggccat 251 tactgagctg agagatgtca ttgctgcagt gaggacctat aggcacatgt aggttgaatg 311 aaactctagt tctaactgga agcccagaca tgggatgggt cagtgagcat ggctctcttc 371 ctagtctcag gccatgcctg tggcactctg attctactct catgacattg gacctgggca 431 gatgtgacaa attcagagaa ctatgatttt gactcaaggg tttgtagatt tcctttttca 491 ctctaatttc agtgtctaaa gtcctcacaa ccatgaacaa tctgagtatt tgatgagaca 551 gggctaaata ttgcagtttt tctcctagaa atcatttgag ggtatttgct ttaaattgat 611 tggaaaaata tggcataact gtttgcacaa actcgggaca aatgatattg ggataacgat 671 ctactagaat agggacattt tacccacagt ttctgggaga aaaaccgagg aatttctatc 731 atgaccagcc ttcaggcctc ctgaaatata tctctcacag tctcctattc ttatgctgag 791 gagcctgagg tccctgtgtg aggattagac agtggattgt tatgtgtgta ggggaatcag 851 cttaatgtgt ctgtccatgt ctgaatttat tgca gaa att gaa aag aag ggg aag 906 ggg aag aaa aga agg gga aga aga tca acg aag aaa aga agg aga agg 954 gga aga aaa gaa ggg gaa gaa gat caa aac cca cca tgc ccc agg 999 taactttcag caattgtgga tgcttaattc tgtgttaaca cctggaggca acagattcag 1059 ggaaaccaga gtgtgtttga tttcatgttt tcaacgaagg ctgaattact cctactgtca 1119 ttgctgttgg ttttcattgc agtagatgtt taggtttcca tttcttcctc cccttatcat 1179 ttactaacgt accataggat gaccatactt caaaagctgt actctcgtgg ccactgcatc 1239 gaattttgag catattttat ggaaaactat tgagctcact cttttcatga tcgcagtttg 1299 ctgtgtgtca tgagggcact aactcagagt gtccttttac tcccttacca gtatgtcacc 1359 tggccaattc actagctcac tttctctctg tctctgtctc tgtctctgtc tctctgtctt 1419 tctctttcat tgttttctac ctggccctgt tctatcccaa cataaaggca ataatttttt 1479 ttttttacct cattaatgga tctatccttt tcttttctta ccacttcctt acgttacttc 1539 tgaaatctag tggggctctg tggtgtctga ttttccctgg ctgcttcttt agttttgtct 1599 gcttttccag g ctc agc ggt gtg ctg atg gaa gtg gaa gag cct gaa atc 1649 ttg cag gac tca ctg gat aga tgt tat tcg act ccg tca atg ttc ttt 1697 gaa cta cct gac tca ttc cag cac tac aga agt gtg ttt tac tca ttt 1745 gag gaa cag cac atc agc ttc gcc ctt gac gtg gac aat agg ttt ctt 1793 act ttg atg gga aca agt ctc cac ctg gtc ttc cag atg gga gtc ata 1841 ttc cca cag taa gcagccctta ctaagccgag agatgtcatt cctgcaggca 1893 ggacctatag gcacgtgaag atttgaatga aactatagtt ccatttggaa gcccagacat 1953 aggatgggtc agtgggcatg gctctattcc tattctcaga ccatgccagt ggcaacctgt 2013 gctcagtctg aagacaatgg acccaagtta ggtgtgacac gttcacataa ctgtgcagca 2073 catgccggga gtgatcagtc agacatttta atttgaacca cgtatctctg ggtagctaca 2133 aagttcctca gggatttcat tttgcaggca tgtctctgag cttctatacc tgctcaaggt 2193 cagtgtcatc tttgtgttta gctcatccaa aggtgttacc ctggtttcaa tgaacctaac 2253 ctcattcttt gtatcttcag tgttgaattg ttttagctga tccatcttta acacaggagg 2313 gatccttggc tgaggattgt atttcagaac caccaactgc tcttgacaat tgttaacccg 2373 ctaggctcct ttggttagag aagccacagt ccttcagcct ccaattggtg tcagtactta 2433 ggaagaccac agctagatgg acaaacagca ttgggaggcc ttagccctgc tcctctcgat 2493 tccatcctgt agagaacagg agtcaggagc cgctggcagg agacagcatg tcacccagga 2553 ctctgccggt gcagaatatg aacaacgcca tgttcttgca gaaaacgctt agcctgagtt 2613 tcataggagg taatcaccag acaactgcag aatgtagaac actgagcagg acaactgacc 2673 tgtctccttc acatagtcca tatcaccaca aatcacacaa caaaaaggag aagagatatt 2733 ttgggttcaa aaaaagtaaa aagataatat agctgcattt ctttagttat tttgaacccc 2793 aaatatttcc tcatcttttt gttgttgtca ttgatggtgg tgacatggac ttgtttatag 2853 aggacaggtc agctgtctgg ctcaatgatc tacattctga agttgtctga aaatgtcttc 2913 atgattaaat tcagcctaaa cgttttgccg ggaacactgc agagacaatg ctgtgagttt 2973 ccaaccttag cccatctgcg ggcagagaag gtctagtttg tccatcagca ttatcatgat 3033 <210> SEQ ID NO 4 <211> LENGTH: 3743 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: exon <222> LOCATION: (711)..(881) <223> OTHER INFORMATION: Exon x <220> FEATURE: <221> NAME/KEY: exon <222> LOCATION: (1596)..(1709) <223> OTHER INFORMATION: Exon y <220> FEATURE: <221> NAME/KEY: exon <222> LOCATION: (2321)..(2563) <223> OTHER INFORMATION: Exon z <400> SEQUENCE: 4 cccctcagct ctgtgcattt tgtctacaag caaggtgact ttgggtttag tgtgttcatg 60 tttcaacaag aatgtaagtt tgggatcaga catatgttac ccctgttgga tagtagcttt 120 gcaatcagtc tttgcaaaaa atatccagaa caaggctaga acaaggtggt acagaaacaa 180 ataacacgtg ttacagttac atatgagctt ggattacctc ctttatagaa ggaagtggag 240 acatccttca tgcagagatt taggatctct cactagcact aaccctcttg cccccaccta 300 gtgtttattt caatcacccc tgttgctttt tatcaaatga aagatacaga tccactttta 360 agagtaaaga agagaggaag cacagtttat taattaccca ttggtatccc aaggacttgt 420 gcttccatta tctcattgtt ttattcattc attaatccaa acactcattc agcagggatt 480 tcttgggggc ctaccttgta ctgggctctg tggtcctggg agatgcagca gggaatagag 540 tcacaggctt gcactcatag agagaacctt ctagctgggg agacagacaa caatgacaaa 600 aaggaagtgc tttttcaacc acttccttat gctacccatg aaacctagtt ggggctctgt 660 tgtgtctgat ttcccctggc ttattcttta ctttttcctc cttttccagg ctc agc 716 agg gag ctg ctg gag gca gta gag cct gaa gtc ttg cag gac tca ctg 764 gat aga tgt tat tca act cct tcc agt tgt ctt gaa cag cct gac tcc 812 tgc ctg ccc tat gga agt tcc ttt tat gca ttg gag gaa aaa cat gtt 860 ggc ttt tct ctt gac gtg gga ggtgagtacc tttctatgaa ggtgataagg 911 atccactgag tcttccatat aaagatcata ttcctgctcc aagtggccat tactgagctg 971 agagatgtca ttgctgcagt gaggacctat aggcacatgt aggttgaatg aaactctagt 1031 tctaactgga agcccagaca tgggatgggt cagtgagcat ggctctcttc ctagtctcag 1091 gccatgcctg tggcactctg attctactct catgacattg gacctgggca gatgtgacaa 1151 attcagagaa ctatgatttt gactcaaggg tttgtagatt tcctttttca ctctaatttc 1211 agtgtctaaa gtcctcacaa ccatgaacaa tctgagtatt tgatgagaca gggctaaata 1271 ttgcagtttt tctcctagaa atcatttgag ggtatttgct ttaaattgat tggaaaaata 1331 tggcataact gtttgcacaa actcgggaca aatgatattg ggataacgat ctactagaat 1391 agggacattt tacccacagt ttctgggaga aaaaccgagg aatttctatc atgaccagcc 1451 ttcaggcctc ctgaaatata tctctcacag tctcctattc ttatgctgag gagcctgagg 1511 tccctgtgtg aggattagac agtggattgt tatgtgtgta ggggaatcag cttaatgtgt 1571 ctgtccatgt ctgaatttat tgca gaa att gaa aag aag ggg aag ggg aag 1622 aaa aga agg gga aga aga tca acg aag aaa aga agg aga agg gga aga 1670 aaa gaa ggg gaa gaa gat caa aac cca cca tgc ccc agg taactttcag 1719 caattgtgga tgcttaattc tgtgttaaca cctggaggca acagattcag ggaaaccaga 1779 gtgtgtttga tttcatgttt tcaacgaagg ctgaattact cctactgtca ttgctgttgg 1839 ttttcattgc agtagatgtt taggtttcca tttcttcctc cccttatcat ttactaacgt 1899 accataggat gaccatactt caaaagctgt actctcgtgg ccactgcatc gaattttgag 1959 catattttat ggaaaactat tgagctcact cttttcatga tcgcagtttg ctgtgtgtca 2019 tgagggcact aactcagagt gtccttttac tcccttacca gtatgtcacc tggccaattc 2079 actagctcac tttctctctg tctctgtctc tgtctctgtc tctctgtctt tctctttcat 2139 tgttttctac ctggccctgt tctatcccaa cataaaggca ataatttttt ttttttacct 2199 cattaatgga tctatccttt tcttttctta ccacttcctt acgttacttc tgaaatctag 2259 tggggctctg tggtgtctga ttttccctgg ctgcttcttt agttttgtct gcttttccag 2319 g ctc agc ggt gtg ctg atg gaa gtg gaa gag cct gaa atc ttg cag gac 2368 tca ctg gat aga tgt tat tcg act ccg tca atg ttc ttt gaa cta cct 2416 gac tca ttc cag cac tac aga agt gtg ttt tac tca ttt gag gaa cag 2464 cac atc agc ttc gcc ctt gac gtg gac aat agg ttt ctt act ttg atg 2512 gga aca agt ctc cac ctg gtc ttc cag atg gga gtc ata ttc cca cag 2560 taa gcagccctta ctaagccgag agatgtcatt cctgcaggca ggacctatag 2613 gcacgtgaag atttgaatga aactatagtt ccatttggaa gcccagacat aggatgggtc 2673 agtgggcatg gctctattcc tattctcaga ccatgccagt ggcaacctgt gctcagtctg 2733 aagacaatgg acccaagtta ggtgtgacac gttcacataa ctgtgcagca catgccggga 2793 gtgatcagtc agacatttta atttgaacca cgtatctctg ggtagctaca aagttcctca 2853 gggatttcat tttgcaggca tgtctctgag cttctatacc tgctcaaggt cagtgtcatc 2913 tttgtgttta gctcatccaa aggtgttacc ctggtttcaa tgaacctaac ctcattcttt 2973 gtatcttcag tgttgaattg ttttagctga tccatcttta acacaggagg gatccttggc 3033 tgaggattgt atttcagaac caccaactgc tcttgacaat tgttaacccg ctaggctcct 3093 ttggttagag aagccacagt ccttcagcct ccaattggtg tcagtactta ggaagaccac 3153 agctagatgg acaaacagca ttgggaggcc ttagccctgc tcctctcgat tccatcctgt 3213 agagaacagg agtcaggagc cgctggcagg agacagcatg tcacccagga ctctgccggt 3273 gcagaatatg aacaacgcca tgttcttgca gaaaacgctt agcctgagtt tcataggagg 3333 taatcaccag acaactgcag aatgtagaac actgagcagg acaactgacc tgtctccttc 3393 acatagtcca tatcaccaca aatcacacaa caaaaaggag aagagatatt ttgggttcaa 3453 aaaaagtaaa aagataatat agctgcattt ctttagttat tttgaacccc aaatatttcc 3513 tcatcttttt gttgttgtca ttgatggtgg tgacatggac ttgtttatag aggacaggtc 3573 agctgtctgg ctcaatgatc tacattctga agttgtctga aaatgtcttc atgattaaat 3633 tcagcctaaa cgttttgccg ggaacactgc agagacaatg ctgtgagttt ccaaccttag 3693 cccatctgcg ggcagagaag gtctagtttg tccatcagca ttatcatgat 3743 <210> SEQ ID NO 5 <211> LENGTH: 48 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <223> OTHER INFORMATION: GenomeWalker adaptor <400> SEQUENCE: 5 gtaatacgac tcactatagg gcacgcgtgg tcgacggccc gggctggt 48 <210> SEQ ID NO 6 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 6 gtaatacgac tcactatagg gc 22 <210> SEQ ID NO 7 <211> LENGTH: 26 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 7 cccctcagct ctgtgcattt tgtcta 26 <210> SEQ ID NO 8 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 8 cctcttgccc ccacctagtg tttattt 27 <210> SEQ ID NO 9 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 9 ggccatgtga accaattctg 20 <210> SEQ ID NO 10 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 10 ggagagctga gtgaggaggg 20 <210> SEQ ID NO 11 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 11 cgcctggcct atttacatgt 20 <210> SEQ ID NO 12 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 12 tgcagcccat aaatacccac 20 <210> SEQ ID NO 13 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 13 cctcgagctg aagccaaatt 20 <210> SEQ ID NO 14 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 14 tggcctccat gctgtaggat 20 <210> SEQ ID NO 15 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 15 tcaaaccccg actttcagat 20 <210> SEQ ID NO 16 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 16 tctgtgctgc ctggattcac 20 <210> SEQ ID NO 17 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 17 gcctgtttca tcaaatgcct g 21 <210> SEQ ID NO 18 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 18 ggagaaatgg cacagaggtg a 21 <210> SEQ ID NO 19 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 19 gagaccaagt tctttcccag 20 <210> SEQ ID NO 20 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 20 gagaccaagt tctttcccag 20 <210> SEQ ID NO 21 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 21 acaagcaaga ctgtgaagcc c 21 <210> SEQ ID NO 22 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 22 ggcttcctgt ttctcctcca g 21 <210> SEQ ID NO 23 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 23 gcctatcagg ccatgatcca 20 <210> SEQ ID NO 24 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 24 ggactccagg acagtggcat 20 <210> SEQ ID NO 25 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 25 accccatctc tttccagcat 20 <210> SEQ ID NO 26 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 26 ttgcctggca ttcatctaga 20 <210> SEQ ID NO 27 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 27 gggtccctgg tagttaacga 20 <210> SEQ ID NO 28 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 28 ccaactcctg accccagaa 19 <210> SEQ ID NO 29 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 29 atggatgggt aaactgaggc c 21 <210> SEQ ID NO 30 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 30 gctgacttcc tgagggaggc 20 <210> SEQ ID NO 31 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 31 cacccaactt tccatgagct c 21 <210> SEQ ID NO 32 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 32 tggtggtgta cccccttgac 20 <210> SEQ ID NO 33 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 33 gaactgtcgc cactcgtctg 20 <210> SEQ ID NO 34 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 34 acaccacagc gggatgatgt 20 <210> SEQ ID NO 35 <211> LENGTH: 516 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 35 gaactgtcgc cactcgtctg gatgtgcatt cgcaagctgc cctgcgagtg ctgtcaattg 60 caaattcagt caattaggac tcagcatcag gcagctggaa tgacacttcc tctagtgaag 120 cctcagagag cttacttatg ccactcattt cagatggaga gcaagggttt gaatttgccc 180 cctctagagc ccatgctcgc acttctgcac cgtatggcaa ggttgagtca ggcagagctt 240 gtcctcaaga agcccgcagt ctgctgtgga gagaggtggg cagtaaaaca catgctccag 300 ctgtagccat gtccctgtct ggaccagtta actcaattca gtttcaactt gcagacagct 360 ccttcaagcc aatcagacat cagagaaata aaaaggatgt gacaaaagag agtgaggtgg 420 agaacacagt ctccctctcc tggacaaact gctctgggaa agtttgcact tggaggtaga 480 tggggatgaa gccaacacat catcccgctg tggtgt 516 <210> SEQ ID NO 36 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 36 aaccccgagt gttgctgaaa 20 <210> SEQ ID NO 37 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 37 ccattcccca agcacctcat 20 <210> SEQ ID NO 38 <211> LENGTH: 789 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 38 aaccccgagt gttgctgaaa tcaaaaggct atgaagaagc agaagtcttg tgaaggtgtt 60 gttgggaaag agaattgttc agatatgggt aagccactga aaggtgtctt gatggttcat 120 ctgaacatgg gctgagaacc tgaagcagat acagaaagca agatgaccat gctggaacaa 180 tgaggacagg gaggatgggc agagtggcta gggagaagga ggtcttggat gaacatctga 240 gatagaaaat gcccctctgg cggctcatgt gtgctctcct gatcacatgc tctgacatgg 300 caggccccag cccattctcc ttacgaacga cacttgctgg gaatccctac tgggcacaca 360 caacccagtc tacaagatag agtggtccaa accccccatc ctgggctgtg gtgcttggaa 420 gatgcaacac accgactggc tacgctgcag ttactgcatc tttctggctg gctggcaagc 480 aaacttccca ctgcctttct ccccaggcct gaccccatta tgacaatgga gccattgttc 540 tgaacagggg ccatgaggca gctgggactg gccgacccta tgctggctcc tcacatctca 600 gaagtcaagc cctcagacag atcaaggaaa gtgataaaat tcagcgggaa gcaggacaga 660 gtattggggg tcctgagcca gcttcttcct ctcagttctg tatcgtgatg ggaatgaata 720 atcaccccaa ttacagagca acctgaagga gacaaaatca cttaactaaa tgaggtgctt 780 ggggaatgg 789 <210> SEQ ID NO 39 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 39 agagctgcac ggcacttctc 20 <210> SEQ ID NO 40 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 40 cacgatgcaa aacgaactac 20 <210> SEQ ID NO 41 <211> LENGTH: 465 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 41 agagctgcac ggcacttctc agcccacaag cccactttcc atgcaccaag cccaccccac 60 cttacacttg gcccctggct ccttaacctt gagctcagcc tccatcttaa ggtttcacca 120 agctgccctt cactatccgg tctgttggag attttccagc tagactctgc tagccacgct 180 ctgactctgt ttgacccagc tcccggggag aagccaagcc gactcccttc cactccctct 240 gcccccgctg ctgtcttaca cagccgtacc ttcctttcct ttgccccctc tcttggctgg 300 tgctgagcca catttagcac cagcctccaa gagcaagcac cctgtgctaa cttgggctcg 360 tgtctcgcaa gctaccaccc tgatcttaga aacccgaagc tcagaaaata gttcctatct 420 tatgtgcgtt atactcttca agaaggtagt tcgttttgca tcgtg 465 <210> SEQ ID NO 42 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 42 gtttggggag attttgagtg tg 22 <210> SEQ ID NO 43 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 43 gggcagcaga ccttagcaac t 21 <210> SEQ ID NO 44 <211> LENGTH: 478 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 44 gtttggggag attttgagtg tgtgggtggc agaaggtact tttaggttgg ggtcacagtg 60 cagcgggccg agcaccaaag cacagatatt ctagaactgg ggttctacat cagactacta 120 ctgtgagagc caagaggctc aaagccccca gagggtgact cattcttcca gccctccgcc 180 tcctcctgcc tgtccaggtc atcttgatca tcccattatc agaactgctg gaggaatcat 240 ctggaaggct tgaagtgact ggggggcatc cgctgggttg tgagagctgc tcggagggtc 300 ccttgtctgt cccagtccac ctcctccacc caccttatgc tgtcaccccc tgcccaggac 360 tggacctcca ttcaactctt ctgagcagaa ggagcagaaa ccatcctatc tctgcactgg 420 cctggaatgg acagtgctcc ccagcatggt tctagggagt tgctaaggtc tgctgccc 478 <210> SEQ ID NO 45 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 45 tcccaaaagg ccagtttcac ac 22 <210> SEQ ID NO 46 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 46 tctgcaggcg tctcatctca ac 22 <210> SEQ ID NO 47 <211> LENGTH: 678 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 47 tcccaaaagg ccagtttcac acactccatt aatgctggct gccactggga caattacaga 60 cagacagctt ttcccatttg agcaacttct taaatttaaa aagcaactgt gcaggaagga 120 aggagacatg tggctgctct actacagacc ttgtaaaagg aggttcttct atgctattac 180 ccaccccctc ccatacctac ctttcctacc acacacaaga gctgaaataa aagttgcatt 240 tcacttgtgt tgtggctgtt attttatttt acactccttg cttaaaaaaa aaaaaagtct 300 tcacttaaaa aaaaatacat cacccaaaca tgtctgagat tttttgcaag gcttgggtct 360 gaacccagtg cctttgatag gggcattttt cttagcctgc tgtggctaaa gatgggcatg 420 gtcggatttc actcgcttgg attaggatgg acttggccct aatattttgt ttcttaatga 480 ttcttccaat ttttaagtgt cccaagagat agctttgact ttccacccca gcctgctgat 540 gttatcttcc taggaactgc tacatctttt aatacaacct gtattcaagt tctccttata 600 ggacctgaga gattcaactg gcagcattta ggactaccag gaatctccag tctggcgttg 660 agatgagacg cctgcaga 678 <210> SEQ ID NO 48 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 48 cccctcagct ctgtgcattt 20 <210> SEQ ID NO 49 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 49 tccctgctga atgagtgttt g 21 <210> SEQ ID NO 50 <211> LENGTH: 478 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 50 cccctcagct ctgtgcattt tgtctacaag caaggtgact ttgggtttag tgtgttcatg 60 tttcaacaag aatgtaagtt tgggatcaga catatgttac ccctgttgga tagtagcttt 120 gcaatcagtc tttgcaaaaa atatccagaa caaggctaga acaaggtggt acagaaacaa 180 ataacacgtg ttacagttac atatgagctt ggattacctc ctttatagaa ggaagtggag 240 acatccttca tgcagagatt taggatctct cactagcact aaccctcttg cccccaccta 300 gtgtttattt caatcacccc tgttgctttt tatcaaatga aagatacaga tccactttta 360 agagtaaaga agagaggaag cacagtttat taattaccca ttggtatccc aaggacttgt 420 gcttccatta tctcattgtt ttattcattc attaatccaa acactcattc agcaggga 478 <210> SEQ ID NO 51 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 51 gaacctggtc tacaaattat ac 22 <210> SEQ ID NO 52 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 52 gactgggacc aatttgttct tc 22 <210> SEQ ID NO 53 <211> LENGTH: 673 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 53 gaacctggtc tacaaattat acaccctggc atgtccaaaa gcaaaatgct gcctacatct 60 cctgaaaatg caggaatgtc agaaaagctg ctgaagtggt ggctaccagg agctccaggg 120 gcctagcacc cactcccagc ccgaccctgg ggtggggagg gtggtgctct tcagagtggc 180 tcattttaga gctgactacc caagtgcaga agaaacaacg ttttaaatat atcgggcagc 240 agagcagcta gatattaagg ttcttctttg caggacatca tgaaatattg ttcatgacga 300 ccctgaccct gggttgggcg cgggtgctct tcagagtggc tcattttaga gctgacttcc 360 caagtgcaga agaaacaact ttttaaatac gtcgggtaac agagcagcta gacattacgg 420 ttcttctttg cagaacatca tgaaatattg atgttaagct aaaacgaata taataaatgt 480 atgattgcct gctaaattgg tcattatctt ttttagattc tggctttgac agaaagtagc 540 aggccccaat ggtttaagaa agaaaggaaa aaattttttt aattgaggaa atcatatcca 600 cgtctttttt tttttaattg ttgaaaagat gtccacagtc agatttcaga ggaagaacaa 660 attggtccca gtc 673 <210> SEQ ID NO 54 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 54 gtacacccac tcacctgtga t 21 <210> SEQ ID NO 55 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 55 tctaaggggg aaaagtaaac aa 22 <210> SEQ ID NO 56 <211> LENGTH: 761 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 56 gtacacccac tcacctgtga tgtacttaat ggagcaggag ggaacaggct gccatcaaag 60 ctaactcctg gaaatgacct agaacccaca gcctgtctca gccgtgctgc atgttccagc 120 agggaacaaa gcgactgttg tattatgtaa aattacttac ctgataataa aatgtttgtg 180 gattggataa atttgaacgg atatattgtt tccttcaccc cacccccact agtggcaaaa 240 gctgctctgt atgaatctga gtacatttct gtgacagtat tcctcatatg tacagcattc 300 tatgtgaatc atctcccaaa aattgccatg gggtcattat ccccagttct taactagaga 360 aactgagatt ctggaagtcc ctctgaatgg cccatacttc cccaggtgtc tctgcaggaa 420 acaatgtgga caatcacagt agttggaagg acaatgactg acctaatgga gttcaggacg 480 ctatgactgt tggcacctga tgtgcacagc tgctcccatc tgcgcagaga gaatataaag 540 gcagtggcgc tgaaacatct gctgctttca ctcaccatca agatggaact gactgtacat 600 gcaagcaaat tttgatgaag agagtgatct cagagtgcga agataagttg tttctccttg 660 acacctagga atgcacctgg ccaagaccct cagttgaaag acaatatcaa ataaatgcaa 720 aatctaaata tccatgtgct tgtttacttt tcccccttag a 761 <210> SEQ ID NO 57 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 57 Ser Ala Val Gly Ser Asp His Ile Phe His Asn 1 5 10 <210> SEQ ID NO 58 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 58 Ser Ala Val Gly Ser Asp His Ile Phe His Asn Ser Lys 1 5 10 <210> SEQ ID NO 59 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 59 Ser Ala Ala Gly Thr Asp His Ile Phe Leu Asn 1 5 10 <210> SEQ ID NO 60 <211> LENGTH: 70 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 60 Val Pro Gly Pro Thr Ser Ser Ala Thr Asn Val Ser Met Val Val Ser 1 5 10 15 Ala Gly Pro Leu Ser Ser Glu Lys Ala Glu Met Asn Ile Leu Glu Met 20 25 30 Asn Glu Lys Leu Arg Pro Gln Leu Ala Glu Lys Lys Gln Gln Phe Arg 35 40 45 Asn Leu Lys Glu Lys Cys Phe Val Thr Gln Leu Ala Gly Phe Leu Ala 50 55 60 Asn Gln Gln Asn Lys Tyr 65 70 <210> SEQ ID NO 61 <211> LENGTH: 70 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 61 Val Pro Gly Pro Thr Ser Ser Ala Thr Asn Val Ser Met Val Val Ser 1 5 10 15 Ala Gly Pro Leu Ser Ser Glu Lys Ala Glu Met Asn Ile Leu Glu Ile 20 25 30 Asn Glu Lys Leu His Pro Gln Leu Ala Glu Lys Lys Gln Gln Phe Arg 35 40 45 Asn Leu Lys Glu Arg Cys Phe Val Thr Gln Leu Ala Gly Phe Leu Ala 50 55 60 Asn Gln Gln Lys Lys Tyr 65 70 <210> SEQ ID NO 62 <211> LENGTH: 70 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 62 Val Pro Gly Pro Thr Ser Ser Ala Thr Asn Val Ser Met Val Val Ser 1 5 10 15 Ala Gly Pro Leu Ser Ser Glu Lys Ala Glu Met Asn Ile Leu Glu Ile 20 25 30 Asn Glu Lys Leu Arg Pro Gln Leu Ala Glu Lys Lys Gln Gln Phe Arg 35 40 45 Ser Leu Lys Glu Lys Cys Phe Val Thr Gln Leu Ala Gly Phe Leu Ala 50 55 60 Lys Gln Gln Asn Lys Tyr 65 70 <210> SEQ ID NO 63 <211> LENGTH: 70 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 63 Val Pro Asp Ser Thr Ser Ser Ala Thr Asn Val Ser Met Val Val Ser 1 5 10 15 Ala Gly Pro Trp Ser Ser Glu Lys Ala Glu Met Asn Ile Leu Glu Ile 20 25 30 Asn Glu Lys Leu Arg Pro Gln Leu Ala Glu Asn Lys Gln Gln Phe Gly 35 40 45 Asn Leu Lys Glu Arg Cys Phe Val Thr Gln Leu Ala Gly Phe Leu Ala 50 55 60 Asn Gln Gln Lys Lys Tyr 65 70 <210> SEQ ID NO 64 <211> LENGTH: 70 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 64 Ile Pro Asp Ser Thr Ser Ser Ala Thr Asn Val Ser Met Val Val Ser 1 5 10 15 Ala Gly Pro Trp Ser Ser Glu Lys Ala Glu Met Asn Ile Leu Glu Ile 20 25 30 Asn Glu Lys Leu Arg Pro Gln Leu Ala Glu Asn Lys Gln Gln Phe Arg 35 40 45 Asn Leu Lys Glu Arg Cys Phe Leu Thr Gln Leu Ala Gly Phe Leu Ala 50 55 60 Asn Arg Gln Lys Lys Tyr 65 70 <210> SEQ ID NO 65 <211> LENGTH: 70 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 65 Val Pro Gly Ser Thr Ser Ser Ala Thr Asn Val Ser Met Val Val Ser 1 5 10 15 Ala Gly Pro Trp Ser Ser Glu Lys Ala Glu Thr Asn Ile Leu Glu Ile 20 25 30 Asn Glu Lys Leu Arg Pro Gln Leu Ala Glu Asn Lys Gln Gln Phe Arg 35 40 45 Asn Leu Lys Glu Lys Cys Phe Val Thr Gln Leu Ala Gly Phe Leu Ala 50 55 60 Asn Arg Gln Lys Lys Tyr 65 70 <210> SEQ ID NO 66 <211> LENGTH: 70 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 66 Ile Pro Gly Ser Thr Ser Ser Ala Thr Asn Val Ser Met Val Val Ser 1 5 10 15 Ala Gly Pro Trp Ser Ser Glu Lys Ala Glu Thr Asn Ile Leu Lys Met 20 25 30 Asn Glu Lys Leu Arg Pro Gln Leu Ala Glu Lys Lys Gln Gln Phe Arg 35 40 45 Asn Leu Lys Glu Lys Cys Phe Val Thr Gln Leu Ala Gly Phe Leu Ala 50 55 60 Asn Arg Gln Lys Lys Tyr 65 70 <210> SEQ ID NO 67 <211> LENGTH: 67 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 67 Ile Pro Gly Pro Thr Ser Ser Ala Thr Asn Val Ser Met Val Val Ser 1 5 10 15 Ala Gly Pro Trp Ser Gly Glu Lys Ala Glu Met Asn Ile Leu Glu Ile 20 25 30 Asn Lys Lys Ser Arg Pro Gln Leu Ala Glu Asn Lys Gln Gln Phe Arg 35 40 45 Asn Leu Lys Gln Lys Cys Leu Val Thr Gln Val Ala Tyr Phe Leu Ala 50 55 60 Asn Arg Gln 65 <210> SEQ ID NO 68 <211> LENGTH: 35 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 68 Lys Tyr Glu Glu Cys Lys Asp Leu Ile Lys Ser Met Leu Arg Asn Glu 1 5 10 15 Leu Gln Phe Lys Glu Glu Lys Leu Ala Glu Gln Leu Lys Gln Ala Glu 20 25 30 Glu Leu Arg 35 <210> SEQ ID NO 69 <211> LENGTH: 35 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 69 Lys Tyr Glu Glu Cys Lys Asp Leu Ile Lys Ser Met Leu Arg Asn Glu 1 5 10 15 Arg Gln Phe Lys Glu Glu Lys Leu Ala Glu Gln Leu Lys Gln Ala Glu 20 25 30 Glu Leu Arg 35 <210> SEQ ID NO 70 <211> LENGTH: 35 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 70 Lys Tyr Glu Glu Cys Lys Asp Leu Ile Lys Phe Met Leu Arg Asn Glu 1 5 10 15 Arg Gln Phe Lys Glu Glu Lys Leu Ala Glu Gln Leu Lys Gln Ala Glu 20 25 30 Glu Leu Arg 35 <210> SEQ ID NO 71 <211> LENGTH: 29 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 71 Asp Leu Ile Lys Ser Met Leu Arg Asn Glu Arg Gln Phe Lys Glu Glu 1 5 10 15 Lys Leu Ala Glu Gln Leu Lys Gln Ala Glu Glu Leu Arg 20 25 <210> SEQ ID NO 72 <211> LENGTH: 35 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 72 Glu Tyr Glu Glu Cys Lys Asp Leu Ile Lys Ser Met Leu Arg Asn Glu 1 5 10 15 Arg Gln Phe Lys Glu Glu Lys Leu Ala Glu Gln Leu Lys Gln Ala Glu 20 25 30 Glu Leu Arg 35 <210> SEQ ID NO 73 <211> LENGTH: 35 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 73 Glu Tyr Glu Glu Cys Lys Asp Leu Ile Lys Cys Met Leu Arg Asn Glu 1 5 10 15 Arg Gln Phe Lys Glu Glu Lys Leu Ala Glu Gln Leu Lys Gln Ala Glu 20 25 30 Glu Leu Arg 35 <210> SEQ ID NO 74 <211> LENGTH: 35 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 74 Lys Tyr Glu Glu Cys Lys Asp Val Ile Lys Phe Met Leu Arg Asn Glu 1 5 10 15 Arg Gln Phe Lys Glu Glu Lys Leu Ala Glu Gln Leu Lys Gln Ala Glu 20 25 30 Glu Leu Arg 35 <210> SEQ ID NO 75 <211> LENGTH: 71 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 75 Gln Tyr Lys Val Leu Val His Ser Gln Glu Arg Glu Leu Thr Gln Leu 1 5 10 15 Arg Glu Lys Leu Arg Glu Gly Arg Asp Ala Ser Arg Ser Leu Asn Glu 20 25 30 His Leu Gln Ala Leu Leu Thr Pro Asp Glu Pro Asp Lys Ser Gln Gly 35 40 45 Gln Asp Leu Gln Glu Gln Leu Ala Glu Gly Cys Arg Leu Ala Gln His 50 55 60 Leu Val Gln Lys Leu Ser Pro 65 70 <210> SEQ ID NO 76 <211> LENGTH: 71 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 76 Gln Tyr Lys Val Leu Val His Ser Gln Glu Arg Glu Leu Thr Gln Leu 1 5 10 15 Arg Glu Lys Leu Arg Glu Gly Arg Asp Ala Ser Arg Ser Leu Asn Glu 20 25 30 His Leu Gln Ala Leu Leu Thr Leu Asp Glu Pro Asp Lys Ser Gln Gly 35 40 45 Gln Asp Leu Gln Glu Gln Leu Ala Glu Gly Cys Arg Leu Ala Gln His 50 55 60 Leu Val Gln Lys Leu Ser Pro 65 70 <210> SEQ ID NO 77 <211> LENGTH: 71 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 77 Gln Tyr Lys Val Leu Val His Ala Gln Glu Arg Glu Leu Thr Gln Leu 1 5 10 15 Arg Glu Lys Leu Arg Glu Gly Arg Asp Ala Ser Arg Ser Leu Asn Glu 20 25 30 His Leu Gln Ala Leu Leu Thr Pro Asp Glu Pro Asp Lys Ser Gln Gly 35 40 45 Gln Asp Leu Gln Glu Gln Leu Ala Glu Gly Cys Arg Leu Ala Gln His 50 55 60 Leu Val Gln Lys Leu Ser Pro 65 70 <210> SEQ ID NO 78 <211> LENGTH: 71 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 78 Gln Tyr Lys Val Leu Val His Ser Gln Glu Arg Glu Leu Thr Gln Leu 1 5 10 15 Arg Glu Lys Leu Arg Glu Gly Arg Asp Ala Ser Arg Ser Leu Asn Glu 20 25 30 His Leu Gln Ala Leu Leu Thr Pro Asp Glu Pro Asp Lys Ser Gln Gly 35 40 45 Gln Asp Leu Gln Glu Gln Leu Ala Glu Gly Cys Arg Leu Ala Gln Gln 50 55 60 Leu Val Gln Lys Leu Ser Pro 65 70 <210> SEQ ID NO 79 <211> LENGTH: 71 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 79 Gln Tyr Lys Val Leu Val His Ser Gln Glu Arg Glu Leu Thr Gln Leu 1 5 10 15 Arg Glu Lys Leu Arg Glu Gly Arg Asp Ala Ser Arg Ser Leu Asn Gln 20 25 30 His Leu Gln Ala Leu Leu Thr Pro Asp Glu Pro Asp Lys Ser Gln Gly 35 40 45 Gln Asp Leu Gln Glu Gln Leu Ala Glu Gly Cys Arg Leu Ala Gln His 50 55 60 Leu Val Gln Lys Leu Ser Pro 65 70 <210> SEQ ID NO 80 <211> LENGTH: 71 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 80 Gln Tyr Lys Val Leu Val His Ser Gln Glu Arg Glu Leu Thr Gln Leu 1 5 10 15 Arg Glu Lys Leu Arg Glu Gly Arg Asp Ala Ser Arg Ser Leu Asn Gln 20 25 30 His Leu Gln Ala Leu Leu Thr Pro Asp Glu Pro Asp Lys Ser Gln Gly 35 40 45 Gln Asp Leu Gln Glu Gln Leu Ala Glu Gly Cys Arg Leu Ala Gln Gln 50 55 60 Leu Phe Gln Lys Leu Ser Pro 65 70 <210> SEQ ID NO 81 <211> LENGTH: 25 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 81 Glu Asn Asp Glu Asp Glu Asp Glu Asp Val Gln Val Glu Glu Ala Glu 1 5 10 15 Lys Val Leu Glu Ser Ser Ala Pro Arg 20 25 <210> SEQ ID NO 82 <211> LENGTH: 25 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 82 Glu Asn Asp Asn Asp Asp Asp Glu Asp Val Gln Val Glu Val Ala Glu 1 5 10 15 Lys Val Gln Lys Ser Ser Ala Pro Arg 20 25 <210> SEQ ID NO 83 <211> LENGTH: 25 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 83 Glu Asn Asp Asn Asp Asp Asp Glu Asp Val Gln Val Glu Val Ala Glu 1 5 10 15 Lys Val Gln Lys Ser Ser Ser Pro Arg 20 25 <210> SEQ ID NO 84 <211> LENGTH: 25 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 84 Glu Asn Asp Asn Asp Asp Asp Glu Asp Val Gln Val Glu Leu Ala Glu 1 5 10 15 Lys Val Gln Lys Ser Ser Ala Pro Arg 20 25 <210> SEQ ID NO 85 <211> LENGTH: 25 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 85 Glu Asn Asp Glu Asp Glu Asp Glu Asp Val Gln Val Glu Glu Ala Glu 1 5 10 15 Lys Val Gln Lys Ser Ser Ala Pro Arg 20 25 <210> SEQ ID NO 86 <211> LENGTH: 25 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 86 Glu Asn Asp Glu Asp Glu Asp Glu Asp Val Gln Val Glu Glu Asp Glu 1 5 10 15 Lys Val Leu Glu Ser Ser Ala Pro Arg 20 25 <210> SEQ ID NO 87 <211> LENGTH: 25 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 87 Glu Asn Asp Glu Asp Glu Asp Glu Asp Val Gln Val Glu Glu Asp Glu 1 5 10 15 Lys Val Leu Glu Ser Ser Ser Pro Arg 20 25 <210> SEQ ID NO 88 <211> LENGTH: 25 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 88 Glu Asn Asp Asn Asp His Asp Glu Asp Val Gln Val Glu Val Ala Glu 1 5 10 15 Lys Val Gln Lys Ser Ser Ala Pro Arg 20 25 <210> SEQ ID NO 89 <211> LENGTH: 70 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 89 Glu Val Gln Lys Ala Glu Glu Ser Lys Val Pro Glu Asp Ser Leu Glu 1 5 10 15 Glu Cys Ala Ile Thr Cys Ser Asn Ser His Gly Pro Cys Asp Ser Asn 20 25 30 Gln Pro His Lys Asn Ile Asn Ile Thr Phe Glu Glu Asp Lys Val Asn 35 40 45 Ser Ala Leu Val Val Asp Arg Glu Ser Ser His Asp Glu Cys Gln Asp 50 55 60 Ala Val Asn Ile Leu Pro 65 70 <210> SEQ ID NO 90 <211> LENGTH: 70 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 90 Glu Met Gln Lys Ala Glu Glu Ser Lys Val Pro Glu Asp Ser Leu Glu 1 5 10 15 Glu Cys Ala Ile Thr Cys Ser Asn Ser His Gly Pro Cys Asp Ser Asn 20 25 30 Gln Pro His Lys Asn Ile Lys Ile Thr Phe Glu Glu Asp Lys Val Asn 35 40 45 Ser Ser Leu Val Val Asp Arg Glu Ser Ser His Asp Glu Cys Gln Asp 50 55 60 Ala Leu Asn Ile Leu Pro 65 70 <210> SEQ ID NO 91 <211> LENGTH: 70 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 91 Glu Val Gln Lys Thr Glu Glu Ser Lys Val Pro Glu Asp Ser Leu Glu 1 5 10 15 Glu Cys Ala Ile Thr Cys Ser Asn Ser His Gly Pro Cys Asp Ser Asn 20 25 30 Gln Pro His Lys Asn Ile Lys Ile Thr Phe Glu Glu Asp Glu Val Asn 35 40 45 Ser Thr Leu Val Val Asp Arg Glu Ser Ser His Asp Glu Cys Gln Asp 50 55 60 Ala Leu Asn Ile Leu Pro 65 70 <210> SEQ ID NO 92 <211> LENGTH: 70 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 92 Glu Val Gln Lys Ala Glu Glu Ser Lys Val Pro Glu Asp Ser Leu Glu 1 5 10 15 Glu Cys Ala Ile Thr Cys Ser Asn Ser His Gly Pro Cys Asp Ser Asn 20 25 30 Gln Pro His Lys Asn Ile Lys Ile Thr Phe Glu Glu Asp Lys Val Asn 35 40 45 Ser Thr Val Val Val Asp Arg Lys Ser Ser His Asp Glu Cys Gln Asp 50 55 60 Ala Leu Asn Ile Leu Pro 65 70 <210> SEQ ID NO 93 <211> LENGTH: 68 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 93 Glu Met Gln Lys Ala Glu Glu Lys Glu Val Pro Glu Asp Ser Leu Glu 1 5 10 15 Glu Cys Ala Ile Thr Cys Ser Asn Ser His Gly Pro Tyr Asp Ser Asn 20 25 30 Gln Pro His Arg Lys Thr Lys Ile Thr Phe Glu Glu Asp Lys Val Asp 35 40 45 Ser Thr Leu Ile Gly Ser Ser Ser His Val Glu Trp Glu Asp Ala Val 50 55 60 His Ile Ile Pro 65 <210> SEQ ID NO 94 <211> LENGTH: 68 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 94 Glu Met Gln Lys Ala Glu Glu Lys Glu Val Pro Glu Asp Ser Gln Glu 1 5 10 15 Glu Cys Ala Ile Thr Tyr Ser Asn Ser His Gly Pro Tyr Asp Ser Asn 20 25 30 Gln Pro His Arg Lys Thr Lys Ile Thr Phe Glu Glu Asp Lys Val Asp 35 40 45 Ser Thr Leu Ile Gly Ser Ser Ser His Val Glu Trp Glu Asp Ala Val 50 55 60 His Ile Ile Pro 65 <210> SEQ ID NO 95 <211> LENGTH: 68 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 95 Glu Met Pro Lys Ala Glu Glu Lys Glu Val Pro Glu Asp Ser Leu Glu 1 5 10 15 Glu Cys Ala Ile Thr Cys Ser Asn Ser His Gly Pro Tyr Asp Ser Asn 20 25 30 Gln Pro His Arg Lys Thr Lys Ile Thr Phe Glu Glu Asp Lys Val Asp 35 40 45 Ser Thr Leu Ile Gly Ser Ser Ser His Val Glu Trp Glu Asp Ala Val 50 55 60 His Ile Ile Pro 65 <210> SEQ ID NO 96 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 96 Glu Asn Glu Ser Asp Asp Glu Glu Glu Glu Glu Lys Gly Pro Val Ser 1 5 10 15 Pro Arg <210> SEQ ID NO 97 <211> LENGTH: 54 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 97 Asn Leu Gln Glu Ser Glu Glu Glu Glu Val Pro Gln Glu Ser Trp Asp 1 5 10 15 Glu Gly Tyr Ser Thr Leu Ser Ile Pro Pro Glu Met Leu Ala Ser Tyr 20 25 30 Gln Ser Tyr Ser Ser Thr Phe His Ser Leu Glu Glu Gln Gln Val Cys 35 40 45 Met Ala Val Asp Ile Gly 50 <210> SEQ ID NO 98 <211> LENGTH: 54 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 98 Asn Leu Gln Glu Ser Glu Glu Glu Glu Val Pro Gln Glu Ser Trp Asp 1 5 10 15 Glu Gly Tyr Ser Thr Leu Ser Ile Pro Pro Glu Met Leu Ala Ser Tyr 20 25 30 Lys Ser Tyr Ser Ser Thr Phe His Ser Leu Glu Glu Gln Gln Val Cys 35 40 45 Met Ala Val Asp Ile Gly 50 <210> SEQ ID NO 99 <211> LENGTH: 27 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 99 Asn Leu Gln Glu Ser Glu Glu Glu Glu Val Pro Gln Glu Ser Trp Asp 1 5 10 15 Glu Gly Tyr Ser Thr Leu Ser Ile Pro Pro Glu 20 25 <210> SEQ ID NO 100 <211> LENGTH: 54 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 100 Asn Leu Gln Glu Ser Glu Glu Glu Glu Val Pro Gln Glu Ser Trp Asp 1 5 10 15 Glu Gly Tyr Ser Thr Leu Ser Ile Pro Pro Glu Met Leu Ala Ser Tyr 20 25 30 Gln Ser Tyr Ser Gly Thr Phe His Ser Leu Glu Glu Gln Gln Val Cys 35 40 45 Val Ala Val Asp Ile Gly 50 <210> SEQ ID NO 101 <211> LENGTH: 54 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 101 Asn Leu Gln Glu Ser Glu Glu Glu Glu Val Pro Gln Glu Ser Trp Asp 1 5 10 15 Glu Gly Tyr Ser Thr Leu Ser Ile Pro Pro Glu Met Leu Ala Ser Tyr 20 25 30 Gln Ser Tyr Ser Gly Thr Phe His Ser Leu Glu Glu Gln Gln Val Cys 35 40 45 Met Ala Val Asp Ile Gly 50 <210> SEQ ID NO 102 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 102 Arg His Arg Trp Asp Gln Val Lys Lys Glu Asp Gln Glu Ala Thr Gly 1 5 10 15 Pro Arg <210> SEQ ID NO 103 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 103 Arg His Arg Trp Asp Gln Val Lys Lys Glu Asp His Glu Ala Thr Gly 1 5 10 15 Pro Arg <210> SEQ ID NO 104 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 104 Gly His Arg Trp Asp Gln Val Lys Lys Glu Asp Gln Glu Ala Thr Gly 1 5 10 15 Pro Arg <210> SEQ ID NO 105 <211> LENGTH: 57 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 105 Leu Ser Arg Glu Leu Leu Ala Glu Lys Glu Pro Glu Val Leu Gln Asp 1 5 10 15 Ser Leu Asp Arg Trp Tyr Ser Thr Pro Ser Val Tyr Leu Gly Leu Thr 20 25 30 Asp Pro Cys Gln Pro Tyr Arg Ser Ala Phe Tyr Val Leu Glu Gln Gln 35 40 45 Arg Val Gly Leu Ala Val Asp Met Asp 50 55 <210> SEQ ID NO 106 <211> LENGTH: 57 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 106 Leu Ser Arg Glu Leu Leu Ala Glu Lys Glu Pro Glu Val Leu Gln Asp 1 5 10 15 Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Val Tyr Leu Gly Leu Thr 20 25 30 Asp Ser Cys Gln Pro Tyr Arg Ser Ala Phe Tyr Val Leu Glu Gln Gln 35 40 45 Arg Val Gly Leu Ala Val Asp Met Asp 50 55 <210> SEQ ID NO 107 <211> LENGTH: 57 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 107 Leu Ser Arg Glu Leu Leu Asp Glu Lys Gly Pro Glu Val Leu Gln Asp 1 5 10 15 Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Cys Leu Glu Leu Thr 20 25 30 Asp Ser Cys Gln Pro Tyr Arg Ser Ala Phe Tyr Val Leu Glu Gln Gln 35 40 45 Arg Val Gly Leu Ala Val Asn Met Asp 50 55 <210> SEQ ID NO 108 <211> LENGTH: 57 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 108 Leu Ser Arg Glu Leu Leu Asp Glu Lys Gly Pro Glu Val Leu Gln Asp 1 5 10 15 Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Cys Leu Glu Leu Thr 20 25 30 Asp Ser Cys Gln Pro Tyr Arg Ser Ala Phe Tyr Ile Leu Glu Gln Gln 35 40 45 Arg Val Gly Leu Ala Val Asp Met Asp 50 55 <210> SEQ ID NO 109 <211> LENGTH: 57 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (47)...(47) <223> OTHER INFORMATION: the ′Xaa′ at position 47 may be any amino acid <400> SEQUENCE: 109 Leu Ser Arg Glu Leu Leu Asp Glu Glu Gly Pro Glu Val Leu Gln Asp 1 5 10 15 Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Cys Leu Glu Leu Thr 20 25 30 Asp Ser Cys Gln Pro Tyr Arg Ser Ala Phe Tyr Val Leu Glu Xaa Gln 35 40 45 Arg Val Gly Leu Ala Val Asp Met Asp 50 55 <210> SEQ ID NO 110 <211> LENGTH: 57 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 110 Leu Ser Gly Glu Leu Leu Asp Glu Lys Glu Pro Glu Val Leu Gln Glu 1 5 10 15 Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Cys Leu Glu Leu Thr 20 25 30 Asp Ser Cys Gln Pro Tyr Arg Ser Ala Phe Tyr Ile Leu Glu Gln Gln 35 40 45 Arg Val Gly Leu Ala Val Asp Met Asp 50 55 <210> SEQ ID NO 111 <211> LENGTH: 57 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 111 Leu Ser Arg Glu Leu Leu Asp Glu Lys Gly Pro Glu Val Leu Gln Asp 1 5 10 15 Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu Thr 20 25 30 Asp Ser Cys Gln Pro Tyr Arg Ser Ala Phe Tyr Ile Leu Glu Gln Gln 35 40 45 Arg Val Gly Trp Ala Leu Asp Met Asp 50 55 <210> SEQ ID NO 112 <211> LENGTH: 56 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (25)...(25) <223> OTHER INFORMATION: the ′Xaa′ at position 25 may be any amino acid <400> SEQUENCE: 112 Leu Asn Arg Glu Leu Leu Asp Glu Lys Gly Pro Glu Val Leu Gln Asp 1 5 10 15 Ser Leu Asp Arg Cys Tyr Ser Thr Xaa Ser Gly Tyr Leu Leu Thr Asp 20 25 30 Ser Cys Gln Pro Tyr Arg Ser Ala Phe Tyr Ile Leu Glu Gln Gln Arg 35 40 45 Val Gly Trp Ala Leu Asp Leu Val 50 55 <210> SEQ ID NO 113 <211> LENGTH: 57 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 113 Leu Ser Arg Glu Leu Leu Asp Glu Lys Glu Pro Glu Val Leu Gln Asp 1 5 10 15 Ser Leu Gly Arg Cys Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu Pro 20 25 30 Asp Leu Gly Gln Pro Tyr Ser Ser Ala Val Tyr Ser Leu Glu Glu Gln 35 40 45 Tyr Leu Gly Leu Ala Leu Asp Val Asp 50 55 <210> SEQ ID NO 114 <211> LENGTH: 57 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 114 Leu Ser Arg Glu Leu Leu Ala Glu Lys Glu Pro Glu Val Leu Gln Asp 1 5 10 15 Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu Pro 20 25 30 Asp Leu Gly Gln Pro Tyr Ser Ser Ala Val Tyr Ser Leu Glu Glu Gln 35 40 45 Tyr Leu Gly Leu Ala Leu Asp Val Asp 50 55 <210> SEQ ID NO 115 <211> LENGTH: 57 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 115 Leu Ser Arg Glu Leu Leu Asp Glu Lys Glu Pro Glu Val Leu Gln Asp 1 5 10 15 Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu Pro 20 25 30 Asp Leu Gly Gln Pro Tyr Arg Ser Ala Val Tyr Ser Leu Glu Glu Gln 35 40 45 Tyr Leu Gly Leu Ala Leu Asp Val Asp 50 55 <210> SEQ ID NO 116 <211> LENGTH: 57 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 116 Leu Ser Arg Glu Leu Leu Ala Glu Lys Glu Pro Glu Val Leu Gln Asp 1 5 10 15 Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu Pro 20 25 30 Asp Leu Gly Gln Pro Tyr Arg Ser Ala Val Tyr Ser Leu Glu Glu Gln 35 40 45 Tyr Leu Gly Leu Ala Leu Asp Val Asp 50 55 <210> SEQ ID NO 117 <211> LENGTH: 57 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 117 Leu Ser Arg Glu Leu Leu Ala Glu Lys Glu Pro Glu Val Leu Gln Asp 1 5 10 15 Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu Pro 20 25 30 Asp Leu Gly Gln Pro Tyr Arg Ser Ala Ala Tyr Ser Leu Glu Glu Gln 35 40 45 Tyr Leu Gly Leu Ala Leu Asp Val Asp 50 55 <210> SEQ ID NO 118 <211> LENGTH: 57 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 118 Leu Ser Arg Glu Leu Leu Asp Glu Lys Gly Pro Glu Val Leu Gln Asp 1 5 10 15 Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Cys Leu Glu Leu Thr 20 25 30 Asp Ser Cys Gln Pro Tyr Arg Ser Ala Phe Tyr Val Leu Glu Gln Gln 35 40 45 Arg Val Gly Leu Ala Val Asp Met Asp 50 55 <210> SEQ ID NO 119 <211> LENGTH: 57 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 119 Leu Ser Arg Glu Leu Leu Asp Glu Lys Glu Pro Glu Val Leu Gln Asp 1 5 10 15 Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu Pro 20 25 30 Asp Leu Gly Gln Pro Tyr Ser Ser Ala Val Tyr Ser Leu Glu Glu Gln 35 40 45 Tyr Leu Gly Leu Ala Leu Asp Val Asp 50 55 <210> SEQ ID NO 120 <211> LENGTH: 57 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 120 Leu Ser Arg Glu Leu Leu Asp Glu Lys Gly Pro Glu Val Leu Gln Asp 1 5 10 15 Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu Thr 20 25 30 Asp Ser Cys Gln Pro Tyr Arg Ser Ala Cys Tyr Ile Leu Glu Gln Gln 35 40 45 Arg Val Gly Trp Ala Leu Asp Met Asp 50 55 <210> SEQ ID NO 121 <211> LENGTH: 57 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 121 Leu Ser Arg Glu Leu Leu Asp Glu Lys Glu Pro Glu Val Leu Gln Asp 1 5 10 15 Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu Pro 20 25 30 Asp Leu Gly Gln Pro Tyr Arg Ser Ala Val His Ser Leu Glu Glu Gln 35 40 45 Tyr Leu Gly Leu Ala Leu Asp Val Asp 50 55 <210> SEQ ID NO 122 <211> LENGTH: 57 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 122 Leu Ser Arg Glu Leu Leu Asp Glu Lys Gly Pro Glu Val Leu Gln Asp 1 5 10 15 Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Cys Leu Glu Leu Thr 20 25 30 Asp Ser Cys Gln Pro Tyr Arg Ser Ala Val Tyr Ile Leu Glu Gln Gln 35 40 45 Cys Val Gly Leu Ala Val Asp Met Asp 50 55 <210> SEQ ID NO 123 <211> LENGTH: 57 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 123 Leu Ser Arg Glu Leu Leu Glu Ala Val Glu Pro Glu Val Leu Gln Asp 1 5 10 15 Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Ser Cys Leu Glu Gln Pro 20 25 30 Asp Ser Cys Leu Pro Tyr Gly Ser Ser Phe Tyr Ala Leu Glu Glu Lys 35 40 45 His Val Gly Phe Ser Leu Asp Val Gly 50 55 <210> SEQ ID NO 124 <211> LENGTH: 57 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 124 Leu Ser Arg Glu Leu Leu Arg Ala Val Glu Pro Glu Val Leu Gln Asp 1 5 10 15 Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Ser Cys Leu Glu Gln Pro 20 25 30 Asp Ser Cys Leu Pro Tyr Gly Ser Ser Phe Tyr Ala Leu Glu Glu Lys 35 40 45 His Val Gly Phe Ser Leu Asp Val Gly 50 55 <210> SEQ ID NO 125 <211> LENGTH: 57 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 125 Leu Ser Arg Glu Leu Leu Glu Val Val Glu Pro Glu Val Leu Gln Asp 1 5 10 15 Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Ser Cys Leu Glu Gln Pro 20 25 30 Asp Ser Cys Gln Pro Tyr Gly Ser Ser Phe Tyr Ala Leu Glu Glu Lys 35 40 45 His Val Gly Phe Ser Leu Asp Val Gly 50 55 <210> SEQ ID NO 126 <211> LENGTH: 57 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 126 Leu Ser Arg Glu Leu Leu Glu Val Val Glu Pro Glu Val Leu Gln Gly 1 5 10 15 Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Ser Cys Leu Glu Gln Pro 20 25 30 Asp Ser Cys Gln Pro Tyr Gly Ser Ser Phe Tyr Ala Leu Glu Glu Lys 35 40 45 His Val Gly Phe Ser Leu Asp Val Gly 50 55 <210> SEQ ID NO 127 <211> LENGTH: 57 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 127 Leu Ser Arg Glu Leu Leu Glu Val Val Glu Pro Glu Val Leu Gln Asp 1 5 10 15 Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Ser Cys Leu Glu Gln Pro 20 25 30 Asp Ser Cys Gln Pro Tyr Arg Ser Ser Phe Tyr Ala Leu Glu Glu Lys 35 40 45 His Val Gly Phe Ser Leu Asp Val Gly 50 55 <210> SEQ ID NO 128 <211> LENGTH: 57 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 128 Leu Ser Arg Glu Leu Leu Glu Val Val Glu Pro Glu Val Leu Gln Asp 1 5 10 15 Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Ser Tyr Leu Glu Leu Pro 20 25 30 Asp Ser Cys Gln Pro Tyr Gly Ser Ser Phe Tyr Ala Leu Glu Glu Lys 35 40 45 His Val Gly Phe Ser Leu Asp Val Gly 50 55 <210> SEQ ID NO 129 <211> LENGTH: 35 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 129 Glu Ile Glu Lys Lys Gly Lys Gly Lys Lys Arg Arg Gly Arg Arg Ser 1 5 10 15 Lys Lys Lys Arg Arg Arg Gly Arg Lys Glu Gly Glu Asp Asp Asn Pro 20 25 30 Pro Cys Pro 35 <210> SEQ ID NO 130 <211> LENGTH: 37 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 130 Glu Ile Glu Lys Lys Gly Lys Gly Lys Lys Arg Arg Gly Arg Arg Ser 1 5 10 15 Lys Lys Lys Arg Arg Arg Gly Arg Lys Glu Gly Glu Glu Asp Gln Asn 20 25 30 Pro Pro Cys Pro Arg 35 <210> SEQ ID NO 131 <211> LENGTH: 37 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 131 Glu Ile Glu Lys Lys Gly Lys Gly Lys Lys Arg Arg Gly Arg Arg Ser 1 5 10 15 Lys Lys Glu Arg Arg Arg Gly Arg Lys Glu Gly Glu Glu Asp Gln Asn 20 25 30 Pro Pro Cys Pro Arg 35 <210> SEQ ID NO 132 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 132 Glu Ile Glu Lys Lys Gly Lys Gly Lys Lys Arg Arg Gly Arg Arg Ser 1 5 10 15 Met Lys Lys Arg Arg Arg Arg Gly Arg Lys Glu Gly Glu Glu Asp Gln 20 25 30 Asn Pro Pro Cys Pro Arg 35 <210> SEQ ID NO 133 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 133 Glu Ile Glu Lys Lys Gly Lys Gly Lys Lys Arg Arg Gly Arg Arg Ser 1 5 10 15 Thr Lys Lys Arg Arg Arg Arg Gly Arg Lys Glu Gly Glu Glu Asp Gln 20 25 30 Asn Pro Pro Cys Pro Arg 35 <210> SEQ ID NO 134 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 134 Glu Ile Glu Lys Lys Gly Lys Gly Lys Lys Arg Arg Gly Arg Arg Ser 1 5 10 15 Thr Lys Lys Arg Arg Arg Arg Gly Ser Lys Glu Gly Glu Glu Asp Gln 20 25 30 Asn Pro Pro Cys Pro Arg 35 <210> SEQ ID NO 135 <211> LENGTH: 25 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 135 Glu Ile Glu Lys Lys Gly Lys Gly Lys Lys Arg Arg Gly Arg Arg Ser 1 5 10 15 Thr Lys Glu Arg Arg Arg Arg Gly Arg 20 25 <210> SEQ ID NO 136 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 136 Glu Ile Glu Lys Ser Gln Lys Trp Lys Lys Thr Gln Asn Pro Ser Cys 1 5 10 15 Pro Arg <210> SEQ ID NO 137 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 137 Glu Ile Glu Lys Tyr Gln Glu Val Glu Glu Asp Gln Asp Pro Ser Cys 1 5 10 15 Pro Arg <210> SEQ ID NO 138 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 138 Arg Ile Lys Lys Asp Gln Glu Glu Glu Glu Asp Gln Gly Pro Pro Cys 1 5 10 15 Pro Arg <210> SEQ ID NO 139 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 139 Arg Thr Lys Lys Asp Gln Glu Glu Glu Glu Asp Gln Gly Pro Pro Cys 1 5 10 15 Pro Arg <210> SEQ ID NO 140 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 140 Arg Ile Lys Lys Asp Gln Glu Glu Glu Glu Asp Gln Gly Pro Pro Cys 1 5 10 15 Ser Arg <210> SEQ ID NO 141 <211> LENGTH: 23 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (2)...(2) <223> OTHER INFORMATION: the ′Xaa′ at position 2 may be any amino acid <400> SEQUENCE: 141 Glu Xaa Ser Glu Gln Glu Ile Lys Lys Tyr Gln Glu Glu Glu Glu Asp 1 5 10 15 Gln Asp Pro Ser Cys Pro Arg 20 <210> SEQ ID NO 142 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 142 Leu Asn Gly Val Leu Met Glu Val Glu Glu Arg Glu Val Leu Gln Asp 1 5 10 15 Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Met Tyr Phe Glu Leu Pro 20 25 30 Asp Ser Phe Gln His Tyr Arg Ser Val Phe Tyr Ser Phe Glu Glu Gln 35 40 45 His Ile Ser Phe Ala Leu Tyr Val Asp Asn Arg Phe Phe Thr Leu Thr 50 55 60 Val Thr Ser Leu His Leu Val Phe Gln Met Gly Val Ile Phe Pro Gln 65 70 75 80 <210> SEQ ID NO 143 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 143 Leu Asn Gly Val Leu Met Glu Val Glu Glu Arg Glu Val Leu Gln Asp 1 5 10 15 Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Met Tyr Phe Glu Leu Pro 20 25 30 Asp Ser Phe Gln His Tyr Arg Ser Val Phe Tyr Ser Phe Glu Glu Gln 35 40 45 His Ile Thr Phe Ala Leu Tyr Val Asp Asn Arg Phe Phe Thr Leu Thr 50 55 60 Val Thr Ser Leu His Leu Val Phe Gln Met Gly Val Ile Phe Pro Gln 65 70 75 80 <210> SEQ ID NO 144 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 144 Leu Asn Gly Val Leu Met Glu Val Glu Glu Pro Glu Val Leu Gln Asp 1 5 10 15 Ser Leu Asp Gly Cys Tyr Ser Thr Pro Ser Met Tyr Phe Glu Leu Pro 20 25 30 Asp Ser Phe Gln His Tyr Arg Ser Val Phe Tyr Ser Phe Glu Glu Gln 35 40 45 His Ile Ser Phe Ala Leu Tyr Val Asp Asn Arg Phe Phe Thr Leu Thr 50 55 60 Val Thr Ser Leu His Leu Val Phe Gln Met Glu Val Ile Phe Pro Gln 65 70 75 80 <210> SEQ ID NO 145 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 145 Leu Asn Ser Val Leu Met Glu Val Glu Glu Pro Glu Val Leu Gln Asp 1 5 10 15 Ser Leu Asp Gly Cys Tyr Ser Thr Pro Ser Met Tyr Phe Glu Leu Pro 20 25 30 Asp Ser Phe Gln His Tyr Arg Ser Val Phe Tyr Ser Phe Glu Glu Glu 35 40 45 His Ile Ser Phe Ala Leu Tyr Leu Asp Asn Arg Phe Phe Thr Leu Thr 50 55 60 Val Thr Ser Leu His Leu Val Phe Gln Met Leu Val Ile Phe Pro Gln 65 70 75 80 <210> SEQ ID NO 146 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 146 Leu Asn Ser Met Leu Met Glu Val Glu Glu Pro Glu Val Leu Gln Asp 1 5 10 15 Ser Leu Asp Ile Cys Tyr Ser Thr Pro Ser Met Tyr Phe Glu Leu Pro 20 25 30 Asp Ser Phe Gln His Tyr Arg Ser Val Phe Tyr Ser Phe Glu Glu Glu 35 40 45 His Ile Ser Phe Ala Leu Tyr Val Asp Asn Arg Phe Phe Thr Leu Thr 50 55 60 Val Thr Ser Leu His Leu Val Phe Gln Met Gly Val Ile Phe Pro Gln 65 70 75 80 <210> SEQ ID NO 147 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 147 Leu Tyr Gly Val Leu Met Glu Val Glu Glu Pro Glu Val Leu Gln Asp 1 5 10 15 Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Met Tyr Phe Glu Gln Pro 20 25 30 Asp Ser Phe Gln His Tyr Arg Ser Val Phe Tyr Ser Phe Glu Glu Glu 35 40 45 His Ile Ser Phe Ala Leu Tyr Val Asp Asn Arg Phe Phe Thr Leu Thr 50 55 60 Val Thr Ser Leu His Leu Val Phe Gln Met Gly Val Ile Phe Pro Gln 65 70 75 80 <210> SEQ ID NO 148 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 148 Ser Tyr Gly Val Leu Met Glu Val Glu Glu Pro Glu Val Leu Gln Asp 1 5 10 15 Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Met Tyr Phe Glu Gln Pro 20 25 30 Asp Ser Phe Gln His Tyr Arg Ser Val Phe Tyr Ser Phe Glu Glu Glu 35 40 45 His Ile Ser Phe Ala Leu Tyr Val Asp Asn Arg Phe Phe Thr Leu Thr 50 55 60 Val Thr Ser Leu His Leu Val Phe Gln Met Gly Val Ile Phe Pro Gln 65 70 75 80 <210> SEQ ID NO 149 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 149 Leu Ser Gly Val Leu Met Glu Val Glu Glu Pro Glu Ile Leu Gln Asp 1 5 10 15 Ser Leu Asp Arg Cys Tyr Ser Thr Leu Ser Leu Phe Phe Glu Leu Pro 20 25 30 Asp Ser Phe Gln His Tyr Arg Ser Val Phe Tyr Ser Phe Glu Glu Gln 35 40 45 His Ile Ser Phe Ala Leu Asp Val Asp Asn Arg Phe Leu Thr Leu Met 50 55 60 Gly Thr Ser Leu His Leu Val Phe Gln Met Gly Val Ile Phe Pro Gln 65 70 75 80 <210> SEQ ID NO 150 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (47)...(47) <223> OTHER INFORMATION: the ′Xaa′ at position 47 may be any amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (55)...(55) <223> OTHER INFORMATION: the ′Xaa′ at position 55 may be any amino acid <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (73)...(73) <223> OTHER INFORMATION: the ′Xaa′ at position 73 may be any amino acid <400> SEQUENCE: 150 Phe Ser Gly Val Leu Met Glu Val Glu Glu Pro Glu Ile Leu Gln Asp 1 5 10 15 Ser Leu Asp Arg Cys Tyr Ser Thr Leu Ser Leu Phe Phe Glu Leu Pro 20 25 30 Asp Ser Phe Gln His Tyr Arg Ser Val Phe Tyr Ser Phe Glu Xaa Gln 35 40 45 His Ile Ser Phe Ala Leu Xaa Val Asp Asn Arg Val Leu Thr Leu Met 50 55 60 Gly Thr Ser Leu His Arg Gly Phe Xaa Met Gly Val Ile Phe Pro Gln 65 70 75 80 <210> SEQ ID NO 151 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 151 Leu Ser Gly Val Leu Met Glu Val Glu Glu Pro Glu Ile Leu Gln Asp 1 5 10 15 Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Leu Phe Phe Glu Leu Pro 20 25 30 Asp Ser Phe Gln His Tyr Arg Ser Val Phe Tyr Ser Phe Glu Glu Gln 35 40 45 His Ile Ser Phe Ala Leu Asp Val Asp Asn Arg Phe Leu Thr Leu Met 50 55 60 Gly Thr Ser Leu His Leu Val Phe Gln Met Gly Val Ile Phe Pro Gln 65 70 75 80 <210> SEQ ID NO 152 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 152 Leu Ser Gly Val Leu Met Glu Val Glu Glu Pro Glu Ile Leu Gln Asp 1 5 10 15 Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Met Phe Phe Glu Leu Pro 20 25 30 Asp Ser Phe Gln His Tyr Arg Ser Val Phe Tyr Ser Phe Glu Glu Gln 35 40 45 His Ile Ser Phe Ala Leu Asp Val Asp Asn Arg Phe Leu Thr Leu Met 50 55 60 Gly Thr Ser Leu His Leu Val Phe Gln Met Gly Val Ile Phe Pro Gln 65 70 75 80 <210> SEQ ID NO 153 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 153 Leu Asn Ser Val Leu Met Glu Val Glu Glu Pro Glu Val Leu Gln Asp 1 5 10 15 Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Met Tyr Cys Glu Leu Arg 20 25 30 Asp Ser Phe Gln His Tyr Arg Ser Val Phe Tyr Ser Phe Glu Glu Gln 35 40 45 His Ile Ser Phe Ala Leu Asp Met Asp Asn Arg Phe Phe Thr Leu Thr 50 55 60 Val Thr Ser Leu Tyr Leu Val Phe Gln Met Gly Val Ile Phe Pro Gln 65 70 75 80 <210> SEQ ID NO 154 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 154 Leu Ser Ser Val Leu Met Glu Val Glu Val Pro Glu Val Leu Gln Asp 1 5 10 15 Ser Leu Asp Arg Tyr Tyr Ser Thr Pro Ser Met Tyr Phe Glu Leu Pro 20 25 30 Asp Ser Phe Gln His Tyr Arg Ser Val Phe Tyr Ser Phe Glu Glu Gln 35 40 45 His Ile Ser Phe Ala Leu Thr Trp Thr Ile Gly Phe Phe Thr Leu Thr 50 55 60 Val Arg Ser Leu His Leu Val Phe Gln Met Gly Val Ile Phe Pro Gln 65 70 75 80 <210> SEQ ID NO 155 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 155 Leu Asn Ser Val Leu Met Glu Val Glu Glu Pro Glu Val Leu Gln Asp 1 5 10 15 Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Met Tyr Phe Glu Leu Pro 20 25 30 Asp Ser Phe Gln His Tyr Arg Ser Val Phe Tyr Ser Phe Glu Glu Gln 35 40 45 His Ile Thr Phe Ala Leu Asp Met Asp Asn Ser Phe Phe Thr Leu Thr 50 55 60 Val Thr Ser Leu His Leu Val Phe Gln Met Gly Val Ile Phe Pro Gln 65 70 75 80 <210> SEQ ID NO 156 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 156 Leu Ser Gly Val Leu Met Glu Val Glu Glu Pro Glu Val Leu Gln Asp 1 5 10 15 Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Met Tyr Phe Glu Leu Pro 20 25 30 Asp Ser Phe Gln His Tyr Arg Ser Val Phe Tyr Ser Phe Glu Glu Gln 35 40 45 His Ile Ser Phe Ala Leu Asp Val Asp Asn Arg Phe Leu Thr Leu Met 50 55 60 Gly Thr Ser Leu His Leu Val Phe Gln Met Gly Val Ile Phe Pro Gln 65 70 75 80 <210> SEQ ID NO 157 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 157 gttgtacccc cttgacttca 20 <210> SEQ ID NO 158 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 158 gtgcccagca ggagattcaa t 21 <210> SEQ ID NO 159 <211> LENGTH: 568 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 159 ggtgtacccc cttgacttca cctgaatgtc agggcaaggc caggagcatg caggaggctt 60 aaagattggg aacccctatt cttgggcctt ctccccattc tttctggagc aattggaaga 120 ggcccatggg agggaggtga ctgtcatgat gtcccccact atgaactatg ggaatggctg 180 gagggtcact gggcctggtg ctccagctgc ctgacctgca gggaagtggt acctgcagga 240 cctacagtga gggagtgttg acaccctggc tctgggaagg agctcatgga aagttgggtg 300 aacttcttgt tagactacgc aggctttcag aagtgcattc catacggagt ggggtggcct 360 ccccagggag gagcagaggg cagccactgg aacaagctac agctacaaaa gaccaccttt 420 atccctctca agttctccca ggggcccctg tgtctgcctg tactagagga agtttccaaa 480 ggattttcct ttccccagga tgaagaatga ggccacactg ccaaagcaag atctcgtgct 540 atgtgtgatt gaatctcctg ctgggcac 568 <210> SEQ ID NO 160 <211> LENGTH: 4512 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (206)..(409) <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1717)..(1770) <220> FEATURE: <223> OTHER INFORMATION: der1 breakpoint-overlapping; Genbank AF379606 <400> SEQUENCE: 160 ctgctctctt cctctctggt tcccatggca gccatgctct gttgcagaga gaacaggatt 60 gcatgtaccc tcttaatggg aacctccagt ttgctttctg ggaccactct cttaatgccg 120 cctgtcaaaa ccagctagga ctccctgggg tccaatccct ctgtgtttaa tcttctgtca 180 tctctgtccc acctggctca tcagg gac atg cag aag gct gaa gaa aag gaa 232 Asp Met Gln Lys Ala Glu Glu Lys Glu 1 5 gtc cct gag gac tca ctg gag gaa tgt gcc atc act tgt tca aat agc 280 Val Pro Glu Asp Ser Leu Glu Glu Cys Ala Ile Thr Cys Ser Asn Ser 10 15 20 25 cat ggc cct tat gac tcc aac cag cca cat agg aaa acc aaa atc aca 328 His Gly Pro Tyr Asp Ser Asn Gln Pro His Arg Lys Thr Lys Ile Thr 30 35 40 ttt gag gaa gac aaa gtc gac tca act ctc att ggc tca tcc tct cat 376 Phe Glu Glu Asp Lys Val Asp Ser Thr Leu Ile Gly Ser Ser Ser His 45 50 55 gtt gaa tgg gag gat gct gta cac att atc cca ggtagcctct gttttccttg 429 Val Glu Trp Glu Asp Ala Val His Ile Ile Pro 60 65 tgtctcatac ctctctctag gctgaggaag ataaactctg aagacaggct ctataaacac 489 aaattcattt gaataaaaaa ctatgatggg tttctaaaca gatatcaggg agtttttttg 549 tccttctcag ctaatgtcat gcctttgtct gccagtcccc agtatcaagt tactcgaccc 609 caggcaagtg tgacaatctc atagtcacct gagtgcagga ggtgcacagg cagtatctgt 669 caggcctcct agcttcgatt cagtatctct tgtcatctgt gattaagtca tctgtccctg 729 aacaatgtcc atggagtttc tatgcctgtt tcaggaagct ggcagccttg cctttgtatt 789 tggaaatatt gttccccagg cttcactgct ctcagctttc atctggatct cctttaagtc 849 agcttgctta gctgcacagt caccctgaaa tcaggatgga aacttttctt ctttactttg 909 ctgatatatt tccataaagc aaggctggac cctggttctc caccctgtca atgcaatggc 969 tgatccaatg tttctttgta gcatcgtgga tttttttttt tttttttttt tttttttttt 1029 tttttttttt ttttttgcga tggagtcttg ctctgtcacc caggctagag tgcagttgca 1089 ccatcttggc ttggtgcaac ctctgcctcc cagattcaag tgattctcct gcctcagcct 1149 cctgagttgc tgggaccaca ggtgcacaac atcacatctg gctaattttt gtatttttag 1209 tagagacagt gtttccccat attggccagg gtagtcctga actcatgacc tcaaatgatt 1269 cacctgtctt ggcctcccaa atcacagatt ctttttaaag caagagttgt tcaaatttat 1329 ctatcagtcg tgtttcatgt atagatgcct ctaaacattt aatgtccatg ttatctggtg 1389 atataagtcc gtattgcagc aacactctta gaaaatggac caatttttgg agattttttt 1449 ggggaaaaaa ttttgtttaa ctttgactca ggcagggaat atggcattat ggtctacacg 1509 tagagggaga ttttggcctg tgggtctgga aagcagggtc atctaattct caccaaagtt 1569 aatctagggc accctagaat attcctgtca gaatccttat tcttgcactg agaatagtta 1629 tgtccttgtg ctatgactgg acagtgattt ggtcatatgt gaagtatgaa ttgcttaatg 1689 tgacctgctt ctctgaattt atttaca gaa aat gaa agt gat gat gag gaa gag 1743 Glu Asn Glu Ser Asp Asp Glu Glu Glu 70 75 gaa gaa aaa ggg cca gtg tct ccc agg taatgttgtg gaattgttgg 1790 Glu Glu Lys Gly Pro Val Ser Pro Arg 80 85 ctgttaattc agtagtgaca tctggagatt gtagatttag ggaaaatgag gaagtgatga 1850 atagaactat ttcttccatt cacccagcta caaattgtgc tgatttacaa tgttgtatgt 1910 tatttgtgac acttgtattg gttttaattt catagtcctc tcaagatagg aacttgccat 1970 cagatgagcc aggtgaacta gccaaacagg gttttcttgt tgatcttttc aaaaaaccag 2030 ccctggattc attgattttt tgaagggttt tttgtgtctc tatctccttt agttctgctc 2090 tgatcttagt tacttcttgt cttctgctag cttttgaatt tgtttgcttt gcttctctag 2150 ttattttaat tgtgatgtta gggtgtcaat tttagatctt ttctgctttc tcttgtgggc 2210 atttagtgct ataattttcc ctctacacat tgctttaaat gtgtcccaga gattctggta 2270 tgttgtgtct ttgttctcat tggtttcaaa gaacatcttt atttctgcct tcattttgtt 2330 attttcccag tagtcattca ggagcaggtt gttcagtttc catgtagttg tgcggttttg 2390 agtgagttcc ttaatcctga gttctaattt gactgcactg tggtctgaca gtttgttgtg 2450 gtttccattc ttttacattt gctgaggagt gctttacctc caactatgtg gtcaattttg 2510 gaataagtgt gatgtggtgc tgagaagaat gtatattctg ttgatttggg gtggagagtt 2570 ctgtagatgt cttttaggtc tgcttggtgg agagctgagt tcaagtcctg gatatccttg 2630 taaagcttct gtctcattga tctgtctaat attgacagtg gggtgttaaa gtctcccatt 2690 atgattgtgt ggagtctaaa tctctttgta ggtctctcag gacttgcttt atgaatctgg 2750 gtgctcctgt atagggtgca tatatattta ggatagttaa ctcttcttgt tgaattgatc 2810 cctttaccat tatgtagtgg ccttctttgt ctcttttgat ctttgttggt ttaaagtctg 2870 ttttatcaga gactaggatt gcaacccctg catttttttg ctttccattt gcttggtaga 2930 tcttcctcca tccctttatt ttgagcctat gtgtgtctct gcatgtgaga taggtttcct 2990 gagtacagca cactgatggg tcttgactct ttgtccaatt tgccattctg tgttttttaa 3050 ctggggcatt tagcccattt acatttaagg ttaatattgt tatgtgtgaa tttgagcctg 3110 tcgttatgat gttagctggt tatttcgccc gttagttgat gcagtttctt cctagcgtca 3170 atggtcttta cagtttggca tgtttttgca gtggctggta ccggttgttc ctttccatgt 3230 ttagtgcttc ctttaggagc tcttgtaagg caggcctggt ggtgacaaaa tctctcagca 3290 tttgcttctc tgtaaaggat ttatttctcc ttcacttatg aagctttgtt tggctggata 3350 tgaaattctg ggttgaaaat tcttttcttt aagaatgttg aagatgctgg agaggatgtg 3410 gagaaatagg aacactttta cactgttggt gagagtgtaa actagttcaa cgattgtgga 3470 aggcagtgtg gcaattcctc agggatctag aactagaaat agcatttgac ccagccatcc 3530 cattactggg tgtataccca aaggattata aatcatgctg ctgtaaagac acatgcacac 3590 atatgtttat tgcggcacta ttcacaatag caaagacttg gaaccaagcc aaatatccag 3650 caatgataga ctggattaag aaaatgtggc acgtatacac catggaatac tatgcagcta 3710 taaaaaatga tgagttcatg tcctttgtag gggcatggat gaagctggaa accatcattc 3770 tcagcaaact atcgcaagga caaaaaacca agtaccgcat gttcttactc acaggtggaa 3830 attgaacaat gagaaaaagc acatagcact aggaagggag ccagtagaat ttcaggtgaa 3890 gagtaatggg agatgggaac ctacacaaac tggagagacc caggaaagcc tcctgagaag 3950 gtcctttaag atgagctgtg aggccaagga agagcaggcc aggcgaaggc agaggggaca 4010 gccttccagt gagtggaaac agcaaatgca aaggcctcga ggcggggcag ggcttgtgct 4070 tttggggagc agaaagaagg tcacggaaaa aaaacagcgt gattcatgga gagaggccca 4130 gggctgaaaa gggagaggca ggagtggggc tcatggtctc tagaaaacag actgggtttg 4190 agtttgtgta atagcctggt gaggacggta ttattatttc tgcttccatt ttacagttac 4250 agaaacagag ggcagcatat gatactgggg ggtactggga tagggctgtg ttattgattg 4310 atgggggacc tttgacggtc agaaatggag ggaggctggt ggtgtacccc cttgacttca 4370 cctgaatgtc agggcaaggc caggagcatg caggaggctt aaagattggg aacccctatt 4430 cttgggcctt ctccccattc tttctggagc aattggaaga ggcccatggg agggaggtga 4490 ctgtcatgat gtcccccact at 4512 <210> SEQ ID NO 161 <211> LENGTH: 86 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <223> OTHER INFORMATION: der1 breakpoint-overlapping; Genbank AF379606 <400> SEQUENCE: 161 Asp Met Gln Lys Ala Glu Glu Lys Glu Val Pro Glu Asp Ser Leu Glu 1 5 10 15 Glu Cys Ala Ile Thr Cys Ser Asn Ser His Gly Pro Tyr Asp Ser Asn 20 25 30 Gln Pro His Arg Lys Thr Lys Ile Thr Phe Glu Glu Asp Lys Val Asp 35 40 45 Ser Thr Leu Ile Gly Ser Ser Ser His Val Glu Trp Glu Asp Ala Val 50 55 60 His Ile Ile Pro Glu Asn Glu Ser Asp Asp Glu Glu Glu Glu Glu Lys 65 70 75 80 Gly Pro Val Ser Pro Arg 85 <210> SEQ ID NO 162 <211> LENGTH: 420 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <223> OTHER INFORMATION: chimera 1; Genbank AF420438 <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)..(207) <400> SEQUENCE: 162 att ggc tca tcc tct cat gtt gaa tgg gag gat gct gta cac att atc 48 Ile Gly Ser Ser Ser His Val Glu Trp Glu Asp Ala Val His Ile Ile 1 5 10 15 cca gaa aat gaa agt gat gat gag gaa gag gaa gaa aaa ggg cca gtg 96 Pro Glu Asn Glu Ser Asp Asp Glu Glu Glu Glu Glu Lys Gly Pro Val 20 25 30 tct ccc agg atg aag aat gag gcc aca ctg cca aag caa gat ctc gtg 144 Ser Pro Arg Met Lys Asn Glu Ala Thr Leu Pro Lys Gln Asp Leu Val 35 40 45 cta tgt gtg att gaa tct cct gct ggg cgc caa gca gga atc tca tca 192 Leu Cys Val Ile Glu Ser Pro Ala Gly Arg Gln Ala Gly Ile Ser Ser 50 55 60 ttt ccc cac agg ccc tgagagcaca caggcctcat ccccacccca ccacagtgca 247 Phe Pro His Arg Pro 65 gtgcactcac tgcagagcca atgaggcctg agctcagggt ctgcgtctgc ctgcatctgc 307 atggccactt ccatctgtgg tacttgttag tttattttaa atgtgcgatt tgtttggttg 367 cattttctcc ttctaaatat acagtagttt ttgcaaaaaa aaaaaaaaaa aaa 420 <210> SEQ ID NO 163 <211> LENGTH: 69 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <223> OTHER INFORMATION: chimera 1; Genbank AF420438 <400> SEQUENCE: 163 Ile Gly Ser Ser Ser His Val Glu Trp Glu Asp Ala Val His Ile Ile 1 5 10 15 Pro Glu Asn Glu Ser Asp Asp Glu Glu Glu Glu Glu Lys Gly Pro Val 20 25 30 Ser Pro Arg Met Lys Asn Glu Ala Thr Leu Pro Lys Gln Asp Leu Val 35 40 45 Leu Cys Val Ile Glu Ser Pro Ala Gly Arg Gln Ala Gly Ile Ser Ser 50 55 60 Phe Pro His Arg Pro 65 <210> SEQ ID NO 164 <211> LENGTH: 457 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <223> OTHER INFORMATION: chimera 2; Genbank AF420439 <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)..(138) <400> SEQUENCE: 164 att ggc tca tcc tct cat gtt gaa tgg gag gat gct gta cac att atc 48 Ile Gly Ser Ser Ser His Val Glu Trp Glu Asp Ala Val His Ile Ile 1 5 10 15 cca gaa aat gaa agt gat gat gag gaa gag gaa gaa aaa ggg cca gtg 96 Pro Glu Asn Glu Ser Asp Asp Glu Glu Glu Glu Glu Lys Gly Pro Val 20 25 30 tct ccc agg tgt ctc tgc agg aaa caa tgt gga caa tca cag 138 Ser Pro Arg Cys Leu Cys Arg Lys Gln Cys Gly Gln Ser Gln 35 40 45 tagttggaag gacaatgact gacctaatgg agttcaggac gctatgactg ttggcacctg 198 atgtgcacag ctgctcccat ctgcgcagag agaatataaa ggcagtggcg ctgaaacatc 258 tgctgctttc actcaccatc aagatggaac tgactgtaca tgcaagcaaa ttttgatgaa 318 gagagtgatc tcagagtgcg aagataagtt gtttctcctt gacacctagg aatgcacctg 378 gccaagaccc tcagttgaaa gacaatatca aataaatgca aaattgtaaa tcaaaaaaaa 438 aaaaaaaaaa aaaaaaaaa 457 <210> SEQ ID NO 165 <211> LENGTH: 46 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <223> OTHER INFORMATION: chimera 2; Genbank AF420439 <400> SEQUENCE: 165 Ile Gly Ser Ser Ser His Val Glu Trp Glu Asp Ala Val His Ile Ile 1 5 10 15 Pro Glu Asn Glu Ser Asp Asp Glu Glu Glu Glu Glu Lys Gly Pro Val 20 25 30 Ser Pro Arg Cys Leu Cys Arg Lys Gln Cys Gly Gln Ser Gln 35 40 45 <210> SEQ ID NO 166 <211> LENGTH: 1677 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <223> OTHER INFORMATION: image: 2550162; Genbank AF379636; cDNA clone AG11 <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)..(1647) <400> SEQUENCE: 166 gtc ttg cag gac tca ctg gat aga tgt tat tca act cct tcc agt tgt 48 Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Ser Cys 1 5 10 15 ctt gaa cag cct gac tcc tgc cag ccc tat gga agt tcc ttt tat gca 96 Leu Glu Gln Pro Asp Ser Cys Gln Pro Tyr Gly Ser Ser Phe Tyr Ala 20 25 30 ttg gag gaa aaa cat gtt ggc ttt tct ctt gac gtg gga gaa att gaa 144 Leu Glu Glu Lys His Val Gly Phe Ser Leu Asp Val Gly Glu Ile Glu 35 40 45 aag aag ggg aag ggg aag aaa aga agg gga aga aga tca aag aag gaa 192 Lys Lys Gly Lys Gly Lys Lys Arg Arg Gly Arg Arg Ser Lys Lys Glu 50 55 60 aga aga agg gga aga aaa gaa ggg gaa gaa gat caa aac cca cca tgc 240 Arg Arg Arg Gly Arg Lys Glu Gly Glu Glu Asp Gln Asn Pro Pro Cys 65 70 75 80 ccc agg ctc agc agg gag ctg ctg gat gag aaa ggg cct gaa gtc ttg 288 Pro Arg Leu Ser Arg Glu Leu Leu Asp Glu Lys Gly Pro Glu Val Leu 85 90 95 cag gac tca ctg gat aga tgt tat tca act cct tca ggt tgt ctt gaa 336 Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Cys Leu Glu 100 105 110 ctg act gac tca tgc cag ccc tac aga agt gcc ttt tac ata ttg gag 384 Leu Thr Asp Ser Cys Gln Pro Tyr Arg Ser Ala Phe Tyr Ile Leu Glu 115 120 125 caa cag tgt gtt ggc ttg gct gtt gac atg gat gaa att gaa aag tac 432 Gln Gln Cys Val Gly Leu Ala Val Asp Met Asp Glu Ile Glu Lys Tyr 130 135 140 caa gaa gtg gaa gaa gac caa gac cca tca tgc ccc agg ctc agc agg 480 Gln Glu Val Glu Glu Asp Gln Asp Pro Ser Cys Pro Arg Leu Ser Arg 145 150 155 160 gag ctg ctg gat gag aaa gag cct gaa gtc ttg cag gac tca ctg gat 528 Glu Leu Leu Asp Glu Lys Glu Pro Glu Val Leu Gln Asp Ser Leu Asp 165 170 175 aga tgt tat tcg act cct tca ggt tat ctt gaa ctg cct gac tta ggc 576 Arg Cys Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu Pro Asp Leu Gly 180 185 190 cag ccc tac agc agt gct gtt tac tca ttg gag gaa cag tac ctt ggc 624 Gln Pro Tyr Ser Ser Ala Val Tyr Ser Leu Glu Glu Gln Tyr Leu Gly 195 200 205 ttg gct ctt gac gtg gac aga att aaa aag gac caa gaa gag gaa gaa 672 Leu Ala Leu Asp Val Asp Arg Ile Lys Lys Asp Gln Glu Glu Glu Glu 210 215 220 gac caa ggc cca cca tgc ccc agg ctc agc agg gag ctg ctg gag gta 720 Asp Gln Gly Pro Pro Cys Pro Arg Leu Ser Arg Glu Leu Leu Glu Val 225 230 235 240 gta gag cct gaa gtc ttg cag gac tca ctg gat aga tgt tat tca act 768 Val Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr 245 250 255 cct tcc agt tgt ctt gaa cag cct gac tcc tgc cag ccc tat gga agt 816 Pro Ser Ser Cys Leu Glu Gln Pro Asp Ser Cys Gln Pro Tyr Gly Ser 260 265 270 tcc ttt tat gca ttg gag gaa aaa cat gtt ggc ttt tct ctt gac gtg 864 Ser Phe Tyr Ala Leu Glu Glu Lys His Val Gly Phe Ser Leu Asp Val 275 280 285 gga gaa att gaa aag aag ggg aag ggg aag aaa aga agg gga aga aga 912 Gly Glu Ile Glu Lys Lys Gly Lys Gly Lys Lys Arg Arg Gly Arg Arg 290 295 300 tca aag aag gaa aga aga agg gga aga aaa gaa ggg gaa gaa gat caa 960 Ser Lys Lys Glu Arg Arg Arg Gly Arg Lys Glu Gly Glu Glu Asp Gln 305 310 315 320 aac cca cca tgc ccc agg ctc agc agg gag ctg ctg gat gag aaa ggg 1008 Asn Pro Pro Cys Pro Arg Leu Ser Arg Glu Leu Leu Asp Glu Lys Gly 325 330 335 cct gaa gtc ttg cag gac tca ctg gat aga tgt tat tca act cct tca 1056 Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser 340 345 350 ggt tgt ctt gaa ctg act gac tca tgc cag ccc tac aga agt gcc ttt 1104 Gly Cys Leu Glu Leu Thr Asp Ser Cys Gln Pro Tyr Arg Ser Ala Phe 355 360 365 tac ata ttg gag caa cag tgt gtt ggc ttg gct gtt gac atg gat gaa 1152 Tyr Ile Leu Glu Gln Gln Cys Val Gly Leu Ala Val Asp Met Asp Glu 370 375 380 att gaa aag tac caa gaa gtg gaa gaa gac caa gac cca tca tgc ccc 1200 Ile Glu Lys Tyr Gln Glu Val Glu Glu Asp Gln Asp Pro Ser Cys Pro 385 390 395 400 agg ctc agc agg gag ctg ctg gat gag aaa gag cct gaa gtc ttg cag 1248 Arg Leu Ser Arg Glu Leu Leu Asp Glu Lys Glu Pro Glu Val Leu Gln 405 410 415 gac tca ctg gat aga tgt tat tcg act cct tca ggt tat ctt gaa ctg 1296 Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu 420 425 430 cct gac tta ggc cag ccc tac agc agt gct gtt tac tca ttg gag gaa 1344 Pro Asp Leu Gly Gln Pro Tyr Ser Ser Ala Val Tyr Ser Leu Glu Glu 435 440 445 cag tac ctt ggc ttg gct ctt gac gtg gac aga att aaa aag gac caa 1392 Gln Tyr Leu Gly Leu Ala Leu Asp Val Asp Arg Ile Lys Lys Asp Gln 450 455 460 gaa gag gaa gaa gac caa ggc cca cca tgc ccc agg ctc agc agg gag 1440 Glu Glu Glu Glu Asp Gln Gly Pro Pro Cys Pro Arg Leu Ser Arg Glu 465 470 475 480 ctg ctg gag gta gta gag cct gaa gtc ttg cag gac tca ctg gat aga 1488 Leu Leu Glu Val Val Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg 485 490 495 tgt tat tca act cct tcc agt tgt ctt gaa cag cct gac tcc tgc cag 1536 Cys Tyr Ser Thr Pro Ser Ser Cys Leu Glu Gln Pro Asp Ser Cys Gln 500 505 510 ccc tat gga agt tcc ttt tat gca ttg gag gaa aaa cat gtt ggc ttt 1584 Pro Tyr Gly Ser Ser Phe Tyr Ala Leu Glu Glu Lys His Val Gly Phe 515 520 525 tct ctt gac gtg gga gaa att gaa aag aag ggg aag ggg aag aaa aga 1632 Ser Leu Asp Val Gly Glu Ile Glu Lys Lys Gly Lys Gly Lys Lys Arg 530 535 540 agg gga aga aga tca aagaaggaaa gaaaaaaaaa aaaaaaaaaa 1677 Arg Gly Arg Arg Ser 545 <210> SEQ ID NO 167 <211> LENGTH: 549 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <223> OTHER INFORMATION: image: 2550162; Genbank AF379636; cDNA clone AG11 <400> SEQUENCE: 167 Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Ser Cys 1 5 10 15 Leu Glu Gln Pro Asp Ser Cys Gln Pro Tyr Gly Ser Ser Phe Tyr Ala 20 25 30 Leu Glu Glu Lys His Val Gly Phe Ser Leu Asp Val Gly Glu Ile Glu 35 40 45 Lys Lys Gly Lys Gly Lys Lys Arg Arg Gly Arg Arg Ser Lys Lys Glu 50 55 60 Arg Arg Arg Gly Arg Lys Glu Gly Glu Glu Asp Gln Asn Pro Pro Cys 65 70 75 80 Pro Arg Leu Ser Arg Glu Leu Leu Asp Glu Lys Gly Pro Glu Val Leu 85 90 95 Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Cys Leu Glu 100 105 110 Leu Thr Asp Ser Cys Gln Pro Tyr Arg Ser Ala Phe Tyr Ile Leu Glu 115 120 125 Gln Gln Cys Val Gly Leu Ala Val Asp Met Asp Glu Ile Glu Lys Tyr 130 135 140 Gln Glu Val Glu Glu Asp Gln Asp Pro Ser Cys Pro Arg Leu Ser Arg 145 150 155 160 Glu Leu Leu Asp Glu Lys Glu Pro Glu Val Leu Gln Asp Ser Leu Asp 165 170 175 Arg Cys Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu Pro Asp Leu Gly 180 185 190 Gln Pro Tyr Ser Ser Ala Val Tyr Ser Leu Glu Glu Gln Tyr Leu Gly 195 200 205 Leu Ala Leu Asp Val Asp Arg Ile Lys Lys Asp Gln Glu Glu Glu Glu 210 215 220 Asp Gln Gly Pro Pro Cys Pro Arg Leu Ser Arg Glu Leu Leu Glu Val 225 230 235 240 Val Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr 245 250 255 Pro Ser Ser Cys Leu Glu Gln Pro Asp Ser Cys Gln Pro Tyr Gly Ser 260 265 270 Ser Phe Tyr Ala Leu Glu Glu Lys His Val Gly Phe Ser Leu Asp Val 275 280 285 Gly Glu Ile Glu Lys Lys Gly Lys Gly Lys Lys Arg Arg Gly Arg Arg 290 295 300 Ser Lys Lys Glu Arg Arg Arg Gly Arg Lys Glu Gly Glu Glu Asp Gln 305 310 315 320 Asn Pro Pro Cys Pro Arg Leu Ser Arg Glu Leu Leu Asp Glu Lys Gly 325 330 335 Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser 340 345 350 Gly Cys Leu Glu Leu Thr Asp Ser Cys Gln Pro Tyr Arg Ser Ala Phe 355 360 365 Tyr Ile Leu Glu Gln Gln Cys Val Gly Leu Ala Val Asp Met Asp Glu 370 375 380 Ile Glu Lys Tyr Gln Glu Val Glu Glu Asp Gln Asp Pro Ser Cys Pro 385 390 395 400 Arg Leu Ser Arg Glu Leu Leu Asp Glu Lys Glu Pro Glu Val Leu Gln 405 410 415 Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu 420 425 430 Pro Asp Leu Gly Gln Pro Tyr Ser Ser Ala Val Tyr Ser Leu Glu Glu 435 440 445 Gln Tyr Leu Gly Leu Ala Leu Asp Val Asp Arg Ile Lys Lys Asp Gln 450 455 460 Glu Glu Glu Glu Asp Gln Gly Pro Pro Cys Pro Arg Leu Ser Arg Glu 465 470 475 480 Leu Leu Glu Val Val Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg 485 490 495 Cys Tyr Ser Thr Pro Ser Ser Cys Leu Glu Gln Pro Asp Ser Cys Gln 500 505 510 Pro Tyr Gly Ser Ser Phe Tyr Ala Leu Glu Glu Lys His Val Gly Phe 515 520 525 Ser Leu Asp Val Gly Glu Ile Glu Lys Lys Gly Lys Gly Lys Lys Arg 530 535 540 Arg Gly Arg Arg Ser 545 <210> SEQ ID NO 168 <211> LENGTH: 1865 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <223> OTHER INFORMATION: image: 2663915; Genbank AF379635; cDNA clone AG10; before frameshift <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (3)..(416) <400> SEQUENCE: 168 ac aaa gtc aac tca gct ctg gtt gta gac aga gaa tcc tct cat gat 47 Lys Val Asn Ser Ala Leu Val Val Asp Arg Glu Ser Ser His Asp 1 5 10 15 gaa tgt cag gat gct gta aac att ctc cca gtc cct ggc ccc acc tct 95 Glu Cys Gln Asp Ala Val Asn Ile Leu Pro Val Pro Gly Pro Thr Ser 20 25 30 tct gcc aca aac gtc agc atg gtg gta tca gcc ggc cct ttg tcc agc 143 Ser Ala Thr Asn Val Ser Met Val Val Ser Ala Gly Pro Leu Ser Ser 35 40 45 gag aag gca gag atg aac att cta gaa atg aat gag aaa ttg cgc ccc 191 Glu Lys Ala Glu Met Asn Ile Leu Glu Met Asn Glu Lys Leu Arg Pro 50 55 60 cag ctg gca gag aag aaa cag cag ttc aga aac ctc aaa gag aaa tgt 239 Gln Leu Ala Glu Lys Lys Gln Gln Phe Arg Asn Leu Lys Glu Lys Cys 65 70 75 ttt gta act caa ctg gcc tgc ttc ctg gcc aac cag cag aac aaa tac 287 Phe Val Thr Gln Leu Ala Cys Phe Leu Ala Asn Gln Gln Asn Lys Tyr 80 85 90 95 aaa tat gaa gag tgc aaa gac ctc ata aaa tct gtg ctg agg aat gag 335 Lys Tyr Glu Glu Cys Lys Asp Leu Ile Lys Ser Val Leu Arg Asn Glu 100 105 110 cga cag ttc aag gag gag aag ctt gca gag cag ctc aag caa gct gag 383 Arg Gln Phe Lys Glu Glu Lys Leu Ala Glu Gln Leu Lys Gln Ala Glu 115 120 125 gag ctc agg caa tat aaa gtc ctg gtt cac tca ggaacgagag ctgacccagt 436 Glu Leu Arg Gln Tyr Lys Val Leu Val His Ser 130 135 taagggagaa gttacgggaa gggagagatg cctcccgctc attgaatcag catctccagg 496 ccctcctcac tccggatgag ccagacaagt cccaggggca ggacctccaa gaacagctgg 556 ctgaggggtg tagactggca cagcaacttt tccaaaagct cagcccagaa aatgacaatg 616 atcacgatga agatgttcaa gttgaggtgg ctgagaaagt gcagaaatcg tctgccccca 676 gggagatgca gaaggctgaa gaaaaggaag tccctgagga ctcactggag gaatgtgcca 736 tcacttgttc aaatagccat ggcccttatg actccaacca gccacatagg aaaaccaaaa 796 tcacatttga ggaagacaaa gtcgactcaa ctctcattgg ctcatcctct catgttgaat 856 gggaggatgc tgtacacatt atcccagaaa atgaaagtga tgatgaggaa gaggaagaaa 916 aagggccagt gtctcccagg aatctgcagg agtctgaaga ggaggaagtc ccccaggagt 976 cctgggatga aggttattcg actctctcaa ttcctcctga aatgttggcc tcgtaccagt 1036 cttacagcgg cacatttcac tcattagagg aacagcaagt ctgcatggct gttgacatag 1096 gcggacatcg gtgggatcaa gtgaaaaagg aggaccaaga ggcaacaggt cccaggctca 1156 gcagggagct gctggatgag aaagggcctg aagtcttgca ggactcactg gatagatgtt 1216 attcaactcc ttcaggttat cttgaactga ctgactcatg ccagccctac agaagtgcct 1276 tttacatatt ggagcaacag cgtgttggct gggctcttga catggatgaa attgaaaagt 1336 accaagaagt ggaagaagac caagacccat catgccccag gctcagcagg gagctgctgg 1396 atgagaaaga gcctgaagtc ttgcaggact cactggatag atgttattcg actccttcag 1456 gttatcttga actgcctgac ttaggccagc cctacagaag tgctgtttac tcattggagg 1516 aacagtacct tggcttggct cttgacgtgg acagaattaa aaaggaccag gaagaggaag 1576 aagaccaagg cccaccatgc cccaggctca gcagggagct gctggaggca gtagagcctg 1636 aagtcttgca ggactcactg gatagatgtt attcaactcc ttccagttgt cttgaacagc 1696 ctgactcctg cctgccctat ggaagttcct tttatgcatt ggaggaaaaa catgttggct 1756 tttctcttga cgtgggagaa attgaaaaga aggggaaggg gaagaaaaga aggggaagaa 1816 gatcaacgaa gaaaagaagg agaaggggaa gaaaagaaaa aaaaaaaaa 1865 <210> SEQ ID NO 169 <211> LENGTH: 138 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <223> OTHER INFORMATION: image: 2663915; Genbank AF379635; cDNA clone AG10; before frameshift <400> SEQUENCE: 169 Lys Val Asn Ser Ala Leu Val Val Asp Arg Glu Ser Ser His Asp Glu 1 5 10 15 Cys Gln Asp Ala Val Asn Ile Leu Pro Val Pro Gly Pro Thr Ser Ser 20 25 30 Ala Thr Asn Val Ser Met Val Val Ser Ala Gly Pro Leu Ser Ser Glu 35 40 45 Lys Ala Glu Met Asn Ile Leu Glu Met Asn Glu Lys Leu Arg Pro Gln 50 55 60 Leu Ala Glu Lys Lys Gln Gln Phe Arg Asn Leu Lys Glu Lys Cys Phe 65 70 75 80 Val Thr Gln Leu Ala Cys Phe Leu Ala Asn Gln Gln Asn Lys Tyr Lys 85 90 95 Tyr Glu Glu Cys Lys Asp Leu Ile Lys Ser Val Leu Arg Asn Glu Arg 100 105 110 Gln Phe Lys Glu Glu Lys Leu Ala Glu Gln Leu Lys Gln Ala Glu Glu 115 120 125 Leu Arg Gln Tyr Lys Val Leu Val His Ser 130 135 <210> SEQ ID NO 170 <211> LENGTH: 1865 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <223> OTHER INFORMATION: image: 2663915; Genbank AF379635; cDNA clone AG10; after frameshift <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (415)..(1863) <400> SEQUENCE: 170 acaaagtcaa ctcagctctg gttgtagaca gagaatcctc tcatgatgaa tgtcaggatg 60 ctgtaaacat tctcccagtc cctggcccca cctcttctgc cacaaacgtc agcatggtgg 120 tatcagccgg ccctttgtcc agcgagaagg cagagatgaa cattctagaa atgaatgaga 180 aattgcgccc ccagctggca gagaagaaac agcagttcag aaacctcaaa gagaaatgtt 240 ttgtaactca actggcctgc ttcctggcca accagcagaa caaatacaaa tatgaagagt 300 gcaaagacct cataaaatct gtgctgagga atgagcgaca gttcaaggag gagaagcttg 360 cagagcagct caagcaagct gaggagctca ggcaatataa agtcctggtt cact cag 417 Gln 1 gaa cga gag ctg acc cag tta agg gag aag tta cgg gaa ggg aga gat 465 Glu Arg Glu Leu Thr Gln Leu Arg Glu Lys Leu Arg Glu Gly Arg Asp 5 10 15 gcc tcc cgc tca ttg aat cag cat ctc cag gcc ctc ctc act ccg gat 513 Ala Ser Arg Ser Leu Asn Gln His Leu Gln Ala Leu Leu Thr Pro Asp 20 25 30 gag cca gac aag tcc cag ggg cag gac ctc caa gaa cag ctg gct gag 561 Glu Pro Asp Lys Ser Gln Gly Gln Asp Leu Gln Glu Gln Leu Ala Glu 35 40 45 ggg tgt aga ctg gca cag caa ctt ttc caa aag ctc agc cca gaa aat 609 Gly Cys Arg Leu Ala Gln Gln Leu Phe Gln Lys Leu Ser Pro Glu Asn 50 55 60 65 gac aat gat cac gat gaa gat gtt caa gtt gag gtg gct gag aaa gtg 657 Asp Asn Asp His Asp Glu Asp Val Gln Val Glu Val Ala Glu Lys Val 70 75 80 cag aaa tcg tct gcc ccc agg gag atg cag aag gct gaa gaa aag gaa 705 Gln Lys Ser Ser Ala Pro Arg Glu Met Gln Lys Ala Glu Glu Lys Glu 85 90 95 gtc cct gag gac tca ctg gag gaa tgt gcc atc act tgt tca aat agc 753 Val Pro Glu Asp Ser Leu Glu Glu Cys Ala Ile Thr Cys Ser Asn Ser 100 105 110 cat ggc cct tat gac tcc aac cag cca cat agg aaa acc aaa atc aca 801 His Gly Pro Tyr Asp Ser Asn Gln Pro His Arg Lys Thr Lys Ile Thr 115 120 125 ttt gag gaa gac aaa gtc gac tca act ctc att ggc tca tcc tct cat 849 Phe Glu Glu Asp Lys Val Asp Ser Thr Leu Ile Gly Ser Ser Ser His 130 135 140 145 gtt gaa tgg gag gat gct gta cac att atc cca gaa aat gaa agt gat 897 Val Glu Trp Glu Asp Ala Val His Ile Ile Pro Glu Asn Glu Ser Asp 150 155 160 gat gag gaa gag gaa gaa aaa ggg cca gtg tct ccc agg aat ctg cag 945 Asp Glu Glu Glu Glu Glu Lys Gly Pro Val Ser Pro Arg Asn Leu Gln 165 170 175 gag tct gaa gag gag gaa gtc ccc cag gag tcc tgg gat gaa ggt tat 993 Glu Ser Glu Glu Glu Glu Val Pro Gln Glu Ser Trp Asp Glu Gly Tyr 180 185 190 tcg act ctc tca att cct cct gaa atg ttg gcc tcg tac cag tct tac 1041 Ser Thr Leu Ser Ile Pro Pro Glu Met Leu Ala Ser Tyr Gln Ser Tyr 195 200 205 agc ggc aca ttt cac tca tta gag gaa cag caa gtc tgc atg gct gtt 1089 Ser Gly Thr Phe His Ser Leu Glu Glu Gln Gln Val Cys Met Ala Val 210 215 220 225 gac ata ggc gga cat cgg tgg gat caa gtg aaa aag gag gac caa gag 1137 Asp Ile Gly Gly His Arg Trp Asp Gln Val Lys Lys Glu Asp Gln Glu 230 235 240 gca aca ggt ccc agg ctc agc agg gag ctg ctg gat gag aaa ggg cct 1185 Ala Thr Gly Pro Arg Leu Ser Arg Glu Leu Leu Asp Glu Lys Gly Pro 245 250 255 gaa gtc ttg cag gac tca ctg gat aga tgt tat tca act cct tca ggt 1233 Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly 260 265 270 tat ctt gaa ctg act gac tca tgc cag ccc tac aga agt gcc ttt tac 1281 Tyr Leu Glu Leu Thr Asp Ser Cys Gln Pro Tyr Arg Ser Ala Phe Tyr 275 280 285 ata ttg gag caa cag cgt gtt ggc tgg gct ctt gac atg gat gaa att 1329 Ile Leu Glu Gln Gln Arg Val Gly Trp Ala Leu Asp Met Asp Glu Ile 290 295 300 305 gaa aag tac caa gaa gtg gaa gaa gac caa gac cca tca tgc ccc agg 1377 Glu Lys Tyr Gln Glu Val Glu Glu Asp Gln Asp Pro Ser Cys Pro Arg 310 315 320 ctc agc agg gag ctg ctg gat gag aaa gag cct gaa gtc ttg cag gac 1425 Leu Ser Arg Glu Leu Leu Asp Glu Lys Glu Pro Glu Val Leu Gln Asp 325 330 335 tca ctg gat aga tgt tat tcg act cct tca ggt tat ctt gaa ctg cct 1473 Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu Pro 340 345 350 gac tta ggc cag ccc tac aga agt gct gtt tac tca ttg gag gaa cag 1521 Asp Leu Gly Gln Pro Tyr Arg Ser Ala Val Tyr Ser Leu Glu Glu Gln 355 360 365 tac ctt ggc ttg gct ctt gac gtg gac aga att aaa aag gac cag gaa 1569 Tyr Leu Gly Leu Ala Leu Asp Val Asp Arg Ile Lys Lys Asp Gln Glu 370 375 380 385 gag gaa gaa gac caa ggc cca cca tgc ccc agg ctc agc agg gag ctg 1617 Glu Glu Glu Asp Gln Gly Pro Pro Cys Pro Arg Leu Ser Arg Glu Leu 390 395 400 ctg gag gca gta gag cct gaa gtc ttg cag gac tca ctg gat aga tgt 1665 Leu Glu Ala Val Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys 405 410 415 tat tca act cct tcc agt tgt ctt gaa cag cct gac tcc tgc ctg ccc 1713 Tyr Ser Thr Pro Ser Ser Cys Leu Glu Gln Pro Asp Ser Cys Leu Pro 420 425 430 tat gga agt tcc ttt tat gca ttg gag gaa aaa cat gtt ggc ttt tct 1761 Tyr Gly Ser Ser Phe Tyr Ala Leu Glu Glu Lys His Val Gly Phe Ser 435 440 445 ctt gac gtg gga gaa att gaa aag aag ggg aag ggg aag aaa aga agg 1809 Leu Asp Val Gly Glu Ile Glu Lys Lys Gly Lys Gly Lys Lys Arg Arg 450 455 460 465 gga aga aga tca acg aag aaa aga agg aga agg gga aga aaa gaa aaa 1857 Gly Arg Arg Ser Thr Lys Lys Arg Arg Arg Arg Gly Arg Lys Glu Lys 470 475 480 aaa aaa aa 1865 Lys Lys <210> SEQ ID NO 171 <211> LENGTH: 483 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <223> OTHER INFORMATION: image: 2663915; Genbank AF379635; cDNA clone AG10; after frameshift <400> SEQUENCE: 171 Gln Glu Arg Glu Leu Thr Gln Leu Arg Glu Lys Leu Arg Glu Gly Arg 1 5 10 15 Asp Ala Ser Arg Ser Leu Asn Gln His Leu Gln Ala Leu Leu Thr Pro 20 25 30 Asp Glu Pro Asp Lys Ser Gln Gly Gln Asp Leu Gln Glu Gln Leu Ala 35 40 45 Glu Gly Cys Arg Leu Ala Gln Gln Leu Phe Gln Lys Leu Ser Pro Glu 50 55 60 Asn Asp Asn Asp His Asp Glu Asp Val Gln Val Glu Val Ala Glu Lys 65 70 75 80 Val Gln Lys Ser Ser Ala Pro Arg Glu Met Gln Lys Ala Glu Glu Lys 85 90 95 Glu Val Pro Glu Asp Ser Leu Glu Glu Cys Ala Ile Thr Cys Ser Asn 100 105 110 Ser His Gly Pro Tyr Asp Ser Asn Gln Pro His Arg Lys Thr Lys Ile 115 120 125 Thr Phe Glu Glu Asp Lys Val Asp Ser Thr Leu Ile Gly Ser Ser Ser 130 135 140 His Val Glu Trp Glu Asp Ala Val His Ile Ile Pro Glu Asn Glu Ser 145 150 155 160 Asp Asp Glu Glu Glu Glu Glu Lys Gly Pro Val Ser Pro Arg Asn Leu 165 170 175 Gln Glu Ser Glu Glu Glu Glu Val Pro Gln Glu Ser Trp Asp Glu Gly 180 185 190 Tyr Ser Thr Leu Ser Ile Pro Pro Glu Met Leu Ala Ser Tyr Gln Ser 195 200 205 Tyr Ser Gly Thr Phe His Ser Leu Glu Glu Gln Gln Val Cys Met Ala 210 215 220 Val Asp Ile Gly Gly His Arg Trp Asp Gln Val Lys Lys Glu Asp Gln 225 230 235 240 Glu Ala Thr Gly Pro Arg Leu Ser Arg Glu Leu Leu Asp Glu Lys Gly 245 250 255 Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser 260 265 270 Gly Tyr Leu Glu Leu Thr Asp Ser Cys Gln Pro Tyr Arg Ser Ala Phe 275 280 285 Tyr Ile Leu Glu Gln Gln Arg Val Gly Trp Ala Leu Asp Met Asp Glu 290 295 300 Ile Glu Lys Tyr Gln Glu Val Glu Glu Asp Gln Asp Pro Ser Cys Pro 305 310 315 320 Arg Leu Ser Arg Glu Leu Leu Asp Glu Lys Glu Pro Glu Val Leu Gln 325 330 335 Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu 340 345 350 Pro Asp Leu Gly Gln Pro Tyr Arg Ser Ala Val Tyr Ser Leu Glu Glu 355 360 365 Gln Tyr Leu Gly Leu Ala Leu Asp Val Asp Arg Ile Lys Lys Asp Gln 370 375 380 Glu Glu Glu Glu Asp Gln Gly Pro Pro Cys Pro Arg Leu Ser Arg Glu 385 390 395 400 Leu Leu Glu Ala Val Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg 405 410 415 Cys Tyr Ser Thr Pro Ser Ser Cys Leu Glu Gln Pro Asp Ser Cys Leu 420 425 430 Pro Tyr Gly Ser Ser Phe Tyr Ala Leu Glu Glu Lys His Val Gly Phe 435 440 445 Ser Leu Asp Val Gly Glu Ile Glu Lys Lys Gly Lys Gly Lys Lys Arg 450 455 460 Arg Gly Arg Arg Ser Thr Lys Lys Arg Arg Arg Arg Gly Arg Lys Glu 465 470 475 480 Lys Lys Lys <210> SEQ ID NO 172 <211> LENGTH: 2594 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <223> OTHER INFORMATION: image: 2186481; Genbak AF379633; cDNA clone AG06 <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (3)..(2579) <400> SEQUENCE: 172 gt tat tcg act cct tca ggt tat ctt gaa ctg cct gac tta ggc cag 47 Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu Pro Asp Leu Gly Gln 1 5 10 15 ccc tac agc agt gct gtt tac tca ttg gag gaa cag tac ctt ggc ttg 95 Pro Tyr Ser Ser Ala Val Tyr Ser Leu Glu Glu Gln Tyr Leu Gly Leu 20 25 30 gct ctt gac gtg gac aga att aaa aag gac caa gaa gag gaa gaa gac 143 Ala Leu Asp Val Asp Arg Ile Lys Lys Asp Gln Glu Glu Glu Glu Asp 35 40 45 caa ggc cca cca tgc ccc agg ctc agc agg gag ctg ctg gag gta gta 191 Gln Gly Pro Pro Cys Pro Arg Leu Ser Arg Glu Leu Leu Glu Val Val 50 55 60 gag cct gaa gtc ttg cag gac tca ctg gat aga tgt tat tca act cct 239 Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro 65 70 75 tcc agt tgt ctt gaa cag cct gac tcc tgc cag ccc tat gga agt tcc 287 Ser Ser Cys Leu Glu Gln Pro Asp Ser Cys Gln Pro Tyr Gly Ser Ser 80 85 90 95 ttt tat gca ttg gag gaa aaa cat gtt ggc ttt tct ctt gac gtg gga 335 Phe Tyr Ala Leu Glu Glu Lys His Val Gly Phe Ser Leu Asp Val Gly 100 105 110 gaa att gaa aag aag ggg aag ggg aag aaa aga agg gga aga aga tca 383 Glu Ile Glu Lys Lys Gly Lys Gly Lys Lys Arg Arg Gly Arg Arg Ser 115 120 125 aag aag gaa aga aga agg gga aga aaa gaa ggg gaa gaa gat caa aac 431 Lys Lys Glu Arg Arg Arg Gly Arg Lys Glu Gly Glu Glu Asp Gln Asn 130 135 140 cca cca tgc ccc agg ctc agc agg gag ctg ctg gat gag aaa ggg cct 479 Pro Pro Cys Pro Arg Leu Ser Arg Glu Leu Leu Asp Glu Lys Gly Pro 145 150 155 gaa gtc ttg cag gac tca ctg gat aga tgt tat tca act cct tca ggt 527 Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly 160 165 170 175 tgt ctt gaa ctg act gac tca tgc cag ccc tac aga agt gcc ttt tac 575 Cys Leu Glu Leu Thr Asp Ser Cys Gln Pro Tyr Arg Ser Ala Phe Tyr 180 185 190 ata ttg gag caa cag tgt gtt ggc ttg gct gtt gac atg gat gaa att 623 Ile Leu Glu Gln Gln Cys Val Gly Leu Ala Val Asp Met Asp Glu Ile 195 200 205 gaa aag tac caa gaa gtg gaa gaa gac caa gac cca tca tgc ccc agg 671 Glu Lys Tyr Gln Glu Val Glu Glu Asp Gln Asp Pro Ser Cys Pro Arg 210 215 220 ctc agc agg gag ctg ctg gat gag aaa gag cct gaa gtc ttg cag gac 719 Leu Ser Arg Glu Leu Leu Asp Glu Lys Glu Pro Glu Val Leu Gln Asp 225 230 235 tca ctg gat aga tgt tat tcg act cct tca ggt tat ctt gaa ctg cct 767 Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu Pro 240 245 250 255 gac tta ggc cag ccc tac agc agt gct gtt tac tca ttg gag gaa cag 815 Asp Leu Gly Gln Pro Tyr Ser Ser Ala Val Tyr Ser Leu Glu Glu Gln 260 265 270 tac ctt ggc ttg gct ctt gac gtg gac aga att aaa aag gac caa gaa 863 Tyr Leu Gly Leu Ala Leu Asp Val Asp Arg Ile Lys Lys Asp Gln Glu 275 280 285 gag gaa gaa gac caa ggc cca cca tgc ccc agg ctc agc agg gag ctg 911 Glu Glu Glu Asp Gln Gly Pro Pro Cys Pro Arg Leu Ser Arg Glu Leu 290 295 300 ctg gag gta gta gag cct gaa gtc ttg cag gac tca ctg gat aga tgt 959 Leu Glu Val Val Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys 305 310 315 tat tca act cct tcc agt tgt ctt gaa cag cct gac tcc tgc cag ccc 1007 Tyr Ser Thr Pro Ser Ser Cys Leu Glu Gln Pro Asp Ser Cys Gln Pro 320 325 330 335 tat gga agt tcc ttt tat gca ttg gag gaa aaa cat gtt ggc ttt tct 1055 Tyr Gly Ser Ser Phe Tyr Ala Leu Glu Glu Lys His Val Gly Phe Ser 340 345 350 ctt gac gtg gga gaa att gaa aag aag ggg aag ggg aag aaa aga agg 1103 Leu Asp Val Gly Glu Ile Glu Lys Lys Gly Lys Gly Lys Lys Arg Arg 355 360 365 gga aga aga tca aag aag gaa aga aga agg gga aga aaa gaa ggg gaa 1151 Gly Arg Arg Ser Lys Lys Glu Arg Arg Arg Gly Arg Lys Glu Gly Glu 370 375 380 gaa gat caa aac cca cca tgc ccc agg ctc agc agg gag ctg ctg gat 1199 Glu Asp Gln Asn Pro Pro Cys Pro Arg Leu Ser Arg Glu Leu Leu Asp 385 390 395 gag aaa ggg cct gaa gtc ttg cag gac tca ctg gat aga tgt tat tca 1247 Glu Lys Gly Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser 400 405 410 415 act cct tca ggt tgt ctt gaa ctg act gac tca tgc cag ccc tac aga 1295 Thr Pro Ser Gly Cys Leu Glu Leu Thr Asp Ser Cys Gln Pro Tyr Arg 420 425 430 agt gcc ttt tac ata ttg gag caa cag tgt gtt ggc ttg gct gtt gac 1343 Ser Ala Phe Tyr Ile Leu Glu Gln Gln Cys Val Gly Leu Ala Val Asp 435 440 445 atg gat gaa att gaa aag tac caa gaa gtg gaa gaa gac caa gac cca 1391 Met Asp Glu Ile Glu Lys Tyr Gln Glu Val Glu Glu Asp Gln Asp Pro 450 455 460 tca tgc ccc agg ctc agc agg gag ctg ctg gat gag aaa gag cct gaa 1439 Ser Cys Pro Arg Leu Ser Arg Glu Leu Leu Asp Glu Lys Glu Pro Glu 465 470 475 gtc ttg cag gac tca ctg gat aga tgt tat tcg att cct tca ggt tat 1487 Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Ile Pro Ser Gly Tyr 480 485 490 495 ctt gaa ctg cct gac tta ggc cag ccc tac agc agt gct gtt tac tca 1535 Leu Glu Leu Pro Asp Leu Gly Gln Pro Tyr Ser Ser Ala Val Tyr Ser 500 505 510 ttg gag gaa cag tac ctt ggc ttg gct ctt gac gtg gac aga att aaa 1583 Leu Glu Glu Gln Tyr Leu Gly Leu Ala Leu Asp Val Asp Arg Ile Lys 515 520 525 aag gac caa gaa gag gaa gaa gac caa ggc cca cca tgc ccc agg ctc 1631 Lys Asp Gln Glu Glu Glu Glu Asp Gln Gly Pro Pro Cys Pro Arg Leu 530 535 540 agc agg gag ctg ctg gag gta gta gag cct gaa gtc ttg cag gac tca 1679 Ser Arg Glu Leu Leu Glu Val Val Glu Pro Glu Val Leu Gln Asp Ser 545 550 555 ctg gat aga tgt tat tca act cct tcc agt tgt ctt gaa cag cct gac 1727 Leu Asp Arg Cys Tyr Ser Thr Pro Ser Ser Cys Leu Glu Gln Pro Asp 560 565 570 575 tcc tgc cag ccc tat gga agt tcc ttt tat gca ttg gag gaa aaa cat 1775 Ser Cys Gln Pro Tyr Gly Ser Ser Phe Tyr Ala Leu Glu Glu Lys His 580 585 590 gtt ggc ttt tct ctt gac gtg gga gaa att gaa aag aag ggg aag ggg 1823 Val Gly Phe Ser Leu Asp Val Gly Glu Ile Glu Lys Lys Gly Lys Gly 595 600 605 aag aaa aga agg gga aga aga tca aag aag gaa aga aga agg gga aga 1871 Lys Lys Arg Arg Gly Arg Arg Ser Lys Lys Glu Arg Arg Arg Gly Arg 610 615 620 aaa gaa ggg gaa gaa gat caa aac cca cca tgc ccc agg ctc agc agg 1919 Lys Glu Gly Glu Glu Asp Gln Asn Pro Pro Cys Pro Arg Leu Ser Arg 625 630 635 gag ctg ctg gat gag aaa ggg cct gaa gtc ttg cag gac tca ctg gat 1967 Glu Leu Leu Asp Glu Lys Gly Pro Glu Val Leu Gln Asp Ser Leu Asp 640 645 650 655 aga tgt tat tca act cct tca ggt tgt ctt gaa ctg act gac tca tgc 2015 Arg Cys Tyr Ser Thr Pro Ser Gly Cys Leu Glu Leu Thr Asp Ser Cys 660 665 670 cag ccc tac aga agt gcc ttt tac ata ttg gag caa cag tgt gtt ggc 2063 Gln Pro Tyr Arg Ser Ala Phe Tyr Ile Leu Glu Gln Gln Cys Val Gly 675 680 685 ttg gct gtt gac atg gat gaa att gaa aag tac caa gaa gtg gaa gaa 2111 Leu Ala Val Asp Met Asp Glu Ile Glu Lys Tyr Gln Glu Val Glu Glu 690 695 700 gac caa gac cca tca tgc ccc agg ctc agc agg gag ctg ctg gat gag 2159 Asp Gln Asp Pro Ser Cys Pro Arg Leu Ser Arg Glu Leu Leu Asp Glu 705 710 715 aaa gag cct gaa gtc ttg cag gac tca ctg gat aga tgt tat tcg act 2207 Lys Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr 720 725 730 735 cct tca ggt tat ctt gaa ctg cct gac tta ggc cag ccc tac agc agt 2255 Pro Ser Gly Tyr Leu Glu Leu Pro Asp Leu Gly Gln Pro Tyr Ser Ser 740 745 750 gct gtt tac tca ttg gag gaa cag tac ctt ggc ttg gct ctt gac gtg 2303 Ala Val Tyr Ser Leu Glu Glu Gln Tyr Leu Gly Leu Ala Leu Asp Val 755 760 765 gac aga att aaa aag gac caa gaa gag gaa gaa gac caa ggc cca cca 2351 Asp Arg Ile Lys Lys Asp Gln Glu Glu Glu Glu Asp Gln Gly Pro Pro 770 775 780 tgc ccc agg ctc agc agg gag ctg ctg gag gta gta gag cct gaa gtc 2399 Cys Pro Arg Leu Ser Arg Glu Leu Leu Glu Val Val Glu Pro Glu Val 785 790 795 ttg cag gac tca ctg gat aga tgt tat tca act cct tcc agt tgt ctt 2447 Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Ser Cys Leu 800 805 810 815 gaa cag cct gac tcc tgc cag ccc tat gga agt tcc ttt tat gca ttg 2495 Glu Gln Pro Asp Ser Cys Gln Pro Tyr Gly Ser Ser Phe Tyr Ala Leu 820 825 830 gag gaa aaa cat gtt ggc ttt tct ctt gac gtg gga gaa att gaa aag 2543 Glu Glu Lys His Val Gly Phe Ser Leu Asp Val Gly Glu Ile Glu Lys 835 840 845 aag ggg aag ggg aag aaa aga agg gga aga aga tca aaaaaaaaaa aaaaa 2594 Lys Gly Lys Gly Lys Lys Arg Arg Gly Arg Arg Ser 850 855 <210> SEQ ID NO 173 <211> LENGTH: 859 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <223> OTHER INFORMATION: image: 2186481; Genbak AF379633; cDNA clone AG06 <400> SEQUENCE: 173 Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu Pro Asp Leu Gly Gln Pro 1 5 10 15 Tyr Ser Ser Ala Val Tyr Ser Leu Glu Glu Gln Tyr Leu Gly Leu Ala 20 25 30 Leu Asp Val Asp Arg Ile Lys Lys Asp Gln Glu Glu Glu Glu Asp Gln 35 40 45 Gly Pro Pro Cys Pro Arg Leu Ser Arg Glu Leu Leu Glu Val Val Glu 50 55 60 Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser 65 70 75 80 Ser Cys Leu Glu Gln Pro Asp Ser Cys Gln Pro Tyr Gly Ser Ser Phe 85 90 95 Tyr Ala Leu Glu Glu Lys His Val Gly Phe Ser Leu Asp Val Gly Glu 100 105 110 Ile Glu Lys Lys Gly Lys Gly Lys Lys Arg Arg Gly Arg Arg Ser Lys 115 120 125 Lys Glu Arg Arg Arg Gly Arg Lys Glu Gly Glu Glu Asp Gln Asn Pro 130 135 140 Pro Cys Pro Arg Leu Ser Arg Glu Leu Leu Asp Glu Lys Gly Pro Glu 145 150 155 160 Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Cys 165 170 175 Leu Glu Leu Thr Asp Ser Cys Gln Pro Tyr Arg Ser Ala Phe Tyr Ile 180 185 190 Leu Glu Gln Gln Cys Val Gly Leu Ala Val Asp Met Asp Glu Ile Glu 195 200 205 Lys Tyr Gln Glu Val Glu Glu Asp Gln Asp Pro Ser Cys Pro Arg Leu 210 215 220 Ser Arg Glu Leu Leu Asp Glu Lys Glu Pro Glu Val Leu Gln Asp Ser 225 230 235 240 Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu Pro Asp 245 250 255 Leu Gly Gln Pro Tyr Ser Ser Ala Val Tyr Ser Leu Glu Glu Gln Tyr 260 265 270 Leu Gly Leu Ala Leu Asp Val Asp Arg Ile Lys Lys Asp Gln Glu Glu 275 280 285 Glu Glu Asp Gln Gly Pro Pro Cys Pro Arg Leu Ser Arg Glu Leu Leu 290 295 300 Glu Val Val Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr 305 310 315 320 Ser Thr Pro Ser Ser Cys Leu Glu Gln Pro Asp Ser Cys Gln Pro Tyr 325 330 335 Gly Ser Ser Phe Tyr Ala Leu Glu Glu Lys His Val Gly Phe Ser Leu 340 345 350 Asp Val Gly Glu Ile Glu Lys Lys Gly Lys Gly Lys Lys Arg Arg Gly 355 360 365 Arg Arg Ser Lys Lys Glu Arg Arg Arg Gly Arg Lys Glu Gly Glu Glu 370 375 380 Asp Gln Asn Pro Pro Cys Pro Arg Leu Ser Arg Glu Leu Leu Asp Glu 385 390 395 400 Lys Gly Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr 405 410 415 Pro Ser Gly Cys Leu Glu Leu Thr Asp Ser Cys Gln Pro Tyr Arg Ser 420 425 430 Ala Phe Tyr Ile Leu Glu Gln Gln Cys Val Gly Leu Ala Val Asp Met 435 440 445 Asp Glu Ile Glu Lys Tyr Gln Glu Val Glu Glu Asp Gln Asp Pro Ser 450 455 460 Cys Pro Arg Leu Ser Arg Glu Leu Leu Asp Glu Lys Glu Pro Glu Val 465 470 475 480 Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Ile Pro Ser Gly Tyr Leu 485 490 495 Glu Leu Pro Asp Leu Gly Gln Pro Tyr Ser Ser Ala Val Tyr Ser Leu 500 505 510 Glu Glu Gln Tyr Leu Gly Leu Ala Leu Asp Val Asp Arg Ile Lys Lys 515 520 525 Asp Gln Glu Glu Glu Glu Asp Gln Gly Pro Pro Cys Pro Arg Leu Ser 530 535 540 Arg Glu Leu Leu Glu Val Val Glu Pro Glu Val Leu Gln Asp Ser Leu 545 550 555 560 Asp Arg Cys Tyr Ser Thr Pro Ser Ser Cys Leu Glu Gln Pro Asp Ser 565 570 575 Cys Gln Pro Tyr Gly Ser Ser Phe Tyr Ala Leu Glu Glu Lys His Val 580 585 590 Gly Phe Ser Leu Asp Val Gly Glu Ile Glu Lys Lys Gly Lys Gly Lys 595 600 605 Lys Arg Arg Gly Arg Arg Ser Lys Lys Glu Arg Arg Arg Gly Arg Lys 610 615 620 Glu Gly Glu Glu Asp Gln Asn Pro Pro Cys Pro Arg Leu Ser Arg Glu 625 630 635 640 Leu Leu Asp Glu Lys Gly Pro Glu Val Leu Gln Asp Ser Leu Asp Arg 645 650 655 Cys Tyr Ser Thr Pro Ser Gly Cys Leu Glu Leu Thr Asp Ser Cys Gln 660 665 670 Pro Tyr Arg Ser Ala Phe Tyr Ile Leu Glu Gln Gln Cys Val Gly Leu 675 680 685 Ala Val Asp Met Asp Glu Ile Glu Lys Tyr Gln Glu Val Glu Glu Asp 690 695 700 Gln Asp Pro Ser Cys Pro Arg Leu Ser Arg Glu Leu Leu Asp Glu Lys 705 710 715 720 Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro 725 730 735 Ser Gly Tyr Leu Glu Leu Pro Asp Leu Gly Gln Pro Tyr Ser Ser Ala 740 745 750 Val Tyr Ser Leu Glu Glu Gln Tyr Leu Gly Leu Ala Leu Asp Val Asp 755 760 765 Arg Ile Lys Lys Asp Gln Glu Glu Glu Glu Asp Gln Gly Pro Pro Cys 770 775 780 Pro Arg Leu Ser Arg Glu Leu Leu Glu Val Val Glu Pro Glu Val Leu 785 790 795 800 Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Ser Cys Leu Glu 805 810 815 Gln Pro Asp Ser Cys Gln Pro Tyr Gly Ser Ser Phe Tyr Ala Leu Glu 820 825 830 Glu Lys His Val Gly Phe Ser Leu Asp Val Gly Glu Ile Glu Lys Lys 835 840 845 Gly Lys Gly Lys Lys Arg Arg Gly Arg Arg Ser 850 855 <210> SEQ ID NO 174 <211> LENGTH: 915 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <223> OTHER INFORMATION: image: 1700501; Genbank AF379632; cDNA clone AG04 <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)..(897) <400> SEQUENCE: 174 ggg gaa aaa cat gtt ggc ttt tct ctt gac gtg gga gaa att gaa aag 48 Gly Glu Lys His Val Gly Phe Ser Leu Asp Val Gly Glu Ile Glu Lys 1 5 10 15 aag ggg aag ggg aag aaa aga agg gga aga aga tca aag aag gaa aga 96 Lys Gly Lys Gly Lys Lys Arg Arg Gly Arg Arg Ser Lys Lys Glu Arg 20 25 30 aga agg gga aga aaa gaa ggg gaa gaa gat caa aac cca cca tgc ccc 144 Arg Arg Gly Arg Lys Glu Gly Glu Glu Asp Gln Asn Pro Pro Cys Pro 35 40 45 agg ctc agc agg gag ctg ctg gat gag aaa ggg cct gaa gtc ttg cag 192 Arg Leu Ser Arg Glu Leu Leu Asp Glu Lys Gly Pro Glu Val Leu Gln 50 55 60 gac tca ctg gat aga tgt tat tca act cct tca ggt tgt ctt gaa ctg 240 Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Cys Leu Glu Leu 65 70 75 80 act gac tca tgc cag ccc tac aga agt gcc ttt tat gta ttg gag caa 288 Thr Asp Ser Cys Gln Pro Tyr Arg Ser Ala Phe Tyr Val Leu Glu Gln 85 90 95 cag cgt gtt ggc ttg gct gtt gac atg gat gaa att gaa aag tac caa 336 Gln Arg Val Gly Leu Ala Val Asp Met Asp Glu Ile Glu Lys Tyr Gln 100 105 110 gaa gtg gaa gaa gac caa gac cca tca tgc ccc agg ctc agc agg gag 384 Glu Val Glu Glu Asp Gln Asp Pro Ser Cys Pro Arg Leu Ser Arg Glu 115 120 125 ctg ctg gat gag aaa gag cct gaa gtc ttg cag gac tca ctg gat aga 432 Leu Leu Asp Glu Lys Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg 130 135 140 tgt tat tcg act cct tca ggt tat ctt gaa ctg cct gac tta ggc cag 480 Cys Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu Pro Asp Leu Gly Gln 145 150 155 160 ccc tac agc agt gct gtt tac tca ttg gag gaa cag tac ctt ggc ttg 528 Pro Tyr Ser Ser Ala Val Tyr Ser Leu Glu Glu Gln Tyr Leu Gly Leu 165 170 175 gct ctt gac gtg gac aga att aaa aag gac caa gaa gag gaa gaa gac 576 Ala Leu Asp Val Asp Arg Ile Lys Lys Asp Gln Glu Glu Glu Glu Asp 180 185 190 caa ggc cca cca tgc ccc agg ctc agc agg gag ctg ctg gag gta gta 624 Gln Gly Pro Pro Cys Pro Arg Leu Ser Arg Glu Leu Leu Glu Val Val 195 200 205 gag cct gaa gtc ttg cag gac tca ctg gat aga tgt tat tca act cct 672 Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro 210 215 220 tcc agt tgt ctt gaa cag cct gac tcc tgc cag ccc tat gga agt tcc 720 Ser Ser Cys Leu Glu Gln Pro Asp Ser Cys Gln Pro Tyr Gly Ser Ser 225 230 235 240 ttt tat gca ttg gag gaa aaa cat gtt ggc ttt tct ctt gac gtg gga 768 Phe Tyr Ala Leu Glu Glu Lys His Val Gly Phe Ser Leu Asp Val Gly 245 250 255 gaa att gaa aag aag ggg aag ggg aag aaa aga agg gga aga aga tca 816 Glu Ile Glu Lys Lys Gly Lys Gly Lys Lys Arg Arg Gly Arg Arg Ser 260 265 270 aag aag atc aaa gaa gaa ggg gaa gaa aaa aag ggg aag aaa aga agg 864 Lys Lys Ile Lys Glu Glu Gly Glu Glu Lys Lys Gly Lys Lys Arg Arg 275 280 285 gga aga aga tca aag aag gaa aga aga agg gga agaaaaaaaa aaaaaaaa 915 Gly Arg Arg Ser Lys Lys Glu Arg Arg Arg Gly 290 295 <210> SEQ ID NO 175 <211> LENGTH: 299 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <223> OTHER INFORMATION: image: 1700501; Genbank AF379632; cDNA clone AG04 <400> SEQUENCE: 175 Gly Glu Lys His Val Gly Phe Ser Leu Asp Val Gly Glu Ile Glu Lys 1 5 10 15 Lys Gly Lys Gly Lys Lys Arg Arg Gly Arg Arg Ser Lys Lys Glu Arg 20 25 30 Arg Arg Gly Arg Lys Glu Gly Glu Glu Asp Gln Asn Pro Pro Cys Pro 35 40 45 Arg Leu Ser Arg Glu Leu Leu Asp Glu Lys Gly Pro Glu Val Leu Gln 50 55 60 Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Cys Leu Glu Leu 65 70 75 80 Thr Asp Ser Cys Gln Pro Tyr Arg Ser Ala Phe Tyr Val Leu Glu Gln 85 90 95 Gln Arg Val Gly Leu Ala Val Asp Met Asp Glu Ile Glu Lys Tyr Gln 100 105 110 Glu Val Glu Glu Asp Gln Asp Pro Ser Cys Pro Arg Leu Ser Arg Glu 115 120 125 Leu Leu Asp Glu Lys Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg 130 135 140 Cys Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu Pro Asp Leu Gly Gln 145 150 155 160 Pro Tyr Ser Ser Ala Val Tyr Ser Leu Glu Glu Gln Tyr Leu Gly Leu 165 170 175 Ala Leu Asp Val Asp Arg Ile Lys Lys Asp Gln Glu Glu Glu Glu Asp 180 185 190 Gln Gly Pro Pro Cys Pro Arg Leu Ser Arg Glu Leu Leu Glu Val Val 195 200 205 Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro 210 215 220 Ser Ser Cys Leu Glu Gln Pro Asp Ser Cys Gln Pro Tyr Gly Ser Ser 225 230 235 240 Phe Tyr Ala Leu Glu Glu Lys His Val Gly Phe Ser Leu Asp Val Gly 245 250 255 Glu Ile Glu Lys Lys Gly Lys Gly Lys Lys Arg Arg Gly Arg Arg Ser 260 265 270 Lys Lys Ile Lys Glu Glu Gly Glu Glu Lys Lys Gly Lys Lys Arg Arg 275 280 285 Gly Arg Arg Ser Lys Lys Glu Arg Arg Arg Gly 290 295 <210> SEQ ID NO 176 <211> LENGTH: 582 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <223> OTHER INFORMATION: image: 450510; Genbank AF379631; cDNA clone AE05 <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)..(522) <400> SEQUENCE: 176 ggc acg agc aaa gtc gac tca act ctc att ggc tca tcc tct cat gtt 48 Gly Thr Ser Lys Val Asp Ser Thr Leu Ile Gly Ser Ser Ser His Val 1 5 10 15 gaa tgg gag gat gct gta cac att att cca gaa aat gaa agt gat gat 96 Glu Trp Glu Asp Ala Val His Ile Ile Pro Glu Asn Glu Ser Asp Asp 20 25 30 gag gaa gag gaa gaa aaa gga cca gtg tct ccc agg aat ctg cag gag 144 Glu Glu Glu Glu Glu Lys Gly Pro Val Ser Pro Arg Asn Leu Gln Glu 35 40 45 tct gaa gag gag gaa gtc ccc cag gag tcc tgg gat gaa ggt tat tcg 192 Ser Glu Glu Glu Glu Val Pro Gln Glu Ser Trp Asp Glu Gly Tyr Ser 50 55 60 act ctc tca att cct cct gaa atg ttg gcc tcg tac aag tct tac agc 240 Thr Leu Ser Ile Pro Pro Glu Met Leu Ala Ser Tyr Lys Ser Tyr Ser 65 70 75 80 agc aca ttt cac tca tta gag gaa cag caa gtc tgc atg gct gtt gac 288 Ser Thr Phe His Ser Leu Glu Glu Gln Gln Val Cys Met Ala Val Asp 85 90 95 ata ggc aga cat cgg tgg gat caa gtg aaa aag gag gac cac gag gca 336 Ile Gly Arg His Arg Trp Asp Gln Val Lys Lys Glu Asp His Glu Ala 100 105 110 aca ggt ccc agg ctc agc aga gag ctg ctg gat gag aaa ggg cct gaa 384 Thr Gly Pro Arg Leu Ser Arg Glu Leu Leu Asp Glu Lys Gly Pro Glu 115 120 125 gtc ttg cag gac tca ctg gat aga tgt tat tca act cct tca ggt tgt 432 Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Cys 130 135 140 ctt gaa ctg act gac tca tgc cag ccc tac aga agt gcc ttt tac gta 480 Leu Glu Leu Thr Asp Ser Cys Gln Pro Tyr Arg Ser Ala Phe Tyr Val 145 150 155 160 ttg gag caa cag cgt gtt ggc ttg gct gtt gac atg gat gaa 522 Leu Glu Gln Gln Arg Val Gly Leu Ala Val Asp Met Asp Glu 165 170 attgaaaagt accaagaaat aaactcgtaa ccctgtcctt caaaaaaaaa aaaaaaaaaa 582 <210> SEQ ID NO 177 <211> LENGTH: 174 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <223> OTHER INFORMATION: image: 450510; Genbank AF379631; cDNA clone AE05 <400> SEQUENCE: 177 Gly Thr Ser Lys Val Asp Ser Thr Leu Ile Gly Ser Ser Ser His Val 1 5 10 15 Glu Trp Glu Asp Ala Val His Ile Ile Pro Glu Asn Glu Ser Asp Asp 20 25 30 Glu Glu Glu Glu Glu Lys Gly Pro Val Ser Pro Arg Asn Leu Gln Glu 35 40 45 Ser Glu Glu Glu Glu Val Pro Gln Glu Ser Trp Asp Glu Gly Tyr Ser 50 55 60 Thr Leu Ser Ile Pro Pro Glu Met Leu Ala Ser Tyr Lys Ser Tyr Ser 65 70 75 80 Ser Thr Phe His Ser Leu Glu Glu Gln Gln Val Cys Met Ala Val Asp 85 90 95 Ile Gly Arg His Arg Trp Asp Gln Val Lys Lys Glu Asp His Glu Ala 100 105 110 Thr Gly Pro Arg Leu Ser Arg Glu Leu Leu Asp Glu Lys Gly Pro Glu 115 120 125 Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Cys 130 135 140 Leu Glu Leu Thr Asp Ser Cys Gln Pro Tyr Arg Ser Ala Phe Tyr Val 145 150 155 160 Leu Glu Gln Gln Arg Val Gly Leu Ala Val Asp Met Asp Glu 165 170 <210> SEQ ID NO 178 <211> LENGTH: 1555 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <223> OTHER INFORMATION: image: 44185; Genbank AF379630; cDNA clone AE03 <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (3)..(1520) <400> SEQUENCE: 178 aa gat ctc ata aaa ttt atg ctg agg aat gag cga cag ttc aag gag 47 Asp Leu Ile Lys Phe Met Leu Arg Asn Glu Arg Gln Phe Lys Glu 1 5 10 15 gag aag ctt gca gag cag ctc aag caa gct gag gag ctc agg caa tat 95 Glu Lys Leu Ala Glu Gln Leu Lys Gln Ala Glu Glu Leu Arg Gln Tyr 20 25 30 aaa gtc ctg gtt cac gct cag gaa cga gag ctg acc cag tta agg gag 143 Lys Val Leu Val His Ala Gln Glu Arg Glu Leu Thr Gln Leu Arg Glu 35 40 45 aag tta cgg gaa ggg aga gat gcc tcc cgc tca ttg aat gag cat ctc 191 Lys Leu Arg Glu Gly Arg Asp Ala Ser Arg Ser Leu Asn Glu His Leu 50 55 60 cag gcc ctc ctc act ccg gat gag ccg gac aag tcc cag ggg cag gac 239 Gln Ala Leu Leu Thr Pro Asp Glu Pro Asp Lys Ser Gln Gly Gln Asp 65 70 75 ctc caa gaa cag ctg gct gag ggg tgt aga ctg aca cag cac ctt gtc 287 Leu Gln Glu Gln Leu Ala Glu Gly Cys Arg Leu Thr Gln His Leu Val 80 85 90 95 caa aag ctc agc cca gaa aat gac aac gat gac gat gaa gat gtt caa 335 Gln Lys Leu Ser Pro Glu Asn Asp Asn Asp Asp Asp Glu Asp Val Gln 100 105 110 gtt gag gtg gct gag aaa gtg cag aaa tcg tct gcc ccc agg gag atg 383 Val Glu Val Ala Glu Lys Val Gln Lys Ser Ser Ala Pro Arg Glu Met 115 120 125 cag aag gct gaa gaa aag gaa gtc cct gag gac tca ctg gag gaa tgt 431 Gln Lys Ala Glu Glu Lys Glu Val Pro Glu Asp Ser Leu Glu Glu Cys 130 135 140 gcc atc act tgt tca aat agc cat ggc cct tat gac tcc aac cag cca 479 Ala Ile Thr Cys Ser Asn Ser His Gly Pro Tyr Asp Ser Asn Gln Pro 145 150 155 cat aag aaa acc aaa atc aca ttt gag gaa gac aaa gtc gac tca act 527 His Lys Lys Thr Lys Ile Thr Phe Glu Glu Asp Lys Val Asp Ser Thr 160 165 170 175 ctc att ggc tca tcc tct cat gtt gaa tgg gag gat gct gta cac att 575 Leu Ile Gly Ser Ser Ser His Val Glu Trp Glu Asp Ala Val His Ile 180 185 190 att cca gaa aat gaa agt gat gat gag gaa gag gaa gaa aaa ggg cca 623 Ile Pro Glu Asn Glu Ser Asp Asp Glu Glu Glu Glu Glu Lys Gly Pro 195 200 205 gtg tct ccc agg aat ctg cag gag tct gaa gag gag gaa gtc ccc cag 671 Val Ser Pro Arg Asn Leu Gln Glu Ser Glu Glu Glu Glu Val Pro Gln 210 215 220 gag tcc tgg gat gaa ggt tat tcg act ctc tca att cct cct gaa atg 719 Glu Ser Trp Asp Glu Gly Tyr Ser Thr Leu Ser Ile Pro Pro Glu Met 225 230 235 ttg gcc tcg tac cag tct tac agc agc aca ttt cac tca tta gag gaa 767 Leu Ala Ser Tyr Gln Ser Tyr Ser Ser Thr Phe His Ser Leu Glu Glu 240 245 250 255 cag caa gtc tgc atg gct gtt gac ata ggc aga cat cgg tgg gat caa 815 Gln Gln Val Cys Met Ala Val Asp Ile Gly Arg His Arg Trp Asp Gln 260 265 270 gtg aaa aag gag gac caa gag gca aca ggt ccc agg ctc agc agg gag 863 Val Lys Lys Glu Asp Gln Glu Ala Thr Gly Pro Arg Leu Ser Arg Glu 275 280 285 ctg ctg gat gag aaa gag cct gaa gtc ttg cag gac tca ctg gat aga 911 Leu Leu Asp Glu Lys Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg 290 295 300 tgt tat tca act cct tca ggt tgt ctt gaa ctg act gac tca tgc cag 959 Cys Tyr Ser Thr Pro Ser Gly Cys Leu Glu Leu Thr Asp Ser Cys Gln 305 310 315 ccc tac aga agt gcc ttt tac gta ttg gag caa cag cgt gtt ggc ttg 1007 Pro Tyr Arg Ser Ala Phe Tyr Val Leu Glu Gln Gln Arg Val Gly Leu 320 325 330 335 gct att gac atg gat gaa att gaa aag tac caa gaa gtg gaa gaa gac 1055 Ala Ile Asp Met Asp Glu Ile Glu Lys Tyr Gln Glu Val Glu Glu Asp 340 345 350 caa gac cca tca tgc ccc agg ctc agc agg gag ctg ctg gat gag aaa 1103 Gln Asp Pro Ser Cys Pro Arg Leu Ser Arg Glu Leu Leu Asp Glu Lys 355 360 365 gag cct gaa gtc ttg cag gac tca ctg gat aga tgt tat tca act cct 1151 Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro 370 375 380 tca gat tat ctt gaa ctg cct gac tta ggc cag ccc tac agc agt gct 1199 Ser Asp Tyr Leu Glu Leu Pro Asp Leu Gly Gln Pro Tyr Ser Ser Ala 385 390 395 gtt tac tca ttg gag gaa cag tac ctt ggc ttg gct ctt gac gtg gac 1247 Val Tyr Ser Leu Glu Glu Gln Tyr Leu Gly Leu Ala Leu Asp Val Asp 400 405 410 415 aga att aaa aag gac caa gaa gag gaa gaa gac caa ggc cca cca tgc 1295 Arg Ile Lys Lys Asp Gln Glu Glu Glu Glu Asp Gln Gly Pro Pro Cys 420 425 430 ccc agg ctc agc agg gag ctg ctg gag gta gta gag cct gaa gtc ttg 1343 Pro Arg Leu Ser Arg Glu Leu Leu Glu Val Val Glu Pro Glu Val Leu 435 440 445 cag gac tca ctg gat aga tgt tat tca act cct tcc agt tgt ctt gaa 1391 Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Ser Cys Leu Glu 450 455 460 cag cct gac tcc tgc cag ccc tat gga agt tcc ttt tat gca ttg gag 1439 Gln Pro Asp Ser Cys Gln Pro Tyr Gly Ser Ser Phe Tyr Ala Leu Glu 465 470 475 gaa aaa cat gtt ggc ttt tct ctt gac gtg gga gaa att gaa aag aag 1487 Glu Lys His Val Gly Phe Ser Leu Asp Val Gly Glu Ile Glu Lys Lys 480 485 490 495 ggg aag ggg aag aaa aga agg gga aga aga tca aaaaaaaaaa aaaaaaaaaa 1540 Gly Lys Gly Lys Lys Arg Arg Gly Arg Arg Ser 500 505 aaaaaaaaaa aaaaa 1555 <210> SEQ ID NO 179 <211> LENGTH: 506 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <223> OTHER INFORMATION: image: 44185; Genbank AF379630; cDNA clone AE03 <400> SEQUENCE: 179 Asp Leu Ile Lys Phe Met Leu Arg Asn Glu Arg Gln Phe Lys Glu Glu 1 5 10 15 Lys Leu Ala Glu Gln Leu Lys Gln Ala Glu Glu Leu Arg Gln Tyr Lys 20 25 30 Val Leu Val His Ala Gln Glu Arg Glu Leu Thr Gln Leu Arg Glu Lys 35 40 45 Leu Arg Glu Gly Arg Asp Ala Ser Arg Ser Leu Asn Glu His Leu Gln 50 55 60 Ala Leu Leu Thr Pro Asp Glu Pro Asp Lys Ser Gln Gly Gln Asp Leu 65 70 75 80 Gln Glu Gln Leu Ala Glu Gly Cys Arg Leu Thr Gln His Leu Val Gln 85 90 95 Lys Leu Ser Pro Glu Asn Asp Asn Asp Asp Asp Glu Asp Val Gln Val 100 105 110 Glu Val Ala Glu Lys Val Gln Lys Ser Ser Ala Pro Arg Glu Met Gln 115 120 125 Lys Ala Glu Glu Lys Glu Val Pro Glu Asp Ser Leu Glu Glu Cys Ala 130 135 140 Ile Thr Cys Ser Asn Ser His Gly Pro Tyr Asp Ser Asn Gln Pro His 145 150 155 160 Lys Lys Thr Lys Ile Thr Phe Glu Glu Asp Lys Val Asp Ser Thr Leu 165 170 175 Ile Gly Ser Ser Ser His Val Glu Trp Glu Asp Ala Val His Ile Ile 180 185 190 Pro Glu Asn Glu Ser Asp Asp Glu Glu Glu Glu Glu Lys Gly Pro Val 195 200 205 Ser Pro Arg Asn Leu Gln Glu Ser Glu Glu Glu Glu Val Pro Gln Glu 210 215 220 Ser Trp Asp Glu Gly Tyr Ser Thr Leu Ser Ile Pro Pro Glu Met Leu 225 230 235 240 Ala Ser Tyr Gln Ser Tyr Ser Ser Thr Phe His Ser Leu Glu Glu Gln 245 250 255 Gln Val Cys Met Ala Val Asp Ile Gly Arg His Arg Trp Asp Gln Val 260 265 270 Lys Lys Glu Asp Gln Glu Ala Thr Gly Pro Arg Leu Ser Arg Glu Leu 275 280 285 Leu Asp Glu Lys Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys 290 295 300 Tyr Ser Thr Pro Ser Gly Cys Leu Glu Leu Thr Asp Ser Cys Gln Pro 305 310 315 320 Tyr Arg Ser Ala Phe Tyr Val Leu Glu Gln Gln Arg Val Gly Leu Ala 325 330 335 Ile Asp Met Asp Glu Ile Glu Lys Tyr Gln Glu Val Glu Glu Asp Gln 340 345 350 Asp Pro Ser Cys Pro Arg Leu Ser Arg Glu Leu Leu Asp Glu Lys Glu 355 360 365 Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser 370 375 380 Asp Tyr Leu Glu Leu Pro Asp Leu Gly Gln Pro Tyr Ser Ser Ala Val 385 390 395 400 Tyr Ser Leu Glu Glu Gln Tyr Leu Gly Leu Ala Leu Asp Val Asp Arg 405 410 415 Ile Lys Lys Asp Gln Glu Glu Glu Glu Asp Gln Gly Pro Pro Cys Pro 420 425 430 Arg Leu Ser Arg Glu Leu Leu Glu Val Val Glu Pro Glu Val Leu Gln 435 440 445 Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Ser Cys Leu Glu Gln 450 455 460 Pro Asp Ser Cys Gln Pro Tyr Gly Ser Ser Phe Tyr Ala Leu Glu Glu 465 470 475 480 Lys His Val Gly Phe Ser Leu Asp Val Gly Glu Ile Glu Lys Lys Gly 485 490 495 Lys Gly Lys Lys Arg Arg Gly Arg Arg Ser 500 505 <210> SEQ ID NO 180 <211> LENGTH: 444 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <223> OTHER INFORMATION: image: 341197; Genbank AF379629; cDNA clone AE02 <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (269)..(433) <400> SEQUENCE: 180 ggcacgagga ttgatccagt cctccttcct tcactaccac atgaatgctg ggcagcccag 60 gatcacactc actgcaccct caactcagac cgttacctgg cacactggcc tcactcttgt 120 cggagactga gctattggca gtgccttcag ctctgagctc aggcacctcg aacattgttt 180 ttgtcgttaa ggatcctaaa gtgctgcggg gactgatcac atttttctca acatccctgg 240 ccccacctct tctgccacaa acgtcagc atg gtg gta tct gcc ggc cct tgg 292 Met Val Val Ser Ala Gly Pro Trp 1 5 tcc ggt gag aag gca gag atg aac att cta gaa atc aac aag aaa tcg 340 Ser Gly Glu Lys Ala Glu Met Asn Ile Leu Glu Ile Asn Lys Lys Ser 10 15 20 cgc ccc cag ctg gca gag aac aaa cag cag ttc aga aac ctc aaa cag 388 Arg Pro Gln Leu Ala Glu Asn Lys Gln Gln Phe Arg Asn Leu Lys Gln 25 30 35 40 aaa tgt ctt gta act caa gtg gcc tac ttc ctg gcc aac cgg caa 433 Lys Cys Leu Val Thr Gln Val Ala Tyr Phe Leu Ala Asn Arg Gln 45 50 55 aaaaaaaaaa a 444 <210> SEQ ID NO 181 <211> LENGTH: 55 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <223> OTHER INFORMATION: image: 341197; Genbank AF379629; cDNA clone AE02 <400> SEQUENCE: 181 Met Val Val Ser Ala Gly Pro Trp Ser Gly Glu Lys Ala Glu Met Asn 1 5 10 15 Ile Leu Glu Ile Asn Lys Lys Ser Arg Pro Gln Leu Ala Glu Asn Lys 20 25 30 Gln Gln Phe Arg Asn Leu Lys Gln Lys Cys Leu Val Thr Gln Val Ala 35 40 45 Tyr Phe Leu Ala Asn Arg Gln 50 55 <210> SEQ ID NO 182 <211> LENGTH: 2630 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <223> OTHER INFORMATION: DKFZp434D0623; Genbank AF379626; cDNA clone AC03 <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (2)..(1507) <400> SEQUENCE: 182 c caa gac cca tca tgc ccc agg ctc agc agg gag ctg ctg gat gag aaa 49 Gln Asp Pro Ser Cys Pro Arg Leu Ser Arg Glu Leu Leu Asp Glu Lys 1 5 10 15 gag cct gaa gtc ttg cag gac tca ctg gat aga tgt tat tcg act cct 97 Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro 20 25 30 tca ggt tat ctt gaa ctg cct gac tta ggc cag ccc tac aga agt gct 145 Ser Gly Tyr Leu Glu Leu Pro Asp Leu Gly Gln Pro Tyr Arg Ser Ala 35 40 45 gtt tac tca ttg gag gaa cag tac ctt ggc ttg gct ctt gac gtg gac 193 Val Tyr Ser Leu Glu Glu Gln Tyr Leu Gly Leu Ala Leu Asp Val Asp 50 55 60 aga att aaa aag gac caa gaa gag gaa gaa gac caa ggc cca cca tgc 241 Arg Ile Lys Lys Asp Gln Glu Glu Glu Glu Asp Gln Gly Pro Pro Cys 65 70 75 80 ccc agg ctc agc agg gag ctg ctg gag gca gta gag cct gaa gtc ttg 289 Pro Arg Leu Ser Arg Glu Leu Leu Glu Ala Val Glu Pro Glu Val Leu 85 90 95 cag gac tca ctg gat aga tgt tat tca act cct tcc agt tgt ctt gaa 337 Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Ser Cys Leu Glu 100 105 110 cag cct gac tcc tgc ctg ccc tat gga agt tcc ttt tat gca ttg gag 385 Gln Pro Asp Ser Cys Leu Pro Tyr Gly Ser Ser Phe Tyr Ala Leu Glu 115 120 125 gaa aaa cat gtt ggc ttt tct ctt gac gtg gga gaa att gaa aag aag 433 Glu Lys His Val Gly Phe Ser Leu Asp Val Gly Glu Ile Glu Lys Lys 130 135 140 ggg aag ggg aag aaa aga agg gga aga aga tca atg aag aaa aga agg 481 Gly Lys Gly Lys Lys Arg Arg Gly Arg Arg Ser Met Lys Lys Arg Arg 145 150 155 160 aga agg gga aga aaa gaa ggg gaa gaa gat caa aac cca cca tgc ccc 529 Arg Arg Gly Arg Lys Glu Gly Glu Glu Asp Gln Asn Pro Pro Cys Pro 165 170 175 agg ctc aac agg gag ctg ctg gat gag aaa ggg cct gaa gtc ttg cag 577 Arg Leu Asn Arg Glu Leu Leu Asp Glu Lys Gly Pro Glu Val Leu Gln 180 185 190 gac tca ctg gat aga tgt tat tca act cct tca ggt tat ctt gaa ctg 625 Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu 195 200 205 act gac tca tgc cag ccc tac aga agt gcc ttt tac ata ttg gag caa 673 Thr Asp Ser Cys Gln Pro Tyr Arg Ser Ala Phe Tyr Ile Leu Glu Gln 210 215 220 cag cgt gtt ggc tgg gct ctt gac atg gat gaa att gaa aag tac caa 721 Gln Arg Val Gly Trp Ala Leu Asp Met Asp Glu Ile Glu Lys Tyr Gln 225 230 235 240 gaa gtg gaa gaa gac caa gac cca tca tgc ccc agg ctc agc agg gag 769 Glu Val Glu Glu Asp Gln Asp Pro Ser Cys Pro Arg Leu Ser Arg Glu 245 250 255 ctg ctg gat gag aaa gag cct gaa gtc ttg cag gac tca ctg gat aga 817 Leu Leu Asp Glu Lys Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg 260 265 270 tgt tat tcg act cct tca ggt tat ctt gaa ctg cct gac tta ggc cag 865 Cys Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu Pro Asp Leu Gly Gln 275 280 285 ccc tac aga agt gct gtt tac tca ttg gag gaa cag tac ctt ggc ttg 913 Pro Tyr Arg Ser Ala Val Tyr Ser Leu Glu Glu Gln Tyr Leu Gly Leu 290 295 300 gct ctt gac gtg gac aga att aaa aag gac caa gaa gag gaa gaa gac 961 Ala Leu Asp Val Asp Arg Ile Lys Lys Asp Gln Glu Glu Glu Glu Asp 305 310 315 320 caa ggc cca cca tgc ccc agg ctc agc agg gag ctg ctg gag gca gta 1009 Gln Gly Pro Pro Cys Pro Arg Leu Ser Arg Glu Leu Leu Glu Ala Val 325 330 335 gag cct gaa gtc ttg cag gac tca ctg gat aga tgt tat tca act cct 1057 Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro 340 345 350 tcc agt tgt ctt gaa cag cct gac tcc tgc ctg ccc tat gga agt tcc 1105 Ser Ser Cys Leu Glu Gln Pro Asp Ser Cys Leu Pro Tyr Gly Ser Ser 355 360 365 ttt tat gca ttg gag gaa aaa cat gtt ggc ttt tct ctt gac gtg gga 1153 Phe Tyr Ala Leu Glu Glu Lys His Val Gly Phe Ser Leu Asp Val Gly 370 375 380 gaa att gaa aag aag ggg aag ggg aag aaa aga agg gga aga aga tca 1201 Glu Ile Glu Lys Lys Gly Lys Gly Lys Lys Arg Arg Gly Arg Arg Ser 385 390 395 400 atg aag aaa aga agg aga agg gga aga aaa gaa ggg gaa gaa gat caa 1249 Met Lys Lys Arg Arg Arg Arg Gly Arg Lys Glu Gly Glu Glu Asp Gln 405 410 415 aac cca cca tgc ccc agg ctc agc ggc atg ctg atg gaa gtg gaa gag 1297 Asn Pro Pro Cys Pro Arg Leu Ser Gly Met Leu Met Glu Val Glu Glu 420 425 430 cct gaa gtc ttg cag gac tca ctg gat aga tgt tat tcg act ccg tca 1345 Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser 435 440 445 atg tac ttt gaa cta cct gac tca ttc cag cac tac aga agt gtg ttt 1393 Met Tyr Phe Glu Leu Pro Asp Ser Phe Gln His Tyr Arg Ser Val Phe 450 455 460 tac tca ttt gag gaa cag cac atc agc ttc gcc ctt gac gtg gac aat 1441 Tyr Ser Phe Glu Glu Gln His Ile Ser Phe Ala Leu Asp Val Asp Asn 465 470 475 480 agg ttt ctt act ttg atg gga aca agt ctc cac ctg gtc ttc cag atg 1489 Arg Phe Leu Thr Leu Met Gly Thr Ser Leu His Leu Val Phe Gln Met 485 490 495 gga gtc ata ttc cca cag taagcagccc ttactaagcc gagagatgtc 1537 Gly Val Ile Phe Pro Gln 500 attcctgcag gcaggaccta taggcacgtg aagatttgaa tgaaactata gttccatttg 1597 gaagcccaga cataggatgg gtcagtgggc atggctctat tcctattctc agaccatgcc 1657 agtggcaacc tgtgctcagt ctgaagacaa tggacccaag ttaggtgtga cacgttcaca 1717 taactgtgca gcacatgccg ggagtgatca gtcagacatt ttaatttgaa ccacttatct 1777 ctgggtagct acaaagttcc tcagggattt cattttgcag tcatgtctct gagcttctat 1837 acctgctcaa ggtcagtgtc atctttgtgt ttagctcatc caaaggtgtt accctggttt 1897 caatgaacct aacctcattc tttgtatctt cagtgttgaa ttgttttagc tgatccatct 1957 ttaacacagg agggatcctt ggctgaggat tgtatttcag aaccaccaac tgctcttgac 2017 aattgttaac ccgctaggct cctttggtta gagaagccag tccttcagcc tccaattggt 2077 gtcagtactt aggaagacca cagctagatg gacaaacagc attgggaggc cttagccctg 2137 ctcctctcga ttccatcctg tagagaacag gagtcaggag ccgctggcag gagacagcat 2197 gtcacccagg actctgccgg tgcagaatat gaacaacgcc atgttcttgc agaaaacgct 2257 tagcctgagt ttcataggag gtaattacca gacaactgca gaatgtagaa cactgagcag 2317 gacaactgac ctgtctcctt cacatagtcc atatcaccac aaatcacaca acaaaaagga 2377 gaagagatat tttgggttca aaaaaagtaa aaagataata tagctgcatt tctttagtta 2437 ttttgaaccc caaatatttc ctcatctttt tgttgttgtc attgatggtg gtgacatgga 2497 cttgtttata gaggacaggt cagctgtctg gctcaatgat ctacattctg aagttgtctg 2557 aaaatgtctt catgattaaa ttcagcctaa acgttttgcc gggaacactg cagaagacaa 2617 tgctgtgagt ttc 2630 <210> SEQ ID NO 183 <211> LENGTH: 502 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <223> OTHER INFORMATION: DKFZp434D0623; Genbank AF379626; cDNA clone AC03 <400> SEQUENCE: 183 Gln Asp Pro Ser Cys Pro Arg Leu Ser Arg Glu Leu Leu Asp Glu Lys 1 5 10 15 Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro 20 25 30 Ser Gly Tyr Leu Glu Leu Pro Asp Leu Gly Gln Pro Tyr Arg Ser Ala 35 40 45 Val Tyr Ser Leu Glu Glu Gln Tyr Leu Gly Leu Ala Leu Asp Val Asp 50 55 60 Arg Ile Lys Lys Asp Gln Glu Glu Glu Glu Asp Gln Gly Pro Pro Cys 65 70 75 80 Pro Arg Leu Ser Arg Glu Leu Leu Glu Ala Val Glu Pro Glu Val Leu 85 90 95 Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Ser Cys Leu Glu 100 105 110 Gln Pro Asp Ser Cys Leu Pro Tyr Gly Ser Ser Phe Tyr Ala Leu Glu 115 120 125 Glu Lys His Val Gly Phe Ser Leu Asp Val Gly Glu Ile Glu Lys Lys 130 135 140 Gly Lys Gly Lys Lys Arg Arg Gly Arg Arg Ser Met Lys Lys Arg Arg 145 150 155 160 Arg Arg Gly Arg Lys Glu Gly Glu Glu Asp Gln Asn Pro Pro Cys Pro 165 170 175 Arg Leu Asn Arg Glu Leu Leu Asp Glu Lys Gly Pro Glu Val Leu Gln 180 185 190 Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu 195 200 205 Thr Asp Ser Cys Gln Pro Tyr Arg Ser Ala Phe Tyr Ile Leu Glu Gln 210 215 220 Gln Arg Val Gly Trp Ala Leu Asp Met Asp Glu Ile Glu Lys Tyr Gln 225 230 235 240 Glu Val Glu Glu Asp Gln Asp Pro Ser Cys Pro Arg Leu Ser Arg Glu 245 250 255 Leu Leu Asp Glu Lys Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg 260 265 270 Cys Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu Pro Asp Leu Gly Gln 275 280 285 Pro Tyr Arg Ser Ala Val Tyr Ser Leu Glu Glu Gln Tyr Leu Gly Leu 290 295 300 Ala Leu Asp Val Asp Arg Ile Lys Lys Asp Gln Glu Glu Glu Glu Asp 305 310 315 320 Gln Gly Pro Pro Cys Pro Arg Leu Ser Arg Glu Leu Leu Glu Ala Val 325 330 335 Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro 340 345 350 Ser Ser Cys Leu Glu Gln Pro Asp Ser Cys Leu Pro Tyr Gly Ser Ser 355 360 365 Phe Tyr Ala Leu Glu Glu Lys His Val Gly Phe Ser Leu Asp Val Gly 370 375 380 Glu Ile Glu Lys Lys Gly Lys Gly Lys Lys Arg Arg Gly Arg Arg Ser 385 390 395 400 Met Lys Lys Arg Arg Arg Arg Gly Arg Lys Glu Gly Glu Glu Asp Gln 405 410 415 Asn Pro Pro Cys Pro Arg Leu Ser Gly Met Leu Met Glu Val Glu Glu 420 425 430 Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser 435 440 445 Met Tyr Phe Glu Leu Pro Asp Ser Phe Gln His Tyr Arg Ser Val Phe 450 455 460 Tyr Ser Phe Glu Glu Gln His Ile Ser Phe Ala Leu Asp Val Asp Asn 465 470 475 480 Arg Phe Leu Thr Leu Met Gly Thr Ser Leu His Leu Val Phe Gln Met 485 490 495 Gly Val Ile Phe Pro Gln 500 <210> SEQ ID NO 184 <211> LENGTH: 4440 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <223> OTHER INFORMATION: DKFZp434G2022 <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (3)..(2903) <400> SEQUENCE: 184 aa gaa aag gaa gtc cct gag gac tca ctg gag gaa tgt gcc atc act 47 Glu Lys Glu Val Pro Glu Asp Ser Leu Glu Glu Cys Ala Ile Thr 1 5 10 15 tgt tca aat agc cat ggc cct tat tac tcc aac cag cca cat agg aaa 95 Cys Ser Asn Ser His Gly Pro Tyr Tyr Ser Asn Gln Pro His Arg Lys 20 25 30 acc aaa atc aca ttt gag gaa gac aaa gtc gac tca act ctc att ggc 143 Thr Lys Ile Thr Phe Glu Glu Asp Lys Val Asp Ser Thr Leu Ile Gly 35 40 45 tca tcc tct cat gtt gaa tgg gag gat gct gta cac att atc cca gaa 191 Ser Ser Ser His Val Glu Trp Glu Asp Ala Val His Ile Ile Pro Glu 50 55 60 aat gaa agt gat gat gag gaa gag gaa gaa aaa ggg cca gtg tct ccc 239 Asn Glu Ser Asp Asp Glu Glu Glu Glu Glu Lys Gly Pro Val Ser Pro 65 70 75 agg aat ctg cag gag tct gaa gag gag gaa gtc ccc cag gag tcc tgg 287 Arg Asn Leu Gln Glu Ser Glu Glu Glu Glu Val Pro Gln Glu Ser Trp 80 85 90 95 gat gaa ggt tat tcg act ctc tca att cct cct gaa atg ttg gcc tcg 335 Asp Glu Gly Tyr Ser Thr Leu Ser Ile Pro Pro Glu Met Leu Ala Ser 100 105 110 tac cag tct tac agc ggc aca ttt cac tca tta gag gaa cag caa gtc 383 Tyr Gln Ser Tyr Ser Gly Thr Phe His Ser Leu Glu Glu Gln Gln Val 115 120 125 tgc atg gct gtt gac ata ggc gga cat cgg tgg gat caa gtg aaa aag 431 Cys Met Ala Val Asp Ile Gly Gly His Arg Trp Asp Gln Val Lys Lys 130 135 140 gag gac caa gag gca aca ggt ccc agg ctc agc agg gag ctg ctg gat 479 Glu Asp Gln Glu Ala Thr Gly Pro Arg Leu Ser Arg Glu Leu Leu Asp 145 150 155 gag aaa ggg cct gaa gtc ttg cag gac tca ctg gat aga tgt tat tca 527 Glu Lys Gly Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser 160 165 170 175 act cct tca ggt tat ctt gaa ctg act gac tca tgc cag ccc tac aga 575 Thr Pro Ser Gly Tyr Leu Glu Leu Thr Asp Ser Cys Gln Pro Tyr Arg 180 185 190 agt gcc ttt tac ata ttg gag caa cag cgt gtt ggc tgg gct ctt gac 623 Ser Ala Phe Tyr Ile Leu Glu Gln Gln Arg Val Gly Trp Ala Leu Asp 195 200 205 atg gat gaa att gaa aag tac caa gaa gtg gaa gaa gac caa gac cca 671 Met Asp Glu Ile Glu Lys Tyr Gln Glu Val Glu Glu Asp Gln Asp Pro 210 215 220 tca tgc ccc agg ctc agc agg gag ctg ctg gat gag aaa gag cct gaa 719 Ser Cys Pro Arg Leu Ser Arg Glu Leu Leu Asp Glu Lys Glu Pro Glu 225 230 235 gtc ttg cag gac tcc ctg gat aga tgt tat tcg act cct tca ggt tat 767 Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Tyr 240 245 250 255 ctt gaa ctg cct gac tta ggc cag ccc tac aga agt gct gtt tac tca 815 Leu Glu Leu Pro Asp Leu Gly Gln Pro Tyr Arg Ser Ala Val Tyr Ser 260 265 270 ttg gag gaa cag tac ctt ggc ttg gct ctt gac gtg gac aga att aaa 863 Leu Glu Glu Gln Tyr Leu Gly Leu Ala Leu Asp Val Asp Arg Ile Lys 275 280 285 aag gac caa gaa gag gaa gaa gac caa ggc cca cca tgc ccc agg ctc 911 Lys Asp Gln Glu Glu Glu Glu Asp Gln Gly Pro Pro Cys Pro Arg Leu 290 295 300 agc agg gag ctg ctg gag gca gta gag cct gaa gtc ttg cag gac tca 959 Ser Arg Glu Leu Leu Glu Ala Val Glu Pro Glu Val Leu Gln Asp Ser 305 310 315 ctg gat aga tgt tat tca act cct tcc agt tgt ctt gaa cag cct gac 1007 Leu Asp Arg Cys Tyr Ser Thr Pro Ser Ser Cys Leu Glu Gln Pro Asp 320 325 330 335 tcc tgc ctg ccc tat gga agt tcc ttt tat gca ttg gag gaa aaa cat 1055 Ser Cys Leu Pro Tyr Gly Ser Ser Phe Tyr Ala Leu Glu Glu Lys His 340 345 350 gtt ggc ttt tct ctt gac gtg gga gaa att gaa aag aag ggg aag ggg 1103 Val Gly Phe Ser Leu Asp Val Gly Glu Ile Glu Lys Lys Gly Lys Gly 355 360 365 aag aaa aga agg gga aga aga tca acg aag aaa aga agg aga agg gga 1151 Lys Lys Arg Arg Gly Arg Arg Ser Thr Lys Lys Arg Arg Arg Arg Gly 370 375 380 aga aaa gaa ggg gaa gaa gat caa aac cca cca tgc ccc agg ctc agc 1199 Arg Lys Glu Gly Glu Glu Asp Gln Asn Pro Pro Cys Pro Arg Leu Ser 385 390 395 agg gag ctg ctg gat gag aaa ggg cct gaa gtc ttg cag gac tca ctg 1247 Arg Glu Leu Leu Asp Glu Lys Gly Pro Glu Val Leu Gln Asp Ser Leu 400 405 410 415 gat aga tgt tat tca act cct tca ggt tat ctt gaa ctg act gac tca 1295 Asp Arg Cys Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu Thr Asp Ser 420 425 430 tgc cag ccc tac aga agt gcc ttt tac ata ttg gag caa cag cgt gtt 1343 Cys Gln Pro Tyr Arg Ser Ala Phe Tyr Ile Leu Glu Gln Gln Arg Val 435 440 445 ggc tgg gct ctt gac atg gat gaa att gaa aag tac caa gaa gtg gaa 1391 Gly Trp Ala Leu Asp Met Asp Glu Ile Glu Lys Tyr Gln Glu Val Glu 450 455 460 gaa gac caa gac cca tca tgc ccc agg ctc agc agg gag ctg ctg gat 1439 Glu Asp Gln Asp Pro Ser Cys Pro Arg Leu Ser Arg Glu Leu Leu Asp 465 470 475 gag aaa gag cct gaa gtc ttg cag gac tcc ctg gat aga tgt tat tcg 1487 Glu Lys Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser 480 485 490 495 act cct tca ggt tat ctt gaa ctg cct gac tta ggc cag ccc tac aga 1535 Thr Pro Ser Gly Tyr Leu Glu Leu Pro Asp Leu Gly Gln Pro Tyr Arg 500 505 510 agt gct gtt tac tca ttg gag gaa cag tac ctt ggc ttg gct ctt gac 1583 Ser Ala Val Tyr Ser Leu Glu Glu Gln Tyr Leu Gly Leu Ala Leu Asp 515 520 525 gtg gac aga att aaa aag gac cag gaa gag gaa gaa gac caa ggc cca 1631 Val Asp Arg Ile Lys Lys Asp Gln Glu Glu Glu Glu Asp Gln Gly Pro 530 535 540 cca tgc ccc agg ctc agc agg gag ctg ctg gag gca gta gag cct gaa 1679 Pro Cys Pro Arg Leu Ser Arg Glu Leu Leu Glu Ala Val Glu Pro Glu 545 550 555 gtc ttg cag gac tca ctg gat aga tgt tat tca act cct tcc agt tgt 1727 Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Ser Cys 560 565 570 575 ctt gaa cag cct gac tcc tgc ctg ccc tat gga agt tcc ttt tat gca 1775 Leu Glu Gln Pro Asp Ser Cys Leu Pro Tyr Gly Ser Ser Phe Tyr Ala 580 585 590 ttg gag gaa aaa cat gtt ggc ttt tct ctt gac gtg gga gaa att gaa 1823 Leu Glu Glu Lys His Val Gly Phe Ser Leu Asp Val Gly Glu Ile Glu 595 600 605 aag aag ggg aag ggg aag aaa aga agg gga aga aga tca acg aag aaa 1871 Lys Lys Gly Lys Gly Lys Lys Arg Arg Gly Arg Arg Ser Thr Lys Lys 610 615 620 aga agg aga agg gga aga aaa gaa ggg gaa gaa gat caa aac cca cca 1919 Arg Arg Arg Arg Gly Arg Lys Glu Gly Glu Glu Asp Gln Asn Pro Pro 625 630 635 tgc ccc agg ctc agc agg gag ctg ctg gat gag aaa ggg cct gaa gtc 1967 Cys Pro Arg Leu Ser Arg Glu Leu Leu Asp Glu Lys Gly Pro Glu Val 640 645 650 655 ttg cag gac tca ctg gat aga tgt tat tca act cct tca ggt tat ctt 2015 Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Tyr Leu 660 665 670 gaa ctg act gac tca tgc cag ccc tac aga agt gcc ttt tac ata ttg 2063 Glu Leu Thr Asp Ser Cys Gln Pro Tyr Arg Ser Ala Phe Tyr Ile Leu 675 680 685 gag caa cag cgt gtt ggc tgg gct ctt gac atg gat gaa att gaa aag 2111 Glu Gln Gln Arg Val Gly Trp Ala Leu Asp Met Asp Glu Ile Glu Lys 690 695 700 tac caa gaa gtg gaa gaa gac caa gac cca tca tgc ccc agg ctc agc 2159 Tyr Gln Glu Val Glu Glu Asp Gln Asp Pro Ser Cys Pro Arg Leu Ser 705 710 715 agg gag ctg ctg gat gag aaa gag cct gaa gtc ttg cag gac tcc ctg 2207 Arg Glu Leu Leu Asp Glu Lys Glu Pro Glu Val Leu Gln Asp Ser Leu 720 725 730 735 gat aga tgt tat tcg act cct tca ggt tat ctt gaa ctg cct gac tta 2255 Asp Arg Cys Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu Pro Asp Leu 740 745 750 ggc cag ccc tac aga agt gct gtt tac tca ttg gag gaa cag tac ctt 2303 Gly Gln Pro Tyr Arg Ser Ala Val Tyr Ser Leu Glu Glu Gln Tyr Leu 755 760 765 ggc ttg gct ctt gac gtg gac aga att aaa aag gac cag gaa gag gaa 2351 Gly Leu Ala Leu Asp Val Asp Arg Ile Lys Lys Asp Gln Glu Glu Glu 770 775 780 gaa gac caa ggc cca cca tgc ccc agg ctc agc agg gag ctg ctg gag 2399 Glu Asp Gln Gly Pro Pro Cys Pro Arg Leu Ser Arg Glu Leu Leu Glu 785 790 795 gca gta gag cct gaa gtc ttg cag gac tca ctg gat aga tgt tat tca 2447 Ala Val Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser 800 805 810 815 act cct tcc agt tgt ctt gaa cag cct gac tcc tgc ctg ccc tat gga 2495 Thr Pro Ser Ser Cys Leu Glu Gln Pro Asp Ser Cys Leu Pro Tyr Gly 820 825 830 agt tcc ttt tat gca ttg gag gaa aaa cat gtt ggc ttt tct ctt gac 2543 Ser Ser Phe Tyr Ala Leu Glu Glu Lys His Val Gly Phe Ser Leu Asp 835 840 845 gtg gga gaa att gaa aag aag ggg aag ggg aag aaa aga agg gga aga 2591 Val Gly Glu Ile Glu Lys Lys Gly Lys Gly Lys Lys Arg Arg Gly Arg 850 855 860 aga tca acg aag aaa aga agg aga agg gga aga aaa gaa ggg gaa gaa 2639 Arg Ser Thr Lys Lys Arg Arg Arg Arg Gly Arg Lys Glu Gly Glu Glu 865 870 875 gat caa aac cca cca tgc ccc agg ctc agc ggt gtg ctg atg gaa gtg 2687 Asp Gln Asn Pro Pro Cys Pro Arg Leu Ser Gly Val Leu Met Glu Val 880 885 890 895 gaa gag cct gaa atc ttg cag gac tca ctg gat aga tgt tat tcg act 2735 Glu Glu Pro Glu Ile Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr 900 905 910 ccg tca atg ttc ttt gaa cta cct gac tca ttc cag cac tac aga agt 2783 Pro Ser Met Phe Phe Glu Leu Pro Asp Ser Phe Gln His Tyr Arg Ser 915 920 925 gtg ttt tac tca ttt gag gaa cag cac atc agc ttc gcc ctt gac gtg 2831 Val Phe Tyr Ser Phe Glu Glu Gln His Ile Ser Phe Ala Leu Asp Val 930 935 940 gac aat agg ttt ctt act ttg atg gga aca agt ctc cac ctg gtc ttc 2879 Asp Asn Arg Phe Leu Thr Leu Met Gly Thr Ser Leu His Leu Val Phe 945 950 955 cag atg gga gtc ata ttc cca cag taagcagccc ttactaagcc gagagatgtc 2933 Gln Met Gly Val Ile Phe Pro Gln 960 965 attcctgcag gcaggaccta taggcacatg aagatttgaa tgaaactata gttccatttg 2993 gaagcccaga cataggatgg gtcagtgggc atggctctat tcctattctc agaccatgcc 3053 agtggcaacc tgtgctcagt ctgaagacaa tggacccaag ttaggtgtga cacgttcaca 3113 taactgtgca gcacatgccg ggagtgatca gtcagacatt tcaatttgaa ccacgtatct 3173 ctgggtagct acaaagttcc tcagggattt cattttgcag gcatgtctct gagcttctat 3233 acctgctcaa ggtcagtgtc atctttgtgt ttagctcatc caaaggtgtt accctggttt 3293 caatgaacct aacctcattc tttgtatctt cagtgttgaa ttgttttagc tgatccatct 3353 ttaacacagg agggatcctt ggctgaggat tgtatttcag aaccaccaac tgctcttgac 3413 aattgttaac ccgctaggct cctttggtta gagaagccac agtccttcag cctccaattg 3473 gtgtcagtac ttaggaagac cacagctaga tggacaaaca gcattgggag gccttagccc 3533 tgctcctctc gattccatcc tgtagagaac aggagtcagg agccgctggc aggagacagc 3593 atgtcaccca ggactctgcc ggtgcagaat atgaacaacg ccatgttctt gcagaaaacg 3653 cttagcctga gtttcatagg aggtaatcac cagacaactg cggaatgtag agcactgagc 3713 aggacagctg gcctgtctcc ttcacatagt ccatgtcaac cacaaatcac acaacaaaaa 3773 ggagaggaga tattttgggt tcaaaaaaag taaaaagata atgtagctgc atttctttgg 3833 ttattttggg ccccaaatat ttcctcatct ttttgttgtt gtcattgatg gtggtgacat 3893 ggacttgttt atagaggaca ggtcagctgt ctggctcagt gatctacatt ctgaagttgt 3953 ctgaaaatgt cttcatgatt aaattcagcc taaacgtttt gccgggaaca ctgcagagac 4013 aatgctgtga gtttccaacc ttagcccatc tgcgggcaga gaaggtctag tttgtccatc 4073 agcattatca tgatatcagg actggttact tggttaagga ggggtctagg agatctgtcc 4133 cttttagaga caccttactt ataatgaagt atttgggagg gtggttttca aaagtagaaa 4193 tgtcctgtat tccgatgatc atcctgtaaa cattttatca tttattaatc atccctgcct 4253 gtgtctatta ttatattcat atctctacgc tggaaacttt ctgcctcaat gtttactgtg 4313 cctttgtttt tgctagtgtg tgttgttgaa aaaaaaaaca ttctctgcct gagttttaat 4373 ttttgtccaa agttatttta atctatacaa ttaaaagctt ttgcctatca aaaaaaaaaa 4433 aaaaaaa 4440 <210> SEQ ID NO 185 <211> LENGTH: 967 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <223> OTHER INFORMATION: DKFZp434G2022 <400> SEQUENCE: 185 Glu Lys Glu Val Pro Glu Asp Ser Leu Glu Glu Cys Ala Ile Thr Cys 1 5 10 15 Ser Asn Ser His Gly Pro Tyr Tyr Ser Asn Gln Pro His Arg Lys Thr 20 25 30 Lys Ile Thr Phe Glu Glu Asp Lys Val Asp Ser Thr Leu Ile Gly Ser 35 40 45 Ser Ser His Val Glu Trp Glu Asp Ala Val His Ile Ile Pro Glu Asn 50 55 60 Glu Ser Asp Asp Glu Glu Glu Glu Glu Lys Gly Pro Val Ser Pro Arg 65 70 75 80 Asn Leu Gln Glu Ser Glu Glu Glu Glu Val Pro Gln Glu Ser Trp Asp 85 90 95 Glu Gly Tyr Ser Thr Leu Ser Ile Pro Pro Glu Met Leu Ala Ser Tyr 100 105 110 Gln Ser Tyr Ser Gly Thr Phe His Ser Leu Glu Glu Gln Gln Val Cys 115 120 125 Met Ala Val Asp Ile Gly Gly His Arg Trp Asp Gln Val Lys Lys Glu 130 135 140 Asp Gln Glu Ala Thr Gly Pro Arg Leu Ser Arg Glu Leu Leu Asp Glu 145 150 155 160 Lys Gly Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr 165 170 175 Pro Ser Gly Tyr Leu Glu Leu Thr Asp Ser Cys Gln Pro Tyr Arg Ser 180 185 190 Ala Phe Tyr Ile Leu Glu Gln Gln Arg Val Gly Trp Ala Leu Asp Met 195 200 205 Asp Glu Ile Glu Lys Tyr Gln Glu Val Glu Glu Asp Gln Asp Pro Ser 210 215 220 Cys Pro Arg Leu Ser Arg Glu Leu Leu Asp Glu Lys Glu Pro Glu Val 225 230 235 240 Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Tyr Leu 245 250 255 Glu Leu Pro Asp Leu Gly Gln Pro Tyr Arg Ser Ala Val Tyr Ser Leu 260 265 270 Glu Glu Gln Tyr Leu Gly Leu Ala Leu Asp Val Asp Arg Ile Lys Lys 275 280 285 Asp Gln Glu Glu Glu Glu Asp Gln Gly Pro Pro Cys Pro Arg Leu Ser 290 295 300 Arg Glu Leu Leu Glu Ala Val Glu Pro Glu Val Leu Gln Asp Ser Leu 305 310 315 320 Asp Arg Cys Tyr Ser Thr Pro Ser Ser Cys Leu Glu Gln Pro Asp Ser 325 330 335 Cys Leu Pro Tyr Gly Ser Ser Phe Tyr Ala Leu Glu Glu Lys His Val 340 345 350 Gly Phe Ser Leu Asp Val Gly Glu Ile Glu Lys Lys Gly Lys Gly Lys 355 360 365 Lys Arg Arg Gly Arg Arg Ser Thr Lys Lys Arg Arg Arg Arg Gly Arg 370 375 380 Lys Glu Gly Glu Glu Asp Gln Asn Pro Pro Cys Pro Arg Leu Ser Arg 385 390 395 400 Glu Leu Leu Asp Glu Lys Gly Pro Glu Val Leu Gln Asp Ser Leu Asp 405 410 415 Arg Cys Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu Thr Asp Ser Cys 420 425 430 Gln Pro Tyr Arg Ser Ala Phe Tyr Ile Leu Glu Gln Gln Arg Val Gly 435 440 445 Trp Ala Leu Asp Met Asp Glu Ile Glu Lys Tyr Gln Glu Val Glu Glu 450 455 460 Asp Gln Asp Pro Ser Cys Pro Arg Leu Ser Arg Glu Leu Leu Asp Glu 465 470 475 480 Lys Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr 485 490 495 Pro Ser Gly Tyr Leu Glu Leu Pro Asp Leu Gly Gln Pro Tyr Arg Ser 500 505 510 Ala Val Tyr Ser Leu Glu Glu Gln Tyr Leu Gly Leu Ala Leu Asp Val 515 520 525 Asp Arg Ile Lys Lys Asp Gln Glu Glu Glu Glu Asp Gln Gly Pro Pro 530 535 540 Cys Pro Arg Leu Ser Arg Glu Leu Leu Glu Ala Val Glu Pro Glu Val 545 550 555 560 Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Ser Cys Leu 565 570 575 Glu Gln Pro Asp Ser Cys Leu Pro Tyr Gly Ser Ser Phe Tyr Ala Leu 580 585 590 Glu Glu Lys His Val Gly Phe Ser Leu Asp Val Gly Glu Ile Glu Lys 595 600 605 Lys Gly Lys Gly Lys Lys Arg Arg Gly Arg Arg Ser Thr Lys Lys Arg 610 615 620 Arg Arg Arg Gly Arg Lys Glu Gly Glu Glu Asp Gln Asn Pro Pro Cys 625 630 635 640 Pro Arg Leu Ser Arg Glu Leu Leu Asp Glu Lys Gly Pro Glu Val Leu 645 650 655 Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Tyr Leu Glu 660 665 670 Leu Thr Asp Ser Cys Gln Pro Tyr Arg Ser Ala Phe Tyr Ile Leu Glu 675 680 685 Gln Gln Arg Val Gly Trp Ala Leu Asp Met Asp Glu Ile Glu Lys Tyr 690 695 700 Gln Glu Val Glu Glu Asp Gln Asp Pro Ser Cys Pro Arg Leu Ser Arg 705 710 715 720 Glu Leu Leu Asp Glu Lys Glu Pro Glu Val Leu Gln Asp Ser Leu Asp 725 730 735 Arg Cys Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu Pro Asp Leu Gly 740 745 750 Gln Pro Tyr Arg Ser Ala Val Tyr Ser Leu Glu Glu Gln Tyr Leu Gly 755 760 765 Leu Ala Leu Asp Val Asp Arg Ile Lys Lys Asp Gln Glu Glu Glu Glu 770 775 780 Asp Gln Gly Pro Pro Cys Pro Arg Leu Ser Arg Glu Leu Leu Glu Ala 785 790 795 800 Val Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr 805 810 815 Pro Ser Ser Cys Leu Glu Gln Pro Asp Ser Cys Leu Pro Tyr Gly Ser 820 825 830 Ser Phe Tyr Ala Leu Glu Glu Lys His Val Gly Phe Ser Leu Asp Val 835 840 845 Gly Glu Ile Glu Lys Lys Gly Lys Gly Lys Lys Arg Arg Gly Arg Arg 850 855 860 Ser Thr Lys Lys Arg Arg Arg Arg Gly Arg Lys Glu Gly Glu Glu Asp 865 870 875 880 Gln Asn Pro Pro Cys Pro Arg Leu Ser Gly Val Leu Met Glu Val Glu 885 890 895 Glu Pro Glu Ile Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro 900 905 910 Ser Met Phe Phe Glu Leu Pro Asp Ser Phe Gln His Tyr Arg Ser Val 915 920 925 Phe Tyr Ser Phe Glu Glu Gln His Ile Ser Phe Ala Leu Asp Val Asp 930 935 940 Asn Arg Phe Leu Thr Leu Met Gly Thr Ser Leu His Leu Val Phe Gln 945 950 955 960 Met Gly Val Ile Phe Pro Gln 965 <210> SEQ ID NO 186 <211> LENGTH: 2647 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <223> OTHER INFORMATION: DKFZp434M0628; Genbank AF379622; cDNA clone AB18 <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)..(1074) <400> SEQUENCE: 186 ggg aag ggg aag aaa aga agg gga aga aga tca atg aag aaa aga agg 48 Gly Lys Gly Lys Lys Arg Arg Gly Arg Arg Ser Met Lys Lys Arg Arg 1 5 10 15 aga agg gga aga aaa gaa ggg gaa gaa gat caa aac cca cca tgc ccc 96 Arg Arg Gly Arg Lys Glu Gly Glu Glu Asp Gln Asn Pro Pro Cys Pro 20 25 30 agg ctc aac agg gag ctg ctg gat gag aaa ggg cct gaa gtc ttg cag 144 Arg Leu Asn Arg Glu Leu Leu Asp Glu Lys Gly Pro Glu Val Leu Gln 35 40 45 gac tca ctg gat aga tgt tat tca act cct tca ggt tat ctt gaa ctg 192 Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu 50 55 60 act gac tca tgc cag ccc tac aga agt gcc ttt tac ata ttg gag caa 240 Thr Asp Ser Cys Gln Pro Tyr Arg Ser Ala Phe Tyr Ile Leu Glu Gln 65 70 75 80 cag cgt gtt ggc tgg gct ctt gac atg gat gaa att gaa aag tac caa 288 Gln Arg Val Gly Trp Ala Leu Asp Met Asp Glu Ile Glu Lys Tyr Gln 85 90 95 gaa gtg gaa gaa gac caa gac cca tca tgc ccc agg ctc agc agg gag 336 Glu Val Glu Glu Asp Gln Asp Pro Ser Cys Pro Arg Leu Ser Arg Glu 100 105 110 ctg ctg gat gag aaa gag cct gaa gtc ttg cag gac tca ctg gat aga 384 Leu Leu Asp Glu Lys Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg 115 120 125 tgt tat tcg act cct tca ggt tat ctt gaa ctg cct gac tta ggc cag 432 Cys Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu Pro Asp Leu Gly Gln 130 135 140 ccc tac aga agt gct gtt tac tca ttg gag gaa cag tac ctt ggc ttg 480 Pro Tyr Arg Ser Ala Val Tyr Ser Leu Glu Glu Gln Tyr Leu Gly Leu 145 150 155 160 gct ctt gac gtg gac aga att aaa aag gac caa gaa gag gaa gaa gac 528 Ala Leu Asp Val Asp Arg Ile Lys Lys Asp Gln Glu Glu Glu Glu Asp 165 170 175 caa ggc cca cca tgc ccc agg ctc agc agg gag ctg ctg gag gca gta 576 Gln Gly Pro Pro Cys Pro Arg Leu Ser Arg Glu Leu Leu Glu Ala Val 180 185 190 gag cct gaa gtc ttg cag gac tca ctg gat aga tgt tat tca act cct 624 Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro 195 200 205 tcc agt tgt ctt gaa cag cct gac tcc tgc ctg ccc tat gga agt tcc 672 Ser Ser Cys Leu Glu Gln Pro Asp Ser Cys Leu Pro Tyr Gly Ser Ser 210 215 220 ttt tat gca ttg gag gaa aaa cat gtt ggc ttt tct ctt gac gtg gga 720 Phe Tyr Ala Leu Glu Glu Lys His Val Gly Phe Ser Leu Asp Val Gly 225 230 235 240 gaa att gaa aag aag ggg aag ggg aag aaa aga agg gga aga aga tca 768 Glu Ile Glu Lys Lys Gly Lys Gly Lys Lys Arg Arg Gly Arg Arg Ser 245 250 255 atg aag aaa aga agg aga agg gga aga aaa gaa ggg gaa gaa gat caa 816 Met Lys Lys Arg Arg Arg Arg Gly Arg Lys Glu Gly Glu Glu Asp Gln 260 265 270 aac cca cca tgc ccc agg ctc agc ggc atg ctg atg gaa gtg gaa gag 864 Asn Pro Pro Cys Pro Arg Leu Ser Gly Met Leu Met Glu Val Glu Glu 275 280 285 cct gaa gtc ttg cag gac tca ctg gat aga tgt tat tcg act ccg tca 912 Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser 290 295 300 atg tac ttt gaa cta cct gac tca ttc cag cac tac aga agt gtg ttt 960 Met Tyr Phe Glu Leu Pro Asp Ser Phe Gln His Tyr Arg Ser Val Phe 305 310 315 320 tac tca ttt gag gaa cag cac atc agc ttc gcc ctt gac gtg gac aat 1008 Tyr Ser Phe Glu Glu Gln His Ile Ser Phe Ala Leu Asp Val Asp Asn 325 330 335 agg ttt ctt act ttg atg gga aca agt ctc cac ctg gtc ttc cag atg 1056 Arg Phe Leu Thr Leu Met Gly Thr Ser Leu His Leu Val Phe Gln Met 340 345 350 gga gtc ata ttc cca cag taagcagccc ttactaagcc gagagatgtc 1104 Gly Val Ile Phe Pro Gln 355 attcctgcag gcaggaccta taggcacgtg aagatttgaa tgaaactata gttccatttg 1164 gaagcccaga cataggatgg gtcagtgggc atggctctat tcctattctc agaccatgcc 1224 agtggcaacc tgtgctcagt ctgaagacaa tggacccaag ttaggtgtga cacgttcaca 1284 taactgtgca gcacatgccg ggagtgatca gtcagacatt ttaatttgaa ccacttatct 1344 ctgggtagct acaaagttcc tcagggattt cattttgcag tcatgtctct gagcttctat 1404 acctgctcaa ggtcagtgtc atctttgtgt ttagctcatc caaaggtgtt accctggttt 1464 caatgaacct aacctcattc tttgtatctt cagtgttgaa ttgttttagc tgatccatct 1524 ttaacacagg agggatcctt ggctgaggat tgtatttcag aaccaccaac tgctcttgac 1584 aattgttaac ccgctaggct cctttggtta gagaagccag tccttcagcc tccaattggt 1644 gtcagtactt aggaagacca cagctagatg gacaaacagc attgggaggc cttagccctg 1704 ctcctctcga ttccatcctg tagagaacag gagtcaggag ccgctggcag gagacagcat 1764 gtcacccagg actctgccgg tgcagaatat gaacaacgcc atgttcttgc agaaaacgct 1824 tggcctgagt ttcataggag gtaattacca gacaactgca gaatgtagaa cactgagcag 1884 gacaactgac ctgtctcctt cacatagtcc atatcaccac aaatcacaca acaaaaagga 1944 gaagagatat tttgggttca aaaaaagtaa aaagataata tagctgcatt tctttagtta 2004 ttttgaaccc caaatatttc ctcatctttt tgttgttgtc attgatggtg gtgacatgga 2064 cttgtttata gaggacaggt cagctgtctg gctcaatgat ctacattctg aagttgtctg 2124 aaaatgtctt catgattaaa ttcagcctaa acgttttgcc gggaacactg cagagacaat 2184 gctgtgagtt tccaacctta gcccatctgc gggcagagaa ggtctagttt gtccatcagc 2244 attatcatga tatcaggact ggttacttgg ttaaggaggg gtctaggaga tctgtccctt 2304 ttagagacac cttacttata atgaagtatt tgggagggtg gttttcaaaa gtagaaatgt 2364 cctgtattcc gatgatcatc ctgtaaacat tttatcattt attaatcatc cctgcctgtg 2424 tctattatta tattcatatc tctacgctgg aaactttctg cctcaatgtt tactgtgcct 2484 ttgtttttgc tagtgtgtgt tgttgaaaaa aaaaacattc tctgcctgag ttttaatttt 2544 tgtccaaagt tattttaatc tatacaatta aaagcttttg cctatcaaaa aaaaaaaaaa 2604 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaa 2647 <210> SEQ ID NO 187 <211> LENGTH: 358 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <223> OTHER INFORMATION: DKFZp434M0628; Genbank AF379622; cDNA clone AB18 <400> SEQUENCE: 187 Gly Lys Gly Lys Lys Arg Arg Gly Arg Arg Ser Met Lys Lys Arg Arg 1 5 10 15 Arg Arg Gly Arg Lys Glu Gly Glu Glu Asp Gln Asn Pro Pro Cys Pro 20 25 30 Arg Leu Asn Arg Glu Leu Leu Asp Glu Lys Gly Pro Glu Val Leu Gln 35 40 45 Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu 50 55 60 Thr Asp Ser Cys Gln Pro Tyr Arg Ser Ala Phe Tyr Ile Leu Glu Gln 65 70 75 80 Gln Arg Val Gly Trp Ala Leu Asp Met Asp Glu Ile Glu Lys Tyr Gln 85 90 95 Glu Val Glu Glu Asp Gln Asp Pro Ser Cys Pro Arg Leu Ser Arg Glu 100 105 110 Leu Leu Asp Glu Lys Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg 115 120 125 Cys Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu Pro Asp Leu Gly Gln 130 135 140 Pro Tyr Arg Ser Ala Val Tyr Ser Leu Glu Glu Gln Tyr Leu Gly Leu 145 150 155 160 Ala Leu Asp Val Asp Arg Ile Lys Lys Asp Gln Glu Glu Glu Glu Asp 165 170 175 Gln Gly Pro Pro Cys Pro Arg Leu Ser Arg Glu Leu Leu Glu Ala Val 180 185 190 Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro 195 200 205 Ser Ser Cys Leu Glu Gln Pro Asp Ser Cys Leu Pro Tyr Gly Ser Ser 210 215 220 Phe Tyr Ala Leu Glu Glu Lys His Val Gly Phe Ser Leu Asp Val Gly 225 230 235 240 Glu Ile Glu Lys Lys Gly Lys Gly Lys Lys Arg Arg Gly Arg Arg Ser 245 250 255 Met Lys Lys Arg Arg Arg Arg Gly Arg Lys Glu Gly Glu Glu Asp Gln 260 265 270 Asn Pro Pro Cys Pro Arg Leu Ser Gly Met Leu Met Glu Val Glu Glu 275 280 285 Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser 290 295 300 Met Tyr Phe Glu Leu Pro Asp Ser Phe Gln His Tyr Arg Ser Val Phe 305 310 315 320 Tyr Ser Phe Glu Glu Gln His Ile Ser Phe Ala Leu Asp Val Asp Asn 325 330 335 Arg Phe Leu Thr Leu Met Gly Thr Ser Leu His Leu Val Phe Gln Met 340 345 350 Gly Val Ile Phe Pro Gln 355 <210> SEQ ID NO 188 <211> LENGTH: 2982 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <223> OTHER INFORMATION: DKFZp434J205; Genbank AF379616; cDNA clone AB06 <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (152)..(1411) <400> SEQUENCE: 188 ccaacatgaa ggcaataatt tgttacctca ttaatggatc tctcctttta ctttttcaac 60 cacttcctta tgctacccat gaaacctagt tggggctctg ttgtgtctga tttcccctgg 120 cttattcttt actttttcct ccttttccag g ctc agc agg gag ctg ctg gag 172 Leu Ser Arg Glu Leu Leu Glu 1 5 gca gta gag cct gaa gtc ttg cag gac tca ctg gat aga tgt tat tca 220 Ala Val Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser 10 15 20 act cct tcc agt tgt ctt gaa cag cct gac tcc tgc ctg ccc tat gga 268 Thr Pro Ser Ser Cys Leu Glu Gln Pro Asp Ser Cys Leu Pro Tyr Gly 25 30 35 agt tcc ttt tat gca ttg gag gaa aaa cat gtt ggc ttt tct ctt gac 316 Ser Ser Phe Tyr Ala Leu Glu Glu Lys His Val Gly Phe Ser Leu Asp 40 45 50 55 gtg gga gaa att gaa aag aag ggg aag ggg aag aaa aga agg gga aga 364 Val Gly Glu Ile Glu Lys Lys Gly Lys Gly Lys Lys Arg Arg Gly Arg 60 65 70 aga tca acg aag aaa aga agg aga agg gga aga aaa gaa ggg gaa gaa 412 Arg Ser Thr Lys Lys Arg Arg Arg Arg Gly Arg Lys Glu Gly Glu Glu 75 80 85 gat caa aac cca cca tgc ccc agg ctc agc agg gag ctg ctg gat gag 460 Asp Gln Asn Pro Pro Cys Pro Arg Leu Ser Arg Glu Leu Leu Asp Glu 90 95 100 aaa ggg cct gaa gtc ttg cag gac tca ctg gat aga tgt tat tca act 508 Lys Gly Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr 105 110 115 cct tca ggt tat ctt gaa ctg act gac tca tgc cag ccc tac aga agt 556 Pro Ser Gly Tyr Leu Glu Leu Thr Asp Ser Cys Gln Pro Tyr Arg Ser 120 125 130 135 gcc ttt tac ata ttg gag caa cag cgt gtt ggc tgg gct ctt gac atg 604 Ala Phe Tyr Ile Leu Glu Gln Gln Arg Val Gly Trp Ala Leu Asp Met 140 145 150 gat gaa att gaa aag tac caa gaa gtg gaa gaa gac caa gac cca tca 652 Asp Glu Ile Glu Lys Tyr Gln Glu Val Glu Glu Asp Gln Asp Pro Ser 155 160 165 tgc ccc agg ctc agc agg gag ctg ctg gat gag aaa gag cct gaa gtc 700 Cys Pro Arg Leu Ser Arg Glu Leu Leu Asp Glu Lys Glu Pro Glu Val 170 175 180 ttg cag gac tca ctg gat aga tgt tat tcg act cct tca ggt tat ctt 748 Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Tyr Leu 185 190 195 gaa ctg cct gac tta ggc cag ccc tac aga agt gct gtt cac tca ttg 796 Glu Leu Pro Asp Leu Gly Gln Pro Tyr Arg Ser Ala Val His Ser Leu 200 205 210 215 gag gaa cag tac ctt ggc ttg gct ctt gac gtg gac aga att aaa aag 844 Glu Glu Gln Tyr Leu Gly Leu Ala Leu Asp Val Asp Arg Ile Lys Lys 220 225 230 gac cag gaa gag gaa gaa gac caa ggc cca cca tgc tcc agg ctc agc 892 Asp Gln Glu Glu Glu Glu Asp Gln Gly Pro Pro Cys Ser Arg Leu Ser 235 240 245 agg gag ctg ctg gag gca gta gag cct gaa gtc ttg ctg gac tca ctg 940 Arg Glu Leu Leu Glu Ala Val Glu Pro Glu Val Leu Leu Asp Ser Leu 250 255 260 gat aga tgt tat tca act cct tcc agt tgt ctt gaa cag cct gac tcc 988 Asp Arg Cys Tyr Ser Thr Pro Ser Ser Cys Leu Glu Gln Pro Asp Ser 265 270 275 tgc ctg ccc tat gga agt tcc ttt tat gca ttg gag gaa aaa cat gtt 1036 Cys Leu Pro Tyr Gly Ser Ser Phe Tyr Ala Leu Glu Glu Lys His Val 280 285 290 295 ggc ttt tct ctt gac gtg gga gaa att gaa aag aag ggg aag ggg aag 1084 Gly Phe Ser Leu Asp Val Gly Glu Ile Glu Lys Lys Gly Lys Gly Lys 300 305 310 aaa aga agg gga aga aga tca acg aag aaa aga agg aga agg gga agt 1132 Lys Arg Arg Gly Arg Arg Ser Thr Lys Lys Arg Arg Arg Arg Gly Ser 315 320 325 aaa gaa ggg gaa gaa gat caa aac cca cca tgc ccc agg ctc agc ggt 1180 Lys Glu Gly Glu Glu Asp Gln Asn Pro Pro Cys Pro Arg Leu Ser Gly 330 335 340 gtg ctg atg gaa gtg gaa gag cct gaa gtc tta cag gac tca ctg gat 1228 Val Leu Met Glu Val Glu Glu Pro Glu Val Leu Gln Asp Ser Leu Asp 345 350 355 aga tgt tat tcg act ccg tca atg tac ttt gaa cta cct gac tca ttc 1276 Arg Cys Tyr Ser Thr Pro Ser Met Tyr Phe Glu Leu Pro Asp Ser Phe 360 365 370 375 cag cac tac aga agt gtg ttt tac tca ttt gag gaa cag cac atc agc 1324 Gln His Tyr Arg Ser Val Phe Tyr Ser Phe Glu Glu Gln His Ile Ser 380 385 390 ttc gcc ctt gac gtg gac aat agg ttt ctt act ttg atg gga aca agt 1372 Phe Ala Leu Asp Val Asp Asn Arg Phe Leu Thr Leu Met Gly Thr Ser 395 400 405 ctc cac ctg gtc ttc cag atg gga gtc ata ttc cca cag taagcagccc 1421 Leu His Leu Val Phe Gln Met Gly Val Ile Phe Pro Gln 410 415 420 tttctaagcc gagagatgtc attcctgcag gcaggaccta taggcacgtg aagatttgaa 1481 tgaaactata gttccatttg gaagcccaga cataggatgg gtcagtgggc gtggctctat 1541 tcctattctc agaccatgcc agtggcaacc tgtgctcagt ctgaagacaa tggacccaag 1601 ttaggtgtga cacgttcaca taactgtgca gcacatgccg ggagtgatca gtcagacatt 1661 ttaatttgaa ccacgtatct ctgggtagct acaaagttcc tcagggattt cattttgcag 1721 gcatgtctct gagcttctat acctgctcaa ggtcagtgtc atctttgtgt ttagctcatc 1781 caaaggtgtt accctggttt caatgaacct aacctcattc tttgtatctt cagtgttgaa 1841 ttgttttagc tgatccatct ttaacacagg agggatcctt ggctgaggat tgtatttcag 1901 aaccaccaac tgctcttgac aattgttaac ccgctaggct cctttggtta gagaagccac 1961 agtccttcag cctccaattg gtgttagtac ttaagaagac cacagctaga tggacaaaca 2021 gcattgggag gccttagccc tgctcctctc gattccatcc tgtagagaac aggagtcagg 2081 agccgctggc aggagacagc atgtcaccca ggactctgcc ggtgcagaat atgaacaacg 2141 ccatgttctt gcagaaaacg cttagcctga gtttcatagg aggtaatcac cagacaactg 2201 cagaatgtgg aacactgagc aggacaactg acctgtctcc ttcacatagt ccatatcacc 2261 acaaatcaca caacagaaag gagaagagat attttgggtt caaaaaaagt aaaaagataa 2321 tatagctgca tttctttagt tattttgaac cccaaatatt tcctcatctt tttgttgttg 2381 tcattgatgg tggtgacatg gacttgttta tagaggacag gtcagctgtc tggctcagtg 2441 atctacattc tgaagttgtc tgaaaatgtc ttcatgatta aattcagcct aaacgttttg 2501 ccgggaacac tgcagagaca atgctgtgag tttccaacct tagcccatct gcgggcagag 2561 aaggtctagt ttgtccatca gcattatcat gatatcagga ctggttactt ggttaaggag 2621 gggtctagga gatgtgtccc ttttagagac accttactta taatgaagta tttgggaggg 2681 tggttttcaa aagtagaaat gtcctgtatt ccgatgatca tcctgtaaac attttatcat 2741 ttattaatca tccctgcctg tgtctattat tatattcata tctctacgct ggaaactttc 2801 tgcctctatg tttactgtgc ctttgttttt gctagtgtgt gttgttgaaa aaaaaaacat 2861 tctctgcctg agttttaatt tttgtccaaa gttattttaa tctatacaat taaaagcttt 2921 tgcctatcaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2981 a 2982 <210> SEQ ID NO 189 <211> LENGTH: 420 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <223> OTHER INFORMATION: DKFZp434J205; Genbank AF379616; cDNA clone AB06 <400> SEQUENCE: 189 Leu Ser Arg Glu Leu Leu Glu Ala Val Glu Pro Glu Val Leu Gln Asp 1 5 10 15 Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Ser Cys Leu Glu Gln Pro 20 25 30 Asp Ser Cys Leu Pro Tyr Gly Ser Ser Phe Tyr Ala Leu Glu Glu Lys 35 40 45 His Val Gly Phe Ser Leu Asp Val Gly Glu Ile Glu Lys Lys Gly Lys 50 55 60 Gly Lys Lys Arg Arg Gly Arg Arg Ser Thr Lys Lys Arg Arg Arg Arg 65 70 75 80 Gly Arg Lys Glu Gly Glu Glu Asp Gln Asn Pro Pro Cys Pro Arg Leu 85 90 95 Ser Arg Glu Leu Leu Asp Glu Lys Gly Pro Glu Val Leu Gln Asp Ser 100 105 110 Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu Thr Asp 115 120 125 Ser Cys Gln Pro Tyr Arg Ser Ala Phe Tyr Ile Leu Glu Gln Gln Arg 130 135 140 Val Gly Trp Ala Leu Asp Met Asp Glu Ile Glu Lys Tyr Gln Glu Val 145 150 155 160 Glu Glu Asp Gln Asp Pro Ser Cys Pro Arg Leu Ser Arg Glu Leu Leu 165 170 175 Asp Glu Lys Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr 180 185 190 Ser Thr Pro Ser Gly Tyr Leu Glu Leu Pro Asp Leu Gly Gln Pro Tyr 195 200 205 Arg Ser Ala Val His Ser Leu Glu Glu Gln Tyr Leu Gly Leu Ala Leu 210 215 220 Asp Val Asp Arg Ile Lys Lys Asp Gln Glu Glu Glu Glu Asp Gln Gly 225 230 235 240 Pro Pro Cys Ser Arg Leu Ser Arg Glu Leu Leu Glu Ala Val Glu Pro 245 250 255 Glu Val Leu Leu Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Ser 260 265 270 Cys Leu Glu Gln Pro Asp Ser Cys Leu Pro Tyr Gly Ser Ser Phe Tyr 275 280 285 Ala Leu Glu Glu Lys His Val Gly Phe Ser Leu Asp Val Gly Glu Ile 290 295 300 Glu Lys Lys Gly Lys Gly Lys Lys Arg Arg Gly Arg Arg Ser Thr Lys 305 310 315 320 Lys Arg Arg Arg Arg Gly Ser Lys Glu Gly Glu Glu Asp Gln Asn Pro 325 330 335 Pro Cys Pro Arg Leu Ser Gly Val Leu Met Glu Val Glu Glu Pro Glu 340 345 350 Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Met Tyr 355 360 365 Phe Glu Leu Pro Asp Ser Phe Gln His Tyr Arg Ser Val Phe Tyr Ser 370 375 380 Phe Glu Glu Gln His Ile Ser Phe Ala Leu Asp Val Asp Asn Arg Phe 385 390 395 400 Leu Thr Leu Met Gly Thr Ser Leu His Leu Val Phe Gln Met Gly Val 405 410 415 Ile Phe Pro Gln 420 <210> SEQ ID NO 190 <211> LENGTH: 1217 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <223> OTHER INFORMATION: image: 2920609; Genbank AF380581; cDNA clone AG03 <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (2)..(1201) <400> SEQUENCE: 190 t gaa gat gtt caa gtt gag gtg gct gag aaa gtg cag aaa tcg tct gcc 49 Glu Asp Val Gln Val Glu Val Ala Glu Lys Val Gln Lys Ser Ser Ala 1 5 10 15 ccc agg gag atg ccg aag gct gaa gaa aag gaa gtc cct gag gac tca 97 Pro Arg Glu Met Pro Lys Ala Glu Glu Lys Glu Val Pro Glu Asp Ser 20 25 30 ctg gag gaa tgt gcc atc act tgt tca aat agc cat ggc cct tat gac 145 Leu Glu Glu Cys Ala Ile Thr Cys Ser Asn Ser His Gly Pro Tyr Asp 35 40 45 tcc aac cag cca cat agg aaa acc aaa atc aca ttt gag gaa gac aaa 193 Ser Asn Gln Pro His Arg Lys Thr Lys Ile Thr Phe Glu Glu Asp Lys 50 55 60 gtc gac tca act ctc att ggc tca tcc tct cat gtt gaa tgg gag gat 241 Val Asp Ser Thr Leu Ile Gly Ser Ser Ser His Val Glu Trp Glu Asp 65 70 75 80 gct gta cac att atc cca gaa aat gaa agt gat gat gag gaa gag gaa 289 Ala Val His Ile Ile Pro Glu Asn Glu Ser Asp Asp Glu Glu Glu Glu 85 90 95 gaa aaa ggg cca gtg tct ccc agg aat ctg cag gag tct gaa gag gag 337 Glu Lys Gly Pro Val Ser Pro Arg Asn Leu Gln Glu Ser Glu Glu Glu 100 105 110 gaa gtc ccc cag gag tcc tgg gat gaa ggt tat tcg act ctc tca att 385 Glu Val Pro Gln Glu Ser Trp Asp Glu Gly Tyr Ser Thr Leu Ser Ile 115 120 125 cct cct gaa atg ttg gcc tcg tac cag tct tac agc agc aca ttt cac 433 Pro Pro Glu Met Leu Ala Ser Tyr Gln Ser Tyr Ser Ser Thr Phe His 130 135 140 tca tta gag gaa cag caa gtc tgc atg gct gtt gac ata ggc gga cat 481 Ser Leu Glu Glu Gln Gln Val Cys Met Ala Val Asp Ile Gly Gly His 145 150 155 160 cag tgg gat caa gtg aaa aag gag gac caa gag gca aca ggt ccc agg 529 Gln Trp Asp Gln Val Lys Lys Glu Asp Gln Glu Ala Thr Gly Pro Arg 165 170 175 ctc agc agg gag ctg ctg gat gag aaa ggg cct gaa gtc ttg cag gac 577 Leu Ser Arg Glu Leu Leu Asp Glu Lys Gly Pro Glu Val Leu Gln Asp 180 185 190 tca ctg gat aga tgt tat tca act cct tca ggt tat ctt gaa ctg cct 625 Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu Pro 195 200 205 gac tca tgc cag ccc tac aga agt gcc ttt tac gta ttg gag caa cag 673 Asp Ser Cys Gln Pro Tyr Arg Ser Ala Phe Tyr Val Leu Glu Gln Gln 210 215 220 cgt gtt ggc ttg act ctt gac atg gat gaa att gaa aag tac caa gaa 721 Arg Val Gly Leu Thr Leu Asp Met Asp Glu Ile Glu Lys Tyr Gln Glu 225 230 235 240 gtg gaa gaa gac caa gac cca tca tgc ccc agg ctc agc agg gag ctg 769 Val Glu Glu Asp Gln Asp Pro Ser Cys Pro Arg Leu Ser Arg Glu Leu 245 250 255 ctg gat gag aaa gag cct gaa gtc ttg cag gac tcc ctg gat aga tgt 817 Leu Asp Glu Lys Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys 260 265 270 tat tcg act cct tca ggt tat ctt gaa ctg cct gac tta ggc cag ccc 865 Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu Pro Asp Leu Gly Gln Pro 275 280 285 tac aga agt gct gtt tac tca ttg gag gaa cag tac ctt ggc ttg gct 913 Tyr Arg Ser Ala Val Tyr Ser Leu Glu Glu Gln Tyr Leu Gly Leu Ala 290 295 300 ctt gac gtg gat aga att aaa aag gac caa gaa gag gaa gaa gac cag 961 Leu Asp Val Asp Arg Ile Lys Lys Asp Gln Glu Glu Glu Glu Asp Gln 305 310 315 320 ggc cca cca tgc ccc agg ctc agc agg gag ctg ctg gag gta gta gag 1009 Gly Pro Pro Cys Pro Arg Leu Ser Arg Glu Leu Leu Glu Val Val Glu 325 330 335 cct gaa gtc ttg cag gac tca ctg gat aga tgt tat tca act cct tcc 1057 Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser 340 345 350 agt tgt ctt gaa cag cct gac tcc tgc cag ccc tat gga agt tcc ttt 1105 Ser Cys Leu Glu Gln Pro Asp Ser Cys Gln Pro Tyr Gly Ser Ser Phe 355 360 365 tat gca ttg gag gaa aaa cat gtt ggc ttt tct ctt gac gtg gga gaa 1153 Tyr Ala Leu Glu Glu Lys His Val Gly Phe Ser Leu Asp Val Gly Glu 370 375 380 att gaa aag aag ggg aag ggg aag aaa aga agg gga aga aga tca acg 1201 Ile Glu Lys Lys Gly Lys Gly Lys Lys Arg Arg Gly Arg Arg Ser Thr 385 390 395 400 aaaaaaaaaa aaaaaa 1217 <210> SEQ ID NO 191 <211> LENGTH: 400 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <223> OTHER INFORMATION: image: 2920609; Genbank AF380581; cDNA clone AG03 <400> SEQUENCE: 191 Glu Asp Val Gln Val Glu Val Ala Glu Lys Val Gln Lys Ser Ser Ala 1 5 10 15 Pro Arg Glu Met Pro Lys Ala Glu Glu Lys Glu Val Pro Glu Asp Ser 20 25 30 Leu Glu Glu Cys Ala Ile Thr Cys Ser Asn Ser His Gly Pro Tyr Asp 35 40 45 Ser Asn Gln Pro His Arg Lys Thr Lys Ile Thr Phe Glu Glu Asp Lys 50 55 60 Val Asp Ser Thr Leu Ile Gly Ser Ser Ser His Val Glu Trp Glu Asp 65 70 75 80 Ala Val His Ile Ile Pro Glu Asn Glu Ser Asp Asp Glu Glu Glu Glu 85 90 95 Glu Lys Gly Pro Val Ser Pro Arg Asn Leu Gln Glu Ser Glu Glu Glu 100 105 110 Glu Val Pro Gln Glu Ser Trp Asp Glu Gly Tyr Ser Thr Leu Ser Ile 115 120 125 Pro Pro Glu Met Leu Ala Ser Tyr Gln Ser Tyr Ser Ser Thr Phe His 130 135 140 Ser Leu Glu Glu Gln Gln Val Cys Met Ala Val Asp Ile Gly Gly His 145 150 155 160 Gln Trp Asp Gln Val Lys Lys Glu Asp Gln Glu Ala Thr Gly Pro Arg 165 170 175 Leu Ser Arg Glu Leu Leu Asp Glu Lys Gly Pro Glu Val Leu Gln Asp 180 185 190 Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu Pro 195 200 205 Asp Ser Cys Gln Pro Tyr Arg Ser Ala Phe Tyr Val Leu Glu Gln Gln 210 215 220 Arg Val Gly Leu Thr Leu Asp Met Asp Glu Ile Glu Lys Tyr Gln Glu 225 230 235 240 Val Glu Glu Asp Gln Asp Pro Ser Cys Pro Arg Leu Ser Arg Glu Leu 245 250 255 Leu Asp Glu Lys Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys 260 265 270 Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu Pro Asp Leu Gly Gln Pro 275 280 285 Tyr Arg Ser Ala Val Tyr Ser Leu Glu Glu Gln Tyr Leu Gly Leu Ala 290 295 300 Leu Asp Val Asp Arg Ile Lys Lys Asp Gln Glu Glu Glu Glu Asp Gln 305 310 315 320 Gly Pro Pro Cys Pro Arg Leu Ser Arg Glu Leu Leu Glu Val Val Glu 325 330 335 Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser 340 345 350 Ser Cys Leu Glu Gln Pro Asp Ser Cys Gln Pro Tyr Gly Ser Ser Phe 355 360 365 Tyr Ala Leu Glu Glu Lys His Val Gly Phe Ser Leu Asp Val Gly Glu 370 375 380 Ile Glu Lys Lys Gly Lys Gly Lys Lys Arg Arg Gly Arg Arg Ser Thr 385 390 395 400 <210> SEQ ID NO 192 <211> LENGTH: 1885 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <223> OTHER INFORMATION: DKFZp434F2323; Genbank AF380580; cDNA clone AG01 <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (3)..(1847) <400> SEQUENCE: 192 aa aaa cat gtt ggc ttt tct ctt gac gtg gga gaa att gaa aag aag 47 Lys His Val Gly Phe Ser Leu Asp Val Gly Glu Ile Glu Lys Lys 1 5 10 15 ggg aag ggg aag aaa aga agg gga aga aga tca aag aag gaa aga aga 95 Gly Lys Gly Lys Lys Arg Arg Gly Arg Arg Ser Lys Lys Glu Arg Arg 20 25 30 agg gga aga aaa gaa ggg gaa gaa gat caa aac cca cca tgc ccc agg 143 Arg Gly Arg Lys Glu Gly Glu Glu Asp Gln Asn Pro Pro Cys Pro Arg 35 40 45 ctc agc agg gag ctg ctg gat gag aaa ggg cct gaa gtc ttg cag gac 191 Leu Ser Arg Glu Leu Leu Asp Glu Lys Gly Pro Glu Val Leu Gln Asp 50 55 60 tca ctg gat aga agt tat tca act cct tca ggt tgt ctt gaa ctg act 239 Ser Leu Asp Arg Ser Tyr Ser Thr Pro Ser Gly Cys Leu Glu Leu Thr 65 70 75 gac tca tgc cag ccc tac aga agt gcc ttt tac gta ttg gag caa cag 287 Asp Ser Cys Gln Pro Tyr Arg Ser Ala Phe Tyr Val Leu Glu Gln Gln 80 85 90 95 cgt gtt ggc ttg gct gtt gac atg gat gaa att gaa aag tac caa gaa 335 Arg Val Gly Leu Ala Val Asp Met Asp Glu Ile Glu Lys Tyr Gln Glu 100 105 110 gtg gaa gaa gac caa gac cca tca tgc ccc agg ctc agc agg gag ctg 383 Val Glu Glu Asp Gln Asp Pro Ser Cys Pro Arg Leu Ser Arg Glu Leu 115 120 125 ctg gat gag aaa gag cct gaa gtc ttg cag gac tca ctg gat aga tgt 431 Leu Asp Glu Lys Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys 130 135 140 tat tcg act cct tca ggt tat ctt gaa ctg cct gac tta ggc cag ccc 479 Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu Pro Asp Leu Gly Gln Pro 145 150 155 tac agc agt gct gtg tac tca ttg gag gaa cag tac ctt ggc ttg gct 527 Tyr Ser Ser Ala Val Tyr Ser Leu Glu Glu Gln Tyr Leu Gly Leu Ala 160 165 170 175 ctt gac gtg gac aga act aaa aag gac caa gaa gag gaa gaa gac caa 575 Leu Asp Val Asp Arg Thr Lys Lys Asp Gln Glu Glu Glu Glu Asp Gln 180 185 190 ggc cca cca tgc ccc agg ctc agc agg gag ctg ctg gag gta gta gag 623 Gly Pro Pro Cys Pro Arg Leu Ser Arg Glu Leu Leu Glu Val Val Glu 195 200 205 cct gaa gtc ttg cag gac tca ctg gat aga tgt tat tca act cct tcc 671 Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser 210 215 220 agt tgt ctt gaa cag cct gac tcc tgc cag ccc tat gga agt tcc ttt 719 Ser Cys Leu Glu Gln Pro Asp Ser Cys Gln Pro Tyr Gly Ser Ser Phe 225 230 235 tat gca ttg gag gaa aaa cat gtt ggc ttt tct ctc gac gtg gga gaa 767 Tyr Ala Leu Glu Glu Lys His Val Gly Phe Ser Leu Asp Val Gly Glu 240 245 250 255 att gaa aag aag ggg aag ggg aag aaa aga agg gga aga aga tca aag 815 Ile Glu Lys Lys Gly Lys Gly Lys Lys Arg Arg Gly Arg Arg Ser Lys 260 265 270 aag gaa aga aga agg gga aga aaa gaa ggg gaa gaa gat caa aac cca 863 Lys Glu Arg Arg Arg Gly Arg Lys Glu Gly Glu Glu Asp Gln Asn Pro 275 280 285 cca tgc ccc agg ctc agc agg gag ctg ctg gat gag aaa ggg cct gaa 911 Pro Cys Pro Arg Leu Ser Arg Glu Leu Leu Asp Glu Lys Gly Pro Glu 290 295 300 gtc ttg cag gac tca ctg gat aga tgt tat tca act cct tca ggt tgt 959 Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Cys 305 310 315 ctt gaa ctg act gac tca tgc cag ccc tac aga agt gcc ttt tac gta 1007 Leu Glu Leu Thr Asp Ser Cys Gln Pro Tyr Arg Ser Ala Phe Tyr Val 320 325 330 335 ttg gag caa cag cgt gtt ggc ttg gct gtt gac atg gat gaa att gaa 1055 Leu Glu Gln Gln Arg Val Gly Leu Ala Val Asp Met Asp Glu Ile Glu 340 345 350 aag tac caa gaa gtg gaa gaa gac caa gac cca tca tgc ccc agg ctc 1103 Lys Tyr Gln Glu Val Glu Glu Asp Gln Asp Pro Ser Cys Pro Arg Leu 355 360 365 agc agg gag ctg ctg gat gag aaa gag cct gaa gtc ttg cag gac tca 1151 Ser Arg Glu Leu Leu Asp Glu Lys Glu Pro Glu Val Leu Gln Asp Ser 370 375 380 ctg gat aga tgt tat tcg act cct tca ggt tat ctt gaa ctg cct gac 1199 Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu Pro Asp 385 390 395 tta ggc cag ccc tac agc agt gct gtt tac tca ttg gag gaa cag tac 1247 Leu Gly Gln Pro Tyr Ser Ser Ala Val Tyr Ser Leu Glu Glu Gln Tyr 400 405 410 415 ctt ggc ttg gct ctt gac gtg gac aga act aaa aag gac caa gaa gag 1295 Leu Gly Leu Ala Leu Asp Val Asp Arg Thr Lys Lys Asp Gln Glu Glu 420 425 430 gaa gaa gac caa ggc cca cca tgc ccc agg ctc agc agg gag ctg ctg 1343 Glu Glu Asp Gln Gly Pro Pro Cys Pro Arg Leu Ser Arg Glu Leu Leu 435 440 445 gag gta gta gag cct gaa gtc ttg cag gac tca ctg gat aga tgt tat 1391 Glu Val Val Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr 450 455 460 tca act cct tcc agt tgt ctt gaa cag cct gac tcc tgc cag ccc tat 1439 Ser Thr Pro Ser Ser Cys Leu Glu Gln Pro Asp Ser Cys Gln Pro Tyr 465 470 475 gga agt tcc ttt tat gca ttg gag gaa aaa cat gtt ggc ttt tct ctt 1487 Gly Ser Ser Phe Tyr Ala Leu Glu Glu Lys His Val Gly Phe Ser Leu 480 485 490 495 gac gtg gga gaa att gaa aag aag ggg aag ggg aag aaa aga agg gga 1535 Asp Val Gly Glu Ile Glu Lys Lys Gly Lys Gly Lys Lys Arg Arg Gly 500 505 510 aga aga tca aag aag aaa aga aga agg gga aga aaa gaa ggg gaa gaa 1583 Arg Arg Ser Lys Lys Lys Arg Arg Arg Gly Arg Lys Glu Gly Glu Glu 515 520 525 gat caa aac cca cca tgc ccc agg ctc aac ggc gtg ctg atg gaa gtg 1631 Asp Gln Asn Pro Pro Cys Pro Arg Leu Asn Gly Val Leu Met Glu Val 530 535 540 gaa gag cct gaa gtc tta cag gac tca ctg gat gga tgt tat tct act 1679 Glu Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Gly Cys Tyr Ser Thr 545 550 555 ccg tca atg tac ttt gaa cta cct gac tca ttc cag cac tac aga agt 1727 Pro Ser Met Tyr Phe Glu Leu Pro Asp Ser Phe Gln His Tyr Arg Ser 560 565 570 575 gtg ttt tac tca ttt gag gaa cag cac atc agc ttc gcc ctt tac gtg 1775 Val Phe Tyr Ser Phe Glu Glu Gln His Ile Ser Phe Ala Leu Tyr Val 580 585 590 gac aat agg ttt ttt act ttg acg gtg aca agt ctc cac ctg gtg ttc 1823 Asp Asn Arg Phe Phe Thr Leu Thr Val Thr Ser Leu His Leu Val Phe 595 600 605 cag atg gga gtc ata ttc cca caa taaacagccc ttactaaaaa aaaaaaaaaa 1877 Gln Met Gly Val Ile Phe Pro Gln 610 615 aaaaaaaa 1885 <210> SEQ ID NO 193 <211> LENGTH: 615 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <223> OTHER INFORMATION: DKFZp434F2323; Genbank AF380580; cDNA clone AG01 <400> SEQUENCE: 193 Lys His Val Gly Phe Ser Leu Asp Val Gly Glu Ile Glu Lys Lys Gly 1 5 10 15 Lys Gly Lys Lys Arg Arg Gly Arg Arg Ser Lys Lys Glu Arg Arg Arg 20 25 30 Gly Arg Lys Glu Gly Glu Glu Asp Gln Asn Pro Pro Cys Pro Arg Leu 35 40 45 Ser Arg Glu Leu Leu Asp Glu Lys Gly Pro Glu Val Leu Gln Asp Ser 50 55 60 Leu Asp Arg Ser Tyr Ser Thr Pro Ser Gly Cys Leu Glu Leu Thr Asp 65 70 75 80 Ser Cys Gln Pro Tyr Arg Ser Ala Phe Tyr Val Leu Glu Gln Gln Arg 85 90 95 Val Gly Leu Ala Val Asp Met Asp Glu Ile Glu Lys Tyr Gln Glu Val 100 105 110 Glu Glu Asp Gln Asp Pro Ser Cys Pro Arg Leu Ser Arg Glu Leu Leu 115 120 125 Asp Glu Lys Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr 130 135 140 Ser Thr Pro Ser Gly Tyr Leu Glu Leu Pro Asp Leu Gly Gln Pro Tyr 145 150 155 160 Ser Ser Ala Val Tyr Ser Leu Glu Glu Gln Tyr Leu Gly Leu Ala Leu 165 170 175 Asp Val Asp Arg Thr Lys Lys Asp Gln Glu Glu Glu Glu Asp Gln Gly 180 185 190 Pro Pro Cys Pro Arg Leu Ser Arg Glu Leu Leu Glu Val Val Glu Pro 195 200 205 Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Ser 210 215 220 Cys Leu Glu Gln Pro Asp Ser Cys Gln Pro Tyr Gly Ser Ser Phe Tyr 225 230 235 240 Ala Leu Glu Glu Lys His Val Gly Phe Ser Leu Asp Val Gly Glu Ile 245 250 255 Glu Lys Lys Gly Lys Gly Lys Lys Arg Arg Gly Arg Arg Ser Lys Lys 260 265 270 Glu Arg Arg Arg Gly Arg Lys Glu Gly Glu Glu Asp Gln Asn Pro Pro 275 280 285 Cys Pro Arg Leu Ser Arg Glu Leu Leu Asp Glu Lys Gly Pro Glu Val 290 295 300 Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Cys Leu 305 310 315 320 Glu Leu Thr Asp Ser Cys Gln Pro Tyr Arg Ser Ala Phe Tyr Val Leu 325 330 335 Glu Gln Gln Arg Val Gly Leu Ala Val Asp Met Asp Glu Ile Glu Lys 340 345 350 Tyr Gln Glu Val Glu Glu Asp Gln Asp Pro Ser Cys Pro Arg Leu Ser 355 360 365 Arg Glu Leu Leu Asp Glu Lys Glu Pro Glu Val Leu Gln Asp Ser Leu 370 375 380 Asp Arg Cys Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu Pro Asp Leu 385 390 395 400 Gly Gln Pro Tyr Ser Ser Ala Val Tyr Ser Leu Glu Glu Gln Tyr Leu 405 410 415 Gly Leu Ala Leu Asp Val Asp Arg Thr Lys Lys Asp Gln Glu Glu Glu 420 425 430 Glu Asp Gln Gly Pro Pro Cys Pro Arg Leu Ser Arg Glu Leu Leu Glu 435 440 445 Val Val Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser 450 455 460 Thr Pro Ser Ser Cys Leu Glu Gln Pro Asp Ser Cys Gln Pro Tyr Gly 465 470 475 480 Ser Ser Phe Tyr Ala Leu Glu Glu Lys His Val Gly Phe Ser Leu Asp 485 490 495 Val Gly Glu Ile Glu Lys Lys Gly Lys Gly Lys Lys Arg Arg Gly Arg 500 505 510 Arg Ser Lys Lys Lys Arg Arg Arg Gly Arg Lys Glu Gly Glu Glu Asp 515 520 525 Gln Asn Pro Pro Cys Pro Arg Leu Asn Gly Val Leu Met Glu Val Glu 530 535 540 Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Gly Cys Tyr Ser Thr Pro 545 550 555 560 Ser Met Tyr Phe Glu Leu Pro Asp Ser Phe Gln His Tyr Arg Ser Val 565 570 575 Phe Tyr Ser Phe Glu Glu Gln His Ile Ser Phe Ala Leu Tyr Val Asp 580 585 590 Asn Arg Phe Phe Thr Leu Thr Val Thr Ser Leu His Leu Val Phe Gln 595 600 605 Met Gly Val Ile Phe Pro Gln 610 615 <210> SEQ ID NO 194 <211> LENGTH: 1528 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <223> OTHER INFORMATION: image: 2782170 (5′ end); Genbank AF419618; cDNA clone AE01 <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (2)..(964) <400> SEQUENCE: 194 g aac aaa tac aag tat gaa gag tgt aaa gac ctc ata aaa ttt atg ctg 49 Asn Lys Tyr Lys Tyr Glu Glu Cys Lys Asp Leu Ile Lys Phe Met Leu 1 5 10 15 agg aat gag cga cag ttc aag gag gag aag ctt gca gag cag ctg aag 97 Arg Asn Glu Arg Gln Phe Lys Glu Glu Lys Leu Ala Glu Gln Leu Lys 20 25 30 caa gct gag gag ctc agg caa tat aaa gtc ctg gtt cac gct cag gaa 145 Gln Ala Glu Glu Leu Arg Gln Tyr Lys Val Leu Val His Ala Gln Glu 35 40 45 cga gag ctg acc cag tta agg gag aag ttg cgg gaa ggg aga gat gcc 193 Arg Glu Leu Thr Gln Leu Arg Glu Lys Leu Arg Glu Gly Arg Asp Ala 50 55 60 tcc cgc tca ttg aat gag cat ctc cag gcc ctc ctc act ccg gat gag 241 Ser Arg Ser Leu Asn Glu His Leu Gln Ala Leu Leu Thr Pro Asp Glu 65 70 75 80 ccg gac aag tcc cag ggg cag gac ctc caa gaa cag ctg gct gag ggg 289 Pro Asp Lys Ser Gln Gly Gln Asp Leu Gln Glu Gln Leu Ala Glu Gly 85 90 95 tgt aga ctg gca cag cac ctt gtc caa aag ctc agc cca gaa aat gac 337 Cys Arg Leu Ala Gln His Leu Val Gln Lys Leu Ser Pro Glu Asn Asp 100 105 110 aac gat gac gat gaa gat gtt caa att gag gtg gct gag aaa gtg cag 385 Asn Asp Asp Asp Glu Asp Val Gln Ile Glu Val Ala Glu Lys Val Gln 115 120 125 aaa tcg tct gcc ccc agg gag atg cag aag gct gaa gaa aag gaa gtc 433 Lys Ser Ser Ala Pro Arg Glu Met Gln Lys Ala Glu Glu Lys Glu Val 130 135 140 cct gag gac tca ctg gag gaa tgt gcc atc act tat tca aat agc cat 481 Pro Glu Asp Ser Leu Glu Glu Cys Ala Ile Thr Tyr Ser Asn Ser His 145 150 155 160 ggc cct tat gac tcc aac cag cca cat agg aaa acc aaa atc aca ttt 529 Gly Pro Tyr Asp Ser Asn Gln Pro His Arg Lys Thr Lys Ile Thr Phe 165 170 175 gag gaa gac aaa gtc gac tca act ctc att ggc tca tcc tct cat gtt 577 Glu Glu Asp Lys Val Asp Ser Thr Leu Ile Gly Ser Ser Ser His Val 180 185 190 gaa cgg gaa gat gct gta cac att att cca gaa aat gaa agt gat gat 625 Glu Arg Glu Asp Ala Val His Ile Ile Pro Glu Asn Glu Ser Asp Asp 195 200 205 gag gaa gag gaa gaa aaa ggg cca gtg tct ccc agg aat ctg cag gag 673 Glu Glu Glu Glu Glu Lys Gly Pro Val Ser Pro Arg Asn Leu Gln Glu 210 215 220 tct gaa gag gag gaa gtc ccc cag gag tcc tgg gat gaa ggt tat tcg 721 Ser Glu Glu Glu Glu Val Pro Gln Glu Ser Trp Asp Glu Gly Tyr Ser 225 230 235 240 act ccc tca att cct cct gaa atg ttg gcc tcg tac aag tct tac agc 769 Thr Pro Ser Ile Pro Pro Glu Met Leu Ala Ser Tyr Lys Ser Tyr Ser 245 250 255 agc aca ttt cac tca tta gag gaa cag caa gtc tgc atg gct gtt gac 817 Ser Thr Phe His Ser Leu Glu Glu Gln Gln Val Cys Met Ala Val Asp 260 265 270 ata ggc aga cat cgg tgg gat caa gtg aaa aag gag gac caa gag gca 865 Ile Gly Arg His Arg Trp Asp Gln Val Lys Lys Glu Asp Gln Glu Ala 275 280 285 aca ggt ccc agg ctc agc agg gag ctg ctg gat gag aaa ggg cct gaa 913 Thr Gly Pro Arg Leu Ser Arg Glu Leu Leu Asp Glu Lys Gly Pro Glu 290 295 300 gtc ttg cag gac tca ctg gat aga tgt tta ttc aac tcc ttc agg ttg 961 Val Leu Gln Asp Ser Leu Asp Arg Cys Leu Phe Asn Ser Phe Arg Leu 305 310 315 320 tct tgaactgact gactcatgcc agccctacag aagtgccttt tacgtattgg 1014 Ser agcaacagcg tgttggcttg gctgttgaca tggatgaaat tgaaaagtac caagaagtgg 1074 aagaagacca agacccatca tgccccaggc tcagcaggga gctgctggat gagaaagagc 1134 ctgaagtctt gcaggactca ctgggtagat ggtattcgac tccttcaggt tatcttgaac 1194 tgcctgactt aggccagccc tacagcagtg ctgtttactc attggaggaa cagtaccttg 1254 gcttggctct tgacttggac agaattaaaa aggaccaaga agaggaagaa gaccaaggcc 1314 caccatgccc caggctcagc agggagctgc tggaggtagt agagcctgaa gtcttgcagg 1374 actcactgga tagatgttat tcaactcctt ccagttgtct tgaacagcct gactcctgcc 1434 agccctatgg aagttccttt tatgcattgg aggaaaaaca tgttggcttt tctcttgacg 1494 tgggagaaat tgaaaagaag gggaagggga agaa 1528 <210> SEQ ID NO 195 <211> LENGTH: 321 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <223> OTHER INFORMATION: image: 2782170 (5′ end); Genbank AF419618; cDNA clone AE01 <400> SEQUENCE: 195 Asn Lys Tyr Lys Tyr Glu Glu Cys Lys Asp Leu Ile Lys Phe Met Leu 1 5 10 15 Arg Asn Glu Arg Gln Phe Lys Glu Glu Lys Leu Ala Glu Gln Leu Lys 20 25 30 Gln Ala Glu Glu Leu Arg Gln Tyr Lys Val Leu Val His Ala Gln Glu 35 40 45 Arg Glu Leu Thr Gln Leu Arg Glu Lys Leu Arg Glu Gly Arg Asp Ala 50 55 60 Ser Arg Ser Leu Asn Glu His Leu Gln Ala Leu Leu Thr Pro Asp Glu 65 70 75 80 Pro Asp Lys Ser Gln Gly Gln Asp Leu Gln Glu Gln Leu Ala Glu Gly 85 90 95 Cys Arg Leu Ala Gln His Leu Val Gln Lys Leu Ser Pro Glu Asn Asp 100 105 110 Asn Asp Asp Asp Glu Asp Val Gln Ile Glu Val Ala Glu Lys Val Gln 115 120 125 Lys Ser Ser Ala Pro Arg Glu Met Gln Lys Ala Glu Glu Lys Glu Val 130 135 140 Pro Glu Asp Ser Leu Glu Glu Cys Ala Ile Thr Tyr Ser Asn Ser His 145 150 155 160 Gly Pro Tyr Asp Ser Asn Gln Pro His Arg Lys Thr Lys Ile Thr Phe 165 170 175 Glu Glu Asp Lys Val Asp Ser Thr Leu Ile Gly Ser Ser Ser His Val 180 185 190 Glu Arg Glu Asp Ala Val His Ile Ile Pro Glu Asn Glu Ser Asp Asp 195 200 205 Glu Glu Glu Glu Glu Lys Gly Pro Val Ser Pro Arg Asn Leu Gln Glu 210 215 220 Ser Glu Glu Glu Glu Val Pro Gln Glu Ser Trp Asp Glu Gly Tyr Ser 225 230 235 240 Thr Pro Ser Ile Pro Pro Glu Met Leu Ala Ser Tyr Lys Ser Tyr Ser 245 250 255 Ser Thr Phe His Ser Leu Glu Glu Gln Gln Val Cys Met Ala Val Asp 260 265 270 Ile Gly Arg His Arg Trp Asp Gln Val Lys Lys Glu Asp Gln Glu Ala 275 280 285 Thr Gly Pro Arg Leu Ser Arg Glu Leu Leu Asp Glu Lys Gly Pro Glu 290 295 300 Val Leu Gln Asp Ser Leu Asp Arg Cys Leu Phe Asn Ser Phe Arg Leu 305 310 315 320 Ser <210> SEQ ID NO 196 <211> LENGTH: 2991 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <223> OTHER INFORMATION: image: 2226413; Genbank AF419617; cDNA clone AG09 <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (542)..(715) <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (718)..(2979) <400> SEQUENCE: 196 attgataaca gtaaagccac actcctcaag tgcctgaaat acccctcatt gtcttcttca 60 ggtggcaagg gctctggaac agccacataa agcccttgaa gataaggatg gtcaaacaaa 120 ataatatcat acctggagaa actcagatct tgctaagatt tactggttgg gaatccaaag 180 ttaatgccaa gaagcagctg ccagttggga tcaaatgtga gcctatggat caaggaatgt 240 ctggacacag tagacaaagg tttttcaact ggatgcctta ggatacatgc ttccaaaaac 300 aaagtagcca aaaagaaacc agagtcacag aatatcagag ccagaggaac atttggagac 360 ggttacctgg cacgctggcc acaatctacc tcactcttat cagagtctga gcagtgcttt 420 cagctctgag ttgaggcacc tcgaaccttg tttttgtggt gaaggatcct aaagtgctgt 480 ggggagtgat cacatttttc acaacatccc tgactccacc tcttctgcca caaacgtcag 540 c atg gtg gta tca gcc ggc cct tgg tcc agc gag aag gca gag atg aac 589 Met Val Val Ser Ala Gly Pro Trp Ser Ser Glu Lys Ala Glu Met Asn 1 5 10 15 att cta gaa atc aac gag aaa ttg cgc ccc cag ttg gca gag aac aaa 637 Ile Leu Glu Ile Asn Glu Lys Leu Arg Pro Gln Leu Ala Glu Asn Lys 20 25 30 cag cag ttc aga aac ctc aaa gag aga tgt ttt cta act caa ctg gcc 685 Gln Gln Phe Arg Asn Leu Lys Glu Arg Cys Phe Leu Thr Gln Leu Ala 35 40 45 ggc ttc ctg gcc aac cga cag aag aaa tac ag caa tat aaa gtc ctg 732 Gly Phe Leu Ala Asn Arg Gln Lys Lys Tyr Gln Tyr Lys Val Leu 50 55 60 gtt cac tct cag gaa cga gag ctg acc cag tta agg gag aag tta cgg 780 Val His Ser Gln Glu Arg Glu Leu Thr Gln Leu Arg Glu Lys Leu Arg 65 70 75 gaa ggg aga gat gcc tcc cgc tca ttg aat gag cat ctc cag gcc ctc 828 Glu Gly Arg Asp Ala Ser Arg Ser Leu Asn Glu His Leu Gln Ala Leu 80 85 90 95 ctc act ccg gat gag ccg gac aag tcc cag ggg cag gac ctc caa gaa 876 Leu Thr Pro Asp Glu Pro Asp Lys Ser Gln Gly Gln Asp Leu Gln Glu 100 105 110 cag ctg gct gag ggg tgt aga ctg gca cag cac ctt gtc caa aag ctc 924 Gln Leu Ala Glu Gly Cys Arg Leu Ala Gln His Leu Val Gln Lys Leu 115 120 125 agc cca gaa aat gac aaa gat gag gat gaa gat gtt caa gtt gag gag 972 Ser Pro Glu Asn Asp Lys Asp Glu Asp Glu Asp Val Gln Val Glu Glu 130 135 140 gat gag aaa gta ctg gaa tca tct gcc ccc agg gag gtg cag aag gct 1020 Asp Glu Lys Val Leu Glu Ser Ser Ala Pro Arg Glu Val Gln Lys Ala 145 150 155 gaa gag agc aaa gtc cct gag gac tca ctg gag gaa tgt gcc atc act 1068 Glu Glu Ser Lys Val Pro Glu Asp Ser Leu Glu Glu Cys Ala Ile Thr 160 165 170 175 tgt tca aat agc cac ggc cct tgt gac tcc atc cag cct cac aag aac 1116 Cys Ser Asn Ser His Gly Pro Cys Asp Ser Ile Gln Pro His Lys Asn 180 185 190 atc aaa atc aca ttt gag gaa gac aaa gtc aac tca tct ctg gtt gta 1164 Ile Lys Ile Thr Phe Glu Glu Asp Lys Val Asn Ser Ser Leu Val Val 195 200 205 gac aga gaa tcc tct cat gat gga tgt cag gat gct cta aac att ctc 1212 Asp Arg Glu Ser Ser His Asp Gly Cys Gln Asp Ala Leu Asn Ile Leu 210 215 220 cca gtc cct ggc ccc acc tct tct gcc aca aac gtc agc atg gtg gta 1260 Pro Val Pro Gly Pro Thr Ser Ser Ala Thr Asn Val Ser Met Val Val 225 230 235 tca gcc ggc cct ttg tcc agc gag aag gca gag atg aac att cta gaa 1308 Ser Ala Gly Pro Leu Ser Ser Glu Lys Ala Glu Met Asn Ile Leu Glu 240 245 250 255 atc aat gag aaa ttg tgc ccc cag ctg gca gag aag aaa cag cag ttc 1356 Ile Asn Glu Lys Leu Cys Pro Gln Leu Ala Glu Lys Lys Gln Gln Phe 260 265 270 aga agc ctc aaa gag aaa tgt ttt gta act caa gtg gcc tgc ttc ctg 1404 Arg Ser Leu Lys Glu Lys Cys Phe Val Thr Gln Val Ala Cys Phe Leu 275 280 285 gcc aag cag cag aac aaa tac aaa tat gaa gag tgc aaa gac ctc ata 1452 Ala Lys Gln Gln Asn Lys Tyr Lys Tyr Glu Glu Cys Lys Asp Leu Ile 290 295 300 aaa tct atg ctg agg aat gag cga cag ttc aag gag gag aag ctt gca 1500 Lys Ser Met Leu Arg Asn Glu Arg Gln Phe Lys Glu Glu Lys Leu Ala 305 310 315 gag cag ctg aag caa gct gag gag ctc agg caa tat aaa gtc ctg gtt 1548 Glu Gln Leu Lys Gln Ala Glu Glu Leu Arg Gln Tyr Lys Val Leu Val 320 325 330 335 cac tct cag gaa cga gag ctg acc cag tta agg gag aag tta cgg gaa 1596 His Ser Gln Glu Arg Glu Leu Thr Gln Leu Arg Glu Lys Leu Arg Glu 340 345 350 ggg aga gat gcc tcc cgc tca ttg aat gag cat ctc cag gcc ctc ctc 1644 Gly Arg Asp Ala Ser Arg Ser Leu Asn Glu His Leu Gln Ala Leu Leu 355 360 365 act ccg gat gag ccg gac aag tcc cag ggg cag gac ctc caa gaa cag 1692 Thr Pro Asp Glu Pro Asp Lys Ser Gln Gly Gln Asp Leu Gln Glu Gln 370 375 380 ctg gct gag ggg tgt aga ctg gca cag cac ctt gtc caa aag ctc agc 1740 Leu Ala Glu Gly Cys Arg Leu Ala Gln His Leu Val Gln Lys Leu Ser 385 390 395 cca gaa aat gat aac gat gac gat gaa gat gtt caa gtt gag gtg gct 1788 Pro Glu Asn Asp Asn Asp Asp Asp Glu Asp Val Gln Val Glu Val Ala 400 405 410 415 gag aaa gtg cag aaa tcg tct tcc ccc agg gag atg cag aag gct gaa 1836 Glu Lys Val Gln Lys Ser Ser Ser Pro Arg Glu Met Gln Lys Ala Glu 420 425 430 gaa aag gaa gtc cct gag gac tca ctg gag gag tgt gcc atc act tgt 1884 Glu Lys Glu Val Pro Glu Asp Ser Leu Glu Glu Cys Ala Ile Thr Cys 435 440 445 tca aat agc cat ggc cct tat gac tcc aac cag cca cat aga aaa acc 1932 Ser Asn Ser His Gly Pro Tyr Asp Ser Asn Gln Pro His Arg Lys Thr 450 455 460 aaa atc aca ttt gag gaa gac aaa gtc gac tca act ctc att ggc tca 1980 Lys Ile Thr Phe Glu Glu Asp Lys Val Asp Ser Thr Leu Ile Gly Ser 465 470 475 tcc tct cat gtt gaa tgg gag gat gct gta cac att atc cca gaa aat 2028 Ser Ser His Val Glu Trp Glu Asp Ala Val His Ile Ile Pro Glu Asn 480 485 490 495 gaa agt gat gat gag gaa gag gaa gaa aaa ggg cca gtg tct ccc agg 2076 Glu Ser Asp Asp Glu Glu Glu Glu Glu Lys Gly Pro Val Ser Pro Arg 500 505 510 aat ctg cag gag tct gaa gag gag gaa gtc ccc cag gag tcc tgg gat 2124 Asn Leu Gln Glu Ser Glu Glu Glu Glu Val Pro Gln Glu Ser Trp Asp 515 520 525 gaa ggt tat tcg act ctc tca att cct cct gaa agg ttg gcc tcg tac 2172 Glu Gly Tyr Ser Thr Leu Ser Ile Pro Pro Glu Arg Leu Ala Ser Tyr 530 535 540 cag tct tac agc agc aca ttt cac tca tta gag gaa cag caa gtc tgc 2220 Gln Ser Tyr Ser Ser Thr Phe His Ser Leu Glu Glu Gln Gln Val Cys 545 550 555 atg gct gtt gac ata ggc aga cat cgg tgg gat caa gtg aaa aag gag 2268 Met Ala Val Asp Ile Gly Arg His Arg Trp Asp Gln Val Lys Lys Glu 560 565 570 575 gac caa gag gca aca ggt ccc agg ctc agc agg gag ctg ctg gat gag 2316 Asp Gln Glu Ala Thr Gly Pro Arg Leu Ser Arg Glu Leu Leu Asp Glu 580 585 590 aaa gag cct gaa gtc ttg cag gac tca ctg gat aga tgt tat tca act 2364 Lys Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr 595 600 605 cct tca gtt tat ctt gga ctg act gac tca tgc cag ccc tac aga agt 2412 Pro Ser Val Tyr Leu Gly Leu Thr Asp Ser Cys Gln Pro Tyr Arg Ser 610 615 620 gcc ttt tac gta ttg gag caa cag cgt att ggc ttg gct gtt gac atg 2460 Ala Phe Tyr Val Leu Glu Gln Gln Arg Ile Gly Leu Ala Val Asp Met 625 630 635 gat gaa att gaa aag tgc caa gaa gtg gaa gaa gac caa gac cca tca 2508 Asp Glu Ile Glu Lys Cys Gln Glu Val Glu Glu Asp Gln Asp Pro Ser 640 645 650 655 tgc ccc agg ctc agc agg gag ctg ctg gct gag aaa gag cct gaa gtc 2556 Cys Pro Arg Leu Ser Arg Glu Leu Leu Ala Glu Lys Glu Pro Glu Val 660 665 670 ttg cag gac tca ctg gat aga tgt tat tcg act cct tca ggt tat ctt 2604 Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Tyr Leu 675 680 685 gaa ctg cct gac tta ggc cag ccc tac agc agt gct gtt tac tca ttg 2652 Glu Leu Pro Asp Leu Gly Gln Pro Tyr Ser Ser Ala Val Tyr Ser Leu 690 695 700 gag gaa cag tac ctt ggc ttg gct ctt gac gtg gac aga att aaa aag 2700 Glu Glu Gln Tyr Leu Gly Leu Ala Leu Asp Val Asp Arg Ile Lys Lys 705 710 715 gac caa gaa gag gaa gaa gac caa ggc cca ccg tgc ccc agg ctc agc 2748 Asp Gln Glu Glu Glu Glu Asp Gln Gly Pro Pro Cys Pro Arg Leu Ser 720 725 730 735 agg gag ctg ctg gag gta gta gag cct gaa gtc ttg cag gac tca ctg 2796 Arg Glu Leu Leu Glu Val Val Glu Pro Glu Val Leu Gln Asp Ser Leu 740 745 750 gat aga tgt tat tca act cct tcc agt tgt ctt gaa cag cct gac tcc 2844 Asp Arg Cys Tyr Ser Thr Pro Ser Ser Cys Leu Glu Gln Pro Asp Ser 755 760 765 tgc cag ccc tac gga agt tcc ttt tat gca ttg gag gaa aaa cat gtt 2892 Cys Gln Pro Tyr Gly Ser Ser Phe Tyr Ala Leu Glu Glu Lys His Val 770 775 780 ggc ttt tct ctt gac gtg gga gaa att gaa aag aag ggg aag ggg aag 2940 Gly Phe Ser Leu Asp Val Gly Glu Ile Glu Lys Lys Gly Lys Gly Lys 785 790 795 aaa aga agg gga aga aga tca aag aag aaa aga aga aaa aaaaaaaaaa aa 2991 Lys Arg Arg Gly Arg Arg Ser Lys Lys Lys Arg Arg Lys 800 805 810 <210> SEQ ID NO 197 <211> LENGTH: 58 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <223> OTHER INFORMATION: image: 2226413; Genbank AF419617; cDNA clone AG09 <400> SEQUENCE: 197 Met Val Val Ser Ala Gly Pro Trp Ser Ser Glu Lys Ala Glu Met Asn 1 5 10 15 Ile Leu Glu Ile Asn Glu Lys Leu Arg Pro Gln Leu Ala Glu Asn Lys 20 25 30 Gln Gln Phe Arg Asn Leu Lys Glu Arg Cys Phe Leu Thr Gln Leu Ala 35 40 45 Gly Phe Leu Ala Asn Arg Gln Lys Lys Tyr 50 55 <210> SEQ ID NO 198 <211> LENGTH: 754 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <223> OTHER INFORMATION: image: 2226413; Genbank AF419617; cDNA clone AG09 <400> SEQUENCE: 198 Gln Tyr Lys Val Leu Val His Ser Gln Glu Arg Glu Leu Thr Gln Leu 1 5 10 15 Arg Glu Lys Leu Arg Glu Gly Arg Asp Ala Ser Arg Ser Leu Asn Glu 20 25 30 His Leu Gln Ala Leu Leu Thr Pro Asp Glu Pro Asp Lys Ser Gln Gly 35 40 45 Gln Asp Leu Gln Glu Gln Leu Ala Glu Gly Cys Arg Leu Ala Gln His 50 55 60 Leu Val Gln Lys Leu Ser Pro Glu Asn Asp Lys Asp Glu Asp Glu Asp 65 70 75 80 Val Gln Val Glu Glu Asp Glu Lys Val Leu Glu Ser Ser Ala Pro Arg 85 90 95 Glu Val Gln Lys Ala Glu Glu Ser Lys Val Pro Glu Asp Ser Leu Glu 100 105 110 Glu Cys Ala Ile Thr Cys Ser Asn Ser His Gly Pro Cys Asp Ser Ile 115 120 125 Gln Pro His Lys Asn Ile Lys Ile Thr Phe Glu Glu Asp Lys Val Asn 130 135 140 Ser Ser Leu Val Val Asp Arg Glu Ser Ser His Asp Gly Cys Gln Asp 145 150 155 160 Ala Leu Asn Ile Leu Pro Val Pro Gly Pro Thr Ser Ser Ala Thr Asn 165 170 175 Val Ser Met Val Val Ser Ala Gly Pro Leu Ser Ser Glu Lys Ala Glu 180 185 190 Met Asn Ile Leu Glu Ile Asn Glu Lys Leu Cys Pro Gln Leu Ala Glu 195 200 205 Lys Lys Gln Gln Phe Arg Ser Leu Lys Glu Lys Cys Phe Val Thr Gln 210 215 220 Val Ala Cys Phe Leu Ala Lys Gln Gln Asn Lys Tyr Lys Tyr Glu Glu 225 230 235 240 Cys Lys Asp Leu Ile Lys Ser Met Leu Arg Asn Glu Arg Gln Phe Lys 245 250 255 Glu Glu Lys Leu Ala Glu Gln Leu Lys Gln Ala Glu Glu Leu Arg Gln 260 265 270 Tyr Lys Val Leu Val His Ser Gln Glu Arg Glu Leu Thr Gln Leu Arg 275 280 285 Glu Lys Leu Arg Glu Gly Arg Asp Ala Ser Arg Ser Leu Asn Glu His 290 295 300 Leu Gln Ala Leu Leu Thr Pro Asp Glu Pro Asp Lys Ser Gln Gly Gln 305 310 315 320 Asp Leu Gln Glu Gln Leu Ala Glu Gly Cys Arg Leu Ala Gln His Leu 325 330 335 Val Gln Lys Leu Ser Pro Glu Asn Asp Asn Asp Asp Asp Glu Asp Val 340 345 350 Gln Val Glu Val Ala Glu Lys Val Gln Lys Ser Ser Ser Pro Arg Glu 355 360 365 Met Gln Lys Ala Glu Glu Lys Glu Val Pro Glu Asp Ser Leu Glu Glu 370 375 380 Cys Ala Ile Thr Cys Ser Asn Ser His Gly Pro Tyr Asp Ser Asn Gln 385 390 395 400 Pro His Arg Lys Thr Lys Ile Thr Phe Glu Glu Asp Lys Val Asp Ser 405 410 415 Thr Leu Ile Gly Ser Ser Ser His Val Glu Trp Glu Asp Ala Val His 420 425 430 Ile Ile Pro Glu Asn Glu Ser Asp Asp Glu Glu Glu Glu Glu Lys Gly 435 440 445 Pro Val Ser Pro Arg Asn Leu Gln Glu Ser Glu Glu Glu Glu Val Pro 450 455 460 Gln Glu Ser Trp Asp Glu Gly Tyr Ser Thr Leu Ser Ile Pro Pro Glu 465 470 475 480 Arg Leu Ala Ser Tyr Gln Ser Tyr Ser Ser Thr Phe His Ser Leu Glu 485 490 495 Glu Gln Gln Val Cys Met Ala Val Asp Ile Gly Arg His Arg Trp Asp 500 505 510 Gln Val Lys Lys Glu Asp Gln Glu Ala Thr Gly Pro Arg Leu Ser Arg 515 520 525 Glu Leu Leu Asp Glu Lys Glu Pro Glu Val Leu Gln Asp Ser Leu Asp 530 535 540 Arg Cys Tyr Ser Thr Pro Ser Val Tyr Leu Gly Leu Thr Asp Ser Cys 545 550 555 560 Gln Pro Tyr Arg Ser Ala Phe Tyr Val Leu Glu Gln Gln Arg Ile Gly 565 570 575 Leu Ala Val Asp Met Asp Glu Ile Glu Lys Cys Gln Glu Val Glu Glu 580 585 590 Asp Gln Asp Pro Ser Cys Pro Arg Leu Ser Arg Glu Leu Leu Ala Glu 595 600 605 Lys Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr 610 615 620 Pro Ser Gly Tyr Leu Glu Leu Pro Asp Leu Gly Gln Pro Tyr Ser Ser 625 630 635 640 Ala Val Tyr Ser Leu Glu Glu Gln Tyr Leu Gly Leu Ala Leu Asp Val 645 650 655 Asp Arg Ile Lys Lys Asp Gln Glu Glu Glu Glu Asp Gln Gly Pro Pro 660 665 670 Cys Pro Arg Leu Ser Arg Glu Leu Leu Glu Val Val Glu Pro Glu Val 675 680 685 Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Ser Cys Leu 690 695 700 Glu Gln Pro Asp Ser Cys Gln Pro Tyr Gly Ser Ser Phe Tyr Ala Leu 705 710 715 720 Glu Glu Lys His Val Gly Phe Ser Leu Asp Val Gly Glu Ile Glu Lys 725 730 735 Lys Gly Lys Gly Lys Lys Arg Arg Gly Arg Arg Ser Lys Lys Lys Arg 740 745 750 Arg Lys <210> SEQ ID NO 199 <211> LENGTH: 4444 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <223> OTHER INFORMATION: DKFZp564A057; Genbank AF419616; cDNA clone AG02 <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)..(2796) <400> SEQUENCE: 199 ctt ggc ttg gct cct gac gtg gac aga act aaa aag gac caa gaa gag 48 Leu Gly Leu Ala Pro Asp Val Asp Arg Thr Lys Lys Asp Gln Glu Glu 1 5 10 15 gaa gaa gac caa ggc cca cca tgc ccc agg ctc agc agg gag ctg ctg 96 Glu Glu Asp Gln Gly Pro Pro Cys Pro Arg Leu Ser Arg Glu Leu Leu 20 25 30 gag gta gta gag cct gaa gtc ttg cag gac tca ctg gat aga tgt tat 144 Glu Val Val Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr 35 40 45 tca act cct tcc agt tgt ctt gaa cag cct gac tcc tgc cag ccc tat 192 Ser Thr Pro Ser Ser Cys Leu Glu Gln Pro Asp Ser Cys Gln Pro Tyr 50 55 60 gga agt tcc ttt tat gca ttg gag gaa aaa cat gtt ggc ttt tct ctc 240 Gly Ser Ser Phe Tyr Ala Leu Glu Glu Lys His Val Gly Phe Ser Leu 65 70 75 80 gac gtg gga gaa att gaa aag aag ggg aag ggg aag aaa aga agg gga 288 Asp Val Gly Glu Ile Glu Lys Lys Gly Lys Gly Lys Lys Arg Arg Gly 85 90 95 aga aga tca aag aag gaa aga aga agg gga aga aaa gaa ggg gaa gaa 336 Arg Arg Ser Lys Lys Glu Arg Arg Arg Gly Arg Lys Glu Gly Glu Glu 100 105 110 gat caa aac cca cca tgc ccc agg ctc agc agg gag ctg ctg gat gag 384 Asp Gln Asn Pro Pro Cys Pro Arg Leu Ser Arg Glu Leu Leu Asp Glu 115 120 125 gaa ggg cct gaa gtc ttg cag gac tca ctg gat aga tgt tat tca act 432 Glu Gly Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr 130 135 140 cct tca ggt tgt ctt gaa ctg act gac tca tgc cag ccc tac aga agt 480 Pro Ser Gly Cys Leu Glu Leu Thr Asp Ser Cys Gln Pro Tyr Arg Ser 145 150 155 160 gcc ttt tac gta ttg gag caa cag cgt gtt ggc ttg gct gtt gac atg 528 Ala Phe Tyr Val Leu Glu Gln Gln Arg Val Gly Leu Ala Val Asp Met 165 170 175 gat gaa att gaa aag tac caa gaa gtg gaa gaa gac caa gac cca tca 576 Asp Glu Ile Glu Lys Tyr Gln Glu Val Glu Glu Asp Gln Asp Pro Ser 180 185 190 tgc ccc agg ctc agc agg gag ctg ctg gat gag aaa gag cct gaa gtc 624 Cys Pro Arg Leu Ser Arg Glu Leu Leu Asp Glu Lys Glu Pro Glu Val 195 200 205 ttg cag gac tca ctg gat aga tgt tat tcg act cct tca ggt tgt ctt 672 Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Cys Leu 210 215 220 gaa ctg cct gac tta ggc cag ccc tac agc agt gct gtt tac tca ttg 720 Glu Leu Pro Asp Leu Gly Gln Pro Tyr Ser Ser Ala Val Tyr Ser Leu 225 230 235 240 gag gaa cag tac ctt ggc ttg gct ctt gac gtg gac aga act aaa aag 768 Glu Glu Gln Tyr Leu Gly Leu Ala Leu Asp Val Asp Arg Thr Lys Lys 245 250 255 gac caa gaa gag gaa gaa gac caa ggc cca cca tgc ccc agg ctc agc 816 Asp Gln Glu Glu Glu Glu Asp Gln Gly Pro Pro Cys Pro Arg Leu Ser 260 265 270 agg gag ctg ctg gag gta gta gag cct gaa gtc ttg cag gac tca ctg 864 Arg Glu Leu Leu Glu Val Val Glu Pro Glu Val Leu Gln Asp Ser Leu 275 280 285 gat aga tgt tat tca act cct tcc agt tgt ctt gaa cag cct gac tcc 912 Asp Arg Cys Tyr Ser Thr Pro Ser Ser Cys Leu Glu Gln Pro Asp Ser 290 295 300 tgc cag ccc tat gga agt tcc ttt tat gca ttg gag gaa aaa cat gtt 960 Cys Gln Pro Tyr Gly Ser Ser Phe Tyr Ala Leu Glu Glu Lys His Val 305 310 315 320 ggc ttt tct ctt gac gtg gga gaa att gaa aag aag ggg aag ggg aag 1008 Gly Phe Ser Leu Asp Val Gly Glu Ile Glu Lys Lys Gly Lys Gly Lys 325 330 335 aaa aga agg gga aga aga tca aag aag gaa aga aga ggg gga aga aaa 1056 Lys Arg Arg Gly Arg Arg Ser Lys Lys Glu Arg Arg Gly Gly Arg Lys 340 345 350 gaa ggg gaa gaa gat caa aac cca cca tgc ccc agg ctc agc agg gag 1104 Glu Gly Glu Glu Asp Gln Asn Pro Pro Cys Pro Arg Leu Ser Arg Glu 355 360 365 ctg ctg gat gag aaa ggg cct gaa gtc ttg cag gac tca ctg gat aga 1152 Leu Leu Asp Glu Lys Gly Pro Glu Val Leu Gln Asp Ser Leu Asp Arg 370 375 380 tgt tat tca act cct tca ggt tgt ctt gaa ctg act gac tca tgc cag 1200 Cys Tyr Ser Thr Pro Ser Gly Cys Leu Glu Leu Thr Asp Ser Cys Gln 385 390 395 400 ccc tac aga agt gcc ttt tac gta ttg gag caa cag cgt gtt ggc ttg 1248 Pro Tyr Arg Ser Ala Phe Tyr Val Leu Glu Gln Gln Arg Val Gly Leu 405 410 415 gct gtt gac atg gat gaa att gaa aag tac caa gaa gtg gaa gaa gac 1296 Ala Val Asp Met Asp Glu Ile Glu Lys Tyr Gln Glu Val Glu Glu Asp 420 425 430 caa gac cca tca tgc ccc agg ctc agc agg gag ctg ctg gat gag aaa 1344 Gln Asp Pro Ser Cys Pro Arg Leu Ser Arg Glu Leu Leu Asp Glu Lys 435 440 445 gag cct gaa gtc ttg cag gac tca ctg gat aga tgt tat tcg act cct 1392 Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro 450 455 460 tca ggt tat ctt gaa ctg cct gac tta ggc cag ccc tac agc agt gct 1440 Ser Gly Tyr Leu Glu Leu Pro Asp Leu Gly Gln Pro Tyr Ser Ser Ala 465 470 475 480 gag tac tca ttg gag gaa cag tac ctt ggc ttg gct ctt gac gtg gac 1488 Glu Tyr Ser Leu Glu Glu Gln Tyr Leu Gly Leu Ala Leu Asp Val Asp 485 490 495 aga act aaa aag gac caa gaa gag gaa gaa gac caa ggc cca cca tgc 1536 Arg Thr Lys Lys Asp Gln Glu Glu Glu Glu Asp Gln Gly Pro Pro Cys 500 505 510 ccc agg ctc agc agg gag ctg ctg gag gta gta gag cct gaa gtc ttg 1584 Pro Arg Leu Ser Arg Glu Leu Leu Glu Val Val Glu Pro Glu Val Leu 515 520 525 cag gac tca ctg gat aga tgt tat tca act cct tcc agt tgt ctt gaa 1632 Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Ser Cys Leu Glu 530 535 540 cag cct gac tcc tgc cag ccc tat gga agt tcc ttt tat gca ttg gag 1680 Gln Pro Asp Ser Cys Gln Pro Tyr Gly Ser Ser Phe Tyr Ala Leu Glu 545 550 555 560 gaa aaa cat gtt ggc ttt tct ctc gac gtg gga gaa att gaa aag aag 1728 Glu Lys His Val Gly Phe Ser Leu Asp Val Gly Glu Ile Glu Lys Lys 565 570 575 ggg aag ggg aag aaa aga ggg gga aga aga tca gag aag gaa aga aga 1776 Gly Lys Gly Lys Lys Arg Gly Gly Arg Arg Ser Glu Lys Glu Arg Arg 580 585 590 agg gga aga aaa gaa ggg gaa gaa gat caa aac cca cca tgc ccc agg 1824 Arg Gly Arg Lys Glu Gly Glu Glu Asp Gln Asn Pro Pro Cys Pro Arg 595 600 605 ctc agc agg gag ctg ctg gat gag aaa ggg cct gaa gtc ttg cag gac 1872 Leu Ser Arg Glu Leu Leu Asp Glu Lys Gly Pro Glu Val Leu Gln Asp 610 615 620 tca ctg gat aga tgt tat tca act cct tca ggt tgt ctt gaa ctg act 1920 Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Cys Leu Glu Leu Thr 625 630 635 640 gac tca tgc cag ccc tac aga agt gcc ttt tac gta ttg gag caa cag 1968 Asp Ser Cys Gln Pro Tyr Arg Ser Ala Phe Tyr Val Leu Glu Gln Gln 645 650 655 cgt gtt ggc ttg gct gtt gac atg gat gaa att gaa aag tac caa gaa 2016 Arg Val Gly Leu Ala Val Asp Met Asp Glu Ile Glu Lys Tyr Gln Glu 660 665 670 gtg gaa gaa gac caa gac cca tca tgc ccc agg ctc agc agg gag ctg 2064 Val Glu Glu Asp Gln Asp Pro Ser Cys Pro Arg Leu Ser Arg Glu Leu 675 680 685 ctg gat gag aaa gag cct gaa gtc ttg cag gac tca ctg gat aga tgt 2112 Leu Asp Glu Lys Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys 690 695 700 tat tcg act cct tca ggt tat ctt gaa ctg cct gac tta ggc cag ccc 2160 Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu Pro Asp Leu Gly Gln Pro 705 710 715 720 tac agc agt gct gtt tac tca ttg gag gaa cag tac ctt ggc ttg gct 2208 Tyr Ser Ser Ala Val Tyr Ser Leu Glu Glu Gln Tyr Leu Gly Leu Ala 725 730 735 ctt gac gtg gac aga act aaa aag gac caa gaa gag gaa gaa gac caa 2256 Leu Asp Val Asp Arg Thr Lys Lys Asp Gln Glu Glu Glu Glu Asp Gln 740 745 750 ggc cca cca tgc ccc agg ctc agc agg gag ctg ctg gag gta gta gag 2304 Gly Pro Pro Cys Pro Arg Leu Ser Arg Glu Leu Leu Glu Val Val Glu 755 760 765 cct gaa gtc ttg cag gac tca ctg aat aga tgt tat tca act cct tcc 2352 Pro Glu Val Leu Gln Asp Ser Leu Asn Arg Cys Tyr Ser Thr Pro Ser 770 775 780 agt tgt ctt gaa cag cct gac tcc tgc cag ccc tat gga agt tcc ttt 2400 Ser Cys Leu Glu Gln Pro Asp Ser Cys Gln Pro Tyr Gly Ser Ser Phe 785 790 795 800 tat gca ttg gag gaa aaa cat gtt ggc ttt tct ctt gac gtg gga gaa 2448 Tyr Ala Leu Glu Glu Lys His Val Gly Phe Ser Leu Asp Val Gly Glu 805 810 815 att gaa aag aag ggg aag ggg aag aaa aga agg gga aga aga tca aag 2496 Ile Glu Lys Lys Gly Lys Gly Lys Lys Arg Arg Gly Arg Arg Ser Lys 820 825 830 aag aaa aga aga agg gga aga aaa gaa ggg gaa gaa gat caa aac cca 2544 Lys Lys Arg Arg Arg Gly Arg Lys Glu Gly Glu Glu Asp Gln Asn Pro 835 840 845 cca tgc ccc agg ccc aac ggc gtg ctg atg gaa gtg gaa ggg cct gaa 2592 Pro Cys Pro Arg Pro Asn Gly Val Leu Met Glu Val Glu Gly Pro Glu 850 855 860 gtc tta cag gac tca ctg gat gga tgt tat tct act ccg tca atg tac 2640 Val Leu Gln Asp Ser Leu Asp Gly Cys Tyr Ser Thr Pro Ser Met Tyr 865 870 875 880 ttt gaa cta cct gac tca ttc cag cac tac aga agt gtg ttt tac tca 2688 Phe Glu Leu Pro Asp Ser Phe Gln His Tyr Arg Ser Val Phe Tyr Ser 885 890 895 ttt gag gaa cag cac atc agc ttc gcc ctt tac gtg gac aat agg ttt 2736 Phe Glu Glu Gln His Ile Ser Phe Ala Leu Tyr Val Asp Asn Arg Phe 900 905 910 ttt act ttg acg gtg aca agt ctc cac ctg gtg ttc cag atg gga gtc 2784 Phe Thr Leu Thr Val Thr Ser Leu His Leu Val Phe Gln Met Gly Val 915 920 925 ata ttc cca caa taaacagccc ttactaagcc gagagatgtc attcctgcag 2836 Ile Phe Pro Gln 930 gcaggaccta taggcacgtg aagatttgaa tgaaagtaca gttccatttg gaagcccaga 2896 cataggatgg gtcagtgggc atggctgtat tcctattctc aaaccatgcc agtggcaacc 2956 tgtgctcagt ctgaagacaa tggacccacg ttaggtgtga cacgttcaca taactgtgca 3016 gcacatgccg ggagtgatca gtcagacatt ttaatttgaa ccacgtatct ctgggtagct 3076 acaaaattcc tcagggattt cattttgcag gcatgtctct gagcttctat acctgctcaa 3136 ggtcattgtc atctttgtgt ttagctcatc caaaggtgtt accctggttt caatgaacct 3196 aacctcattc tttgtgtctt cagtgttggc ttgttttagc tgatccatct gtaacacagg 3256 agggatccct ggttgaggat tgtatttcag aaccaccaac tgctcttgac aattgttaac 3316 ccgctaggct cctttggtta gagaagccac agtccttcag cctccaattg gtgtcagtac 3376 ttaggaagac cacagctaga tggacaaaca gcattgggag gccttagccc tgctcctctc 3436 aattccatcc tgtagagaac aggagtcagg agccgctggc aggagacagc atgtcaccca 3496 ggactctgcc ggtgcagaat atgaacagtg ccatgttctt gcagaaaacg cttagcctga 3556 gtttcatagg aggtaatcac cagacaactg cagaatgtgg aacactgagc gggacagctg 3616 acctgtctcc ttcacatagt ccatgtcacc acaaatcaca caacaaaaag gagaagagat 3676 attttgggtt caaaaaacgt aaaaagataa tgtagctgca tttctttagt tattttgggc 3736 cccaaatatt tcctcatctt tttgttgttg tcatggatgg tggtgacatg gacttgttta 3796 tagaggacag gtcagctgtc tggctcagtg atctacattc tgaagttgtc tgaaaatgtc 3856 ttcatgatta aattcagcct aaacgttttg ccgggaacac tgcagagaca atgctgtgag 3916 tttccaacct cagcccatct gcgggcagag aaggtctagt ttgtccatca ccattatgat 3976 atcaggactg gttacttggt taaggagggg tctaggagat ctgtcccttt tagagacacc 4036 ttacttataa tgaagaagta cttgggaaag cggttttcaa gagtataaat atcctgtatt 4096 ctaatgatca tcctctaaac attttatcat ttattaatcc tccctgcctg tgtctattat 4156 tatattcata tctctacact gcaaattttg ggtctcaatt tttactgtgc ctttgttttt 4216 actagtgtct gctgttgcaa aaagaaggag acattctctg cctgagtttt aatttttgtc 4276 caaagttaat tttaatctat acaattaaaa ccttttgcct atcactctgg acttctggat 4336 tgttttttac attcagtgtt ataatatttg attatgctga ttggttttgg tgggtactga 4396 tgcgaattaa taaaaacatt tcatttccaa aaaaaaaaaa aaaaaaaa 4444 <210> SEQ ID NO 200 <211> LENGTH: 932 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <223> OTHER INFORMATION: DKFZp564A057; Genbank AF419616; cDNA clone AG02 <400> SEQUENCE: 200 Leu Gly Leu Ala Pro Asp Val Asp Arg Thr Lys Lys Asp Gln Glu Glu 1 5 10 15 Glu Glu Asp Gln Gly Pro Pro Cys Pro Arg Leu Ser Arg Glu Leu Leu 20 25 30 Glu Val Val Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr 35 40 45 Ser Thr Pro Ser Ser Cys Leu Glu Gln Pro Asp Ser Cys Gln Pro Tyr 50 55 60 Gly Ser Ser Phe Tyr Ala Leu Glu Glu Lys His Val Gly Phe Ser Leu 65 70 75 80 Asp Val Gly Glu Ile Glu Lys Lys Gly Lys Gly Lys Lys Arg Arg Gly 85 90 95 Arg Arg Ser Lys Lys Glu Arg Arg Arg Gly Arg Lys Glu Gly Glu Glu 100 105 110 Asp Gln Asn Pro Pro Cys Pro Arg Leu Ser Arg Glu Leu Leu Asp Glu 115 120 125 Glu Gly Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr 130 135 140 Pro Ser Gly Cys Leu Glu Leu Thr Asp Ser Cys Gln Pro Tyr Arg Ser 145 150 155 160 Ala Phe Tyr Val Leu Glu Gln Gln Arg Val Gly Leu Ala Val Asp Met 165 170 175 Asp Glu Ile Glu Lys Tyr Gln Glu Val Glu Glu Asp Gln Asp Pro Ser 180 185 190 Cys Pro Arg Leu Ser Arg Glu Leu Leu Asp Glu Lys Glu Pro Glu Val 195 200 205 Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Cys Leu 210 215 220 Glu Leu Pro Asp Leu Gly Gln Pro Tyr Ser Ser Ala Val Tyr Ser Leu 225 230 235 240 Glu Glu Gln Tyr Leu Gly Leu Ala Leu Asp Val Asp Arg Thr Lys Lys 245 250 255 Asp Gln Glu Glu Glu Glu Asp Gln Gly Pro Pro Cys Pro Arg Leu Ser 260 265 270 Arg Glu Leu Leu Glu Val Val Glu Pro Glu Val Leu Gln Asp Ser Leu 275 280 285 Asp Arg Cys Tyr Ser Thr Pro Ser Ser Cys Leu Glu Gln Pro Asp Ser 290 295 300 Cys Gln Pro Tyr Gly Ser Ser Phe Tyr Ala Leu Glu Glu Lys His Val 305 310 315 320 Gly Phe Ser Leu Asp Val Gly Glu Ile Glu Lys Lys Gly Lys Gly Lys 325 330 335 Lys Arg Arg Gly Arg Arg Ser Lys Lys Glu Arg Arg Gly Gly Arg Lys 340 345 350 Glu Gly Glu Glu Asp Gln Asn Pro Pro Cys Pro Arg Leu Ser Arg Glu 355 360 365 Leu Leu Asp Glu Lys Gly Pro Glu Val Leu Gln Asp Ser Leu Asp Arg 370 375 380 Cys Tyr Ser Thr Pro Ser Gly Cys Leu Glu Leu Thr Asp Ser Cys Gln 385 390 395 400 Pro Tyr Arg Ser Ala Phe Tyr Val Leu Glu Gln Gln Arg Val Gly Leu 405 410 415 Ala Val Asp Met Asp Glu Ile Glu Lys Tyr Gln Glu Val Glu Glu Asp 420 425 430 Gln Asp Pro Ser Cys Pro Arg Leu Ser Arg Glu Leu Leu Asp Glu Lys 435 440 445 Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro 450 455 460 Ser Gly Tyr Leu Glu Leu Pro Asp Leu Gly Gln Pro Tyr Ser Ser Ala 465 470 475 480 Glu Tyr Ser Leu Glu Glu Gln Tyr Leu Gly Leu Ala Leu Asp Val Asp 485 490 495 Arg Thr Lys Lys Asp Gln Glu Glu Glu Glu Asp Gln Gly Pro Pro Cys 500 505 510 Pro Arg Leu Ser Arg Glu Leu Leu Glu Val Val Glu Pro Glu Val Leu 515 520 525 Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Ser Cys Leu Glu 530 535 540 Gln Pro Asp Ser Cys Gln Pro Tyr Gly Ser Ser Phe Tyr Ala Leu Glu 545 550 555 560 Glu Lys His Val Gly Phe Ser Leu Asp Val Gly Glu Ile Glu Lys Lys 565 570 575 Gly Lys Gly Lys Lys Arg Gly Gly Arg Arg Ser Glu Lys Glu Arg Arg 580 585 590 Arg Gly Arg Lys Glu Gly Glu Glu Asp Gln Asn Pro Pro Cys Pro Arg 595 600 605 Leu Ser Arg Glu Leu Leu Asp Glu Lys Gly Pro Glu Val Leu Gln Asp 610 615 620 Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Cys Leu Glu Leu Thr 625 630 635 640 Asp Ser Cys Gln Pro Tyr Arg Ser Ala Phe Tyr Val Leu Glu Gln Gln 645 650 655 Arg Val Gly Leu Ala Val Asp Met Asp Glu Ile Glu Lys Tyr Gln Glu 660 665 670 Val Glu Glu Asp Gln Asp Pro Ser Cys Pro Arg Leu Ser Arg Glu Leu 675 680 685 Leu Asp Glu Lys Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys 690 695 700 Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu Pro Asp Leu Gly Gln Pro 705 710 715 720 Tyr Ser Ser Ala Val Tyr Ser Leu Glu Glu Gln Tyr Leu Gly Leu Ala 725 730 735 Leu Asp Val Asp Arg Thr Lys Lys Asp Gln Glu Glu Glu Glu Asp Gln 740 745 750 Gly Pro Pro Cys Pro Arg Leu Ser Arg Glu Leu Leu Glu Val Val Glu 755 760 765 Pro Glu Val Leu Gln Asp Ser Leu Asn Arg Cys Tyr Ser Thr Pro Ser 770 775 780 Ser Cys Leu Glu Gln Pro Asp Ser Cys Gln Pro Tyr Gly Ser Ser Phe 785 790 795 800 Tyr Ala Leu Glu Glu Lys His Val Gly Phe Ser Leu Asp Val Gly Glu 805 810 815 Ile Glu Lys Lys Gly Lys Gly Lys Lys Arg Arg Gly Arg Arg Ser Lys 820 825 830 Lys Lys Arg Arg Arg Gly Arg Lys Glu Gly Glu Glu Asp Gln Asn Pro 835 840 845 Pro Cys Pro Arg Pro Asn Gly Val Leu Met Glu Val Glu Gly Pro Glu 850 855 860 Val Leu Gln Asp Ser Leu Asp Gly Cys Tyr Ser Thr Pro Ser Met Tyr 865 870 875 880 Phe Glu Leu Pro Asp Ser Phe Gln His Tyr Arg Ser Val Phe Tyr Ser 885 890 895 Phe Glu Glu Gln His Ile Ser Phe Ala Leu Tyr Val Asp Asn Arg Phe 900 905 910 Phe Thr Leu Thr Val Thr Ser Leu His Leu Val Phe Gln Met Gly Val 915 920 925 Ile Phe Pro Gln 930 <210> SEQ ID NO 201 <211> LENGTH: 5166 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <223> OTHER INFORMATION: Full-size DNA sequence of representative NBG gene <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (55)..(5166) <400> SEQUENCE: 201 gatcacattt ttcacaacat ccctgactcc acctcttctg ccacaaacgt cagc atg 57 Met 1 gtg gta tca gcc ggc cct tgg tcc agc gag aag gca gag atg aac att 105 Val Val Ser Ala Gly Pro Trp Ser Ser Glu Lys Ala Glu Met Asn Ile 5 10 15 cta gaa atc aac gag aaa ttg cgc ccc cag ttg gca gag aac aaa cag 153 Leu Glu Ile Asn Glu Lys Leu Arg Pro Gln Leu Ala Glu Asn Lys Gln 20 25 30 cag ttc aga aac ctc aaa gag aga tgt ttt cta act caa ctg gcc ggc 201 Gln Phe Arg Asn Leu Lys Glu Arg Cys Phe Leu Thr Gln Leu Ala Gly 35 40 45 ttc ctg gcc aac cga cag aag aaa tac aag tat gaa gag tgt aaa gac 249 Phe Leu Ala Asn Arg Gln Lys Lys Tyr Lys Tyr Glu Glu Cys Lys Asp 50 55 60 65 ctc ata aaa ttt atg ctg agg aat gag cga cag ttc aag gag gag aag 297 Leu Ile Lys Phe Met Leu Arg Asn Glu Arg Gln Phe Lys Glu Glu Lys 70 75 80 ctt gca gag cag ctg aaa caa gct gag gag ctc agg caa tat aaa gtc 345 Leu Ala Glu Gln Leu Lys Gln Ala Glu Glu Leu Arg Gln Tyr Lys Val 85 90 95 ctg gtt cac tct cag gaa cga gag ctg acc cag tta agg gag aag tta 393 Leu Val His Ser Gln Glu Arg Glu Leu Thr Gln Leu Arg Glu Lys Leu 100 105 110 cgg gaa ggg aga gat gcc tcc cgc tca ttg aat gag cat ctc cag gcc 441 Arg Glu Gly Arg Asp Ala Ser Arg Ser Leu Asn Glu His Leu Gln Ala 115 120 125 ctc ctc act ccg gat gag ccg gac aag tcc cag ggg cag gac ctc caa 489 Leu Leu Thr Pro Asp Glu Pro Asp Lys Ser Gln Gly Gln Asp Leu Gln 130 135 140 145 gaa cag ctg gct gag ggg tgt aga ctg gca cag caa ctt gtc caa aag 537 Glu Gln Leu Ala Glu Gly Cys Arg Leu Ala Gln Gln Leu Val Gln Lys 150 155 160 ctc agc cca gaa aat gat gaa gat gag gat gaa gat gtt caa gtt gag 585 Leu Ser Pro Glu Asn Asp Glu Asp Glu Asp Glu Asp Val Gln Val Glu 165 170 175 gag gat gag aaa gta ctg gaa tca tct gcc ccc agg gag gtg cag aag 633 Glu Asp Glu Lys Val Leu Glu Ser Ser Ala Pro Arg Glu Val Gln Lys 180 185 190 gct gaa gag agc aaa gtc cct gag gac tca ctg gag gaa tgt gcc atc 681 Ala Glu Glu Ser Lys Val Pro Glu Asp Ser Leu Glu Glu Cys Ala Ile 195 200 205 act tgt tca aat agc cac ggc cct tgt gac tcc aac cag cct cac aag 729 Thr Cys Ser Asn Ser His Gly Pro Cys Asp Ser Asn Gln Pro His Lys 210 215 220 225 aac atc aaa atc aca ttt gag gaa gac aaa gtc aac tca act gtg gtt 777 Asn Ile Lys Ile Thr Phe Glu Glu Asp Lys Val Asn Ser Thr Val Val 230 235 240 gta gac aga aaa tcc tct cat gat gaa tgt cag gat gct cta aac att 825 Val Asp Arg Lys Ser Ser His Asp Glu Cys Gln Asp Ala Leu Asn Ile 245 250 255 ctc cca gtc cct ggc ccc acc tct tct gcc aca aac gtc agc atg gtg 873 Leu Pro Val Pro Gly Pro Thr Ser Ser Ala Thr Asn Val Ser Met Val 260 265 270 gta tca gcc ggc cct ttg tcc agc gag aag gca gag atg aac att cta 921 Val Ser Ala Gly Pro Leu Ser Ser Glu Lys Ala Glu Met Asn Ile Leu 275 280 285 gaa atc aat gag aag ttg cgc ccc cag ctg gca gag aag aaa cag cag 969 Glu Ile Asn Glu Lys Leu Arg Pro Gln Leu Ala Glu Lys Lys Gln Gln 290 295 300 305 ttc aga agc ctc aaa gag aaa tgt ttt gta act caa ctg gcc ggc ttc 1017 Phe Arg Ser Leu Lys Glu Lys Cys Phe Val Thr Gln Leu Ala Gly Phe 310 315 320 ctg gcc aag cag cag aac aaa tac aaa tat gaa gag tgc aaa gac ctc 1065 Leu Ala Lys Gln Gln Asn Lys Tyr Lys Tyr Glu Glu Cys Lys Asp Leu 325 330 335 ata aaa tct atg ctg agg aat gag cta cag ttc aag gag gag aag ctt 1113 Ile Lys Ser Met Leu Arg Asn Glu Leu Gln Phe Lys Glu Glu Lys Leu 340 345 350 gca gag cag ctg aag caa gct gag gag ctc agg caa tat aaa gtc ctg 1161 Ala Glu Gln Leu Lys Gln Ala Glu Glu Leu Arg Gln Tyr Lys Val Leu 355 360 365 gtt cac tct cag gaa cga gag ctg acc cag tta agg gag aag tta cgg 1209 Val His Ser Gln Glu Arg Glu Leu Thr Gln Leu Arg Glu Lys Leu Arg 370 375 380 385 gaa ggg aga gat gcc tcc cgc tca ttg aat gag cat ctc cag gcc ctc 1257 Glu Gly Arg Asp Ala Ser Arg Ser Leu Asn Glu His Leu Gln Ala Leu 390 395 400 ctc act ccg gat gag ccg gac aag tcc cag ggg cag gac ctc caa gaa 1305 Leu Thr Pro Asp Glu Pro Asp Lys Ser Gln Gly Gln Asp Leu Gln Glu 405 410 415 cag ctg gct gag ggg tgt aga ctg gca cag cac ctt gtc caa aag ctc 1353 Gln Leu Ala Glu Gly Cys Arg Leu Ala Gln His Leu Val Gln Lys Leu 420 425 430 agc cca gaa aat gat gaa gat gag gat gaa gat gtt caa gtt gag gag 1401 Ser Pro Glu Asn Asp Glu Asp Glu Asp Glu Asp Val Gln Val Glu Glu 435 440 445 gat gag aaa gtg ctg gaa tca tct tcc ccc agg gag atg cag aag gct 1449 Asp Glu Lys Val Leu Glu Ser Ser Ser Pro Arg Glu Met Gln Lys Ala 450 455 460 465 gaa gaa agc aaa gtc cct gag gac tca ctg gag gaa tgt gcc atc act 1497 Glu Glu Ser Lys Val Pro Glu Asp Ser Leu Glu Glu Cys Ala Ile Thr 470 475 480 tgt tca aat agc cac ggc cct tgt gac tcc aac cag cct cac aag aac 1545 Cys Ser Asn Ser His Gly Pro Cys Asp Ser Asn Gln Pro His Lys Asn 485 490 495 atc aaa atc aca ttt gag gaa gac aaa gtc aac tca tct ctg gtt gta 1593 Ile Lys Ile Thr Phe Glu Glu Asp Lys Val Asn Ser Ser Leu Val Val 500 505 510 gac aga gaa tcc tct cat gat gaa tgt cag gat gct cta aac att ctc 1641 Asp Arg Glu Ser Ser His Asp Glu Cys Gln Asp Ala Leu Asn Ile Leu 515 520 525 cca gtc cct ggc ccc acc tct tct gcc aca aac gtc agc atg gtg gta 1689 Pro Val Pro Gly Pro Thr Ser Ser Ala Thr Asn Val Ser Met Val Val 530 535 540 545 tca gcc ggc cct ttg tcc agc gag aag gca gag atg aac att cta gaa 1737 Ser Ala Gly Pro Leu Ser Ser Glu Lys Ala Glu Met Asn Ile Leu Glu 550 555 560 atc aat gag aag ttg cgc ccc cag ctg gca gag aag aaa cag cag ttc 1785 Ile Asn Glu Lys Leu Arg Pro Gln Leu Ala Glu Lys Lys Gln Gln Phe 565 570 575 aga agc ctc aaa gag aaa tgt ttt gta act caa gtg gcc tgc ttc ctg 1833 Arg Ser Leu Lys Glu Lys Cys Phe Val Thr Gln Val Ala Cys Phe Leu 580 585 590 gcc aag cag cag aac aaa tac aaa tat gaa gag tgc aaa gac ctc ata 1881 Ala Lys Gln Gln Asn Lys Tyr Lys Tyr Glu Glu Cys Lys Asp Leu Ile 595 600 605 aaa tct atg ctg agg aat gag cta cag ttc aag gag gag aag ctt gca 1929 Lys Ser Met Leu Arg Asn Glu Leu Gln Phe Lys Glu Glu Lys Leu Ala 610 615 620 625 gag cag ctg aag caa gct gag gag ctc agg caa tat aaa gtc ctg gtt 1977 Glu Gln Leu Lys Gln Ala Glu Glu Leu Arg Gln Tyr Lys Val Leu Val 630 635 640 cac tct cag gaa cga gag ctg acc cag tta agg gag aag tta cgg gaa 2025 His Ser Gln Glu Arg Glu Leu Thr Gln Leu Arg Glu Lys Leu Arg Glu 645 650 655 ggg aga gat gcc tcc cgc tca ttg aat gag cat ctc cag gcc ctc ctc 2073 Gly Arg Asp Ala Ser Arg Ser Leu Asn Glu His Leu Gln Ala Leu Leu 660 665 670 act ccg gat gag ccg gac aag tcc cag ggg cag gac ctc caa gaa cag 2121 Thr Pro Asp Glu Pro Asp Lys Ser Gln Gly Gln Asp Leu Gln Glu Gln 675 680 685 ctg gct gag ggg tgt aga ctg gca caa cac ctt gtc caa aag ctc agc 2169 Leu Ala Glu Gly Cys Arg Leu Ala Gln His Leu Val Gln Lys Leu Ser 690 695 700 705 cca gaa aat gat aac gat gac gat gaa gat gtt caa gtt gag gtg gct 2217 Pro Glu Asn Asp Asn Asp Asp Asp Glu Asp Val Gln Val Glu Val Ala 710 715 720 gag aaa gtg cag aaa tcg tct tcc ccc agg gag atg cag aag gct gaa 2265 Glu Lys Val Gln Lys Ser Ser Ser Pro Arg Glu Met Gln Lys Ala Glu 725 730 735 gaa aag gaa gtc cct gag gac tca ctg gag gag tgt gcc atc act tgt 2313 Glu Lys Glu Val Pro Glu Asp Ser Leu Glu Glu Cys Ala Ile Thr Cys 740 745 750 tca aat agc cat ggc cct tat tac tcc aac cag cca cat agg aaa acc 2361 Ser Asn Ser His Gly Pro Tyr Tyr Ser Asn Gln Pro His Arg Lys Thr 755 760 765 aaa atc aca ttt gag gaa gac aaa gtc gac tca act ctc att ggc tca 2409 Lys Ile Thr Phe Glu Glu Asp Lys Val Asp Ser Thr Leu Ile Gly Ser 770 775 780 785 tcc tct cat gtt gaa tgg gag gat gct gta cac att atc cca gaa aat 2457 Ser Ser His Val Glu Trp Glu Asp Ala Val His Ile Ile Pro Glu Asn 790 795 800 gaa agt gat gat gag gaa gag gaa gaa aaa ggg cca gtg tct ccc agg 2505 Glu Ser Asp Asp Glu Glu Glu Glu Glu Lys Gly Pro Val Ser Pro Arg 805 810 815 aat ctg cag gag tct gaa gag gag gaa gtc ccc cag gag tcc tgg gat 2553 Asn Leu Gln Glu Ser Glu Glu Glu Glu Val Pro Gln Glu Ser Trp Asp 820 825 830 gaa ggt tat tcg act ctc tca att cct cct gaa atg ttg gcc tcg tac 2601 Glu Gly Tyr Ser Thr Leu Ser Ile Pro Pro Glu Met Leu Ala Ser Tyr 835 840 845 cag tct tac agc ggc aca ttt cac tca tta gag gaa cag caa gtc tgc 2649 Gln Ser Tyr Ser Gly Thr Phe His Ser Leu Glu Glu Gln Gln Val Cys 850 855 860 865 atg gct gtt gac ata ggc gga cat cgg tgg gat caa gtg aaa aag gag 2697 Met Ala Val Asp Ile Gly Gly His Arg Trp Asp Gln Val Lys Lys Glu 870 875 880 gac caa gag gca aca ggt ccc agg ctc agc agg gag ctg ctg gat gag 2745 Asp Gln Glu Ala Thr Gly Pro Arg Leu Ser Arg Glu Leu Leu Asp Glu 885 890 895 aaa ggg cct gaa gtc ttg cag gac tca ctg gat aga tgt tat tca act 2793 Lys Gly Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr 900 905 910 cct tca ggt tat ctt gaa ctg act gac tca tgc cag ccc tac aga agt 2841 Pro Ser Gly Tyr Leu Glu Leu Thr Asp Ser Cys Gln Pro Tyr Arg Ser 915 920 925 gcc ttt tac ata ttg gag caa cag cgt gtt ggc tgg gct ctt gac atg 2889 Ala Phe Tyr Ile Leu Glu Gln Gln Arg Val Gly Trp Ala Leu Asp Met 930 935 940 945 gat gaa att gaa aag tac caa gaa gtg gaa gaa gac caa gac cca tca 2937 Asp Glu Ile Glu Lys Tyr Gln Glu Val Glu Glu Asp Gln Asp Pro Ser 950 955 960 tgc ccc agg ctc agc agg gag ctg ctg gat gag aaa gag cct gaa gtc 2985 Cys Pro Arg Leu Ser Arg Glu Leu Leu Asp Glu Lys Glu Pro Glu Val 965 970 975 ttg cag gac tcc ctg gat aga tgt tat tcg act cct tca ggt tat ctt 3033 Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Tyr Leu 980 985 990 gaa ctg cct gac tta ggc cag ccc tac aga agt gct gtt tac tca ttg 3081 Glu Leu Pro Asp Leu Gly Gln Pro Tyr Arg Ser Ala Val Tyr Ser Leu 995 1000 1005 gag gaa cag tac ctt ggc ttg gct ctt gac gtg gac aga att aaa aag 3129 Glu Glu Gln Tyr Leu Gly Leu Ala Leu Asp Val Asp Arg Ile Lys Lys 1010 1015 1020 1025 gac caa gaa gag gaa gaa gac caa ggc cca cca tgc ccc agg ctc agc 3177 Asp Gln Glu Glu Glu Glu Asp Gln Gly Pro Pro Cys Pro Arg Leu Ser 1030 1035 1040 agg gag ctg ctg gag gca gta gag cct gaa gtc ttg cag gac tca ctg 3225 Arg Glu Leu Leu Glu Ala Val Glu Pro Glu Val Leu Gln Asp Ser Leu 1045 1050 1055 gat aga tgt tat tca act cct tcc agt tgt ctt gaa cag cct gac tcc 3273 Asp Arg Cys Tyr Ser Thr Pro Ser Ser Cys Leu Glu Gln Pro Asp Ser 1060 1065 1070 tgc ctg ccc tat gga agt tcc ttt tat gca ttg gag gaa aaa cat gtt 3321 Cys Leu Pro Tyr Gly Ser Ser Phe Tyr Ala Leu Glu Glu Lys His Val 1075 1080 1085 ggc ttt tct ctt gac gtg gga gaa att gaa aag aag ggg aag ggg aag 3369 Gly Phe Ser Leu Asp Val Gly Glu Ile Glu Lys Lys Gly Lys Gly Lys 1090 1095 1100 1105 aaa aga agg gga aga aga tca acg aag aaa aga agg aga agg gga aga 3417 Lys Arg Arg Gly Arg Arg Ser Thr Lys Lys Arg Arg Arg Arg Gly Arg 1110 1115 1120 aaa gaa ggg gaa gaa gat caa aac cca cca tgc ccc agg ctc agc agg 3465 Lys Glu Gly Glu Glu Asp Gln Asn Pro Pro Cys Pro Arg Leu Ser Arg 1125 1130 1135 gag ctg ctg gat gag aaa ggg cct gaa gtc ttg cag gac tca ctg gat 3513 Glu Leu Leu Asp Glu Lys Gly Pro Glu Val Leu Gln Asp Ser Leu Asp 1140 1145 1150 aga tgt tat tca act cct tca ggt tat ctt gaa ctg act gac tca tgc 3561 Arg Cys Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu Thr Asp Ser Cys 1155 1160 1165 cag ccc tac aga agt gcc ttt tac ata ttg gag caa cag cgt gtt ggc 3609 Gln Pro Tyr Arg Ser Ala Phe Tyr Ile Leu Glu Gln Gln Arg Val Gly 1170 1175 1180 1185 tgg gct ctt gac atg gat gaa att gaa aag tac caa gaa gtg gaa gaa 3657 Trp Ala Leu Asp Met Asp Glu Ile Glu Lys Tyr Gln Glu Val Glu Glu 1190 1195 1200 gac caa gac cca tca tgc ccc agg ctc agc agg gag ctg ctg gat gag 3705 Asp Gln Asp Pro Ser Cys Pro Arg Leu Ser Arg Glu Leu Leu Asp Glu 1205 1210 1215 aaa gag cct gaa gtc ttg cag gac tcc ctg gat aga tgt tat tcg act 3753 Lys Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr 1220 1225 1230 cct tca ggt tat ctt gaa ctg cct gac tta ggc cag ccc tac aga agt 3801 Pro Ser Gly Tyr Leu Glu Leu Pro Asp Leu Gly Gln Pro Tyr Arg Ser 1235 1240 1245 gct gtt tac tca ttg gag gaa cag tac ctt ggc ttg gct ctt gac gtg 3849 Ala Val Tyr Ser Leu Glu Glu Gln Tyr Leu Gly Leu Ala Leu Asp Val 1250 1255 1260 1265 gac aga att aaa aag gac cag gaa gag gaa gaa gac caa ggc cca cca 3897 Asp Arg Ile Lys Lys Asp Gln Glu Glu Glu Glu Asp Gln Gly Pro Pro 1270 1275 1280 tgc ccc agg ctc agc agg gag ctg ctg gag gca gta gag cct gaa gtc 3945 Cys Pro Arg Leu Ser Arg Glu Leu Leu Glu Ala Val Glu Pro Glu Val 1285 1290 1295 ttg cag gac tca ctg gat aga tgt tat tca act cct tcc agt tgt ctt 3993 Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Ser Cys Leu 1300 1305 1310 gaa cag cct gac tcc tgc ctg ccc tat gga agt tcc ttt tat gca ttg 4041 Glu Gln Pro Asp Ser Cys Leu Pro Tyr Gly Ser Ser Phe Tyr Ala Leu 1315 1320 1325 gag gaa aaa cat gtt ggc ttt tct ctt gac gtg gga gaa att gaa aag 4089 Glu Glu Lys His Val Gly Phe Ser Leu Asp Val Gly Glu Ile Glu Lys 1330 1335 1340 1345 aag ggg aag ggg aag aaa aga agg gga aga aga tca acg aag aaa aga 4137 Lys Gly Lys Gly Lys Lys Arg Arg Gly Arg Arg Ser Thr Lys Lys Arg 1350 1355 1360 agg aga agg gga aga aaa gaa ggg gaa gaa gat caa aac cca cca tgc 4185 Arg Arg Arg Gly Arg Lys Glu Gly Glu Glu Asp Gln Asn Pro Pro Cys 1365 1370 1375 ccc agg ctc agc agg gag ctg ctg gat gag aaa ggg cct gaa gtc ttg 4233 Pro Arg Leu Ser Arg Glu Leu Leu Asp Glu Lys Gly Pro Glu Val Leu 1380 1385 1390 cag gac tca ctg gat aga tgt tat tca act cct tca ggt tat ctt gaa 4281 Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Tyr Leu Glu 1395 1400 1405 ctg act gac tca tgc cag ccc tac aga agt gcc ttt tac ata ttg gag 4329 Leu Thr Asp Ser Cys Gln Pro Tyr Arg Ser Ala Phe Tyr Ile Leu Glu 1410 1415 1420 1425 caa cag cgt gtt ggc tgg gct ctt gac atg gat gaa att gaa aag tac 4377 Gln Gln Arg Val Gly Trp Ala Leu Asp Met Asp Glu Ile Glu Lys Tyr 1430 1435 1440 caa gaa gtg gaa gaa gac caa gac cca tca tgc ccc agg ctc agc agg 4425 Gln Glu Val Glu Glu Asp Gln Asp Pro Ser Cys Pro Arg Leu Ser Arg 1445 1450 1455 gag ctg ctg gat gag aaa gag cct gaa gtc ttg cag gac tcc ctg gat 4473 Glu Leu Leu Asp Glu Lys Glu Pro Glu Val Leu Gln Asp Ser Leu Asp 1460 1465 1470 aga tgt tat tcg act cct tca ggt tat ctt gaa ctg cct gac tta ggc 4521 Arg Cys Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu Pro Asp Leu Gly 1475 1480 1485 cag ccc tac aga agt gct gtt tac tca ttg gag gaa cag tac ctt ggc 4569 Gln Pro Tyr Arg Ser Ala Val Tyr Ser Leu Glu Glu Gln Tyr Leu Gly 1490 1495 1500 1505 ttg gct ctt gac gtg gac aga att aaa aag gac cag gaa gag gaa gaa 4617 Leu Ala Leu Asp Val Asp Arg Ile Lys Lys Asp Gln Glu Glu Glu Glu 1510 1515 1520 gac caa ggc cca cca tgc ccc agg ctc agc agg gag ctg ctg gag gca 4665 Asp Gln Gly Pro Pro Cys Pro Arg Leu Ser Arg Glu Leu Leu Glu Ala 1525 1530 1535 gta gag cct gaa gtc ttg cag gac tca ctg gat aga tgt tat tca act 4713 Val Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr 1540 1545 1550 cct tcc agt tgt ctt gaa cag cct gac tcc tgc ctg ccc tat gga agt 4761 Pro Ser Ser Cys Leu Glu Gln Pro Asp Ser Cys Leu Pro Tyr Gly Ser 1555 1560 1565 tcc ttt tat gca ttg gag gaa aaa cat gtt ggc ttt tct ctt gac gtg 4809 Ser Phe Tyr Ala Leu Glu Glu Lys His Val Gly Phe Ser Leu Asp Val 1570 1575 1580 1585 gga gaa att gaa aag aag ggg aag ggg aag aaa aga agg gga aga aga 4857 Gly Glu Ile Glu Lys Lys Gly Lys Gly Lys Lys Arg Arg Gly Arg Arg 1590 1595 1600 tca acg aag aaa aga agg aga agg gga aga aaa gaa ggg gaa gaa gat 4905 Ser Thr Lys Lys Arg Arg Arg Arg Gly Arg Lys Glu Gly Glu Glu Asp 1605 1610 1615 caa aac cca cca tgc ccc agg ctc agc ggt gtg ctg atg gaa gtg gaa 4953 Gln Asn Pro Pro Cys Pro Arg Leu Ser Gly Val Leu Met Glu Val Glu 1620 1625 1630 gag cct gaa atc ttg cag gac tca ctg gat aga tgt tat tcg act ccg 5001 Glu Pro Glu Ile Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro 1635 1640 1645 tca atg ttc ttt gaa cta cct gac tca ttc cag cac tac aga agt gtg 5049 Ser Met Phe Phe Glu Leu Pro Asp Ser Phe Gln His Tyr Arg Ser Val 1650 1655 1660 1665 ttt tac tca ttt gag gaa cag cac atc agc ttc gcc ctt gac gtg gac 5097 Phe Tyr Ser Phe Glu Glu Gln His Ile Ser Phe Ala Leu Asp Val Asp 1670 1675 1680 aat agg ttt ctt act ttg atg gga aca agt ctc cac ctg gtc ttc cag 5145 Asn Arg Phe Leu Thr Leu Met Gly Thr Ser Leu His Leu Val Phe Gln 1685 1690 1695 atg gga gtc ata ttc cca cag 5166 Met Gly Val Ile Phe Pro Gln 1700 <210> SEQ ID NO 202 <211> LENGTH: 1704 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <223> OTHER INFORMATION: Full-size DNA sequence of representative NBG gene <400> SEQUENCE: 202 Met Val Val Ser Ala Gly Pro Trp Ser Ser Glu Lys Ala Glu Met Asn 1 5 10 15 Ile Leu Glu Ile Asn Glu Lys Leu Arg Pro Gln Leu Ala Glu Asn Lys 20 25 30 Gln Gln Phe Arg Asn Leu Lys Glu Arg Cys Phe Leu Thr Gln Leu Ala 35 40 45 Gly Phe Leu Ala Asn Arg Gln Lys Lys Tyr Lys Tyr Glu Glu Cys Lys 50 55 60 Asp Leu Ile Lys Phe Met Leu Arg Asn Glu Arg Gln Phe Lys Glu Glu 65 70 75 80 Lys Leu Ala Glu Gln Leu Lys Gln Ala Glu Glu Leu Arg Gln Tyr Lys 85 90 95 Val Leu Val His Ser Gln Glu Arg Glu Leu Thr Gln Leu Arg Glu Lys 100 105 110 Leu Arg Glu Gly Arg Asp Ala Ser Arg Ser Leu Asn Glu His Leu Gln 115 120 125 Ala Leu Leu Thr Pro Asp Glu Pro Asp Lys Ser Gln Gly Gln Asp Leu 130 135 140 Gln Glu Gln Leu Ala Glu Gly Cys Arg Leu Ala Gln Gln Leu Val Gln 145 150 155 160 Lys Leu Ser Pro Glu Asn Asp Glu Asp Glu Asp Glu Asp Val Gln Val 165 170 175 Glu Glu Asp Glu Lys Val Leu Glu Ser Ser Ala Pro Arg Glu Val Gln 180 185 190 Lys Ala Glu Glu Ser Lys Val Pro Glu Asp Ser Leu Glu Glu Cys Ala 195 200 205 Ile Thr Cys Ser Asn Ser His Gly Pro Cys Asp Ser Asn Gln Pro His 210 215 220 Lys Asn Ile Lys Ile Thr Phe Glu Glu Asp Lys Val Asn Ser Thr Val 225 230 235 240 Val Val Asp Arg Lys Ser Ser His Asp Glu Cys Gln Asp Ala Leu Asn 245 250 255 Ile Leu Pro Val Pro Gly Pro Thr Ser Ser Ala Thr Asn Val Ser Met 260 265 270 Val Val Ser Ala Gly Pro Leu Ser Ser Glu Lys Ala Glu Met Asn Ile 275 280 285 Leu Glu Ile Asn Glu Lys Leu Arg Pro Gln Leu Ala Glu Lys Lys Gln 290 295 300 Gln Phe Arg Ser Leu Lys Glu Lys Cys Phe Val Thr Gln Leu Ala Gly 305 310 315 320 Phe Leu Ala Lys Gln Gln Asn Lys Tyr Lys Tyr Glu Glu Cys Lys Asp 325 330 335 Leu Ile Lys Ser Met Leu Arg Asn Glu Leu Gln Phe Lys Glu Glu Lys 340 345 350 Leu Ala Glu Gln Leu Lys Gln Ala Glu Glu Leu Arg Gln Tyr Lys Val 355 360 365 Leu Val His Ser Gln Glu Arg Glu Leu Thr Gln Leu Arg Glu Lys Leu 370 375 380 Arg Glu Gly Arg Asp Ala Ser Arg Ser Leu Asn Glu His Leu Gln Ala 385 390 395 400 Leu Leu Thr Pro Asp Glu Pro Asp Lys Ser Gln Gly Gln Asp Leu Gln 405 410 415 Glu Gln Leu Ala Glu Gly Cys Arg Leu Ala Gln His Leu Val Gln Lys 420 425 430 Leu Ser Pro Glu Asn Asp Glu Asp Glu Asp Glu Asp Val Gln Val Glu 435 440 445 Glu Asp Glu Lys Val Leu Glu Ser Ser Ser Pro Arg Glu Met Gln Lys 450 455 460 Ala Glu Glu Ser Lys Val Pro Glu Asp Ser Leu Glu Glu Cys Ala Ile 465 470 475 480 Thr Cys Ser Asn Ser His Gly Pro Cys Asp Ser Asn Gln Pro His Lys 485 490 495 Asn Ile Lys Ile Thr Phe Glu Glu Asp Lys Val Asn Ser Ser Leu Val 500 505 510 Val Asp Arg Glu Ser Ser His Asp Glu Cys Gln Asp Ala Leu Asn Ile 515 520 525 Leu Pro Val Pro Gly Pro Thr Ser Ser Ala Thr Asn Val Ser Met Val 530 535 540 Val Ser Ala Gly Pro Leu Ser Ser Glu Lys Ala Glu Met Asn Ile Leu 545 550 555 560 Glu Ile Asn Glu Lys Leu Arg Pro Gln Leu Ala Glu Lys Lys Gln Gln 565 570 575 Phe Arg Ser Leu Lys Glu Lys Cys Phe Val Thr Gln Val Ala Cys Phe 580 585 590 Leu Ala Lys Gln Gln Asn Lys Tyr Lys Tyr Glu Glu Cys Lys Asp Leu 595 600 605 Ile Lys Ser Met Leu Arg Asn Glu Leu Gln Phe Lys Glu Glu Lys Leu 610 615 620 Ala Glu Gln Leu Lys Gln Ala Glu Glu Leu Arg Gln Tyr Lys Val Leu 625 630 635 640 Val His Ser Gln Glu Arg Glu Leu Thr Gln Leu Arg Glu Lys Leu Arg 645 650 655 Glu Gly Arg Asp Ala Ser Arg Ser Leu Asn Glu His Leu Gln Ala Leu 660 665 670 Leu Thr Pro Asp Glu Pro Asp Lys Ser Gln Gly Gln Asp Leu Gln Glu 675 680 685 Gln Leu Ala Glu Gly Cys Arg Leu Ala Gln His Leu Val Gln Lys Leu 690 695 700 Ser Pro Glu Asn Asp Asn Asp Asp Asp Glu Asp Val Gln Val Glu Val 705 710 715 720 Ala Glu Lys Val Gln Lys Ser Ser Ser Pro Arg Glu Met Gln Lys Ala 725 730 735 Glu Glu Lys Glu Val Pro Glu Asp Ser Leu Glu Glu Cys Ala Ile Thr 740 745 750 Cys Ser Asn Ser His Gly Pro Tyr Tyr Ser Asn Gln Pro His Arg Lys 755 760 765 Thr Lys Ile Thr Phe Glu Glu Asp Lys Val Asp Ser Thr Leu Ile Gly 770 775 780 Ser Ser Ser His Val Glu Trp Glu Asp Ala Val His Ile Ile Pro Glu 785 790 795 800 Asn Glu Ser Asp Asp Glu Glu Glu Glu Glu Lys Gly Pro Val Ser Pro 805 810 815 Arg Asn Leu Gln Glu Ser Glu Glu Glu Glu Val Pro Gln Glu Ser Trp 820 825 830 Asp Glu Gly Tyr Ser Thr Leu Ser Ile Pro Pro Glu Met Leu Ala Ser 835 840 845 Tyr Gln Ser Tyr Ser Gly Thr Phe His Ser Leu Glu Glu Gln Gln Val 850 855 860 Cys Met Ala Val Asp Ile Gly Gly His Arg Trp Asp Gln Val Lys Lys 865 870 875 880 Glu Asp Gln Glu Ala Thr Gly Pro Arg Leu Ser Arg Glu Leu Leu Asp 885 890 895 Glu Lys Gly Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser 900 905 910 Thr Pro Ser Gly Tyr Leu Glu Leu Thr Asp Ser Cys Gln Pro Tyr Arg 915 920 925 Ser Ala Phe Tyr Ile Leu Glu Gln Gln Arg Val Gly Trp Ala Leu Asp 930 935 940 Met Asp Glu Ile Glu Lys Tyr Gln Glu Val Glu Glu Asp Gln Asp Pro 945 950 955 960 Ser Cys Pro Arg Leu Ser Arg Glu Leu Leu Asp Glu Lys Glu Pro Glu 965 970 975 Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Tyr 980 985 990 Leu Glu Leu Pro Asp Leu Gly Gln Pro Tyr Arg Ser Ala Val Tyr Ser 995 1000 1005 Leu Glu Glu Gln Tyr Leu Gly Leu Ala Leu Asp Val Asp Arg Ile Lys 1010 1015 1020 Lys Asp Gln Glu Glu Glu Glu Asp Gln Gly Pro Pro Cys Pro Arg Leu 1025 1030 1035 1040 Ser Arg Glu Leu Leu Glu Ala Val Glu Pro Glu Val Leu Gln Asp Ser 1045 1050 1055 Leu Asp Arg Cys Tyr Ser Thr Pro Ser Ser Cys Leu Glu Gln Pro Asp 1060 1065 1070 Ser Cys Leu Pro Tyr Gly Ser Ser Phe Tyr Ala Leu Glu Glu Lys His 1075 1080 1085 Val Gly Phe Ser Leu Asp Val Gly Glu Ile Glu Lys Lys Gly Lys Gly 1090 1095 1100 Lys Lys Arg Arg Gly Arg Arg Ser Thr Lys Lys Arg Arg Arg Arg Gly 1105 1110 1115 1120 Arg Lys Glu Gly Glu Glu Asp Gln Asn Pro Pro Cys Pro Arg Leu Ser 1125 1130 1135 Arg Glu Leu Leu Asp Glu Lys Gly Pro Glu Val Leu Gln Asp Ser Leu 1140 1145 1150 Asp Arg Cys Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu Thr Asp Ser 1155 1160 1165 Cys Gln Pro Tyr Arg Ser Ala Phe Tyr Ile Leu Glu Gln Gln Arg Val 1170 1175 1180 Gly Trp Ala Leu Asp Met Asp Glu Ile Glu Lys Tyr Gln Glu Val Glu 1185 1190 1195 1200 Glu Asp Gln Asp Pro Ser Cys Pro Arg Leu Ser Arg Glu Leu Leu Asp 1205 1210 1215 Glu Lys Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser 1220 1225 1230 Thr Pro Ser Gly Tyr Leu Glu Leu Pro Asp Leu Gly Gln Pro Tyr Arg 1235 1240 1245 Ser Ala Val Tyr Ser Leu Glu Glu Gln Tyr Leu Gly Leu Ala Leu Asp 1250 1255 1260 Val Asp Arg Ile Lys Lys Asp Gln Glu Glu Glu Glu Asp Gln Gly Pro 1265 1270 1275 1280 Pro Cys Pro Arg Leu Ser Arg Glu Leu Leu Glu Ala Val Glu Pro Glu 1285 1290 1295 Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Ser Cys 1300 1305 1310 Leu Glu Gln Pro Asp Ser Cys Leu Pro Tyr Gly Ser Ser Phe Tyr Ala 1315 1320 1325 Leu Glu Glu Lys His Val Gly Phe Ser Leu Asp Val Gly Glu Ile Glu 1330 1335 1340 Lys Lys Gly Lys Gly Lys Lys Arg Arg Gly Arg Arg Ser Thr Lys Lys 1345 1350 1355 1360 Arg Arg Arg Arg Gly Arg Lys Glu Gly Glu Glu Asp Gln Asn Pro Pro 1365 1370 1375 Cys Pro Arg Leu Ser Arg Glu Leu Leu Asp Glu Lys Gly Pro Glu Val 1380 1385 1390 Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr Pro Ser Gly Tyr Leu 1395 1400 1405 Glu Leu Thr Asp Ser Cys Gln Pro Tyr Arg Ser Ala Phe Tyr Ile Leu 1410 1415 1420 Glu Gln Gln Arg Val Gly Trp Ala Leu Asp Met Asp Glu Ile Glu Lys 1425 1430 1435 1440 Tyr Gln Glu Val Glu Glu Asp Gln Asp Pro Ser Cys Pro Arg Leu Ser 1445 1450 1455 Arg Glu Leu Leu Asp Glu Lys Glu Pro Glu Val Leu Gln Asp Ser Leu 1460 1465 1470 Asp Arg Cys Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu Pro Asp Leu 1475 1480 1485 Gly Gln Pro Tyr Arg Ser Ala Val Tyr Ser Leu Glu Glu Gln Tyr Leu 1490 1495 1500 Gly Leu Ala Leu Asp Val Asp Arg Ile Lys Lys Asp Gln Glu Glu Glu 1505 1510 1515 1520 Glu Asp Gln Gly Pro Pro Cys Pro Arg Leu Ser Arg Glu Leu Leu Glu 1525 1530 1535 Ala Val Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser 1540 1545 1550 Thr Pro Ser Ser Cys Leu Glu Gln Pro Asp Ser Cys Leu Pro Tyr Gly 1555 1560 1565 Ser Ser Phe Tyr Ala Leu Glu Glu Lys His Val Gly Phe Ser Leu Asp 1570 1575 1580 Val Gly Glu Ile Glu Lys Lys Gly Lys Gly Lys Lys Arg Arg Gly Arg 1585 1590 1595 1600 Arg Ser Thr Lys Lys Arg Arg Arg Arg Gly Arg Lys Glu Gly Glu Glu 1605 1610 1615 Asp Gln Asn Pro Pro Cys Pro Arg Leu Ser Gly Val Leu Met Glu Val 1620 1625 1630 Glu Glu Pro Glu Ile Leu Gln Asp Ser Leu Asp Arg Cys Tyr Ser Thr 1635 1640 1645 Pro Ser Met Phe Phe Glu Leu Pro Asp Ser Phe Gln His Tyr Arg Ser 1650 1655 1660 Val Phe Tyr Ser Phe Glu Glu Gln His Ile Ser Phe Ala Leu Asp Val 1665 1670 1675 1680 Asp Asn Arg Phe Leu Thr Leu Met Gly Thr Ser Leu His Leu Val Phe 1685 1690 1695 Gln Met Gly Val Ile Phe Pro Gln 1700 <210> SEQ ID NO 203 <211> LENGTH: 263 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: cDNA of exon A and B <400> SEQUENCE: 203 tcagggacat gcagaaggct gaagaaaagg aagtccctga ggactcactg gaggaatgtg 60 ccatcacttg ttcaaatagc catggccctt atgactccaa ccagccacat aggaaaacca 120 aaatcacatt tgaggaagac aaagtcgact caactctcat tggctcatcc tctcatgttg 180 aatgggagga tgctgtacac attatcccag aaaatgaaag tgatgatgag gaagaggaag 240 aaaaagggcc agtgtctccc agg 263 

1. An isolated tumor suppressor gene product, comprising SEQ ID N° 202 or a functional fragment, variant or fusion protein thereof.
 2. A functional fragment of a tumor suppressor gene product according to claim 1, whereby said functional fragment comprises at least SEQ ID N° 2 or SEQ ID N°
 161. 3. A variant of a tumor suppressor gene product according to claim 1, whereby said variant comprises at least a sequence selected from the group consisting of SEQ ID N° 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 191, 193, 195, 197, 198 and
 200. 4. A fusion protein of a tumor suppressor gene product according to claim 1, whereby said fusion product comprises SEQ ID N° 163 or SEQ ID N°
 165. 5. An isolated nucleic acid encoding a tumor suppressor gene product or a tumor suppressor gene product fragment, variant, or fusion product according to claim any of the claims 1-4.
 6. An isolated nucleic acid according to claim 5, comprising the sequence presented in SEQ ID N°
 1. 7. An isolated nucleic acid according to claim 5, comprising the sequence presented in SEQ ID N°
 3. 8. An isolated nucleic acid according to claim 5, comprising the sequence presented in SEQ ID N°
 4. 9. An isolated nucleic acid according to claim 5, comprising the sequence presented in SEQ ID N°
 201. 10. An isolated nucleic acid according to claim 5, comprising the sequence presented in SEQ ID N°
 203. 11. An isolated nucleic acid according to claim 5, comprising the sequence presented in SEQ ID N°
 160. 12. An isolated nucleic acid according to claim 5, comprising the sequence selected from the group consisting of SEQ ID N° 166, 168, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196 and
 199. 13. An isolated nucleic acid according to claim 5, comprising the sequence presented in SEQ ID N° 162 or SEQ ID N°
 164. 14. The use of a nucleic acid according to any of the claims 5-13, or a nucleic acid with at least 60% identity to said nucleic acid, or a functional fragment thereof in diagnosis of cancer and/or prediction of the likelihood of developing cancer.
 15. The use of a nucleic acid according to any of the claims 5-12, or a nucleic acid with at least 60% identity to said nucleic acid, or a functional fragment thereof in treatment of cancer.
 16. The use of a tumor suppressor gene product, or a functional fragment or a variant thereof according to any of the claims 1 to 4, or a protein with at least 60% identity to said tumor suppressor gene product, for the manufacture of a medicament to treat cancer.
 17. The use according to any of the claims 14-16, whereby said cancer is meningioma, colorectal cancer, gastric carcinoma and/or breast cancer.
 18. The use according to any of the claims 14-16, whereby said cancer is neuroblastoma.
 19. The use of a tumor suppressor gene product, or a functional fragment or a variant thereof according to any of the claims 1 to 4, or a protein with at least 60% identity to said tumor suppressor gene product for the generation of micronuclei and/or the removal of amplified DNA
 20. A method for the production of antibodies against a tumor suppressor gene product, using a tumor suppressor gene product, or a functional fragment, variant or fusion product thereof according to any of the claims 1-4, or a protein with at least 60% identity to said tumor suppressor gene product, or an isolated nucleic acid encoding such polypeptide.
 21. An antibody obtainable by the use according to claim
 20. 22. The use of an antibody according to claim 21 in diagnosis of cancer and/or prediction of the likelihood of developing cancer.
 23. The use of an antibody according to claim 22, whereby the cancer is meningioma, colorectal cancer, gastric carcinoma and/or breast cancer.
 24. The use of an antibody according to claim 22, whereby the cancer is neuroblastoma
 25. The use of a tumor suppressor gene product or a functional fragment, variant or fusion product thereof according to any of the claims 1-4, or a protein with at least 60% identity to said tumor suppressor gene product, for the isolation of an interacting compound. 